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Abstract
PAUL S. SHEERAN: Optimizing the Performance of Phase-Change Contrast Agents
for Medical Ultrasonography.
(Under the direction of Paul A. Dayton)
In the past two decades, perfluorocarbon (PFC) droplets have been investigated for
biomedical applications in several imaging modalities. More recently, interest has in-
creased in ‘phase-change’ PFC droplets (or ‘phase-change’ contrast agents (PCCAs)),
which can convert from liquid to gas with an external energy input. In the field of
ultrasound, phase-change droplets present an attractive alternative to traditional mi-
crobubble agents for many diagnostic and therapeutic applications.
In this thesis, new techniques are presented to enhance the performance of PCCAs
and ultimately drive the platform closer to clinical use. It is demonstrated that the
efficiency of activation can be improved by incorporating highly volatile compounds,
and new particle generation methods are developed to produce PCCAs from these
compounds. Next it is shown that these methods can be adapted to highly tune the
performance of the droplets with regard to both sensitivity to ultrasound and thermal
stability - allowing one to ‘tune’ the droplets for an intended application. Next, an
alternative method of determining appropriate ultrasound activation parameters for
nanoscale emulsions is demonstrated based on changes in the bubble population pro-
duced. Through high-speed video microscopy,the physics of particle expansion after
droplet activation are studied to show that droplets produce unique, size-dependent
acoustic ‘signatures’ during vaporization that can be detected at diagnostic ultrasound
frequencies and used to isolate droplet vaporization events from tissue and standard
iii
microbubble contrast agents. Finally, the benefits of these techniques both in vitro and
in vivo are demonstrated in applications such as ultrasound diagnostic and molecular
imaging, ultrasound-mediated tissue ablation, and drug delivery across the blood-brain
barrier.
The results shown here demonstrate that PCCAs can be highly tuned to perform
ideally across a wide range of ultrasound-related applications, which bolsters the ar-
gument for their use as diagnostic and therapeutic clinical ultrasound agents. Future
refinement of the techniques in this thesis will help drive PCCAs toward eventual use
in improving human health.
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CHAPTER 1
Phase-Change Contrast Agents in Medical Ultrasonography
1.1 Introduction
The relatively recent concept of designing diagnostic and therapeutic phase-change
contrast agents (PCCAs) based on an ultrasound triggered phase-transition has pro-
vided medical researchers with a ‘middle-ground’ between the inert liquid emulsion and
gas-based microbubble contrast agent (MCA) platforms. PCCAs can be generated in
a wide range of useful sizes and, once activated, show high echogenicity (Figure 1.1).
The ability to ultrasonically induce activation with temporal and spatial specificity
has resulted in the emergence of a diverse set of techniques for in vivo and in vitro
applications.
Perfluorochemicals and perfluorocarbons (referred to collectively here as PFCs), in
both the liquid and gaseous state, have proven to be favorable compounds for inert
liquid emulsions, MCAs, and PCCAs due to their unique properties. When adminis-
tered in vivo, liquid emulsions of high boiling point PFCs are inert, non-toxic in small
doses, and can have relative stability in circulation due to high molecular weight, im-
miscibility in water, and low surface tension [1; 2]. Depending on the choice of PFC,
c© 2012 Bentham Science Publishers (benthamscience.com) Portions reprinted, from PS Sheeran
and PA Dayton. “Phase-Change Contrast Agents for Imaging and Therapy” Curr Pharm Des, 2012
Jan; 18: 2152-2165.
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Figure 1.1: Vaporization of PFC droplets as a result of exposure to ultrasonic pulses.
Shown here, a droplet of dodecafluoropentane encapsulated in a lipid shell is stable in
vitro at 37◦C, but vaporizes upon exposure to a 5 MHz ultrasonic pulse. The phase-
transition results in a bubble approximately 5 to 6 times larger.
the emulsions may persist stably in vivo for hours to days [3], which is attractive for
applications involving gradual accumulation at a target site and/or sustained release
of drugs. Applications are not strictly intravascular because liquid PFC emulsions can
be generated with a broad range of sizes, including the hundred-nanometer range. A
number of applications have been proposed, including molecular imaging and therapy
of thrombi, tumor angiogenesis, and atherosclerosis-related diseases [4; 5; 6; 7], quanti-
tative in vivo imaging and contrast enhancement [1; 3; 8], and cell tracking [9; 10]. The
ability to solubilize large amounts of gas into liquid PFCs has resulted in the develop-
ment of oxygen delivery applications that may be useful for extending tissue viability
during hypoxic events (such as cardiac bypass and hemorrhagic shock), enhancement of
tumor radiation therapy, and liquid breathing [11; 12; 13; 14; 15; 16]. Although some
PFCs exhibit echogenicity due to a lower speed-of-sound and higher density than water
[17; 18; 19], the contrast provided is much lower than that of MCAs. Some studies have
shown that once bound to a surface, a liquid PFC-core agent can increase the acoustic
reflectivity of the target, and that the reflectivity may be optimized by the choice of
PFC [17; 20]. Additionally, liquid PFC-based agents are convenient for multimodal
2
imaging beyond ultrasound either through endogenous PFC properties or through the
inclusion of other agents. PFCs, particularly those with higher boiling points, carry a
high number of fluorine atoms that can be used for 19F MR spectroscopy [21; 22]. In-
clusion of paramagnetic nanoparticles, fluorescent nanoparticles, and/or radioisotopes
enable these PFC emulsions to be extended to 1H MR T1-weighted imaging, SPECT-
CT [4; 5; 23; 21; 22], and optical fluorescence imaging [9; 10]. Particular PFCs may
also serve as radiopaque blood pool agents for CT due to the long intravascular half-life
[1; 3; 8].
MCAs for diagnostic and therapeutic ultrasound have provided a promising plat-
form for addressing a number of issues, including applications in echocardiography,
microvascular perfusion imaging, thermal ablation enhancement, molecular imaging,
drug and gene delivery, and thrombolysis [24; 25; 26; 27; 28; 29; 30; 31; 32; 33; 34;
35; 36; 37; 38; 39; 40; 41]. PFCs have been favored for the gaseous core for more
than a decade because of low solubility compared to other gases [41; 42]. MCAs are
typically produced with diameters in the 1 to 5 µm range, which is a compromise be-
tween enabling free passage through capillary beds, and maximizing ultrasound imaging
sensitivity. When excited by ultrasound energy, the highly compressible microbubbles
exhibit nonlinear behavior. This has led to microbubble-specific imaging modes that
enable contrast imaging with high sensitivity and low background signal from tissue
[43; 44; 45; 46; 47; 48]. However, sizes optimal for contrast enhancement limit passage
to within the vascular space [38], and microbubble persistence in vivo is typically only
on the order of minutes [49].
Preclinical studies have suggested that, in contrast to MCAs, PCCAs can be de-
signed to have relative stability in circulation prior to ultrasound-induced vaporization.
Once vaporized, they exhibit contrast enhancement similar to what MCAs provide
[50; 51; 52; 53; 54]. Several reviews on MCAs [35; 55; 56], liquid PFC contrast agents
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[57], and methods of drug/gene delivery [58] have included discussions of PCCAs, and
a few review articles have centered on the unique properties of these agents [59; 60; 61].
In this chapter, a brief survey of the history of phase-change contrast agents and
the multiple environmental, design, and ultrasound-based factors that influence droplet
vaporization is presented. The many proposed applications at both the microscale and
nanoscale are discussed with a summary of the in vivo studies performed to date that
show promising results for future use in humans. Issues involved with PCCA design as
well as possibilities for future studies and applications are addressed.
1.2 History and Influencing Factors
Although the general physics of droplet vaporization has been well-described in
the literature, phase-transition as a result of ultrasound energy and the range of di-
agnostic and therapeutic possibilities for PCCAs have only begun to emerge in the
past two decades. Phase-change colloids for ultrasonic imaging were first proposed by
Quay in 1996 [62], resulting in development of the contrast agent EchoGen R©, although
clinical trials were ultimately discontinued. EchoGen R©was fundamentally different
in application than most PCCAs being developed currently in that stable emulsions
of dodecafluoropentane (DDFP) were pre-conditioned to induce phase-transition into
gas-filled contrast agents in the 2 to 5 µm diameter range prior to intravenous injection
[63; 64; 65], rather than activation while in circulation. In 1998, Apfel proposed su-
perheated droplets that, while circulating in vivo, could be activated with a degree of
spatial specificity by ionizing radiation or ultrasound for enhanced diagnostic capability,
drug delivery, and targeted vessel occlusion [66].
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Perfluorocarbons and perfluorochemicals have been particularly attractive com-
pounds in conjunction with PCCAs - not only due to the properties stated earlier, but
also because many have boiling points near physiological temperatures, which allows
for the design of droplets in or near a superheated state. Table 1.1 lists selected PFCs
that have been used for inert liquid emulsions, MCAs, and PCCAs along with their
physical properties, if available, gathered from several sources of literature [17; 19; 67].
DDFP, in particular, has been the most often-used compound because its boiling point
of 29◦C allows for the possibility of droplet generation at room temperature, and expo-
sure to physiological temperatures results in a superheated droplet that can be easily
converted with ultrasound - although in practice, droplet size becomes a factor due to
the effects of surface tension.
Surface tension plays a large role in both the threshold of vaporization for a droplet
and the subsequent volumetric expansion. Beyond ambient pressure, a PFC droplet
will experience an additional Laplace pressure as a result of surface tension effects over
a defined radius [52]:
∆P = Pinside − Poutside = 2σ
r
(1.1)
where Pinside represents the pressure inside the droplet, Poutside represents the pres-
sure outside the droplet, σ represents surface tension, and r represents radius. Although
liquid PFCs have characteristically low interfacial surface tension with air, their hy-
drophobicity may lead to relatively high interfacial surface tension when dispersed in
water [68; 69], and therefore the pressure exerted on the liquid core at the microscale
and nanoscale may reach several atmospheres above ambient pressure. Through encap-
sulation in a lipid or polymer shell, Kandadai and colleagues showed that the interfacial
surface tension of DDFP droplets may be modified by the choice of emulsifier to pro-
vide more favorable properties for dispersion in aqueous media [69]. The relationship
6
between the ambient pressure a compound experiences and the temperature required
to induce phase-transition is approximated by the Antoine vapor-pressure equation,
which is a derivation of the Clausius-Clapeyron relation. The Antoine vapor-pressure
equation is defined as:
T =
B
A− logP − C (1.2)
where T is the ambient temperature, P is the ambient pressure exerted on the
droplet, and A, B, and C are experimentally derived constants observed for a particular
temperature range. The relation shows that as the pressure is raised on the droplet core,
the energy (in the form of temperature and/or ultrasound) required to induce phase
transition increases. Because the Laplace pressure is an inverse function of radius, this
effect becomes more pronounced for droplets in the nanometer range. By ideal gas laws
with surface tension included, once a PFC droplet is vaporized, the resulting bubble
will theoretically expand approximately 3 to 6 times in diameter, depending on initial
droplet size, ambient pressure, and the density of the PFC selected [70]. Several studies
have shown in vitro that bubbles may expand beyond ideal gas law predictions due to
the influx of dissolved gases present in the surrounding media [71; 72]. In theory, this
additional expansion is likely to be more pronounced for larger bubbles than smaller
bubbles, as the internal pressure of the gas core due to surface tension is less.
The exact mechanisms that cause a droplet to undergo a phase change as a result
of ultrasonic energy - termed acoustic droplet vaporization (ADV) - are the subject
of much discussion in the literature. Because the phase-transition boundary of a pure
compound is governed by the relationship of temperature and vapor pressure, one hy-
pothesis is that the phase-transition occurs due to acoustic heating of the droplet. Were
this the sole mechanism, then increasing ultrasonic pulse duration should increase the
degree of acoustic heating and trigger phase-transition of droplets. However, most
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studies have shown that increasing pulse duration at clinically relevant ultrasound fre-
quencies results in no significant decrease in the vaporization pressure needed to achieve
ADV, unless the duration is on the order of 1 millisecond or greater [73; 74; 75; 76]. For
these longer pulse lengths, a decrease in the ultrasound pressure needed to induce va-
porization has been observed. Although this may seem to be indicative of acoustically-
induced heating, Lo and colleagues found that by using shorter periodic pulses unlikely
to cause heating, but with an equivalent total ‘on-time’ as the longer pulses, a similar
decrease in required ultrasound pressure resulted - indicating heating may not be the
primary mechanism at work [74]. Other studies have provided convincing evidence that
acoustic droplet vaporization may be initiated primarily by mechanical effects such as
acoustic and hydrodynamic cavitation. Kripfgans and colleagues used high-speed op-
tical microscopy to observe droplet deformations due to acoustic pressure, and showed
that droplets with diameters in the micrometer range vaporized once a deformational
threshold was reached, independent of original size [77]. More recent studies have shown
vaporization can be induced independently of inertial acoustic cavitation, which has a
number of implications for safety in vivo [75; 76].
Starting with some of the earliest studies on ADV agents, researchers noticed a
frequency dependence on the pressure required to vaporize droplets of a specific size
[71; 50]. These results implied that the absolute pressure to induce vaporization could
be lowered by choosing a higher ultrasound frequency - which conveniently also reduces
the possibility of causing unwanted cavitation-based bioeffects that are more prominent
at lower frequencies. A recent study has proposed that this frequency dependence is
due to acoustic focusing of the pulse harmonics within the droplet - increasing the
absolute pressure experienced by the droplet [78]. These effects increase with the
nonlinearity of the pulse at high amplitudes, and are dependent on droplet size. For
frequencies relevant to medical imaging with humans, the frequency effect is observed
8
for droplets greater than 2 micrometers in diameter, but appears to be insignificant for
sub-micrometer droplets.
Although the all of the mechanisms involved in ADV have not been completely re-
vealed, a number of mathematical and physical models have been developed to simulate
various properties of droplet vaporization. Ye and Bull have developed several models
to describe the possible effects of post-vaporization expansion on wall stress to deter-
mine potential for damaging blood vessels [79; 80]. Other models have investigated the
effect of surface tension on boiling point elevation, freezing point depression, volumet-
ric expansion, and the oscillatory evolution of bubbles [70; 81]. Several recent studies
by Shpak et al. have modeled the growth of vaporizing particles as a result of heat
transfer and included effects induced by the vaporization pulse [82; 83]. Regardless of
the primary mechanism, a large number of factors have been shown to influence the
ultrasound pressure needed to induce vaporization of a droplet. These can be separated
into three principle categories: environmental factors, droplet design, and ultrasound
parameters (Table 1.2). Many of the applications proposed for PCCAs stem from the
numerous factors that influence their vaporization.
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The stability of circulating PCCAs in vivo is not well characterized to date, although
a few studies have suggested that certain PCCAs show greater circulation times than
their counterpart perfluorocarbon-filled MCAs. Rapoport and colleagues have pub-
lished several in vivo studies using polymer-coated, drug-loaded DDFP nanodroplets
suggesting that a significant amount of nanodroplets were still in circulation as much
as 4 to 5 hours after intravenous injection in mice [51; 52; 89]. When subjecting these
droplets to ultrasonic energy, a substantial reduction in tumor growth was achieved
over controls. Recent studies from this group using higher boiling-point perfluorocar-
bons have suggested that the residence time may also be significantly influenced by the
design of the encapsulating shell [53]. Zhang and colleagues recently published results
showing that micron-sized droplets of DDFP were able to achieve an equivalent ef-
fect when activated 30 minutes after intravenous injection in a canine model compared
to those activated immediately after injection, although they did not test timepoints
beyond 30 minutes [54]. In general, it is likely that longevity in circulation will be
a function of PFC boiling point, design of the encapsulating shell, and droplet size,
although many preclinical studies are needed to characterize these effects in vivo.
1.3 Applications
Phase-change contrast agent applications can be roughly divided into two categories:
those with droplets in the micrometer range and those with droplets in the nanome-
ter range. While droplets in both size categories have been proposed as drug delivery
agents, droplets at the microscale, which are confined to vascular flow, hold unique
possibilities for applications such as targeted vessel occlusion, ultrasound aberration
correction, enhancing cavitation activity, and creation of internal markers for intraop-
erative guidance. Droplets at the nanoscale are primarily designed to take advantage
of the well-studied enhanced permeability and retention (EPR) effect of solid tumors.
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As tumors grow and recruit new vasculature, the rapidly-formed vessels often exhibit a
degree of ‘loose’ organization. Inter-endothelial gaps that normally prevent passage of
large molecules into interstitial space are characteristically wider depending on tumor
type, and can allow for extravasation of particles well in to the hundreds of nanometers
in size [90; 91]. PCCAs that can take advantage of the EPR effect have been proposed
for applications such as ultrasound-mediated drug delivery, diagnostic imaging, and
enhanced thermal ablation. In both size ranges, droplets can be administered intra-
arterially, intravenously, or through direct intra-tumoral injection and then vaporized
[50; 92; 93; 85]. In a few cases, the applications proposed for nanoscale droplets are
similar to those for microscale droplets - such as drug delivery to solid tumors and
enhancing the effects of HIFU therapy. Future in vivo work will be needed to develop
an understanding of the tradeoffs inherent in choosing to pursue these techniques with
microscale vs. nanoscale droplets. The specific applications are discussed below.
Figure 1.2: PCCA tissue occlusion demonstrated in a canine kidney with droplets in-
jected intravenously. Pulse-wave Doppler spectrum taken at the targeted spot in the
renal artery before (a) and immediately after ADV (b), where blood flow reversal
and narrowing of the waveform along with significant shadowing in the kidney is ob-
served possibly because of substantial vascular occlusion. Reprinted from Ultrasound
in Medicine and Biology, Vol. 52, Zhang M, Fabiilli ML, Haworth KJ, et al., “Initial
investigation of acoustic droplet vaporization for occlusion in canine kidney”, 1691-703
(2010), with permission from Elsevier.
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1.3.1 Microscale Applications
Vascular Occlusion Agents
Beginning with some of the earliest literature available on ADV, there has been
significant interest in designing droplets in the micrometer size range for the purpose
of vessel occlusion [50; 71]. Once vaporized, droplets near 5 µm in diameter will result
in microbubbles that are on the order of 30 µm - sufficient to occlude microvasculature.
By using focused ultrasound transducers, vaporization can be induced in the feeder
arteries of kidneys (and by extension, tumors), resulting in the ability to occlude with
a high degree of spatial specificity (Figure 1.2) [92; 85]. This type of occlusion may be
especially beneficial in enhancing thermal therapy of tumors, such as in radio-frequency
ablation. Often the blood supply of the tumor can act as a heat sink - dissipating the
heat and reducing the efficacy of the treatment. By occluding nearby vasculature,
thermal delivery may be more successful. Reduced blood flow by occlusion may also be
used to induce hypoxia in tumors, although future studies will be needed to determine
whether the influence of PFC oxygen solubility reduces the degree of induced hypoxia
in practice [50]. ADV-based occlusion appears to provide significant opportunity with
regard to drug delivery. Residence time of drugs could be increased through reduced
blood flow, allowing for enhanced diffusion into a targeted region. Drugs may be
coinjected systemically or in the form of drug delivery vehicles such as liposomes, or
alternately could be incorporated into the ADV occlusion agent through a dual-phase
emulsion or multiple emulsions. Perhaps the most promising illustration of ADV-based
occlusion was given by Fabiilli and colleagues [94]:
1. Through drug-incorporated emulsions, targeted occlusion can coincide with re-
lease of a chemical embolic agent - thus sustaining embolization.
2. The resulting ischemia may increase the residence time of a therapeutic agent
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locally, enhancing efficacy of therapeutic delivery.
3. Hypoxia as a result of prolonged ischemia may be useful for activation of biore-
ductive prodrugs - which potentially can be encapsulated in the emulsion process.
Although no in vivo validation is available to date, Fabiilli and colleagues have
shown preliminary in vitro proof-of-concept of encapsulation of thrombin and chloram-
bucil in PCCA emulsions, followed by release with ultrasound-triggered vaporization
[94; 95]. These studies also demonstrate the need for further optimization of formula-
tion and drug loading as well as control over non-US induced drug release and droplet
size prior to preclinical studies. How these emulsion techniques perform compared to
alternative platforms, such as microscale PFC droplets co-injected with drug loaded
liposomes or micelles, will also need to be characterized. Ultimately, the success of
ADV-based occlusion techniques depends on the dynamics involved in the transport
and lodging of microbubbles generated from PCCAs. Due to a number of influencing
factors, these bubbles may become lodged in the microvasculature near the site of va-
porization, may slide along the vascular space, or may interact in a complex manner
with vessel bifurcations downstream. It is also important that the occlusive bubbles
not be so large as to damage or rupture the vessel wall. Several physical models
have been developed by the University of Michigan group to simulate these dynamics
[79; 80; 81; 96; 97; 98]. Although some experimental studies are available on non-ADV
microbubble embolization [99; 100], further experimental results from ADV-generated
microbubbles are needed to validate these models as they extend to pulsatile blood flow
in the microvasculature.
Aberration Correction
Phase aberration of reconstructed ultrasound images is a result of cumulative error
in estimating the speed-of-sound in the tissue the ultrasonic wave travels through. On
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Figure 1.3: Ultrasound transcranial radiofrequency lines gathered using ex vivo human
skulls. Misalignment of the peak amplitude of an ADV point beacon due to aberration
(top) was corrected using time-reversal focusing (bottom). Reprinted from Ultrasound
in Medicine and Biology, Vol. 34, Haworth KJ, Fowlkes JB, Carson PL, Kripfgans
OD, “Towards aberration correction of transcranial ultrasound using acoustic droplet
vaporization”, 435-45 (2008), with permission from Elsevier.
the transmit side, this leads to the transducer not focusing as desired, and on the
receive/reconstruction side results in poor, blurry images [50]. Aberration becomes
especially prominent when imaging through dense tissue or bone - such as the skull,
and worsens as ultrasound frequency increases. One proposed mechanism for aberration
correction is to use disperse point targets in the form of echogenic gas bubbles at
defined locations in the volume-of-interest. Using iterative methods, the ‘brightness’
of the point target can be used as a measure of aberration correction, and transducer
timing can be adjusted to create optimal focusing and image reconstruction. Phase-
change contrast agents present a unique opportunity for aberration correction in that
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low-concentration droplets can be vaporized with a degree of spatial specificity, lodge
in a vessel, and create a stationary point beacon for iterative methods [50; 71; 101].
Preliminary results using acoustic droplet vaporization have been promising for focusing
on transmit (Figure 1.3), but have not yet been extended to image reconstruction [101].
Cavitation Nucleation Agents
Bioeffects caused by ultrasound-induced cavitation in vivo range from cell sonopo-
ration (increasing permeability of the cell wall) to cell lysis and tissue homogenization
[102]. In addition, beyond certain pressure thresholds significant heating can occur
[103]. These phenomena can be harnessed for both hyperthermic and non-thermal tu-
mor treatments - such as cell lysis in combination with enhanced gene transfection due
to sonoporation. However, optimal tumor treatment would require precise spatial and
temporal control of the cavitation events [84]. Cavitation nuclei are relatively sparse
in blood and tissue, but it has been shown that microbubble contrast agents can act as
cavitation nuclei and lower the energy needed to induce bioeffects [104; 105; 106]. As
mentioned previously, microbubbles exhibit low circulation times in vivo, and so phase-
change contrast agents may present a novel means of producing more stable cavitation
nuclei with control of spatial and temporal activation for therapeutic applications.
Early studies by Miller and colleagues have shown that hemolysis by lithotripter shock
waves was more pronounced in the presence of PCCAs in vitro than for MCAs [84]. An
in vivo study resulted in enhanced cell transfection of DNA plasmids and growth-rate
reduction similar to that produced by MCAs and macroscopic air bubbles when all
were injected intra-tumorally [107]. Lo and colleagues proposed that spatial control of
droplet vaporization could be used to create predictable lesion formation and demon-
strated the concept in tissue- mimicking phantoms [108]. A recent study by Zhang
and colleagues showed that microscale droplets of DDFP significantly enhanced lesion
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formation in vitro as well as in vivo [54]. When droplets were introduced to tissue-
mimicking phantoms, the exposure time needed to create similar lesions as controls was
decreased by a factor of 2.5. When equal exposure times were used, the average lesion
volume was 7-fold greater than phantoms without droplets. In vivo results proved even
more promising, resulting in a 15- fold increase in volume for lesions formed in the
canine liver at equal exposure time to controls without droplets.
Internal Markers for Intraoperative Guidance
One of the most recently-developed applications for PCCAs involves harnessing
their sensitivity to heat and ultrasound pressure to create internal markers that may
assist during therapeutic or surgical procedures. Huang and colleagues proposed a
method where PCCAs designed to vaporized at a specific temperature are injected near
the periphery of a tumor site and activated once the tissue reaches a lethal thermal
dose - providing real-time feedback on intraoperative ablation margins [109]. They
demonstrated this concept in vitro using micron-sized PLGA-encapsulated PCCAs.
More recently, Couture and colleagues proposed ‘internal tattooing’, where PCCAs
loaded with payloads of fluorescent markers are activated to release the fluorescent
payload at the transducer focus [110]. This could be used to label areas of interest
and delineate regions preoperatively with a high degree of spatial specificity that would
then be visible intraoperatively through fluorescence imaging. They demonstrate proof-
of-concept in vivo by ultrasonically activating PCCAs and labeling tissues at different
locations in a chicken embryo.
1.3.2 Nanoscale Applications
Intra-tumoral Diagnostics and Therapeutic Delivery
Phase-change contrast agents provide a novel means of addressing diagnostics and
drug delivery of solid tumors. Kawabata and colleagues, who published some of the
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Figure 1.4: Schematic representation of passive drug targeting through the defective
tumor microvasculature using an echogenic drug delivery system. The system com-
prises micelles (small circles), PFC nanodroplets (stars), and PFC microbubbles (large
circles). Lipophilic drugs can be localized in the micelle cores and in the walls of
nanodroplets/microbubbles. Tumors are characterized by defective vasculature with
large gaps between the endothelial cells, which allows extravasation of drug-loaded mi-
celles and small nanodroplets into the tumor interstitium. Primary microbubbles are
formed from the vaporization of nanodroplets due to hyperthermia or ultrasound, and
larger microbubbles appear due to coalescence of the primary microbubbles. Rapoport
N, Gao Z, Kennedy A, “Multifunctional nanoparticles for combining ultrasonic tumor
imaging and targeted chemotherapy”, J Natl Cancer Inst, 2007, Vol. 99, 1095-106, by
permission of Oxford University Press.
earliest studies of nanoscale PCCAs activated by ultrasound, showed successful vapor-
ization of nanodroplets consisting of mixtures of liquid perfluorocarbons [86]. Through
the EPR effect, droplets generated in the nanometer size range may diffuse out of the
vascular space before undergoing phase-change triggered by ultrasound. By ideal gas
laws, droplets 200 nm or larger should result in gas microbubbles on the order of 1 µm
[70], which would provide significant contrast enhancement of tumor interstitium. This
would effectively extend microbubble-based imaging beyond the vascular space and
create new opportunities for tumor detection and treatment. Rapoport and colleagues
have proposed a multi-faceted imaging and treatment platform using nanoscale PC-
CAs with drug-loaded polymer shells in conjunction with drug-loaded micelles where
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ultrasound combined with droplet vaporization enhances local drug delivery (Figure
1.4) [111]. The resulting microbubbles (as well as larger secondary bubbles formed
by coalescence) can be used as real-time delivery confirmation. Over a wide range of
studies, her group has demonstrated the promise of PCCAs for delivery of paclitaxel
and doxorubicin in vitro and in vivo for various cancer models using DDFP droplets
encapsulated in a polymer shell [51; 52; 89; 93; 112; 111; 113]. The group has recently
begun to explore the use of much higher boiling-point PFCs for increased stability,
reversible bubble formation, and co-registration with 19F MRI, although they conclude
that the temporary bubbles observed in the study may be due to gases dissolved in the
PFC rather than actual vaporization of the PFC itself [53]. Matsuura and colleagues
have provided promising preliminary evidence that incorporated nanoparticles such as
quantum dots may act as additional cavitation nuclei within the core, and appear to
decrease the ultrasound vaporization threshold significantly [87]. They suggest that
PCCAs with incorporated nanoparticles may offer a means of spatially and temporally
controlling nanoparticle deposition, and could produce a means to extend ADV-based
agents to other therapeutic and imaging modalities.
Thermal Ablation Therapy and Therapeutic Bioeffects
PCCAs that have diffused into tumor interstitial space could also be used to aid in
HIFU tumor ablation or to produce therapeutic bioeffects such as those that Miller and
colleagues showed for microscale droplets. Once vaporized, the resulting bubbles can
act as extravascular cavitation nuclei that enhance tissue heating and lesion formation
from HIFU therapy. Although no published studies to date have explored the ability
of nanoscale droplets to produce the bioeffects that Miller and colleagues observed
at the microscale [84; 107], it is possible that nano-PCCAs may be similarly used to
produce cell lysis, sonoporation, and enhanced gene transfer. Zhang and Porter have
19
Figure 1.5: Presence of bubbles formed by vaporized DDFP nanodroplets increased the
thermal delivery by ultrasound to a tissue-mimicking phantom. Temperature elevations
were measured during a 10-second HIFU exposure with and without an ADV pulse.
The function generator was switched from continuous to pulse mode to fire the ADV
pulse, and then back to continuous mode for heat deposition. The switching period
led to the temperature drop during that period of time. The measured temperature
reached a plateau in the presence of vaporized nanodroplets, most likely because of
shielding effects. Reprinted from Ultrasound in Medicine & Biology, Vol 36, Zhang
P, Porter T, “An in vitro study of a phase-shift nanoemulsion: a potential nucleation
agent for bubble enhanced HIFU tumor ablation”, 1856-66 (2010), with permission
from Elsevier.
recently reported on the ability of PCCA nanodroplets to significantly enhance thermal
delivery in the region of focus once vaporized in gel phantoms (Figure 1.5) [114]. They
suggest that resulting interstitial bubbles in vivo, which would theoretically be in the
low micrometer range, would have resonance frequencies similar to MCAs used in HIFU
[115], and therefore would be uniquely suited for tumor ablation and lesion formation.
Future studies are needed to characterize how interstitial bubbles produced by PCCAs
interact with the HIFU beam, and the resulting effect on cavitation activities.
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Other Applications
Nanoscale PCCAs were used by Mohan and Rapoport to aid in the study of intra-
cellular delivery of doxorubicin, including factors that influence penetration into the
cell nucleus [116]. Their results suggest that ultrasound in the presence of microbub-
bles, including those created by vaporized nanodroplets, transiently permeabilizes the
cell nucleus and allows penetration of therapeutic drugs into the nucleus. Asami and
colleagues have also proposed that nanoscale PCCAs could be used to characterize vis-
coelastic properties of tumors by analyzing the waveforms received post-vaporization
[117].
Many possible applications of the PCCA platform await additional exploration:
1. Targeting ligands could be incorporated in the encapsulating shell to provide a
means of PCCA-based molecular imaging similar to that of microbubbles and
inert liquid PFC emulsions [33; 118; 119; 120; 121]. The effect that incorporated
ligands may have on in vivo aspects such as stability in circulation and clearance
by the reticuloendothelial system will need to be carefully addressed. Once va-
porized, PCCAs may be manipulated to enhance targeting through ultrasound
phenomena such as acoustic radiation force [122; 123; 124].
2. Studies have shown that lipid-coated microbubbles and liquid perfluorocarbon
droplets can be internalized into neutrophils, macrophages, and tumor cells [125;
126; 127; 128]. Kang and colleagues recently demonstrated preliminary studies
of PCCA uptake into peritoneal macrophages followed by acoustic vaporization
[129]. The internalization of targeted or non-targeted PCCAs into similar cells
and subsequent vaporization could lead to new methods of tissue-specific treat-
ments.
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3. Several of the previously mentioned sources have either suggested or given prelim-
inary demonstration of the possibility of co-imaging with CT and MR techniques,
and through incorporation of nanoparticles this may be extended to additional
modalities. Strohm and colleagues recently showed that incorporation of PbS
nanoparticles into micron-sized droplets of DDFP allowed the droplets to be va-
porized by near-infrared laser irradiation due to heat generated by the particles
[130]. This may be harnessed in the future to develop new techniques in photoa-
coustic imaging.
4. PCCAs could be co-injected with other platforms to create novel imaging and
treatment techniques. Lo and colleagues showed that co-injection with MCAs
significantly decreased the vaporization threshold for PCCAs by enhancing the
acoustic field in the vicinity of the droplets [74]. Therefore, microbubbles, which
could also be targeted for angiogenesis, might be useful in reducing the vapor-
ization threshold for extravasated nanodroplets and improving drug delivery ef-
ficiency. A platform of drug-carrying liposomes/micelles and PCCAs could be
developed such that the vaporized droplets confirm therapeutic delivery and
cavitation-based effects from the resulting bubbles enhance release of drugs. Fi-
nally, a coinjection of both nanoscale and microscale PCCAs could create a treat-
ment where drugs are simultaneously released in the tumor interstitium by ex-
travasated nanodroplets and in the vascular space by larger droplets that vaporize
to form tissueoccluding microbubbles.
5. The nonlinear acoustic response from microbubbles excited in an ultrasound field
has been harnessed to create contrast-specific techniques which can provide high
contrast sensitivity while suppressing tissue background [45; 46; 47; 48; 131].
Two recent studies have demonstrated that the time-dependent spectral content of
evolving bubbles resulting from vaporized PCCAs may have significantly different
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spectral information than MCAs [72; 132], which could lead to further contrast-
specific imaging techniques.
1.4 Selection of PFCs
When designing phase-change contrast agents, the choice of which PFC comprises
the core will create inherent trade-offs. As the energy needed to vaporize droplets
of a certain size increases, the likelihood of inducing unwanted bioeffects for certain
applications also increases. However, some applications may place a premium on high
droplet stability over how easily the droplets can be vaporized. The optimal choice of
PFC can largely be determined by considering:
1. The ideal size-regime of the droplets (nanoscale vs. microscale)
2. The ultrasound frequency used
3. Whether intended for diagnostic or therapeutic ultrasound machines
4. Whether ultrasound-induced bioeffects are acceptable
Droplets in the micrometer range require substantially less ultrasound pressure to
induce vaporization than droplets in the nanometer range, presumably due to less
Laplace pressure on the droplet core by interfacial surface tension. Additionally, the
pressure required to vaporize decreases as the compound boiling point decreases. While
increasing the ultrasound frequency has been shown to decrease the pressure needed
to vaporize, higher frequencies will provide less penetration depth into tissues and
will therefore limit the ability to successfully vaporize droplets in deep-tissue targets.
Studies are needed to examine optimization of droplet vaporization as a function of
frequency for deep-tissue targets in vitro and in vivo. For some applications, the ability
to vaporize droplets from the lowest possible pressures would be ideal. In these cases,
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the droplets should be made from the PFC with the lowest possible boiling point
that allows for stable circulation at physiological temperatures. For some therapeutic
applications, the pressures used are already relatively high to create desired bioeffects,
and droplets should remain stable until a desired activation pulse is delivered. For these
applications, PFCs with a higher boiling point may be more suitable.
Most studies have shown that for applications such as vascular occlusion and aber-
ration correction, microscale dodecafluoropentane- based droplets appear to be suffi-
ciently stable and are able to be vaporized in vitro at pressures within what diagnostic
imaging machines typically provide [75; 76], although the pressures used to vaporize in
vivo can be much higher [85]. DDFP and perfluorohexane (PFH) have been the most
commonly-studied PFCs for use with nanoscale droplets. At these sizes, the optimal
PFC choice is chiefly application-dependent. In a study with DDFP nanoemulsions
for the purposes of enhancing thermal delivery to tumors and creating focal lesions,
Zhang and Porter suggest that as the temperature rises in tissues, the nanodroplets
just outside of the focal region may vaporize more easily and lead to unpredictable
prefocal lesions [114]. A PFC with a higher boiling point, such as PFH, may prove
better in this case, as it could still be vaporized and would lead to more predictable
lesion formation. For co-imaging with 19F MR, a PFC with a higher number of Fluorine
atoms per molecule may be desirable, although PFCs with more Fluorine atoms also
have higher boiling points [53].
For some applications in both the nanometer and micrometer size regimes, it might
be beneficial for the vaporization to occur at lower pressures than DDFP allows. Di-
agnostic image enhancement of tumors by extravasated nanodroplets requires that the
droplets can be activated with little to no bioeffects, and by parameters within the
range of a clinical imaging system. In addition, the degree of drug delivery or vascu-
lar occlusion from PCCAs is dictated partly by the efficiency of vaporization within
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the focal region, and so lower thresholds may lead to a greater number of vaporized
droplets and increased drug delivery and/or flow reduction. A number of the previously
mentioned in vitro studies have shown that DDFP droplets have remarkable stability
at body temperature, even though the bulk boiling point of DDFP is much lower than
body temperature. A study by Giesecke and Hynynen demonstrated that vaporizing
micron-sized albumin-coated DDFP droplets by heat alone required temperatures as
much as 40◦C above the typical boiling point of DDFP as a bulk fluid [73], and the
difference may increase as droplet size is reduced to the nanometer range. Therefore,
methods of making PCCAs inherently more sensitive to ultrasound energy are necessary
for expanding use toward diagnostic applications. This may be possible by including
agents to facilitate nucleation within the droplet core (reducing the purity of the PFC),
or by choosing alternative compounds that require less energy to vaporize.
One additional method of droplet design is to alter the amount of energy needed to
vaporize a specific droplet by creating a mixture of PFCs with different boiling points.
This technique was first proposed by Kawabata and colleagues, who demonstrated that
mixing DDFP (b.p. 29◦C) and 2H,3H-DDFP (b.p. 53◦C) resulted in a droplet that
required more energy to vaporized than if it contained only DDFP, but less than if it
contained only 2H,3H-DDFP [86]. This technique could be useful in designing PCCAs
for an optimal trade-off between stability in circulation and pressure required to induce
vaporization.
1.5 In Vivo Studies
Although fewer articles are available for phase-change contrast agents compared to
microbubbles and inert liquid PFC emulsions, a high proportion of the studies have
shown promising in vivo results for a variety of animal models and anatomical targets -
summarized in Table 1.3. In general, researchers have shown that PCCAs are able to be
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Figure 1.6: Demonstration of drug delivery by the interaction of ultrasound and drug-
loaded nanodroplets/micelles. A nu/nu mouse bearing two ovarian carcinoma tumors
immediately before (A) and 3 weeks after the treatment (B). The mouse was treated
by four systemic injections of paclitaxel-loaded nanodroplets given twice weekly, while
only the right tumor was sonicated by 1 MHz continuous-wave ultrasound 4 hours after
the injection. The left tumor grew at the same rate as the controls, while the right
tumor regressed, demonstrating paclitaxel release into the tumor volume. Reprinted
from J Control Release, Vol. 138, Rapoport NY, Kennedy AM, Shea JE, Scaife CL,
Nam KH, “Controlled and targeted tumor chemotherapy by ultrasound-activated na-
noemulsions/microbubbles”, 268-76 (2009), with permission from Elsevier.
vaporized in vivo to produce desired effects such as reduced blood perfusion and ther-
apeutic drug delivery (Figure 1.6). In a few instances, droplet-induced bioeffects were
observed. An early occlusion-based study by Kripfgans and colleagues using a rabbit
model showed that filtering droplet emulsions to transcapillary sizes (99.99% < 6 µm in
diameter) and lowering doses to approximately 2×107 droplets/kg eliminated instances
of pulmonary hyperinflation [92]. They suggest that because the rabbit model may be
more susceptible to this bioeffect [133], it may be possible to use much higher doses for
greater embolization in humans. Another occlusion-based study in a canine model by
Zhang and colleagues noted instances of cardiac arrhythmia and one instance of animal
death when droplets (99.9% < 10 µm in diameter) were administered in doses on the
order of 1×108 droplets/kg to 4×108 droplets/kg through an intracardiac method [85].
The effect seemed to stabilize once animals were placed on forced ventilation. They
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hypothesized that these effects were a result of droplets occluding a coronary arteri-
ole, inducing ischemia. Although no cardiac arrhythmia was observed for intravenous
administration, doses approaching 2 × 109 droplets/kg resulted in respiratory distress
and changes in blood chemistry. A dose of 3× 109 droplets/kg of droplets this size (a
total perfluorocarbon dose of 0.2 g/kg) was determined to be fatal to the canines. In
a recent study by Zhang and colleagues aimed at assessing microscale DDFP droplets
for thermal ablation, a dose of 1 × 108 droplets/kg (99% < 8 µm in diameter) was
administered intravenously in a canine model and no adverse bioeffects were reported
[54]. All other studies noted no significant undesired bioeffects. Future studies are
needed to optimize ultrasonic vaporization in vivo.
While these in vivo studies have given ample evidence of the breadth that the
PCCA platform may provide for future use in humans, more preclinical studies are
needed to evaluate the potential for bioeffects as a result of PCCA administration.
Characterizing the chemical effects of PFCs, possibility of vascular damage by very
large bubbles, stability of agents in circulation, and ultrasound-induced effects from
PCCAs combined with high pressures and/or pulse lengths will be vital in moving
the platform toward clinical studies. For applications involving droplets extravasated
via the EPR effect, the impact of diffusion gradients and uneven interstitial pressure
within the tumor on the accumulation and delivery of drug payloads requires further
investigation [93; 134].
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1.6 Current Challenges
A thorough literature review of the current state of PCCAs reveals several areas to
fundamentally improve the clinical potential of the PCCA platform:
1. Overcoming the Increase in Vaporization Energy at Nanoscale: In some
of the earliest publications surrounding PCCAs, investigators assumed that droplets
would vaporize once the ambient temperature was greater than the boiling point
of the PFC core (typically DDFP) [51; 52; 63]. Further investigation revealed
that DDFP droplets not only remained in the liquid state once exposed to phys-
iological temperatures (37 ◦C), but only vaporized once exposed to temperatures
at least 40 ◦C above their normal boiling point [73]. In addition, the droplets also
required fairly significant acoustic pressures to vaporize that increased as droplet
diameter decreased [71; 75; 76]. The delay in thermal vaporization may be in part
due to the purity of the PFC allowing the droplet to exist in a superheated state
for much longer than anticipated [136], but it is expected that Laplace pressure is
one of the primary mechanisms of the increasing vaporization threshold as droplet
size diminishes (eqn. 1.1). The increase in boiling point that results from this
at the nanoscale is directly related to the acoustic energy required to vaporize
a droplet. This explains the generally high vaporization thresholds reported for
nanoscale PCCAs of DDFP - activation pressures large enough in magnitude to
prevent conventional formulations from being used for diagnostic and molecular
imaging purposes. Even for therapeutic purposes where higher ultrasound energy
delivery into tissue is acceptable, this effect translates to a decrease in general
efficiency of vaporization. Methods that reduce these vaporization thresholds will
be vital to increasing the effectiveness of PCCAs in therapeutic applications and
expanding their use toward diagnostic applications.
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2. Increasing the Uniformity of Activation: Because the activation pressure
of a droplet depends on the initial diameter, polydisperse distributions result in
non-uniform activation. The techniques involved in preparing sub-micron emul-
sions typically yield polydisperse distributions, but for applications involving mi-
croscale droplets the uniformity of response (and therefore the effectiveness of
the treatment) may be improved by creating monodisperse distributions through
techniques such as microfluidic particle generation.
3. Tailoring Droplet Performance to Desired Application: Nearly all the
studies to date have investigated PCCAs composed of a single perfluorocarbon.
Although not well explored in the literature, the ability to manipulate the in-
terplay of vaporization energy and thermal stability (resistance to spontaneous
vaporization) for a droplet are essential in order to maximize the performance for
a given application. As the range of applications is wide and continues to grow
yearly, designing an agent that is optimally stable and one that vaporizes with
ideal pressures may require a careful balance of effects. Choosing single perflu-
orocarbon species inherently limits the researcher to discrete points in the sen-
sitivity/stability continuum, and so developing methods to more precisely ‘tune’
droplets will be essential in clinical translation.
4. Determining Appropriate Activation Thresholds for Polydisperse Sub-
micron Distributions: Most studies aimed at determining appropriate acti-
vation thresholds in vitro and in vivo are either unable to resolve sub-micron
particles (primarily optical methods), or are highly influenced by large outliers in
the distributions (primarily acoustic methods). This makes assessing activation
thresholds for the typically broad nanoscale distributions challenging, and results
in high variability in studies across different groups [61]. Alternative measures
of activation thresholds are needed in order to efficiently activate polydisperse
30
nanoscale emulsions in vivo.
5. Isolation of Signals Specific to PCCAs for in vivo Detection of Activa-
tion: The nonlinear oscillations produced by conventional microbubble contrast
agents while under the influence of an ultrasonic pulse can be easily detected and
isolated from tissue through a variety of techniques (see Section 1.1). However,
no such ‘signature’ exists for PCCAs that allows differentiation from tissue or
standard microbubbles. If such a signature were to be discovered, it would enable
new forms of ultrasound contrast imaging and would allow spatial and tempo-
ral mapping of PCCA activation to correlate with therapeutic and/or diagnostic
goals.
6. Demonstration of Utility for Diagnostic and Molecular Imaging Pur-
poses: A wealth of studies have shown the utility of PCCAs as therapeutic
agents. However, as a result of the relatively high vaporization thresholds for
typical PCCA formulations, few studies have shown that they can be used as
purely diagnostic agents (that is, their use as agents to generate imaging con-
trast) or molecular imaging agents. If vaporization thresholds can be reduced,
demonstrations of the diagnostic potential of PCCAs will greatly aid the push
toward clinical use.
1.7 Thesis Outline
In the following chapters we present techniques to modify the performance of phase-
change contrast agents for ultrasound and demonstrate new methods of characterizing
activation optically and acoustically. We hypothesize that these techniques will afford
increased efficacy in therapeutic applications of ultrasound, and that they will enable
previously unexplored applications in diagnostic and molecular imaging.
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We first address the need to develop PCCAs inherently more sensitive to ultrasound
energy by exploring the incorporation of more volatile compounds than had previously
been considered in the literature. In Chapter 2 we first treat the Laplace pressure in-
crease theoretically to explore alternative perfluorocarbons to form the droplet core, and
then provide proof-of-principle that droplets can be crafted from these compounds, re-
sulting in emulsions with reduced vaporization thresholds compared to similar droplets
of DDFP or PFH.
In Chapter 3, we present a novel particle generation technique termed ‘microbubble
condensation’ that allows formation of nanoscale emulsions from volatile perfluorocar-
bons (i.e. that exist as a gas at room temperature). By first generating a population of
perfluorocarbon microbubbles ideal for ultrasound interaction, PCCAs can be formed
by condensing the gaseous precursors to the liquid state through a combination of de-
creased ambient temperature and increased ambient pressure. We demonstrate that
the resulting droplets have size distribution peaks on the order of 200-300 nm in diam-
eter, and can be vaporized with ultrasound pressures within the limits of those set for
clinical diagnostic imaging. Once vaporized, the particles expand to form bubbles of
ideal size for ultrasound imaging and therapy.
In Chapter 4 we explore the inherent tradeoffs involved with forming PCCAs
from volatile compounds. Though gains are made with regard to reduced vaporiza-
tion thresholds, in vitro thermal stability of the emulsions decrease as PFC volatility
increases, which suggests reduced circulation profiles in vivo. We show that the sensi-
tivity to ultrasound energy and the thermal stability of an emulsion can be modified
by creating PFC mixtures during microbubble condensation - allowing fine-tuning of
the droplet performance for the intended application.
Methods to measure vaporization thresholds typically take two forms - physical
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(e.g. optical verification of individual droplet vaporization events) or phenomenolog-
ical (e.g. measure of ultrasound backscatter produced after a vaporization pulse has
been delivered). Both of these are limited for the typically broad distributions of
nanoscale emulsions. In physical (optical) methods, the initial size of the droplets is
below the wavelength of visible light, and therefore unresolvable. Phenomenological
methods are often highly skewed by the presence of large outliers in the distribution,
and so associating the measurement with a representative size is not straightforward.
In Chapter 5 we present an alternative method of assessing in vitro activation thresh-
olds for nanoscale emulsions based on optical measurements of the change in resulting
bubble distribution with increasing ultrasound pressure. We also give preliminary ev-
idence that once droplets are vaporized, they may be destroyed or made to fuse with
nearby bubbles by the continuing vaporization pulse - highlighting the importance of
optimized vaporization pulse sequences.
In Chapter 6 we demonstrate that the underlying physics of droplet vaporization
and expansion can, under certain conditions, produce new acoustic information that
can be detected and differentiated from typical tissue and microbubble signals. When
droplets formed from volatile compounds are activated with brief ultrasonic pulses,
the momentum of expansion drives the bubbles to overexpand and oscillate to a final
bubble diameter. These oscillations produce exponentially decaying sinusoids on the
order of 1 MHz with size-dependent frequency and amplitude properties that can be
captured with an ultrasonic transducer. A simple droplet-detection algorithm is imple-
mented to characterize activation as a function of peak negative pressure and droplet
concentration.
As a demonstration of the potential of microbubble condensation and PCCAs de-
rived from volatile perfluorocarbons, in Chapter 7 we perform a simple proof-of-
principle showing the ability to target droplets to molecular expression of angiogenesis
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in the HUVEC cell line. We first generate targeted droplets by modifying the precursor
bubbles to contain targeting ligands and then revert the particles to the liquid state.
After a period of incubation with the cells, we are able to assess the level of angiogenic
expression by activating the droplets with a clinical diagnostic ultrasound machine.
In Chapter 8 we summarize our ongoing in vivo work to assess circulation profiles
and imaging contrast generated using custom imaging sequences from a diagnostic
ultrasound probe, and frame the future of PCCA development in the context of the
platform improvements demonstrated in this thesis.
Although not an integral portion of this thesis, we have included an appendix of 6 ad-
ditional studies that stem from the concepts and improvements herein. In Appendices
B, C, and D we use the microfluidics platform to generate monodisperse microscale
droplets of DDFP encapsulated in a phospholipid shell. The results show that when
the size distributions are monodisperse, activation thresholds are highly uniform from
droplet to droplet. For applications requiring microscale droplets (such as temporary
embolization), this will translate to an increased efficiency of vaporization compared
to polydisperse distributions. In Appendix D we demonstrate that the microflu-
idics approach can generate sub-micron emulsions under certain conditions, although
monodispersity is not preserved. In Appendix E we give evidence of the benefit of
generating emulsions with greater sensitivity to ultrasound by demonstrating that PC-
CAs derived from volatile perfluorocarbons can induce temporary blood-brain barrier
opening by low-intensity transcranial focused ultrasound in mice, enabling new tech-
niques in drug delivery. In Appendices F and G we show in vitro that PFC mixing
in conjunction with microbubble condensation can create agents ideal for ultrasound-
mediated tissue ablation - having ideal vaporization thresholds and thermal stability
for ablation procedures.
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CHAPTER 2
PCCAs Composed of Low Boiling Point Perfluorocarbons
2.1 Introduction
FDA-approved microbubble contrast agents are commonly produced with the ma-
jority of the population between 1 and 5 µm in diameter to allow for safe passage
through the circulatory system and provide significant contrast for imaging. Many
tumor types exhibit characteristically permeable vasculature, with endothelial gaps
typically between 200 to 600 nm and show poor lymphatic clearance, also known as the
EPR effect [90; 91; 137]. A gas-filled contrast agent small enough to extravasate into
tumor interstitium would ultimately be much less echogenic than commonly studied
microscale MCAs and would provide limited US contrast [138]. Therefore, an agent
capable of clearing inter-endothelial gaps and subsequently being transformed into a
gas-filled MCA would have unique possibilities.
The application of acoustic droplet vaporization is a potential method of designing
c© 2011 World Federation for Ultrasound in Medicine & Biology (wfumb.org) Portions reprinted,
from PS Sheeran, VP Wong, S Luois, RJ McFarland, WD Ross, S Feingold, TO Matsunaga, and
PA Dayton. “Decafluorobutane as a Phase-Change Contrast Agent for Low-Energy Extravascular
Ultrasonic Imaging” Ultrasound Med Biol, 2011 Sept; 37(9): 1518-1530.
c© 2011 American Chemical Society (acs.org) Portions reprinted, from PS Sheeran, S Luois, PA
Dayton, and TO Matsunaga. “Formulation and Acoustic Studies of a New Phase-Shift Agent for
Diagnostic and Therapeutic Ultrasound” Langmuir, 2011 July; 27: 10412-10420.
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a contrast agent that can exploit the EPR effect and provide imaging contrast in tumor
extravascular space. In brief, the vaporization of a liquid droplet depends primarily on
the properties of the surrounding fluid (viscosity, ambient temperature and pressure),
the droplet diameter, and the energy introduced into the system (heating, mechani-
cal energy) (see Table 1.2). Often a lipid or polymer shell is used to both stabilize
the droplet from coalescence and to alter the droplet surface tension. Most studies
involving ADV-based liposomal nano/micro-emulsions have used either stabilized or
superheated liquids in the perfluorocarbon (PFC) family, as many have boiling points
near physiologic temperatures and are similar to commonly-used MCA perfluorocar-
bons that have significant advantages in imaging applications with less toxicity at the
small volumes used [1]. The most common PFCs used to date, dodecafluoropentane
and perfluorohexane (PFH), are liquids at room temperature. When encased in lipid
or polymer shells, nano/micro-emulsions of DDFP and PFH are able to stay in solution
at body temperature and can be activated by additional energy input.
An agent with sufficient stability to extravasate into the extracellular space, yet
labile enough to be vaporized at sufficiently low acoustic intensities so as to not induce
unwanted bioeffects would be optimal. Most studies of phase-change contrast agents
to date have shown that DDFP droplets near the desired size range vaporize with the
least energy input compared with alternative compounds. The input pressure needed
to vaporize them can be lowered even further by altering the duration of the excitation
acoustic pulse [74]. By using ultrasound frequencies above 1 MHz and pulse lengths in
the millisecond range, micron-sized droplets can be vaporized with pressures considered
safe for diagnostic procedures [75]. However, data suggest that the vaporization of sub-
micron droplets may require substantially more energy.
Thus, sub-micron ADV, which requires high mechanical indices, would enhance
the possibility of bioeffects, an undesirable side effect for imaging-only applications.
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Choosing alternative lower boiling point PFCs could lower the vaporization threshold
for sub-micron droplets, although they then have the potential to be relatively unstable
compared with their higher boiling point counterparts. In some applications, such as
thermal ablation enhancement, droplet stability through a range of temperatures above
37 ◦C may be a priority over low vaporization thresholds [114].
In this chapter, it is demonstrated that low boiling point perfluorocarbons can be
manipulated to achieve the desired low vaporization threshold. Theoretical estimations
of boiling point elevation are used to reveal that two previously unused compounds -
decafluorobutane (DFB) and octafluoropropane (OFP) - may be able to be formed into
metastable droplets that remain in the liquid state at body temperature. DFB, for
example, has a boiling point of -1.7 ◦C, significantly lower than other PFCs commonly
used in ADV, which may allow vaporization at much lower pressures. This could,
in turn, significantly decrease the chance of unwanted bioeffects due to ultrasound
exposure. To date, no study of phase-change contrast agents has explored the use of
these compounds, which are used as the gas core component in several MCAs approved
for clinical applications. The aim of this study is to develop a better understanding
of the trade-offs inherent in choosing a lower boiling-point PFC. The results show
the ability to produce stable lipid-encapsulated phase-change agents of DFB that can
vaporize at lower pressures than similarly sized emulsions of higher boiling-point PFCs.
2.2 Materials & Methods
2.2.1 Theory
To investigate alternative compounds with potential as a phase-change contrast
agents at physiologic temperatures, pilot study calculations were performed using the
Antoine vapor-pressure equation, which was derived from the Clausius-Clapeyron re-
lation by Antoine in 1888 and when re-arranged for temperature is expressed as eqn.
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1.2. This equation uses experimental results to develop a basic relationship between
temperature and pressure as a droplet of a particular substance vaporizes. Following
reasoning outlined by Rapoport et al., a droplet will experience an additional pressure
due to interfacial surface tension effects, defined as the Laplace pressure (eqn. 1.1)
[112]. PFCs typically have fairly low surface tension values against air (on the order
of 10 mN/m at room temperature), but high surface tension against aqueous solutions
(on the order of 60 mN/m). Because the Laplace pressure is an inverse function of
radius, smaller droplets will experience greater pressure. Encapsulating the droplets in
a lipid or polymer shell stabilizes the droplets from coalescence and alters the interfacial
surface tension. Depending on the properties of the encapsulating shell, a larger re-
sulting surface tension may cause an increase in the pressure exerted, which essentially
increases the vaporization temperature of the droplet. In designing agents for human
medical imaging purposes, the ambient pressure may be defined as
Pamb = Patm + Pbody (2.1)
where Patm = 101.325 kPa and Pbody is a representative pressure inside the human
body (vascular or other). Although intravascular pressure is inherently pulsatile, for
the purposes of these calculations, an average value of Pbody = 12.67 kPa was used.
With a total pressure exerted on the droplet of:
P = Pamb + ∆P = Patm + Pbody +
2σ
r
(2.2)
The resulting modified Antoine vapor-pressure equation is:
T =
B
A− log (Patm + Pbody + 2σr )
− C (2.3)
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Published surface tensions often vary between 25 mN/m and 50-60 mN/m, depend-
ing on surfactant properties [139; 140]. Although the exact surface tension of lipid
solutions used in this study were not known, a value near 51 mN/m was sufficient for
the purposes of these initial calculations in that it provided a Laplace pressure near
the upper limit of what can be expected. The constants A, B and C were gathered
from the National Institute of Standards and Technology (NIST) Chemistry WebBook
[19] for the nearest available temperature range. Figure 2.1 shows the relationship be-
tween droplet diameter and predicted vaporization temperature for octafluoropropane,
decafluorobutane, dodecafluoropentane, and perfluorohexane (natural boiling points of
-37.6 ◦C, -1.7 ◦C, 29◦C and 56.6◦C, respectively). While the constants used are not
expected to predict the vaporization relationship completely accurately in the desired
temperature range, the calculation shows that DFB droplets appear to have the poten-
tial to remain stable in the 200 − 600 nm diameter range at temperatures just above
body temperature. This suggests that they may require a small amount of additional
energy (such as US) to induce vaporization compared with other PFCs, if droplets
can be generated stably. Although the temperature required to induce vaporization
increases substantially for droplets near 200− 300 nm in diameter, others have shown
successful vaporization of droplets through ultrasonic energy at temperatures as much
as 40◦C below their boiling point, as in the case of perfluorohexane droplets vaporizing
at room and body temperature [73; 75]. According to the estimations, octafluoro-
propane droplets have the potential to remain stable at sizes near 200 nm, although
the -37.6 ◦C boiling point presents significant production challenges. With a boiling
point of -1.7 ◦C, DFB droplet generation can be explored under more practical experi-
mental conditions.
Ideal gas laws (PV = nRT , where n, P , V , and T represent the number of moles
of PFC, pressure, volume and temperature, respectively) can be used to approximate
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Figure 2.1: Predicted vaporization temperature of lipid encapsulated perfluorocarbons
based on Antoine vapor pressure equation. As droplet diameter decreases, the temper-
ature required to vaporize increases exponentially.
the expansion factor when a liquid undergoes a phase conversion to the gaseous state.
Because perfluorocarbons are immiscible in the liquid state and have low diffusivity in
the gaseous state, it is assumed that the number of moles is constant from the liquid
phase to the gaseous phase (nl = ng). The moles of PFC in the spherical droplet can
be computed as
nl =
4pir3l ρl
3M
(2.4)
where rl is the radius of the liquid droplet, ρl is the liquid density and M is the
molar mass. Substituting this into the ideal gas law and simplifying as a ratio of the
gas-phase radius to liquid-phase radius gives:
rg
rl
=
3
√
ρlRT
MP
(2.5)
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Expanding with eqn 2.2 gives:
rg
rl
= 3
√
ρlRT
M(Patm + Pbody +
2σ
rg
)
(2.6)
As rg approaches very large values, the surface tension component becomes negli-
gible.
Decafluorobutane has a molar mass of M = 0.238 kg/mol and at 37◦C (310 K)
ρl = 1500 kg/m
3. Evaluating eqn 2.6 with in vivo (Pbody = 12.67 kPa) and in vitro
(Pbody = 0 kPa) conditions and neglecting surface tension effects reveals that, based on
the assumptions given, a droplet of DFB can be predicted to expand to an approximate
upper limit of 5.2 to 5.4 times its original diameter once vaporized (neglecting any
deviations from ideal gas laws). Rearranging eqn 2.6 such that it is solved for liquid
droplet radius becomes:
rl =
3
√
Mr2g [rg(Patm + Pbody) + 2σ]
ρlRT
(2.7)
This allows one, based on ideal gas laws and surface tension effects, to estimate the
size of the droplet that vaporized to become a bubble of a known size. Evans et al.
show that eqn 2.7 can also be solved for rg, providing a numerically equivalent, though
much more complex, solution [70].
2.2.2 Preparation of Micron-Sized Perfluorocarbon Droplets
Lipid thin films were prepared with a cocktail of three different lipids: dipalmi-
toylphosphatidylcholine (DPPC), 1-palmitoyl-2-hydroxy-sn- glycero-3-phosphocholine
(LPC), and 1,2- dipalmitoyl-sn- glycero-3- phosphoethanolamine-N- [methoxy (polyethy-
lene glycol)-2000] (DPPE-PEG-2000) (Avanti Polar Lipids, Alabaster, AL, USA). Chlo-
roform (EMD Chemicals; Gibbstown, NJ, USA) was used to dissolve the lipids, which
were then dried over a stream of nitrogen gas. To remove residual solvent, the lipids
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were stored in vacuo overnight.
The lipid films were rehydrated with approximately 1 mL of (4-(2-hydroxyethyl)
piperazine-1-ethanesulfonic acid) (HEPES) buffer (pH = 7.4) (Sigma-Aldrich, Co., St.
Louis, MO, USA) and sonicated for 10 min in a water bath sonicator (Branson 1510;
Branson Ultrasonic Corporation, Danbury, CT, USA) at 50 to 60◦C. The rehydrated
films were then subjected to 10 freeze-thaw cycles. The solution was then stirred for 10
min at 50 to 60◦C. The resulting concentration of the lipid solution was approximately
20 mg/mL.
Three compounds with boiling points above room temperature were selected for
comparison to decafluorobutane. Perfluoro (2-methyl-3-pentanone) (PFMP), DDFP
and PFH were purchased from FluoroMed (Round Rock, TX, USA). Their physical
properties are listed in Table 2.1 [19]. Each perfluorocarbon was added to the lipid so-
lution and multiple extrusions were performed using an Avanti mini-extruder (Avanti
Polar Lipids, Alabaster, AL, USA) with a 19 mm diameter, 1µm pore size nucle-
pore polycarbonate track-etch membrane filter (Whatman Ltd., Maidstone, Kent, UK)
at room temperature (25◦C). Extrusions were completed after 20 passes through the
membrane filter. Each sample was placed in a 1.5 mL centrifuge tube. Afterwards, the
resulting emulsions underwent centrifugation using a Beckman TJ-6 centrifuge (Beck-
man Coulter, Inc., Brea, CA, USA) for 15 min at 1000 rpm. The emulsions were stored
immediately in the refrigerator (4◦C).
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2.2.3 Experimental Apparatus
A water bath constructed of acrylic was mounted on top of an inverted microscope
(Olympus IX71) and interfaced with a high-speed camera (FastCam SA1.1, Photron
USA, Inc., San Diego, CA, USA) to capture monochrome videos and still images of
particles and microbubbles (Figure 2.2). A ×100 water immersion objective with a
working distance of 1.5 mm was used to provide image magnification. The optical
resolution of the system was measured to be approximately 0.5 µm, as determined by a
polystyrene latex sphere resolution test (Ted Pella, Inc., Redding, CA, USA). Baseline
water oxygen saturation was measured to be 5 parts per million (PPM) at 37◦C, as
measured by a chemical test kit (Oxygen CHEMets, CHEMetrics, Inc., Calverton, VA,
USA). In the case of degassed experiments, an in-line degasser was allowed to operate
until the water oxygenation in the water tank measured less than or equal to 1.5 PPM.
The water bath was passively heated to a consistent 37◦C by heating water in an
auxiliary tank and continuously pumping it through copper coils lining the main tank
such that vibration in the water bath was minimized. The temperature of the auxiliary
tank was adjusted until the desired temperature of the water in the experiment region of
the main tank along with any additional light-heating was reached. The droplet solution
was pumped through a nearly optically and acoustically transparent cellulose tube with
a 200 µm inner diameter (Spectrum Labs, Inc., Greensboro, NC, USA) using a custom-
built manual injector allowing for precise administration of the droplets into the field of
view. A 3-axis micropositioner (MMO-203; Narishige Group, East Meadow, NY, USA)
was utilized to manipulate the sample holder and, therefore, the droplets/bubbles in
the field of view. By this means we were able to locate and manipulate droplets to stay
on-screen throughout the test and track the resulting bubbles.
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Figure 2.2: Experimental setup for vaporization of perfluorocarbon droplets.
2.2.4 Acoustics
A spherically focused 5 MHz transducer with a focal length of 3.8 cm (IL0506HP;
Valpey Fisher Corp., Hopkinton, MA, USA) was used to insonify droplet samples. The
transducer had -6 dB beam widths of 0.7 mm laterally and 13.2 mm axially for peak
positive pressure, while widths were 1.3 mm laterally and 22.8 mm axially for peak
negative pressure. Waveforms were constructed using an arbitrary waveform generator
(AWG 2021; Tektronix, Inc., Beaverton, OR, USA), which allowed for adjustment of
the transmission waveform pulse length and amplitude. A manually-triggered signal of
adjustable amplitude was used for these experiments consisting of a 10-cycle sinusoid
at 5 MHz resulting in a total insonification time of 2 µs. A synchronization pulse from
the waveform generator was relayed to the high speed camera to trigger a marker with
the acoustic pulse on the digital video. The waveform from the function generator
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was amplified approximately 60 dB using an RF amplifier (A500; ENI, Rochester, NY,
USA) to excite the transducer. For optical-acoustic alignment, the transducer focus was
matched with the optical focus by positioning the tip of a needle hydrophone (HNA-
0400; Onda Corp., Sunnyvale, CA, USA) in center of the microscope field of view. The
transducer was then calibrated at focus over the range of amplitudes used so that the
pressure exerted on the droplets in the field of view was known.
2.2.5 Sizing Droplets
Perfluorocarbon emulsions were prepared for sizing on a Malvern Nano ZS (Malvern
Instruments Ltd., Malvern, Worcestershire, UK). The ZetaSizer was set to automat-
ically detect up to three local distribution peaks (multi-modal). Briefly, a 150 µL
sample was introduced into a 12 mm disposable square polystyrene cuvette and 1 mL
of HEPES buffer was added. The associated software was utilized to help identify the
average sizes of the droplets along with the dispersity and size distributions. Sizing in
the micrometer range was performed with an Accusizer 780A (Particle Sizing Systems,
Santa Barbara, CA) for distribution statistics, with sample volumes of 25− 50 µL.
2.2.6 Analysis of Images
Still images and videos were captured and stored on a computer using proprietary
camera software (PFV; Photron USA, Inc., San Diego, CA, USA). The software was
set to start recording just before the manually triggered ultrasound signal so that
the transition from droplet to bubble could be observed continuously. Image analysis
was performed on the recordings (ImageJ; NIH, Bethesda, MD, USA) to calculate the
diameter of the droplets and resulting bubbles.
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2.2.7 Vaporization Thresholds of Droplets and Expansion
The vaporization threshold of individual PFC droplets was performed by first vent-
ing the undiluted samples with a 20-gauge needle and then diluting in phosphate-
buffered saline (PBS) until only one to two droplets were visible on screen at any
particular time after injection into the cellulose tube. This typically ranged from 1-
20 µL /mL PBS and depended on the concentration of larger droplets present in the
original sample. In the degassed experiments, the PBS, which normally measured
approximately 6 PPM oxygen, was placed under vacuum prior to dilution until the
oxygenation measured less than or equal to 3 PPM so that both the water tank and
diluent were degassed. As larger PFC droplets tended to flow near the bottom of the
cellulose tube due to weight and because the largest droplet on screen vaporizes with
the least amount of energy input, there was little chance of out-of-focus droplets, which
tended to be very small and toward the top of the tube, interfering with vaporization
threshold determination. The droplets were held on screen with the position manip-
ulator and ultrasound pressure in the form of a 2 µm pulse at 5 MHz was increased
in incremental steps of approximately 0.115 MPa with 1 to 2 s of rest time between
each trigger. The earliest pressure that induced observed vaporization was recorded to
correlate to droplet diameter and the tube was shifted by micro-manipulator so that
the focus was fully on the resulting bubble diameter. This diameter of the bubble was
observed and measured over several seconds to capture any phenomena. For analysis,
the pressure that induced vaporization was converted to mechanical index (MI), defined
as:
MI =
Peak Negative Pressure (MPa)√
US Frequency (MHz)
(2.8)
When switching between samples, the cellulose tube was either re-made with new
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tubing or flushed with a sequence of: (1) 1 mL 95% ethanol, (2) 3 mL of air and (3) 1
mL de-ionized water and for tests involving larger droplets inspected optically to ensure
no droplets were present in the remaining fluid.
2.3 Results
Several hundred droplets of DFB, DDFP, PFMP and PFH were insonified with
varying ultrasound pressure at 5 MHz. A total of 153 successfully vaporized droplets
across all PFCs investigated were evaluated for the relationship between initial diameter
and pressure required for vaporization, as well as resulting bubble characteristics.
2.3.1 Droplet Sizing and Optical Verification
DFB, DDFP, PFMP and PFH extrusion through membrane filters resulted in sub-
micron and micron-sized content. The largest DFB droplet observed optically after
being heated to 37◦C over all tests performed was measured to be approximately 13µm
in diameter. Information about initial droplet concentration was not obtained through
the sizing techniques used, but did not affect the results, as each sample was diluted to
an optimal concentration for each test.
2.3.2 Vaporization Threshold for Individual Droplets
Through high-dilution, individual PFC droplets were exposed to ultrasound peak
negative pressures ranging from 1.43 MPa to 4.97 MPa during the course of the 2µs
signal, or a mechanical index between 0.64 and 2.22. Vaporization of DFB, DDFP
and PFMP droplets in the 1 to 30 µm diameter range was recorded optically and the
vaporization threshold plotted as a function of initial droplet diameter (Figure 2.3).
PFH droplets, the largest of which measured approximately 9 µm, were unable to be
vaporized at the pressures used for this study and are not represented in the figure.
Studies by others have shown that PFH can be vaporized in other test conditions and
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size ranges. A minimum of 15 droplets of each PFC were used to curve-fit threshold
values across the size range. The average diameter of both DFB and DDFP droplets
vaporized in this set of experiments was 5±3 µm while PFMP droplets measured an
average of 14±6 µm. As demonstrated by many studies, the vaporization threshold
appeared to increase as the droplet diameter decreased. Curves that produced the best
fits for the vaporized droplets were logarithmic, resulting in R2 values of 0.84, 0.84 and
0.74 for DFB, DDFP and PFMP, respectively. For the smaller droplet sizes observed,
the pressure required to vaporize DDFP and PFMP was approximately 50% and 75%
more than that required for DFB, respectively. As droplet size increased, the difference
in activation pressure compared with DFB decreased, reducing to only 30% and 60%
more pressure for DDFP and PFMP, respectively, for droplets of approximately 10µm.
All micron-sized droplets of DFB were seen to vaporize at a MI lower than 1.5,
while comparable pressures were only able to vaporize droplets greater than 10 µm
in size for both comparison PFCs. The relatively short 2µs pulse was sufficient to
induce vaporization for all PFCs other than PFH. Additionally, bubbles created by
vaporization of DFB droplets were subjected to secondary pulses administered several
seconds after formation, during which no instances of bubble destruction were observed.
2.3.3 Resulting Bubble Diameter
The experimental set-up allowed for verification of specific droplet vaporization,
so resulting bubbles could be correlated directly to the initial droplet diameter. This
continuous observation allowed for noting of any effects that occurred subsequently
to vaporization. Ideal gas laws at these initial sizes predict that the phase change
should result in a gas bubble approximately 5.2 to 5.4 times larger than the original
droplet diameter. During the course of the vaporization thresholds in the un-degassed
experimental setup, it was noticed that the resulting bubbles tended to be much larger
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Figure 2.3: Vaporization threshold of individual droplets as a function of initial droplet
diameter for DFB, DDFB, and PFMP droplets sonicated at 5 MHz with a 2µs pulse.
The curves fit to the measurement points are MI = −0.18 ln(d) + 1.57 for DFB, MI =
−0.34 ln(d) + 2.28 for DDFP, and MI = −0.50 ln(d) + 3.03 for PFMP, where d is the
droplet diameter in µm.
than the predicted size. Because the bubbles were continually observed in an extremely
dilute state, it could be confirmed that this did not occur due to bubble coalescence
after droplet vaporization. The experiment was repeated in a degassed experimental
set-up for both DFB and DDFP and the resulting diameter plotted as a function
of initial diameter (Figure 2.4). The results in the un-degassed experiment follow
an approximately linear fit (R2 = 0.84), while the degassed results show a strongly
linear fit (R2 = 0.98). The average un-degassed expansion over 46 observed droplets
was 10 ± 2 times the original diameter, while the degassed experiment resulted in an
average expansion over 37 droplets of 6± 1 times the original diameter. In both cases
the increase in expansion beyond the predicted values did not appear to depend on
initial droplet diameter. Two videos of individual bubbles observed over a longer time
period were analyzed for both degassed and un-degassed setups. Figure 2.5 shows
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examples of the observed phenomenon in both scenarios. The bubbles in the un-
degassed experiments grew an average of 22% of their original observed diameter over
the experiment duration, while those in the degassed experiments only grew an average
of 4% over the same time period.
Figure 2.4: Bubble size post-vaporization for both DDFP and DFB shows a dependence
on the dissolved gas level of the local fluids. Bubbles in a degassed environment showed
resulting sizes nearer to those predicted by ideal gas laws, while normal tests resulted
in bubbles significantly larger than the predicted size.
2.4 Discussion and Conclusion
In this study, the vaporization threshold for micron sized decafluorobutane droplets
was examined in contrast to other commonly studied perfluorocarbons to determine
efficacy as a candidate phase-change contrast agent in applications such as intra-tumoral
deposition and imaging. The results show that lipid-encapsulated DFB droplets can
be successfully manufactured in the micron range, which implies the ability to produce
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Figure 2.5: Bubble growth from individual droplets observed over several seconds. (a)
through (d) show an approximately 7 µm diameter droplet in a normal test environment
growing to a bubble near 52 µm after 6 s of observation. In a test using degassed
fluids, (e) through (h) show an approximately 8.5 µm diameter droplet growing to
approximately 50 µm after the same time period.
them at sub-micron sizes where increased stability is expected. The additional pressure
exerted by the lipid membrane on the liquid droplet was proven sufficient to keep small-
sized droplets in solution at physiologically relevant temperatures prior to vaporization
by additional energy input, in this case by ultrasound at clinically relevant frequencies
and pressures.
When sized by the Malvern and Accusizer, DFB suspensions yielded content in
both the sub-micrometer and the micrometer size range. Upon exposure to ultrasonic
energy, vaporization of the largest content present in the samples droplets larger than 1
µm, which could be resolved optically was achieved at clinically relevant pressures such
that an inverse relationship between initial diameter and pressure required to vaporize
could be observed. Even when left undiluted and exposed to high mechanical indices,
samples produced by this method did not yield a significant amount of bubbles in the
1 to 5 µm range, suggesting that the sub-micrometer sizings were a small portion of
the total sample, were not viable droplets, were aggregated micelles, or were droplets
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that required higher acoustic pressures than currently used (the highest pressure used
was MI = 2.25). Micrometer-sized droplets were observed to be as large as 13 µm in
diameter on occasion, demonstrating that lipid-encapsulated DFB has the potential to
remain meta-stable at 37 ◦C for a wide range of sizes relevant to medical imaging and
therapeutic applications. That droplets this large existed after extrusion through a 1 µm
pore membrane may be due to some coalescence, but it is expected that this is primarily
a result of the low perfluorocarbon surface tension. This taken in conjunction with the
high lipid concentrations used in this formulation and the lack of small bubbles upon
acoustic energy provide evidence that the sub-micrometer content most likely consists
of naturally forming vesicles rather than DFB droplets.
These results serve as an early indicator of the high potential of low boiling point
perfluorocarbons as future phase-change contrast agents, especially for extravascular
applications. The curve fit to the thresholds of individual droplets predicts an increasing
gap in the energy difference needed to vaporize DFB when compared with its higher
boiling point counterparts as the droplet diameter decreases. For example, a 300 nm
droplet of DDFP with the same short waveform and frequency used in these tests is
predicted by the curve fits to require approximately a MI of 2.69 to vaporize, while a
DFB droplet is only predicted to require a MI of 1.78, below the current clinical limit
of 1.9 for diagnostic imaging. The demonstrated threshold values for DDFP seem to be
consistent within the range reported by others in similar experiments, although longer
pulse lengths were used in most other studies.
The pulse lengths used in this study were relatively short, so that the temperature
increase induced by the acoustic signal can be assumed to be negligible. This implies
that the thresholds observed by this study were primarily due to absolute pressure and
any mechanical interactions that may be occurring [77]. Whether or not the curves fit
to vaporization thresholds accurately predict the pressure required for submicron-sized
53
droplets of both DDFP and DFB necessitates further studies. It can be reasonably
argued that as the diameter of the droplet is reduced into the nanometer range, the
observed effects at the micrometer scale will not hold.
The observation that bubbles tended to be larger than anticipated in a gas-saturated
environment matches that of Kripfgans et al. [71]. Their study posits that the resulting
bubbles may expand due to absorption of dissolved gases present in the host fluid,
which is in line with our observation of gradual bubble growth over a several-second
time period. We were able to optically observe the transition of individual droplets
into the resulting bubbles and confirm that almost immediately after vaporization was
induced, the resulting bubble was larger than that predicted by ideal gas laws. The
optical set-up also allowed for confirmation that bubbles were not the result of the
effects of coalescence. In the case of undegassed fluid, the resulting bubble averaged
an expansion factor of 10 over initial droplet size, while in the degassed set-up the
expansion factor was 6. We hypothesize that the expansion factor observed with the
degassed set-up, which was higher than ideal gas predictions, was likely due to the
diffusion of dissolved gas still present (oxygenation measured at 1.5 PPM). In both
cases, the measurements were made within seconds after vaporization and even after
this measurement the bubbles appeared to still be growing in diameter gradually. We
estimated that the growth rate was four to five times as quick in the case of un-degassed
fluid, which explains the higher variation in the measured expansion factor (some may
have had more time to expand than others prior to measurement). The presence of a
lipid shell could serve to damp the intake of dissolved gases and result in gradual growth
over a much longer period after vaporization, although determining whether bubbles
approach a maximal or steady-state size will require future studies. The initial results
suggest that ADV agents may experience a similar effect post-vaporization with regard
to gas-saturation levels as Kwan and Borden recently showed for gas-filled MCAs [142].
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In applications where an upper limit on bubble size is essential, thorough studies of
the effect of local gas-saturation will be needed to ensure that the bubble does not
expand to beyond the required size and cause unwanted effects. Although some tumors
are known to be hypoxic, they cannot be assumed to be gas-free and, therefore, an
expansion beyond that predicted by ideal gas laws may be observed in practice.
Evaluating eqn 2.7 for differing parameter values reveals the effect of scaling on the
interplay of ambient pressure and Laplace pressure (Figure 2.6). For droplets in the
nanometer size range, surface tension effects become dominant and the largest expan-
sion is predicted by the lowest surface tension. A transition occurs at the low microm-
eter range, resulting in ambient pressure becoming the dominant effect on expansion
for larger droplets. The largest expansion in this region can be predicted by the lowest
ambient pressure. Additionally, a sharp decline in the expansion factor is observed as
droplet sizes approach the lower nanometer range. This can have fundamental implica-
tions in design of phase-change contrast agents for purposes of extravasation. To take
advantage of the EPR effect, droplets of 100 to 200 nm in size would be ideal, resulting
in enhanced intratumoral diffusion. However, once these droplets are vaporized, they
may only increase by a factor of 2.5 to 3.5 times the original diameter, resulting in bub-
bles on the order of 250 to 700 nm. While bubbles of this size may still be useful for
cavitation-based effects and enhancing thermal therapy or drug delivery, they are much
smaller than preferable for diagnostic imaging, where bubbles are ideally on the order
of 1 to 5 µm. Through post-extravasation droplet/bubble coalescence, these may still
provide increased echogenicity, although no studies have characterized to what degree
this type of coalescence may actually occur in vivo. Therefore, there exists a design
trade-off in echogenicity and droplet diffusivity. Droplets near 250 to 350 nm in size
may still diffuse into interstitial space due the EPR effect and will produce bubbles on
the order of 1 µm or greater, providing ideal image enhancement for applications such
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as early tumor detection and real-time confirmation of targeted therapeutic delivery.
Figure 2.6: Effect of droplet size on expansion factor according to ideal gas laws with
Laplace pressure included. Calculations are presented for two variations of both am-
bient pressure (Pin−vitro = Patm;Pin−vivo = Patm + Pbody) and surface tension (σ1 = 30
mN/m; σ2 = 51 mN/m). Droplets on the order of 10 µm can be expected to expand
less in vivo than in vitro regardless of surface tension, while droplets 500 nm or less
will expand less at higher surface tension values.
In all of the tests on DFB droplets, short pulse lengths appeared to be adequate to
activate both droplets at clinically relevant pressures. In practice, it may be possible
to further reduce the likelihood of unwanted bioeffects by creating a custom activa-
tion/imaging pulse. A brief “activation” pulse could be delivered at the front-end of
each frame acquisition followed by gathering of image lines at a much lower MI, rather
than imaging at the “activation” MI for the entirety of the imaging session. This is
similar to commonly employed functional diagnostic imaging schemes centered on con-
trast agent perfusion imaging in kidney and tumor vasculature, where a high-MI pulse
is used to destroy contrast agents and lower-MI pulses are used to image the subsequent
56
vascular reperfusion.
It has been shown that decafluorobutane can be successfully generated as lipid-
encapsulated micron sized droplets that remain in a superheated, metastable state at
physiologic temperatures. Most studies of phase-change contrast agents to date have
chosen PFCs that are liquids at room temperature, presumably due to simplicity of
droplet generation. This study is the first to explore the use of lower boiling-point
PFCs by using shell encapsulation to produce stable liquid droplets from PFCs that are
normally gas at room and body temperature. Phase-change contrast agents based on
low boiling point PFCs show significant potential for applications such as intratumoral
deposition of chemotherapeutics and the imaging of interstitial space.
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CHAPTER 3
Microbubble Condensation
3.1 Introduction
In the previous chapter, proof-of-principle was given that low boiling point perflu-
orocarbons can be used to generate PCCAs, resulting in greatly reduced vaporization
thresholds. However, the extrusion-based method was not capable of producing pre-
dominantly sub-micron droplets. Many of the applications proposed for PCCAs involve
their potential for use as extravascular agents. Work by others involving nanodroplets
capable of diffusing past the vascular endothelial membrane in solid tumors for the pur-
pose of ADV or as liquid ultrasound scatterers has typically utilized perfluorocarbons
with boiling points above room temperature (22◦C) and relied on extrusion or emul-
sification to generate droplets [114; 52; 86; 143]. Initial studies in the laboratory of
Rapoport and co-workers [52] used the Antoine vapor pressure equation [144] to assess
the theoretical vaporization temperature dependence upon droplet diameter of selected
c© 2011 World Federation for Ultrasound in Medicine & Biology (wfumb.org) Portions reprinted,
from PS Sheeran, VP Wong, S Luois, RJ McFarland, WD Ross, S Feingold, TO Matsunaga, and
PA Dayton. “Decafluorobutane as a Phase-Change Contrast Agent for Low-Energy Extravascular
Ultrasonic Imaging” Ultrasound Med Biol, 2011 Sept; 37(9): 1518-1530.
c© 2011 American Chemical Society (acs.org) Portions reprinted, from PS Sheeran, S Luois, PA
Dayton, and TO Matsunaga. “Formulation and Acoustic Studies of a New Phase-Shift Agent for
Diagnostic and Therapeutic Ultrasound” Langmuir, 2011 July; 27: 10412-10420.
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perfluorocarbons as a result of the influence of interfacial surface tension. They con-
cluded that the temperatures required to vaporize smaller droplets increased geometri-
cally as droplet size decreased into the sub-micrometer range. Extending this model to
investigate the influence of perfluorocarbon boiling points reveals that less volatile PFC
compounds such as dodecafluoropentane, perfluorohexane, perfluoroheptane, etc., may
require a relatively large amount of energy in order to elicit droplet vaporization at
a size that would practically be able to extravasate through endothelial gap junctions
into the extravascular space (see Figure 2.1). Assuming a correlation between the tem-
perature increase over body temperature needed to vaporize and ultrasound energies,
the lower boiling PFCs, such as decafluorobutane and octafluoropropane, may be more
attractive for certain applications since the acoustic energy required to induce ADV
would be significantly less. This issue becomes especially important when designing an
agent for extravascular diagnostic ultrasound imaging, as high acoustic energies may
result in unwanted bioeffects.
However, utilization of decafluorobutane (boiling point from -1.1 to -2 ◦C)[19] and
other compounds with boiling points far below physiological and room temperatures can
make stabilized droplet formulation somewhat challenging. Nonetheless, should these
PFCs be successfully condensed and stabilized, their utility as ultrasound-mediated
bubble precursors for extravascular applications would expand the possibilities of diag-
nostic ultrasound imaging and drug delivery. An ideal extravascular ultrasound con-
trast agent for applications where thermal and cavitation-based bioeffects are mini-
mized should be (1) stable in the vasculature for a sufficient time period, (2) capable
of extravasation out of the vascular space, and (3) labile enough to be activated and
interrogated by clinical ultrasound machines at clinically relevant acoustic intensities.
This chapter details development of decafluorobutane nanodroplets with the afore-
mentioned characteristics in mind using a novel particle generation technique. The
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new technique, which we have termed “microbubble condensation”, involves a simple
process of first generating lipid-coated microbubbles through standard agitation-based
techniques [145] followed by ambient air pressurization and slow cooling to condense
the gas core of the microbubbles, resulting in sub-micrometer liquid droplets. This
offers the advantage of making smaller, more uniform droplet sizes with peaks on the
order of 200 to 300 nm, small enough for potential extravasation into solid tumors.
Vaporization of the droplets generated is performed at acoustic energy parameters
compatible with clinical diagnostic ultrasound machines. When exposed in vitro to a
2 µs ultrasound pulse at 5 MHz and MI = 1.2, the generated nanodroplets yield a dis-
tribution of microbubbles that corresponds well with expected expansion of the initial
droplets through ideal gas law predictions with surface tension effects included [70].
These results indicate the potential usefulness of decafluorobutane nanodroplets as an
ultrasound contrast agent for extravascular imaging.
3.2 Materials & Methods
3.2.1 Nanodroplet Formulation via Microbubble Condensation
Decafluorobutane microbubbles were formulated by dissolution of 1,2-dipalmitoyl-
sn-glycero-3- phosphatidyl choline (DPPC), 1,2-dipalmitoyl- sn-glycero- 3- phosphatidyl
ethanolamine- polyethylene glycol- 2000 (DPPE-PEG-2000), and 1,2-dipalmitoyl-3-
trimethyl ammonium propane (chloride salt; 16:0 TAP) in a molar ratio of 65:5:30
and a total lipid concentration of 0.75, 1.5, and 3 mg/mL. The excipient liquid was
comprised of propylene glycol, glycerol, and normal saline (15:5:80). After adding 1.5
mL of the resulting solution to a 2 mL vial, microbubbles were formed via agitation
using a Vialmix shaker (Bristol-Myers-Squibb, New York, NY) for 45 s. The 2 mL
vial containing the formed microbubbles were then immersed in an isopropanol bath
controlled to a temperature between -5 and -10 ◦C. A 25 G syringe needle containing
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30 mL of room air was then inserted into the vial septum and the plunger depressed
slowly until the headspace of the vial was pressurized to between 600 and 750 kPa
(approximately 85 − 110 psi). Lipid freezing was avoided by observing the contents
of the vial as well as the temperature of the isopropanol solution periodically. The
syringe needle was removed from the vial after pressurizing, leaving a pressure head on
the solution.
3.2.2 Sample Sizing
Samples prepared by each method were tested in the nanometer range using a
Malvern Nano ZS (Malvern Instruments Ltd., Malvern, Worcestershire, U.K.) and in
the micrometer range using an Accusizer 780A (Particle Sizing Systems, Santa Barbara,
CA) for distribution statistics. For Accusizer samples, volumes were typically 3 µL for
bubbles produced by agitation and 25−50 µL for droplets. Nano ZS sample volumes of
1 mL (undiluted) were used for microbubble-condensed nanodroplets and lipid solution
controls. The upper sizing sensitivity on the Nano ZS was 6 µm in diameter, while the
lower sizing sensitivity on the Accusizer 780A was 0.54 µm in diameter, such that an
accurate representation of the content over a wide range of sizes could be obtained.
3.2.3 Experimental Apparatus
The setup used for these experiments was identical to that described in section 2.2.3.
3.2.4 Image Analysis
Still images and videos were captured using proprietary camera software (PFV,
Photron USA, Inc., San Diego, CA). Image analyses were performed on the recordings
using ImageJ software (NIH, Bethesda).
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3.2.5 Vaporization Thresholds and Precursor Size
Due to the fact that droplets smaller than 1 µm were beyond the resolution ca-
pabilities of the experimental setup, the approach to vaporize sub-micrometer droplet
samples differed from the individual droplet described in the previous chapter. Samples
were left undiluted to maximize the number of droplets and resulting bubbles in the
field of view. Oxygenation in the excipient solution after microbubble condensation
was typically on the order of 2 − 3 PPM. Once injected into the in vitro setup, the
sub-micrometer droplet samples at each lipid concentration (0.75, 1.5, and 3.0 mg/mL)
were exposed to 5 MHz ultrasound pulses 2 µs in duration at a mechanical index (eqn.
2.8) of either 1.2 or 1.7. These mechanical indices were chosen because they represent
pressures at the middle to higher end of what is currently available on standard diagnos-
tic ultrasound machines. Videos of droplet vaporization were taken at the ‘midplane’
of the cellulose tube to observe bubbles as they floated past the focus and at the top of
the tube to observe the bubbles accumulating due to buoyancy. Bubbles were counted
and measured to determine any differences in size distributions and/or quantity based
on lipid concentration. The size distributions of bubbles obtained at each mechanical
index were compared to determine the impact of the pressure level on the resulting size
distribution.
An additional, independent test of the relationship between droplet and bubble size
was performed by setting the vaporization pulse to a mechanical index of 1.7 with the
same pulse length and frequency as before. By the ideal gas law estimations (eqn.
2.7), bubbles with diameters of 5 µm or less should result from droplets originally sized
less than 1 µm. After the vaporization pulse was applied to a sample of 3 mg/mL
lipid solution, the resulting bubbles floated to the top of the tube and were counted,
measured and correlated to sizing results as indirect evidence of sub-micron droplet
vaporization.
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3.3 Results and Discussion
Figure 3.1: Representative bubble populations prior to microbubble condensation.
Mean bubble size for each lipid in order of increasing lipid concentration was 1.03,
1.01, and 1.20 µm, while mode bubble size was 0.93 µm for all three. Concentrations
in particles/mL were 4.8× 109, 3.1× 109, and 9.9× 109, respectively.
3.3.1 Microbubble Size Prior to Condensation
To test our hypothesis that the size of resultant nanodroplets condensed from pre-
formulated microbubbles correlates with the original microbubble populations, initial
sizing was performed on prepared microbubbles at three lipid concentrations (Figure
3.1). In general, the mode bubble size for each concentration was relatively similar,
although for the 3 mg/mL formulation a much larger percentage of bubbles measuring
greater than 1.5 µm in diameter resulted. This was not surprising as the higher lipid
concentration may stabilize larger bubbles and skew the distribution somewhat.
3.3.2 Sub-micrometer Particle Analysis of Nanodroplets
By assuming the number of moles is preserved between the liquid state and the
gaseous state, a theoretical relationship can be developed from ideal gas laws that relates
the size of the gas microbubbles to the size of the droplets that should be produced from
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Figure 3.2: Example of sub-micrometer particle sizing of nanodroplets produced by
the microbubble condensation method. Peak sizes of 200 − 300 nm resulted, which
appeared to be independent of lipid concentration. Mean droplet size for each curve
in order of increasing lipid concentration was 229± 120, 345± 97, and 325± 268 nm,
respectively, while mode droplet size was 220, 295, and 255 nm.
microbubble condensation (eqn. 2.7). Sizing of resultant nanodroplets by the Malvern
ZS demonstrated that the microbubble condensation method routinely produced peaks
in the 200 to 300 nm range, which corresponds well with ideal gas law estimates of
droplet sizes produced by the microbubble condensation method originating from bub-
bles in the 1 to 2 µm range (as was the case with all microbubble preparations). While
sub-micrometer particle sizing did not allow for information about concentration, all
three lipid concentrations appeared to result in mode droplet sizes between 200 and 300
nm. A significant amount of variation across samples was observed with regard to the
deviation from the mode size. Some samples were measured to have content below 100
nm, while others had only content greater than 200 nm (Figure 3.2). We believe this
variability may have resulted from inconsistencies in applied pressure and temperature
at the time of condensation but may be partly due to formation of micelles and lipo-
somes as a function of lipid concentration, and due to ZetaSizer measurement variation
from samples that were too highly concentrated (producing much more scattering).
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This variability is reduced in the following chapters as refinements to the methodology
are applied.
Sizing of controls (i.e., prior to any microbubble generation) showed that the con-
trol 3 mg/mL formulation produced a peak near 100 nm at a low count rate (Figure
3.3), which may be attributed to naturally forming vesicles (as described previously).
This peak was not present in any nanodroplet samples resulting from the 3mg/mL
lipid concentration, most likely as a result of the process of microbubble generation.
Although the Malvern was not able to produce stable, consistent sizing results for the
0.75 and 1.5 mg/mL samples, some content was present in the low nanometer range
at lower count rates. These results suggest that the sub-micrometer sizings most likely
represent viable, DFB-filled nanodroplets.
Figure 3.3: Lipid control solution sub-micrometer sizing. A peak at 105 nm with a
low count rate was detected for the 3 mg/mL lipid solution, which did not appear in
droplet samples at the same lipid concentration.
3.3.3 Micrometer-Range Sizing of Droplets
The Malvern Nano ZS, which had an upper sizing threshold of 6 µm, showed the
majority of the sample content to be in the nanometer range. However, to better
characterize the content present in the micrometer range, the same samples previously
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presented in Figure 3.2 were sized using an Accusizer 780A (Figure 3.4). The results
showed that after microbubble condensation, some content as large as 2 − 4 µm was
present in the sample, and the upper size limit seemed to increase with lipid concentra-
tion. The nature of this larger content is discussed later. These measurements help to
support the success of the condensation method, as they show the mode particle size
shifting toward the lower limit of sensitivity from the original bubble distribution near 1
µm. The distribution peaks of Figure 3.4 taken in conjunction with the sub-micrometer
sizings of the same samples in Figure 3.2 suggest that the content in the micrometer
range represents a relatively small portion of the overall sample. We estimate that
droplets larger than 600 nm typically only comprise between 1.5% and 4% of the over-
all sample by count while less than 1.5% of the total sample is between 1 and 6 µm.
The concentration measured by the particle sizer decreased by approximately 2 orders
of magnitude, presumably due to a reduction in particle size and a significant portion
of the sample condensing to sizes below the sensitivity threshold, although secondary
effects occurring during generation (such as bubble breakage) could be occurring.
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Figure 3.4: Condensation of original microbubble samples shows a shift of mode size
into the sub-micrometer range, as captured by an Accusizer 780A. For each lipid con-
centration, the resulting mode size (0.64, 0.57, and 0.54 µm in order of increasing
concentration) was near the lower sensitivity of the machine (0.54 µm), indicating the
sample is likely better represented by the results of the sub-micrometer particle sizing
(Figure 3.2). The data corresponds well with measured resultant microbubble size after
ADV as shown in Table 3.1. Concentrations in particles/mL were 1.2× 107, 2.4× 107,
and 8.4× 107, respectively.
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3.3.4 Vaporization of Microbubble Condensation Nanodroplets
Images with the focus positioned near the midplane of the microcellulose tube re-
flected droplet conversion captured immediately after vaporization, offering a true in-
dication of the size distribution of microbubbles resulting from droplet vaporization
as they passed through the optical focus due to buoyancy, although the rapid bub-
ble rise toward the top of the tube resulted in some picture degradation (see Figure
3.5). Alternatively, images captured at the top of the tube (data not shown) when
the bubbles had risen and collected (typically several seconds after the vaporization
event) were useful for visualizing the ‘bulk’ group of microbubbles in focus and taking
more accurate measurements. It was noticed that measurements taken at the top of
the tube reflected a somewhat skewed bubble size distribution when compared to the
general sizes of bubbles observed during midplane videos and is likely due to the effect
of larger bubbles at the apex of the tube obscuring smaller nearby bubbles. This was
confirmed in multiple instances where smaller bubbles could be seen to be ‘orbiting’
much larger bubbles and fell out of view shortly afterward. While the midplane vapor-
ization was useful for a snapshot shortly after vaporization, the measurements taken at
the top of the tube were more useful because the bubbles were stationary and the opti-
cal focus could be adjusted to capture a more complete distribution. Nonetheless, both
approaches demonstrated the effect of lipid concentration on the number of bubbles
produced from droplet vaporization.
As the droplets were not within the optical resolution of the experimental appara-
tus, it was necessary to measure the resulting bubbles as precisely as possible. Several
studies have demonstrated the tendency of perfluorocarbon-filled microbubbles to up-
take dissolved ambient gases [71; 146] (Chapter 2). To reveal the influence of dissolved
gas in the resulting microbubble population produced from vaporized nanodroplets,
samples produced with a lipid concentration of 0.75 mg/mL were exposed to a 10 cycle
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Figure 3.5: Midplane droplet vaporization revealed microbubble sizes occurring pre-
dominantly in the 1 to 3 µm range, with an increasing number of bubbles produced as
lipid concentration increased. Vaporization was induced with a 10 cycle pulse at 5 MHz
with a mechanical index of 1.7: (left) 0.75 and (right) 3.0 mg/mL lipid concentration.
pulse at 5 MHz (mechanical index of 1.7). Using the same sample throughout the test,
bubbles resulting from droplet vaporization were measured at the top of the tube first
in an undegassed water bath (N = 239) followed by a degassed water bath (N = 228).
The results show that simply degassing the water bath media reduced the maximum
bubble size observed by 62% (from 32 to 12 µm). The mean and mode bubble sizes
were reduced by 36% and 20%, respectively.
Midplane observations in a degassed water bath revealed vaporization did produce
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a majority of bubbles in the 1 to 3 µm range independently of lipid concentration, al-
though the number of bubbles produced increased dramatically when the lipid content
was increased to 3 mg/mL (Figure 3.5). This may be because the higher lipid concen-
tration produces better stabilization of bubbles through the condensation process and
upon vaporization. Table 3.1 lists the mean, mode, and maximum bubble size (rounded
to the nearest 0.5 µm) observed for each lipid formulation at the two different pressures
tested using bubbles measured from the top of the tube (N > 150 for each pressure).
The mean and mode sizes were presumably higher than the true sample values due to
reasons mentioned above. Minimum sizes were not included due to the fact that these
could not be accurately compared across samples due to resolution limits, although in
each lipid formulation the smallest bubble measured was near the optical resolution
limit. In general, mean bubble size was similar across all samples but mode bubble size
decreased significantly as lipid concentration increased, indicating increased efficiency
in preserving nanodroplets. This could be observed in images of resulting bubbles,
where higher lipid concentrations yielded not only more resulting bubbles per ultra-
sound pulse but aa proportionately higher distribution of small bubbles (see Figure
3.5).
Using the same 5 MHz frequency, it was observed that relatively similar distributions
occurred at mechanical indices of 1.2 and 1.7, indicating the ultrasound pressure at MI
= 1.2 was sufficient to induce vaporization across the same size ranges. However, a
mechanical index of 1.7 did skew the population toward a larger proportion of smaller
bubbles, implying the higher energy was more efficiently vaporizing nanodroplets (Table
3.1). The histograms of bubble sizes from each sample did not generally resemble
original bubble sizing data well until a lipid concentration of 3 mg/mL was used. At 3
mg/mL, resulting bubble sizes displayed a strong peak in the 1 to 3 µm range with a
precipitous drop off toward higher sizes (Figure 3.6).
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Figure 3.6: Resulting bubble diameter as a function of increasing acoustic pressure for
samples originating from 3 mg/mL lipid solutions measured from bubbles collected at
the top of the microcellulose tube. Sizing profiles resemble original microbubble sizing
profiles, indicating successful generation and vaporization of condensed microbubbles.
Mechanical indices of 1.2 and 1.7 result in similar bubble distributions; however, it is
noted that higher pressure produces a greater proportion of bubbles in the 1 to 2 µm
range.
The extended tail in Figure 3.6 is most likely due to the increased efficiency of
vaporization for larger droplets - amplifying their presence proportionately. However,
the presence of bubbles generally larger than those in the original agitated microbubbles
requires further discussion. It was noticed that in several samples, especially those
from higher lipid concentrations, some vaporizable droplets were present as large as
1 to 2 µm (< 1.5%) and on occasion could be observed as large as 3 to 4 µm. This
indicates that the upper sizes shown in Figure 3.4 most likely represent droplet sizes
rather than bubbles remaining in the sample (which were rarely observed). By ideal
gas law estimations, these droplets should result in bubbles on the order of 10 to 25 µm
(see Table 3.1), explaining the presence of the larger vaporization-produced bubbles.
These micrometer sized droplets may be formed by larger microbubbles present after
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agitation, as the particle sizer does detect some bubbles as large as 25 to 30 µm in
diameter; however, that bubbles larger than 15 µm typically comprise less than 0.09%
of the overall population suggests that there may be other mechanisms at work. Because
the samples were tested at high concentrations, it is possible that bubble fusion could
result from vaporization of droplets in very close proximity. If this were occurring, it
would have the effect of generally increasing the mode and mean bubble size compared
to the original population. It is possible that the higher dissolved gas content of the
samples due to room-air pressurization could lead to an increase in measured bubble
size, although some of the dissolved gas would diffuse through the porous microcellulose
tube into the degassed water bath before reaching the optical focus. This could be
mediated in future studies by pressurization with low boiling point, low solubility gases.
Alternately, secondary effects may be occurring during the condensation process. A
brief experiment was performed to explore the interplay of pressure and temperature
on microbubble condensation.
Figure 3.7: Agitated microbubbles (3 mg/mL lipid concentration) exposed to room-air
pressure only show transition of mode size into the sub-micrometer range, although the
presence of bubbles in the 20 to 30 µm size range increases in proportion, suggesting
secondary effects may be occurring to some degree. Concentrations in particles/mL for
the control bubbles and pressurized sample were 4.8× 109 and 2.5× 108, respectively.
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3.3.5 Influence of Secondary Effects
Agitated bubble samples were exposed to pressurization with room-air only to deter-
mine effects on the bubble population (Figure 3.7). Results show that when exposed to
pressure only, the bubble population begins shifting toward the sub-micrometer range
(as shown previously); however, bubbles in the 20 to 30 µm size range begin to appear
in higher proportion. This suggests that some degree of secondary effects - such as
Ostwald ripening or bubble fusion - may be present during the pressurization process,
which requires further investigation. Future studies will assess the resultant microbub-
ble size as a function of the rate and degree of pressurization in order to ascertain
whether these larger bubbles formed can be eliminated by refining of the process. In
addition to secondary effects that result in the presence of larger bubbles, the effect that
increased ambient pressure may have on causing a degree of microbubble dissolution
prior to condensation will need to be studied further to optimize the technique.
3.3.6 Estimation of Originating Droplet Size
In a final experiment confirming the expected relationship between bubbles pro-
duced from vaporization and the measured droplet sizes, droplets formed from 3 mg/mL
lipid solutions were diluted to 10% of the original concentration and exposed to a va-
porization pulse with a mechanical index of 1.7. Once ultrasound pressure was applied,
bubbles were immediately present (Figure 3.8). The resulting measured bubble di-
ameters within optical resolution produced over several tests with the same conditions
(outliers greater than 5 µm excluded as they may be a result of coalescence or secondary
effects), had a mean of 2± 1 µm (N = 148).
The bubble measurements obtained from this set of experiments were used to esti-
mate the size of the originating droplets for comparison with the initial particle sizing.
The experimentally observed expansion factor of 6 for droplets in the micrometer range
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Figure 3.8: Still-frame images before and immediately after sub-micron DFB droplets
were subject to an ultrasound pulse at a mechanical index of 1.7
(Figure 2.4) was not used for this estimation due to the assumption that surface-tension
effects will become much more dominant for droplets in the nanometer range. It cannot
be assumed that the observed expansion due to ambient dissolved gas will affect the
expansion of nanometer-sized droplets as it does micron-sized droplets due to the signif-
icantly increased internal pressure of the droplet. Therefore, ideal gas law estimations
are preferable in this size range. Equation 2.7 was evaluated for 148 measured bub-
bles with the parameters Pamb = 101.325 kPa and a surface tension of σ = 30 mN/m,
which may be suitable for the lipid solution used for these droplets. A histogram of the
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estimated droplet sizes that produced the measured bubbles (Figure 3.9) shows that
the peak estimated droplet sizes occurred in the 300 to 350 nm bin, which matches
extremely well with the original sizing results produced by dynamic light scattering
(Figure 3.2). The histogram appears to be skewed to the right of the central peak,
which may be anticipated due to the stochastic nature of droplet vaporization; even at
sufficient pressures to vaporize droplets smaller than 350 nm, droplets larger than 350
nm will vaporize with greater efficiency. The curve fits for DFB in the micron sized
droplet experiments predict a MI of 1.78 for vaporization of 300 nm droplets (Figure
2.3), which is in good agreement with the observed MI of 1.71 necessary to vaporize
content near this size.
Figure 3.9: Histogram of estimated size of droplets resulting from observed bubbles 5
µm or smaller (N = 148)
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3.3.7 Comparison of Methods
Direct comparison of the two methods employed (formation by extrusion presented
in the previous chapter, and microbubble condensation presented in this chapter) is not
appropriate in light of the different lipid and buffer formulations used. In the extrusion
process, the aqueous solution was prepared in a way to lower the freezing point signif-
icantly in order to operate at temperatures where the bulk DFB solution would stay
in the liquid phase. For the microbubble condensation method, the aqueous solution
was prepared primarily to produce desired microbubble population characteristics. In
these preliminary tests, the microbubble condensation method appeared to be a much
simpler approach that could produce DFB droplets in large quantities. Although it
is possible that an extrusion-based approach could be optimized in formulation and
technique to produce comparable results, the low surface tension of perfluorocarbons
and the high viscosity of the aqueous phase at the lower temperatures used present a
significant challenge.
3.4 Conclusion
These preliminary results demonstrate that pressurization and temperature-induced
condensation of preformed microbubbles may be both an effective and an advantageous
means of producing contrast agents for ADV applications compared to conventional
extrusion and emulsion-based methods for some PFCs. The extent to which the method
can be applied to PFCs of lower boiling points will be investigated in the following
chapters. The samples formed by microbubble condensation produced a high number of
viable nanodroplets that could be vaporized at clinically feasible pressures, resulting in
a distribution of contrast-providing microbubbles resembling the original microbubble
sample. This method may have advantages with regard to commercialization of ADV
technology, as nanodroplets can be formed easily by adding a simple technique after
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traditional microbubble preparation.
These results highlight only two lipid formulations that can be used. Other lipid
formulations should make this technology amenable to not only ultrasound imaging
but drug and gene delivery and therapy as well. Incorporation of 16:0 TAP in the lipid
formulation used for microbubble condensation, which helped minimize aggregation and
coalescence, is currently being pursued in our laboratories as a means of plasmid/gene
delivery. In addition, the low concentrations of lipids (0.75 to 3.0 mg/mL) utilized
to stabilize the DFB droplets makes these formulations more amenable to human use
while minimizing the possibility of toxicity or bioeffects.
This study represents our initial efforts to develop an extravascular ultrasound con-
trast agent based upon vaporizable nanodroplet technology. Results have demonstrated
that ADV of sub-micrometer sized droplets can be induced in vitro with pressures avail-
able to clinical diagnostic ultrasound machines.
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CHAPTER 4
Modifying Sensitivity and Stability through PFC Mixing
4.1 Introduction
The ability to selectively trigger changes in the physical properties of a material
or compound has led to a number of innovations in biomedical technology. Many
‘intelligent materials’ and nanoparticles have been designed to respond to external
stimuli such as electric/magnetic fields, heat, light, and sound [147]. In the field of
ultrasound medical imaging, recent interest has focused upon the development of phase-
change contrast agents (PCCAs), which convert from a liquid to a gaseous state upon
exposure to thermal and/or acoustic energy [71]. Phase-change contrast agents can
be considered a hybrid of the gas-core MCAs and the inert liquid core droplets in
that the perfluorocarbons selected have a boiling point near enough to body or room
temperature that they can be ‘tipped’ from the liquid phase to the highly echogenic
gas phase through the addition of thermal and/or acoustic energy. The result is a
dynamic, high-contrast agent with very low toxicity that can be activated with spatial
and temporal specificity [71; 62; 66].
c© 2012 Elsevier Ltd. (elsevier.com) Portions reprinted, from PS Sheeran, S Luois, LB Mullin, TO
Matsunaga, and PA Dayton. “Design of Ultrasonically-Activatable Nanoparticles Using Low Boiling
Point Perfluorocarbons” Biomaterials, 2012 April; 33(11): 3262-3269.
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Figure 4.1: Exposing pre-formed PFC microbubbles to decreased ambient tempera-
ture and increased ambient pressure results in condensation of the gaseous core. The
decreased size results in an increased Laplace pressure, which serves to preserve the par-
ticle in the liquid state. Once exposed to increased temperature and energy delivered
via ultrasound, vaporization of the droplet core results in a larger, highly echogenic gas
microbubble.
In the previous chapter, a unique ‘microbubble condensation’ technique was demon-
strated that allows for the ability to generate nanoscale decafluorobutane PCCAs in a
simple manner. By exposing pre-formed DFB MCAs to decreased ambient tempera-
ture and increased ambient pressure, a condensation of the perfluorocarbon core occurs
(Figure 4.1). As the DFB core condenses, the increased Laplace pressure allows the
droplets to remain in the liquid state when exposed to the original ambient temperature
and pressure until vaporization is induced by thermal or acoustic energy.
Although it has been relatively unexplored in the literature, there is expected to
be a tradeoff between the stability of the resulting emulsions and the acoustic pressure
required to induce vaporization. Therefore, design of PCCAs from low boiling point
perfluorocarbons for biomedical applications requires the ability to balance the overall
stability through manipulation of factors such as PFC boiling point and droplet size.
In this chapter, we explore the ability of the microbubble condensation technique to
generate PCCAs from perfluorocarbons with even lower boiling points than DFB, such
as octafluoropropane (OFP, b.p. −36.7◦C), and the tradeoff between relative in vitro
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stability and vaporization thresholds at both room and body temperature that results.
Furthermore, we examine whether the balance between thermal stability and sensitivity
to ultrasound-induced activation can be further manipulated by mixing different species
of gaseous PFCs to a desired ratio prior to condensation. This concept is similar to
one proposed by Kawabata and colleagues for liquid perfluorocarbons [86], however, it
has not been previously shown to be possible with low boiling point, gaseous PFCs.
4.2 Materials & Methods
4.2.1 Microbubble Preparation
Polydisperse decafluorobutane and octafluoropropane microbubbles were formulated
by dissolution of DSPC and DSPE-PEG2000 in a 9:1 M ratio and a total lipid concen-
tration of 1.0 mg/mL. All lipids were purchased from Avanti Polar Lipids (Alabaster,
AL) and perfluorocarbons purchased from Fluoromed (Round Rock, TX). The excipi-
ent solution was comprised of phosphate-buffered saline (PBS), propylene glycol, and
glycerol (16:3:1). After adding 1.5 mL of the resulting solution to a 3 mL glass vial, the
headspace of the vial was gas-exchanged with each perfluorocarbon. Samples contain-
ing a mixture of perfluorocarbons were prepared by first filling a 30 mL syringe with
DFB and OFP in a 1:1 ratio and then conducting a gas-exhange of the headspace of a
lipid-containing 3 mL glass vial with the perfluorocarbon mixture. Microbubbles were
formed via standard agitation techniques using a Vialmix shaker (Bristol-Myers-Squibb,
New York, NY).
4.2.2 Microbubble Condensation Procedure
The 3 mL vials containing PFC microbubble samples were immersed in an iso-
propanol bath controlled to a temperature between −5◦C and −10◦C and swirled gen-
tly for approximately 1 min. The vials were connected to an adjustable high pressure
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air source and headspace pressure in the vial was increased until a change in consis-
tency was noted in the microbubble sample - indicating the onset of condensation. The
combination of propylene glycol, glycerol, and PBS prevented sample freezing during
the short exposure to reduced temperatures (a total of approximately 2 min). After
condensation, the pressure source was removed from the vial, leaving a pressure head
on the solution until further use.
4.2.3 Sample Sizing
As in Chapter 3, microbubble sample size distributions were measured using an
Accusizer 780. Sample statistics were measured and averaged for 3 samples of each
polydisperse group (DFB only, OFP only, 1 : 1 DFB + OFP). Dynamic light scattering
(Malvern Nano ZS, Malvern Instruments Ltd., Malvern, Worcestershire, U.K.) was used
to characterize content at the nanoscale for droplet samples. Approximately 1.5 mL of
each condensed droplet sample was transferred to a cuvette by micropipette and the
undiluted contents sized for each.
4.2.4 Sample Stability
To determine the relative stability of PFC droplet emulsions, samples were trans-
ferred by micropipette to a 3 mL syringe and capped with no gas headspace. The
syringes were exposed to either room temperature (22◦C) or body temperature (37◦C)
by submerging the syringe in a heated water bath. Instability in the sample due to am-
bient temperature should manifest as the spontaneous phase-transition of the largest
droplets in the sample (the least thermally stable), resulting in bubbles at the mi-
croscale. To capture this instability, the samples were sized using the Accusizer 780A
at 10 min intervals over the course of an hour to determine changes in the size distri-
bution as well as concentration. Three samples of each group (DFB only, OFP only,
1 : 1 DFB + OFP) were measured at each temperature and the resulting distributions
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averaged. To display the change in concentration concurrently, the distribution at each
time point was normalized and weighted relative to the peak concentration over the
entire test.
4.2.5 Experimental Apparatus
The acoustic setup used for these experiments was similar to that described in
section 2.2.3. Depending on the experiment, the water bath temperature was either
maintained at 22◦C or 37◦C. A spherically focused transducer with a 7.5 MHz center
frequency and focal length of 5 cm (V321, Panametrics, Inc., Waltham, MA) was used
to transmit acoustic pulses into droplet samples. Signals consisting of a 2 cycle sinusoid
of adjustable amplitude at 8 MHz (total insonification time of 250 ns) were provided
using an arbitrary waveform generator (AFG 3101, Tektronix, Inc., Beaverton, OR)
and amplified approximately 60 dB using an RF amplifier (A500, ENI, Rochester, NY)
before being delivered to the transducer. For optical-acoustic alignment, the focus of
the transducer was positioned to be confocal with the microscope objective focus by a
calibrated needle hydrophone (HNA-0400, Onda Corp., Sunnyvale, CA). The range of
transducer output pressures was calibrated at the focus to determine the approximate
pressures experienced by droplets in the field of view.
Microscale Droplet Vaporization Threshold
Based on preliminary studies involving microbubble condensation (Chapter 3), the
majority of the droplets in each sample have diameters in the hundreds of nanometers.
However, the presence of optically resolvable microscale outlier droplets enables simple
measurement of individual droplet vaporization thresholds, which is convenient for
comparison of the thresholds between different perfluorocarbons. Samples were first
vented with a 20 G needle and diluted in PBS until only a few droplets were visible on
screen at any time. This was typically on the order of 1/10th dilution, but varied from
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sample to sample based on the number of outlier droplets present. The large outlier
droplets, which rested near the bottom of the microcellulose tube, were maintained
in focus using the position manipulator. Ultrasound pulses were delivered in pressure
increments of approximately 55 kPa (rarefactional) with approximately 1 to 2 seconds
of rest time between each manual pulse trigger. The rarefactional pressure that induced
phase transition in the droplet was recorded for correlation with droplet diameter.
4.3 Results
4.3.1 Microbubble and Droplet Size Distribution
All microbubble samples showed similar distribution characteristics regardless of
which perfluorocarbon or perfluorocarbon mixture was selected for the core (Table
4.1), although there was a significant increase in mean concentration for the 1 : 1 DFB
+ OFP microbubbles compared to DFB microbubbles (p = 0.01 by student’s 2-sided
unpaired t-test), and a significant decrease in size for 1 : 1 DFB + OFP microbubbles
compared to DFB and OFP microbubbles (p = 0.01 and p = 0.05, respectively).
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4.3.2 Droplet Size Distribution
Dynamic light scattering (DLS) showed that the decrease in the size of the particles
after condensation resulted in droplet distributions primarily in the sub-micron range,
which is consistent with the preliminary microbubble condensation studies in Chapter
3. Samples containing DFB appeared to condense with very little additional pressure
(4 to 5 psi), while the 1 : 1 DFB + OFP mixture samples and pure OFP samples
required substantially more (25 to 30 psi and 45 to 50 psi, respectively). Nanodroplets
originating from DFB microbubble samples and 1 : 1 DFB + OFP mixture microbubble
samples both condensed to form peaks at 295 nm (Figure 4.2). The DFB nanodroplets
had slightly higher average diameters than the samples created from a 1 : 1 PFC
mixture (363 ± 161 nm and 296 ± 94 nm, respectively). Pure OFP samples did not
show sufficient stability to be sized by DLS, although the optical data and vaporization
data (see below) confirms the condensation of OFP into both microscale and nanoscale
droplets.
Figure 4.2: Dynamic light scattering results for two different nanodroplet formulations
(N = 3 for each group). Both DFB and 1 : 1 DFB + OFP droplets resulting from
polydisperse bubbles showed peaks at 295 nm in diameter.
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4.3.3 Droplet Emulsion Stability
The content of each sample at the beginning of the 60 min test period showed
that the mode particle size was near the lower sensitivity threshold of the Accusizer.
This confirms that the actual size distribution of the sample is best represented by the
submicron sizing (DLS). The Accusizer, however, allows for simple characterization of
the change in distribution and concentration over time of the content greater than 500
nm in diameter. Because the largest content in the phase-change emulsions is the least
stable, the greatest change in distribution and concentration over time should occur in
the upper portion of the sample distribution.
DFB exhibited remarkable stability in vitro at both temperatures, with a preser-
vation of distribution characteristics (Figure 4.3a and b) and no significant change in
mean concentration (Figure 4.4a and b) over the period. The PFC mixture samples
showed a general preservation of distribution characteristics (Figure 4.3c), but a 17%
drop in mean concentration over the time period at 22◦C (p = 0.05, Figure 4.4a). At
37◦C, the PFC mixture samples showed a 45% decrease in mean concentration over the
test period (p = 0.03, Figure 4.4b), and an increase in the content between 3 and 10 µm
was observed in the distribution profile (Figure 4.3d). OFP samples showed significant
instability at both temperatures. At both 22◦C and 37◦C, an 82% decrease in mean
concentration was observed over the time period (p = 0.04 and p = 0.01, respectively,
Figure 4.4a and b), although the decrease in concentration was more gradual over time
in the 22◦C case. At 37◦C, OFP samples decrease to their final concentration with the
first 10 to 20 min, and a corresponding increase in the content between 3 and 10 µm
was observed in the distribution profile (Figure 4.3f).
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Figure 4.3: Perfluorocarbon droplet distributions in vitro over a 1 h period: Pure
decafluorobutane at a) 22◦C and b) 37◦C; DFB + OFP mixture at c) 22◦C and d)
37◦C; and pure octafluoropropane at e) 22◦C and f) 37◦C. The distribution at each
time point was scaled to the relative mean concentration (concentration-weighted) to
simultaneously reflect changes in concentration over the time period.
4.3.4 Microscale Droplet Thresholds
Diluting droplet samples in PBS allowed microscale outlier droplets to be isolated
and vaporized individually (Figure 4.5). By exposing 20− 30 droplets of each PFC to
acoustic pressure, the peak rarefactional pressure that initiated droplet vaporization
could be mapped against droplet diameter to observe general trends in vaporization
thresholds (Figures 4.6 and 4.7). Results show that both perfluorocarbon boiling point
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Figure 4.4: Change in concentration over time for droplet samples of each perfluoro-
carbon at a) 22◦C and b) 37◦C.
and ambient temperature greatly influenced the rarefactional pressure needed to vapor-
ize droplets, as expected, and that the vaporization pressure generally increased with
decreasing diameter in the small range tested. Additionally, a droplet core composed of
a mixture of perfluorocarbons resulted in droplets with vaporization thresholds between
each of the ‘pure’ perfluorocarbons (Figure 4.7).
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Figure 4.5: A microscale droplet of OFP exposed to a 0.25 µs pulse at approximately
0.55 MPa vaporizes to form a gas bubble approximately 5-fold larger.
4.4 Discussion
The results in this chapter demonstrate the extent to which low boiling point per-
fluorocarbons can be manipulated with regard to stability and vaporization thresholds
in order to design phase-change ultrasound contrast agents with desirable properties.
Perhaps the most surprising result of these studies was that OFP, which comprises the
PFC gas core of the commercial MCA Definity (Lantheus Medical Imaging, Inc., USA),
can be condensed to form droplets that exhibit some stability at 22◦C - nearly 60◦C
above its normal boiling point of -36.7 ◦C. Furthermore, OFP droplets as large as 5
to 8 µm were able to be optically resolved and vaporized (Figure 4.7). It is expected
that the large content present in the distributions are in a high state of superheat -
perhaps only existent due to the purity of the perfluorocarbon delaying the seeding
of nucleation and spontaneous vaporization. Once exposed to physiological tempera-
tures, however, the upper distribution of OFP emulsions represented by the Accusizer
show rapid spontaneous vaporization. While this may be unfavorable for most PCCA
applications where only ultrasonic activation is desired, it may be useful for creating
ultrasound contrast agents that vaporize immediately upon injection.
Both the sizing and concentration data over the course of the 1 h test period re-
vealed the remarkable stability of DFB droplets when exposed to both room and body
temperature in vitro. In contrast, the portion of the OFP samples registered by the
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Figure 4.6: Vaporization pressure for microscale DFB and OFP droplets at 22◦C and
37◦C. The vaporization threshold increased with increasing boiling point and decreasing
diameter for the small range observed.
Accusizer were greatly sensitive to both room and body temperature - showing rapid
changes in the size distributions and in concentration. Samples composed of 1 : 1 mix-
tures of OFP and DFB showed generally favorable stability at room temperature with
regard to both distribution and concentration. Once exposed to body temperature,
the samples retained the distribution profiles, although the concentration dropped at
a much faster rate than at room temperature. These results highlight the expected
relationship between general thermal stability and PFC boiling point, including the ef-
fect of modulating the boiling point by mixing perfluorocarbons. The thermal stability
of droplets with diameters smaller than 500 nm (not registered by the Accusizer) for
all PFC compositions requires further investigation. For example: while the portion
of OFP samples greater than 500 nm appeared generally unstable, it is possible that
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Figure 4.7: Droplets composed of a mixture of PFCs vaporized at 22◦C with rarefac-
tional pressures between each of the composing PFCs - indicating condensation of the
mixed gases resulted in a miscible dual-PFC core. By adjusting the ratio of PFCs, the
vaporization threshold may be further ‘tuned’.
droplets in the 100− 300 nm range may be sufficiently stable for use at body temper-
ature as a result of the increased Laplace overpressure. If so, then future refinement
of the size distribution to isolate this small content along with optimization of the
shell composition may sufficiently stabilize OFP samples to remain in the liquid state
upon injection. Additionally, the droplet samples in the present study were measured
under atmospheric pressure, and so the higher in vivo pressures may further stabilize
circulating and extravasated droplets.
In this study, all microscale droplets were vaporizable at both room temperature
and body temperature using very short pulses (2 cycles) and with mechanical indices
less than 1.9 (approximately equivalent to 5.4 MPa at 8 MHz). The trends confirm
the inverse relationship between PFC boiling point and droplet vaporization threshold
as well as the expected inverse relationship between ambient temperature and droplet
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vaporization threshold. Microscale DFB droplets were vaporized at pressures near 2
MPa (MI of approximately 0.71) at body temperature (Figure 4.6), which is nearly
30% lower than the pressures needed to vaporize at 5 MHz obtained from a previous
study [33]. Although the acoustic pulse lengths were slightly different in this study
than the previous, decreasing vaporization pressure as a function of increasing US
frequency has been reported previously in the literature and is confirmed here [50; 76].
Microscale OFP droplets could be vaporized with pressures on the order of 0.5 MPa (MI
of approximately 0.18) at body temperature. In many applications, it may be preferable
to perform investigatory imaging at low pressures and vaporize injected PCCAs at a
desired point using an activation pulse of higher pressure. For these purposes, the low
vaporization threshold of microscale OFP droplets may be unsuitable, and droplets
composed of a mixture of PFCs or pure DFB may be more appropriate.
The concept of mixing liquid perfluorocarbons to modulate emulsion properties was
initially proposed by Kawabata and colleagues [86]. This study is the first to show
that stability and activation energy of emulsions can be modified by applying a similar
concept to gaseous perfluorocarbons prior to microbubble condensation. As shown
in Figure 4.7, droplets composed of a mixture of PFCs were vaporized at pressures
between those required to vaporize ‘pure’ droplets of either OFP or DFB, similar to the
stability characteristics observed (Figures 4.3 and 4.4). Although a significant amount
of variation is present in the thresholds, no overlapping points occurred between the
perfluorocarbon groups, which suggests that the PFCs were miscible and could be
condensed to form a mixed droplet.
As an additional test of the possibilities of PFC mixing, droplet samples were pre-
pared with a 1:1 mixture of DFB (gas at room temperature) and DDFP (liquid at room
temperature). This was accomplished by combining the compounds at -20 ◦C while
both were in the liquid state and allowing the mixture to evaporate at room temperature
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Figure 4.8: 1:1 mixtures of DFB + DDFP showed similar sizing to droplets formed from
other mixtures. Shown here is a representative distribution averaged from 3 samples,
with a mean droplet diameter of 240 ± 65 nm
.
before gas-exchange into the lipid-solution vial. The mechanical agitation produced a
distribution of bubbles of this 1:1 mixture, which condensed easily at the reduced tem-
perature with no additional headspace pressure. By DLS sizing, the droplets showed
similar distributions as the DFB-only and DFB + OFP mixtures (Figure 4.8). Because
these droplets contained a less volatile element (DDFP), the balance of sensitivity to
ultrasound and thermal stability should shift in favor of increased thermal stability and
decreased sensitivity to ultrasound compared to DFB-only droplets. This was apparent
in concentration measurements taken over a 48 hour period (Figure 4.9). When exposed
to 37 ◦C in vitro, the concentration of DFB droplets decreased significantly (p = 0.024)
over 48 hours to a final concentration near 25% of the original, while the 1:1 DFB +
DDFP mixture remained highly stable over the entire period (p = 0.673). The in vitro
stability exhibited by DFB may be suitable for certain applications, but is expected
to fare much worse in vivo. Therefore, for applications that demand long circulation
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Figure 4.9: DFB droplets showed concentration drop-off over 48 hours when exposed
to 37 ◦C in vitro, while a 1:1 DFB + DDFP mixture showed high stability over the
same period.
profiles, a mixture such as the 1:1 DFB + DDFP droplets may be preferable. These
additional results show that PFC mixing may be implemented across a wide range of
perfluorocarbons (both liquid and gas) in order to optimally tune droplets.
It is expected that the acoustic field near the bottom of the microcellulose tube is
complex due to interaction with the tube itself [148]. This may explain some of the
variability present in the droplet vaporization thresholds, as the microscale droplets
rested on the tube prior to vaporization. It may also be possible that the tube damped
the pressure experienced by the droplets, and that the actual pressures used to vaporize
were lower than those reported here. Additionally, it was noted during testing that very
slight changes in transducer position could yield significant changes in the reported
vaporization threshold for microscale droplets. This variation in transducer alignment
can be seen in the values reported for both DFB and OFP droplets at room temperature
in Figures 4.6 and 4.7, where the trends appear to be shifted upward to some degree in
the latter image because they were collected under a slightly different alignment. To
ensure this source of variation did not influence conclusions drawn regarding the efficacy
of PFC mixing or relative vaporization energy, each figure represents data collected on
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the same day under the same alignment conditions.
Figure 4.10: OFP droplet sample exposed to a 0.25 µs pulse at 1.1 MPa initiated at
t = 0 forms bubbles in the 1 to 5 µm range, confirming the presence of viable nanoscale
OFP droplets.
Measuring droplet vaporization thresholds for microscale droplets is convenient to
compare the general influence of factors such as PFC choice and temperature. Eval-
uating appropriate vaporization pressures for nanoscale droplets, on the other hand,
is confounded by the inability to resolve them optically. In this study, the presence
of microscale OFP droplets implies the presence of nanoscale OFP droplets, although
the samples were too unstable to prove this by DLS. To verify the expected presence
of vaporizable nanoscale OFP droplets, a sample of OFP droplets was diluted 50% in
PBS and exposed to an acoustic rarefactional pressure of 1.1 MPa (MI of approximately
0.4) at 37◦C (Figure 4.10). This pressure was selected based on being approximately
twice the pressure required to vaporize microscale droplets. The resulting bubbles,
which were between 1 and 5 µm, confirm the presence of vaporizable sub-micron OFP
droplets as small as 200− 300 nm by ideal gas law estimations [70].
The size of a PCCA also plays a key role in the relationship between thermal sta-
bility and sensitivity to ultrasound. Previously described methods of controlling or
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altering size distributions of PFC droplets have relied on microfluidic sorting, microflu-
idic droplet generation, or filtering [50; 110; 73; 149; 150]. Because the size of a PFC
droplet produced by microbubble condensation is largely dependent on the initial mi-
crobubble size, the size distribution of PFC droplets could be tailored as desired by
simply controlling the size distribution of the initial microbubble samples through well
described techniques such as differential centrifugation or microfluidics [151; 152]. Com-
bining precursor microbubble size-selection with PFC mixing may provide a means of
highly-tuning droplet sample characteristics to specific applications.
4.5 Conclusion
In this study, we have demonstrated proof-of-principle that it is possible to de-
sign PCCAs from a variety of low boiling point PFCs that have not been previously
considered. The results show that a given droplet’s balance between stability and
‘vaporizability’ is a tradeoff of several factors such as PFC composition and ambient
temperature. Through the methods presented and discussed here, it is conceivable
that one could customize the droplet characteristics (size, thermal stability, vaporiza-
tion threshold) with a particular application in mind. These results demonstrate the
promise for low boiling point PFCs as a useful new class of compounds for phase-change
contrast agents.
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CHAPTER 5
Measuring Activation of Nanoscale PCCAs
5.1 Introduction
Numerous studies have proposed and investigated nanoscale PCCAs that, once va-
porized, form microbubbles ideal for ultrasound imaging contrast and cavitation within
the ultrasound beam (i.e. having resonance frequencies near the insonation frequency)
[112; 72]. Such an agent would have utility for applications where imaging, drug de-
livery, and ablation are facilitated by passive diffusion of agents via the enhanced per-
meability and retention effect of solid tumors [91], as well as the potential to be used
for general diagnostic/molecular imaging of other vascular targets. Determining appro-
priate ultrasonic conditions to initiate vaporization is vital for understanding both the
physics behind droplet interactions with the ultrasound beam and for developing prac-
tical in vivo sequences for each application. However, measuring the phase-transition
conditions for these nanoemulsions is complicated by a variety of factors. For a bulk
compound, the phase-transition temperature and pressure can be predicted simply, but
for micro- and nanoemulsions of the same compound, scaling effects significantly alter
c© 2013 IOP Publishing (ioppublishing.org) Portions reprinted, from PS Sheeran, TO Matsunaga,
and PA Dayton. “Phase-Transition Thresholds and Vaporization Phenomena for Ultrasound Phase-
Change Nanoemulsions Assessed via High-Speed Optical Microscopy” Physics in Medicine and Biology,
2013 June; 58: 4513-4534.
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these properties. The internal pressure of the droplet is increased beyond ambient pres-
sure as a result of the Laplace pressure - and reaches several additional atmospheres of
pressure for perfluorocarbon droplets with diameters in the 100s of nanometers [70; 52].
This greatly increases the ‘effective’ boiling point (boiling point elevation) as well as
the ultrasound intensity necessary for vaporization. In addition, myriad other factors
of droplet design, ambient conditions, and ultrasound parameters have been shown to
influence activation of phase-change perfluorocarbon droplets (Table 1.2). As such, a
model to predict the phase-transition point of an individual droplet that incorporates
these influences is yet to be developed.
Researchers have instead approached determining phase-transition conditions for
their emulsions experimentally. Historically, measuring activation has taken two forms:
direct and phenomenological. In order to discern the underlying physics (precise re-
lations between droplet design and the phase-transition point), the minimum ultra-
sound conditions required to vaporize a droplet are typically of interest. As such, di-
rect measurements often involve high-magnification microscopy and high-speed imaging
such that researchers can isolate individual droplets optically and observe the phase-
transition as it occurs while manipulating the activation parameters [77; 130; 82]. By
gathering a large number of observations, general trends and conclusions can be drawn
regarding the relationship of activation parameters with the variety of design factors.
However, if the desire is to ultimately use the agents in vivo, measurements must in-
corporate spatial aspects of vaporization such as degree of activation in a region where
many droplets are present (as the goal is rarely to activate only a single droplet).
Therefore, those more interested in measuring how well the emulsions can deliver a de-
sired effect typically approach measures of activation through phenomenological means,
such as echo/image/fluorescence intensity [71; 74; 75; 110; 153], reduction in blood flow
[92; 85], degree of stable or inertial cavitation [73; 75; 76], size of lesion or bubble cloud
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formed [54; 108], tumor volume reduction and cell death [135; 52; 154], and degree
of thermal or drug/gene delivery [135; 114]. By altering the activation parameters
and observing the change in a desired effect, practical activation conditions can be
determined.
Each of these approaches can be extremely limiting with regard to determining
phase transition thresholds for nanoemulsions, in particular. Direct optical observations
do not allow measure of the initial size of individual particles below 8˜00 nm with
reasonable accuracy due to brightfield resolution limits (though they are visible at
sizes > 500 nm), so trends for larger microscale particles must be used to predict
parameters at the nanoscale (Figure 2.5). The accuracy of these trends through the
entire nanoscale must be called into question. In addition, the interaction between
the acoustic beam and the experimental setup (often a microcellulose tube) can lead
to a heterogeneous pressure distribution within the tube and introduce a high level
of spatial variation in results [77; 148]. Lastly, methods of producing PCCAs often
result in polydisperse emulsions, as is commonly the case for nanoscale agents [86; 52;
114; 72; 155]. Because bubble nucleation is a stochastic process [156], and because
an inverse relationship between particle size and vaporization pressure exists, larger
droplets will phase-shift with greater efficiency at a given ultrasound pressure. Even
a small presence of large outliers can highly skew phenomenological measures such
as echogenicity/echo amplitude as the contribution by larger particles overshadows
the more subtle contribution of the nanoscale particles. Though the researcher can
measure the degree to which the effect occurs at given ultrasound parameters, there is
no simple link between these observed effects and a ‘representative size’ being activated
unless the emulsions have very narrow distributions (which is difficult to achieve with
nanoemulsions). Some have chosen to relate the activation parameters with distribution
mean, median, or mode sizes, while others have found a high correlation with the larger
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content in the distribution (such as the 99th percentile size) [75; 76; 114; 72; 157; 158;
154].
Thus, there is a need for methods that better assess the activation of PCCA na-
noemulsions for studies of underlying physics and for defining practical in vivo param-
eters. We hypothesize that one method to achieve baseline measures of nanoemulsion
activation for many formulations is to capture the distribution of bubbles generated by
each ultrasound pulse and track how these distributions change with varying ultrasound
pressure. This method of ‘distribution-tracking’ begins from the simple observation that
individual droplets in a nanoemulsion cannot be measured optically, but the bubbles
they produce once vaporized are typically on the order of 500 nm or larger - sufficient
in size to resolve and measure on many optical systems. By relating the microbubble
size to the original droplet size by using ideal gas law relations, the changes in bubble
distribution can be used to assess the efficiency of activating the originally nanoscale
content of the emulsion. This also avoids the interfering effects of large outliers present
in polydisperse populations: even though large content will be activated with high
efficiency at a given pressure and result in very large bubbles, they will compose a
very small portion of the distribution once the nanoscale content is being vaporized
efficiently.
In order to use the bubble distribution resulting from an individual pulse as a mea-
sure of activation, it is essential to ensure that the droplet-to-bubble transition proceeds
with minimal secondary effects - allowing the diameter of a bubble to be related to the
originating droplet’s size by ideal gas law relations. These secondary effects include the
intake of ambient dissolved gases and interaction with subsequent ultrasound cycles in
the vaporization pulse. In Chapter 2, vaporization of decafluorobutane microdroplets
showed that even within a few seconds post-vaporization, the bubbles could be as much
as twice the predicted size due to influx of dissolved gases. When the experiments were
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duplicated with degassed water, droplets expanded to very near the predicted size, and
showed only minor growth over the course of several minutes. Therefore, we hypothe-
size that in order to assess activation by the bubbles produced, the experimental setup
must be degassed, and the distributions must be captured shortly after vaporization.
It is also possible that the distribution of bubbles resulting from a vaporization event
will be influenced by the ultrasound pulse itself - although very little has been reported
to this effect in PCCA literature to date. Even when formulated with highly volatile
components, nanodroplet vaporization can require pressures significantly higher than
what is commonly used for microbubble imaging [52; 114](also see Chapters 2 through
4). With high pressures and long pulse lengths comes an increased possibility for sec-
ondary effects such as microbubble destruction, fusion, and radiation force interactions
[159; 160]. Therefore, we additionally hypothesize that in order to minimally effect
the resulting bubble population, pulses as short as possible must be used to initiate
vaporization. Though long insonation periods at low amplitudes may ultimately cause
droplet conversion by interaction with nearby bubbles produced earlier in the period
[74] and/or by thermal means [109], activation by a pressure-only means is desired here.
In this chapter, we first investigate the influence of the vaporization pulse on the
bubbles produced from DFB nanoemulsions through ultra-high-speed microscopy in
order to determine the likelihood of secondary effects occurring within long vaporization
pulses. We next demonstrate that in vitro activation of nanoemulsions by short pulses
at several clinically relevant frequencies can be measured by tracking changes in the
distribution of produced bubbles - providing practical in vivo activation parameters
that optimally vaporize the nanoscale content at given frequencies and pulse lengths.
Here, we consider droplet vaporization to be optimal when the majority of the bubbles
produced originate from droplets forming the mode of the polydisperse size distribution.
We further demonstrate that activation of low boiling point nanoscale PCCAs can
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be accomplished using pulse lengths and pressures within the output capabilities of
common clinical ultrasound machines.
5.2 Materials & Methods
5.2.1 Decafluorobutane Nanodroplet Preparation
Polydisperse lipid-coated nanodroplets were prepared using the same protocol in
Chapter 4. Droplet suspensions were stored at 4◦C for up to 2 h prior to use. Droplets
were sized with dynamic light scattering (Malvern Nano ZS, Malvern Instruments Ltd,
Malvern, Worcestershire, UK) by placing approximately 1.5 mL of a 10% dilution of the
droplet emulsion in a plastic sizing cuvette. Nanodroplet emulsions yielded consistent
size distributions with peaks on the order of 200 nm in diameter when weighted to
either intensity or number, with a mean diameter on the order of 200−300 nm (Figure
5.1).
5.2.2 Experimental Setup
The experimental setup used here was similar to that described in Chapters 2
through 4. An acrylic-lined, continuously degassed water bath was maintained at 37◦C
and mounted onto an inverted microscope. Images of bubble generation were captured
using a 100x (NA = 1.0) water immersion objective interfaced with either an ultra-
high-speed framing camera with a 24-frame buffer (SIMD24, Specialized Imaging, Simi
Valley, CA) capable of imaging up to 200 million frames per second (for investigat-
ing activity within a single pulse), or a high-speed framing camera (FastCam SA1.1,
Photron USA, Inc., San Diego, CA) set to 60 frames per second with a long buffer (for
capturing bubbles generated after the pulse). For use with the ultra-high-speed cam-
era, a high-intensity xenon strobe was interfaced with the microscope system to provide
sufficient illumination. Otherwise, a standard 100 Watt halogen illuminator was used.
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Figure 5.1: Dynamic light scattering measurements of DFB nanoemulsions produced by
microbubble condensation. Lines show the result of sizing averaged for three repeated
measurements per sample over three samples (nine total measurements), in both a
number-weighted and intensity-weighted format. When number-weighted, the mode
diameter occurs at 164 nm, with a mean droplet diameter of 192 ± 85 nm; when
intensity-weighted, mode size occurs at 190 nm with mean size of 297± 323 nm. Note:
Malvern Nano ZS set to ‘Multiple Narrow Modes’ for high-resolution analysis.
Images and videos resulting from the experiments were analyzed using ImageJ software
(NIH, Bethesda, MD). All optical measurements were calibrated by reticle. The prac-
tical optical resolution of the system limited measurement of particles to those greater
than approximately 800 nm in diameter to maintain reasonable accuracy. While in the
liquid state, droplets tended to settle toward the bottom of the tube, but once vapor-
ized floated to the top due to buoyancy. By manipulating both the volume injector
and the micropositioner, the entire volume of fluid being investigated before and after
vaporization can be brought into focus and captured.
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Figure 5.2: Experimental setup. A piston ultrasound transducer is manually triggered
to deliver a short pulse to the portion of the microcellulose tube resting in the optical
plane. Prior to droplet vaporization, large droplets can be visualized near the bottom
of the tube with no significant presence of bubbles near the top of the tube. After
vaporization is induced, the focal plane is adjusted to the top of the microcellulose
tube to capture images of bubbles produced. Axes indicate the elevational, lateral, and
axial dimensions of the incident ultrasound pulse.
5.2.3 Acoustics
Three different ultrasound piston transducers were used in these studies to investi-
gate the influence of frequency on droplet vaporization. In all cases, the piston trans-
ducers were driven by an arbitrary waveform generator signal (AFG 3101, Tektronix,
Inc., Beaverton, OR) amplified 60 dB using an RF amplifier (A500, ENI, Rochester,
NY). For ultra-high-speed imaging investigating activity within a single pulse, a 1 MHz
center frequency spherically focused transducer with a 2.2 cm diameter and focal length
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of 3.75 cm (IL0106HP, Valpey Fisher Corp., Hopkinton, MA) was driven with a 20-cycle
sinusoid of adjustable amplitude at 1 MHz (total insonification time of 20 µs; approx-
imately the maximum imaging time allowed by the flash bulb). The camera frame
spacing was set to record at either 20 million frames per second with 30 ns exposure
times to capture many frames within one cycle, or set to record at 1 million frames
per second with 30 ns exposure to capture events occurring across several cycles. To
capture bubble distributions in the second set of experiments, the previously described
1 MHz transducer was used as well as transducers with 5 MHz (2.2 cm diameter, 5 cm
focus; IL0506HP, Valpey Fisher Corp., Hopkinton, MA) and 7.5 MHz (2.2 cm diameter,
5 cm focus; V321, Panametrics, Inc., Waltham, MA) center frequencies. These trans-
ducers were driven using 2-cycle pulse excitation waveforms with variable amplitude at
1 MHz, 5.5 MHz, and 8 MHz, respectively. Because brief, high-intensity pulses typi-
cally in the nonlinear regime were used, all transducers were calibrated at focus using
a needle hydrophone (HNA-0400, Onda Corp., Sunnyvale, CA) with a magnitude-only
hydrophone deconvolution method [161].
5.2.4 Droplet Vaporization and Imaging of Bubble Distributions
During bubble distribution measurements, samples were diluted to between 10 to
30% in order to reduce the number of bubbles produced from each pulse (such that the
majority of the bubbles were not obscured from measurement by other bubbles). The
droplet emulsions were injected via the custom volume injector and the forward flow
stopped prior to initiation of the ultrasound pulse. The tube position relative to the
acoustic/optical focus was adjusted so that the optical focus rested at an elevational
plane approximately 70 µm from the microcellulose tube bottom (1/3 of the tube
diameter). Once the ultrasound pulse was triggered manually, the tube was repositioned
such that the focal plane was near the tube top, and several seconds were allowed to
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pass for bubbles to float to the focal plane. The micromanipulator was then used to
translate through the tube elevationally and laterally to capture all bubbles present
resulting from the single pulse. Starting from a lateral position downstream of the
particle injection direction, the region of the tube in the optical focus was translated
in a square wave pattern along the lateral and elevational dimensions across the lateral
length of the bubble cloud produced. This type of translation allowed resolution of
bubbles beyond the microscope objectives depth of view. Between pulses, forward
flow of the sample volume was restored in order to bring an unvaporized volume into
the optical focus. Ultrasound parameters were selected by observing the lowest input
parameters that repeatably generated a sufficient number of bubbles for measurement
purposes (typically on the order of 30 bubbles per pulse), and 7 to 8 test pressures
between this and the maximum output of each transducer were chosen. For each
sample, the emulsion was either diluted to 30% in PBS (in order to produce larger
number of bubbles at lower pressures where less activation is occurring) or 10% (in
order to prevent obscuration of bubbles at higher pressures where high activation is
occurring), and the bubbles emerging from each pulse recorded. Any bubble that was
not stationary at the top of the tube was excluded, as well as any bubble with edges that
could not be reasonably discerned. Bubbles from at least two pulses were captured at
each test pressure (often 4− 5 pulses for lower pressures) to ensure a sufficient number
of bubble samples at each pressure were obtained. This process was repeated for three
samples at each frequency (1, 5.5, 8 MHz).
5.2.5 Distribution Tracking Theory and Processing
A modified ideal gas law equation that includes the effects of Laplace pressure can
be derived to predict the relationship between the expanded bubble and the originat-
ing droplet (eqn. 2.7) [70]. Using values reported earlier for DFB, the expansion of
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lipid-encapsulated DFB droplets originally 200 to 250 nm in diameter should result
in microbubbles approximately 800 nm to 1.1 µm in diameter after vaporization. As
the smallest size practically measurable in brightfield imaging is often on the order
of 800 nm, tracking the bubble distribution that emerges after a vaporization event
can provide substantial insight into the efficiency of vaporizing droplet distributions
with peaks on the order of 200 nm in diameter or larger. In order for the resulting
distributions to be accurate, however, any secondary effects such as bubble growth by
intake of dissolved gases, dissolution by gas exchange, and fusion or destruction by the
ultrasound pulse must be minimized.
The concept of distribution tracking can be illustrated simply by assuming the DFB
droplet distribution is Gaussian in nature, with a peak of 200 nm in diameter. By the
ideal gas law relationship, if the emulsion is completely vaporized, the resulting mode
bubble size would be 800 nm in diameter, which is large enough to capture by standard
optical measures. Theoretically one could predict the resulting mean bubble size as well,
though optical resolution limits would prevent experimentally recovering this (bubbles
much smaller than 500-600 nm in diameter would not be visible or measurable). At a
given ultrasound peak rarefactional pressure, the likelihood of vaporizing a droplet of
a specific size is stochastic in nature, with the probability increasing as the droplet size
increases (see Chapter 1). Thus, at low pressures, the upper tail of the distribution will
constitute most of the droplet vaporization activity, with very little activation of smaller
droplets. The resulting bubble distribution, in this case, will have a much larger mean
and mode size than would be present for a highly optimized activation pulse. As the
rarefactional pressure magnitude increases, the smaller emulsion droplets will vaporize
with greater efficiency, and mode/mean sizes will continue to decrease. Once the peak
in the droplet distribution begins to vaporize more efficiently, a transition will occur
and the mode bubble size should remain stationary - as droplets smaller than this
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will produce fewer numbers of bubbles - though the mean will continue to decrease as
the rarefactional pressure magnitude increases. As such, the interaction of the mean
and mode bubble sizes as the pulse pressure increases should theoretically provide an
indication of the peak droplet size activation.
In practice, there are experimental obstacles that prevent the ideal case from full
realization. First, while the generation of droplets typically provides a uniform distribu-
tion, the ‘tails’ of the distribution are likely to be much more variable than a Gaussian
distribution, and likely to be highly variable between samples, as this portion represents
extreme outliers in the distribution. Therefore, statistics of the bubble distributions are
expected to be highly variable within samples and between samples until a significant
portion of the main distribution (common to all samples) is being vaporized. Once the
vaporization pulse is efficiently activating the main portion of the droplet distribution,
these statistics should stabilize. Second, the optical resolution limits prevent contin-
ued tracking of the mode at sizes much smaller than 800 nm in diameter. With this
limitation, once droplets that form bubbles on the order of 500 nm - 1 µm are being va-
porized in significant numbers, the bubble distributions should still provide evidence of
optimized activation (higher pressures will create a higher percentage of small bubbles;
mean size will continue to decrease).
In these experiments, the area of all bubbles produced for an individual pulse that re-
mained stationary in position near the top of the tube was measured by hand, converted
to diameter, and collected in Excel. Within each emulsion sample, bubble measure-
ments taken for a given ultrasound pressure across all pulses recorded were grouped so
that the overall bubble distribution for each pressure could be assessed. All statistical
outliers were removed from the measurements before statistics were calculated. The
distribution mean and median were calculated from the resulting distribution. Samples
were then rounded to the nearest 1 µm increment for calculation of the mode size such
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that bubbles on the order of 500 nm to 1.5 µm represented the smallest histogram bin.
These measurements were repeated on all samples and the results averaged between
samples to generate trends.
Figure 5.3: Ultra-high-speed microscopy (20 million frames per second) of bubbles pro-
duced during a 1 MHz, 20-cycle vaporization pulse of 1.45 MPa rarefactional pressure.
Many bubbles are observed to emerge through the first rarefactional phase (a)-(d), but
as the transition through the second compression phase occurs (e)-(g) the bubbles are
observed to compress and disappear from view. Upon the second rarefactional phase
(h) and (i), many of the bubbles re-emerge (denoted by white arrows), but those in-
dicated by black arrows in (d) do not re-appear. During the third compression phase
(j)-(i), the bubbles are observed to compress again. Scale bars indicate 5 µm. Note:
this image comprises 12 selected frames from a longer source video.
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5.3 Results
5.3.1 Influence of Vaporization Pulse
Using 20-cycle pulses at 1 MHz, ultrasound parameters were increased gradually
until they were observed to be sufficient to consistently vaporize DFB droplets into
bubbles on the order of 1 − 5 µm in diameter. For these investigations into interac-
tions within a single pulse, a peak rarefactional pressure of 1.45 MPa was found to
be sufficient. In each case, the droplet emulsion was diluted to 50% in PBS. When
set to record at 20 million frames per second, the vaporization activity within each
single cycle could be visualized in high detail (Figure 5.3). Near the trough of the
first rarefactional half-cycle, non-visible nanodroplets began to vaporize (Figure 5.3b),
resulting in a high number of bubbles visible within the focus that appeared to reach
their maximal size within 150 − 200 ns of their vaporization (Figure 5.3d). As the
transition to the compressional half-cycle began, all of the bubbles began to visibly
compress and have disappeared from view completely by the peak of the compression
(Figure 5.3g). In the sequential rarefactional trough, many of the previously visualized
bubbles re-emerged, indicating they were not destroyed by the compression phase (Fig-
ure 5.3i), although many bubbles that were present in the first rarefactional cycle did
not re-emerge, suggesting that each positive pressure phase has the potential to destroy
some portion of the bubbles produced in the prior rarefactional phase. At these imag-
ing and ultrasound parameters, this type of interaction between the resulting bubbles
and the compression/rarefaction half-cycles was highly repeatable.
When recording at 1 million frames per second, vaporization activity across several
cycles could be investigated. When the focus was kept approximately 70 µm from
the tube bottom, some frames caught instances of the expansion/compression activity
shown in Figure 5.3, though the frame-rate was not high enough to capture in high
detail. By re-focusing toward the bottom of the tube where the large outlier droplets
111
rested due to weight, vaporization of the very large droplets could be observed over
several sequential cycles (Figure 5.4). In the first compressional half-cycle, unvaporized
droplets with diameters on the order of 1 − 5 µm could easily be resolved (Figure
5.4a), and began to vaporize in the first rarefactional half-cycle (not pictured). The
much larger microscale droplets took longer to completely vaporize than the sub-micron
droplets in Figure 5.3, requiring on the order of 2 µs or more to fully expand, depending
on size. As they result from much larger droplets, these outliers of the distribution
formed bubbles on the order of 5 µm in diameter or larger (much larger than those in
Figure 5.3). With the repeated sequence of compression/rarefaction, several phenomena
previously noted for microbubbles [160] could be observed and were highly repeatable.
During the rarefactional phase, fully expanded bubbles in close proximity could fuse
and form larger bubbles (Figure 5.4b-d, white arrows), possibly as a result of over-
expansion stretching the lipid membrane and allowing the gas interface of bubbles to
come into contact. Over the course of several cycles, the bubbles were seen to cavitate
violently, potentially causing jetting behavior, and move toward each other with each
cycle due to secondary radiation force (Figure 5.4c-i). Bubbles of this size were not
destroyed by the ultrasound pulse as in Figure 5.3, and as a result tended to fuse into
a smaller number of larger bubbles over the course of the pulse. Images taken in this
plane also highlight the complex, stochastic nature of droplet vaporization. Of the
visible droplets (Figure 5.4a), the ones that ultimately vaporized in subsequent frames
could not be predicted by size alone. In fact, one extreme outlier on the order of 5
µm in diameter could be visualized (Figure 5.4a, black arrow) that did not vaporize
over several repeated rarefactional cycles, while much smaller droplets did vaporize.
Whether this type of behavior is influenced by the complex acoustic field inside the
tube [77; 148], or as a result of a mechanical coupling of the droplet to the tube as it
rests at the bottom will require further investigation.
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Figure 5.4: Ultra-high-speed microscopy (1 million frames per second) of bubbles pro-
duced during a 1 MHz, 20-cycle vaporization pulse of 1.45 MPa rarefactional pressure.
Droplets are observed to vaporize in the first rarefactional phases and fully expand
within 1− 2 µs (a)-(d). Microbubble phenomena of fusion (b)-(d), white arrows) and
radiation force (d)-(i) can be seen, indicating that large bubbles may combine to form
much larger bubbles under the influence of long vaporization pulses. Scale bars indicate
5 µm. Note: this image comprises nine selected frames from a longer source video.
5.3.2 Bubble Distribution Tracking
In order to minimize the effects shown in the previous section, droplet emulsions
diluted to between 10% and 30% (see Materials and Methods) were vaporized using
short pulses at 1, 5.5, and 8 MHz (Figure 5.5). Though the transducers were driven
with a 2-cycle waveform, the bandwidth of the piston transducers resulted in additional
ringing behavior that exposed droplets to additional compression and rarefactional
cycles - most evident in the case of the 5.5 MHz transducer (Figure 5.5b).
As the ultrasound output increased, the overall number of bubbles produced also
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Figure 5.5: Representative vaporization pulses at (a) 1, (b) 5.5, and (c) 8 MHz when
driven with a 2-cycle sinusoid. Low transducer bandwidth for the high-power piston
transducers resulted in additional ringing behavior such that droplets were exposed to
more than just two compression/rarefaction phases. Nonlinear propagation effects are
clearly visible at these pressures.
increased, and the number of bubbles on the order of 1 µm increased in proportion
- indicating greater efficiency of vaporizing the non-visible nanodroplets (Figure 5.6).
At the lowest pressures tested, bubbles tended to be on the order of 5 µm or larger
in diameter (Figure 5.6a), while at the highest pressures used the majority of bubbles
present were near 1 µm in diameter (Figure 5.6b). It is worth noting that the lowest
ultrasound output used was not a lower limit of vaporization, but that it produced
enough bubbles to simplify distribution measurements. It is highly likely that some
droplet vaporization is occurring at pressures below these, though it is not likely to be
primarily from the nanoscale content.
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The diameter of all bubbles in focus post-vaporization for each sample at the test
pressures used were analyzed from images such as Figure 5.6. In order to ensure the
fidelity of the conclusions, a high number of bubbles were counted for each sample -
approximately 3,200 bubbles per sample (or 9,700 total sizings for each frequency). The
total number of bubbles sized over all experiments was nearly 30,000.
As is common with PCCAs involving low boiling point perfluorocarbons, some de-
gree of spontaneous bubble generation is present. In these experiments, bubbles present
without exposure to ultrasound were observed very sparsely, and were typically not
present in the optical focus at the time of insonation. Videos of these bubbles in three
control DFB droplet samples (not exposed to ultrasound) were sized, and showed that
without ultrasound, bubbles present in solution (N = 610) had mean diameters of
8.6± 3.3 µm, with a mode of approximately 3 µm (Figure 5.7).
Bubbles resulting from vaporization pulses were analyzed (as described in Materi-
als and Methods) with regard to mean, median, and mode bubble diameter at each
pressure in order to ascertain trends occurring with increasing acoustic parameters,
and averaged across all samples at each frequency. In general, mean bubble size at
the lowest ultrasound pressure used in each case tended to be 7 − 8 µm in size, and
decreased significantly (p < 0.01) to a mean between 4 − 5 µm at the highest ultra-
sound pressure used (Figure 5.8a) due to the increase in the number of small bubbles
at higher pressures. Median size showed virtually identical trends as mean size, and is
not shown here. Like the mean size, the mode of the bubble distribution was on the
order of 7− 9 µm in diameter at lower ultrasound output (Figure 5.9b). As expected,
high variation in the mode size at low pressures was observed between samples. As ul-
trasound output increased with each frequency, the mode generally decreased with high
variation until settling at 1 µm, the smallest bin used. Past this transition, the mode
remained stable at all higher output pressures, and the difference in the measurements
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at the highest output for each frequency were highly significant compared to the lowest
output pressures (p < 0.01).
These results also show that, even when driving parameters were relatively similar,
frequency of the incident ultrasound pulse appeared to play a role in the pressures
required for vaporization. At the lowest ultrasound frequency used, significant bubble
formation was noted at rarefactional pressures as low as 1 MPa, while at 8 MHz,
the same distribution of bubbles was not present until rarefactional pressure reached
approximately 3 MPa. Similarly, the mode size for 1 MHz ultrasound appeared to reach
its final value at rarefactional pressures near 2−2.25 MPa, while this transition did not
occur for 8 MHz ultrasound until rarefactional pressures near 3.75 MPa. In each case,
the 5.5 MHz ultrasound characteristics were in between those obtained with 1 and 8
MHz ultrasound.
5.4 Discussion
5.4.1 Vaporization Pulse
Some prior studies have explored the dynamics of dodecafluoropentane microdroplet
vaporization on a short timescale and noted instances of complex vaporization behav-
ior. In particular, Wong et al. [162] showed that bubble evolution may proceed in
stages after initial nucleation, while Haworth and Kripfgans [101] demonstrated that
longer pulse lengths increased the probability of an individual microdroplet vaporizing
and reported instances of coalescence of bubbles in close proximity. Reznik et al. [155]
recently demonstrated sub-micron agents may recondense back to the liquid state after
vaporization, but that coalescence of bubbles increased the chance of bubble survival.
Finally, Shpak et al. [83] revealed that pulse length and frequency can significantly af-
fect the rate at which bubble evolution occurs in the initial stages, and that, depending
on the extent of inward gas diffusion, DDFP vapor bubbles may re-condense within
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Figure 5.6: Examples of bubble distributions generated as a function of ultrasound
output at 5.5 MHz. At rarefactional pressures near (a) 2 MPa, few bubbles on the
order of 1 µm in diameter were present, while increasing the pressure to approximately
(b) 3 MPa and (c) 4.25 MPa increased the proportion of small bubbles present. Scale
bar represents 5 µm.
the pulse compression phase. Similarly, the results reported here demonstrate prelim-
inary evidence that bubbles produced early in the pulse can be significantly affected
by the ultrasound pulse itself through destruction or coalescence, and that these types
of interactions increase with pulse length. For many therapeutic applications, such as
cavitation enhancement, this type of acoustic activity may be acceptable and/or de-
sired. Haworth and Kripfgans [101] suggest coalescence may be useful for applications
such as vessel occlusion, but not for others such as phase aberration correction. For
applications that seek to generate a large number of bubbles for contrast while min-
imizing bubble-induced bioeffects, a better understanding of these types of effects is
needed. It may be that small bubbles are more likely to be destroyed by compres-
sion, while the large bubbles resist destruction by compression and are more likely to
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Figure 5.7: Histogram of sparse bubbles present in three droplet emulsion samples
(N=610) without the use of a vaporization pulse as a result of spontaneous thermal
vaporization. Without ultrasonic vaporization, the small number of bubbles present
had a mean size of 8.6± 3.3 µm, with a mode of approximately 3 µm.
fuse and form larger bubbles. The precise interplay between droplet activation and
the rarefaction/compression cycles may not be simply that more cycles will produce
more bubbles, but that there is a balance between maximizing bubbles produced from
the rarefactional phase, and minimizing secondary effects caused by the compression
phase. Effects such as these are also sources of skew when measuring droplet activation
through echogenicity or echo amplitude produced.
5.4.2 Optimizing Activation via Distribution Tracking
Aside from the sources of error presented above (selective bubble destruction/fusion),
other effects do influence the accuracy of distribution tracking. Because larger bubbles
are much more buoyant than very small bubbles, it is expected that some of the small
bubbles were obscured by large bubbles in the optical focus. Additionally, the very
small bubbles were more subject to the inertial forces of the surrounding fluid, and
were often seen to be translating laterally just beyond the focal plane. Because the
118
Figure 5.8: Changes in distribution statistics as a function of frequency and rarefac-
tional pressure averaged for three separate samples. Mean diameter (a) decreased in a
generally linear fashion as rarefactional pressure increased, and all samples settled at a
similar mean diameter at the highest ultrasound pressure that could be delivered.
criterion for measurement was that the bubbles were stationary at the top of the tube,
both of these effects resulted in a possible skew toward larger bubbles in the mea-
surements. Any gas-exchange that may have occurred between vaporization and data
collection would also have resulted in a skew toward a larger distribution, although this
was limited by degassing the experimental setup. As such, the trends reported may be
overestimates of the actual pressures needed to result in the distribution produced.
The changes in the bubble distributions as a function of ultrasound pressure can
be illustrated clearly by combining all of the sizings obtained over all samples for an
individual frequency (Figure 5.10). Once ultrasound pressure is high enough to cause
bubble generation, the main lobe of the distribution at first shifts to values much
higher than the spontaneous control bubbles (Figure 5.7), and only a small portion of
the distribution is represented by the smallest bin size. As pressure increases, the peak
of the main lobe begins to decrease, and the number of very small bubbles increases
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Figure 5.9: Changes in distribution statistics as a function of frequency and rarefac-
tional pressure averaged for three separate samples. Mode diameter fluctuated highly
at the lowest pressures used for each frequency, but once pressures increased past a
threshold, the mode settled to the lowest resolvable bin size - indicating bubbles pri-
marily resulted from activation of the modal peak. The rarefactional pressure required
to achieve a similar mode size was seen to increase with frequency.
until it becomes the peak of the distribution - now much lower than the control values.
As pressure continues to increase, this peak increases in proportion to the rest of the
distribution, indicating greater efficiency of vaporization.
Many multi-variable metrics can be chosen in order to capture the dynamic changes
in bubble distribution occurring as a function of rarefactional pressure, such as Wasser-
stein metrics [163] or other more basic measures of histogram skew [164]. In this study,
we demonstrate this through use of Pearson’s first skewness coefficient (Pearson’s mode)
in order to combine several aspects of Figures 5.8 and 5.9 into one measure:
skew =
mean−mode
std dev
(5.1)
Theoretically, when pressures are low, both the mean and the mode should be
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Figure 5.10: Histogram of all bubble sizings taken at 5.5 MHz (N = 11,654) as a
function of rarefactional pressure (bin size 0.5 µm). At the lowest pressures tested, the
distribution peak shifts to much higher than the controls with no ultrasound (Figure
5.7). As pressure increases, the number of small bubbles increases in proportion until
the smallest bin size overtakes as the peak in the distribution. Continued increase in
the pressure amplifies the proportion of these small bubbles relative to other bubbles
present in the distribution.
relatively large and of similar value (although high variability is expected), and so skew
should be near zero. As activation of smaller droplets becomes more efficient, the mode
will shift rapidly, while the mean shifts gradually, causing a sharp increase in the skew
measure. Once the mode settles, the mean will continue to decrease slowly, resulting
in a gradual decrease of the skew. Using this measure on the previously presented
distribution data, and averaging across the samples at each frequency, a clear picture
of the transition can be obtained (Figure 5.11). As expected, the variability at low
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pressures for each frequency is relatively high, and compounded by the combination of
variation in mean and mode, but the skew peaks at a transitional pressure and remains
constant or decreases slightly past this.
Figure 5.11: Measures of distribution skew (Pearsons first skewness coefficient) averaged
for all samples at each frequency. At the lowest pressures used, skew was near zero,
but increased with pressure until a transitional pressure - past which skew remained
constant or decreased slightly. The transitional pressure (indicating bubbles primarily
resulted from nanoscale droplets in the modal peak) appears to increase with frequency.
The skew analysis further demonstrates the relationship between frequency and
droplet vaporization - that under these experimental parameters, the pressure required
to activate nanodroplets increased with ultrasound frequency. The transitional pressure
past which a similar distribution skew was achieved occurred near 2 MPa for 1 MHz,
near 3 MPa for 5.5 MHz, and near 3.75 MPa for 8 MHz. Figure 5.5 demonstrates the
pressure waveforms when driven at pressures near the transition points in Figure 5.11.
One would initially expect that the 5.5 MHz transition pressure would occur nearer to
the pressure required at 8 than 1 MHz. However, the low bandwidth of the 5.5 MHz
transducer resulted in many more additional ultrasound cycles (Figure 5.5b) that may
have reduced the pressures needed to obtain similar distributions.
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These results contradict an early and longstanding view in the PCCA literature
that the pressures needed to achieve droplet vaporization can be reduced by increasing
the ultrasound frequency [71; 50; 76; 88], although recent studies (including this one)
have found the contrary to be true [154]. Shpak et al. have shown that this effect
may be rooted in pulse harmonics focusing within the droplets [78]. The magnitude
of the focusing depends on the frequency, pulse nonlinearity, and droplet size. Given
the sub-micron droplet sizes and the relatively low pulse pressures (compared to many
droplet studies), the effect may not be a significant factor - explaining the contradicting
results.
The current FDA guidelines for maximum pressure output on a diagnostic machine
in soft tissue is a mechanical index (defined as the derated peak negative pressure in
MPa divided by the square root of the ultrasound frequency in MHz) of 1.9. For this
study, this corresponds to peak negative pressures of 1.9 MPa, 4.5 MPa, and 5.4 MPa
for 1 MHz, 5.5 MHz, and 8 MHz, respectively. Its worth noting, however, that even
though the threshold pressures reported here do not appear to decrease with increasing
frequency, the mechanical index needed does decrease with ultrasound frequency - which
is important for in vivo implementation in many cases.
Part of the variation across the literature may be as a result of the type of measure-
ment (most reporting this trend use phenomenological measures based on echo ampli-
tude), but also may be due to variation in choice of ultrasound parameters at different
frequencies, such as whether to match total pulse length or number of cycles. Matching
the total pulse length results in a similar exposure time, but means that droplets at
higher frequencies will experience significantly more compression/rarefaction cycles -
likely influencing the probability of an individual droplet vaporizing. In this study, we
chose to match the number of compression/rarefaction cycles in short bursts as closely
as possible in order to minimize secondary effects. With these parameters, the increase
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in pressure needed with increasing frequency may be partly explained by the beam
width of the transducer itself. According to Cobbold [165], the lateral and axial full-
width half-max of the pressure field delivered from a concave piston are approximated
as:
FWHMlat =
1.4λZf
D
(5.2)
FWHMax = 7.2λ(
Zf
D
)2 (5.3)
where λ is the wavelength, Zf is the radial distance to the focus, and D is the
transducer diameter. With the transducers used, the theoretical lateral FWHM was
3.60 mm, 0.90 mm, and 0.62 mm, for 1 MHz, 5.5 MHz, and 8 MHz, respectively,
while the axial FWHM was 18.7 mm, 4.6 mm, and 3.2 mm, respectively. Because
the microcellulose tube only measured 200 m in diameter, the difference in the axial
beam width between the frequencies likely played little role. However, the bubble
cloud generated inside the tube typically spanned 1 mm or more laterally, and so the
lateral beam width likely played a high role in the difference between frequencies. In
other words, in order to create a similar distribution of bubbles between 8 and 1 MHz,
it may be that the peak rarefactional pressure at 8 MHz needed to be much larger
in order to compensate for the rapid pressure drop-off laterally and make the FWHM
pressure comparable. Because the transition threshold measured by bubble distribution
tracking takes into account aspects such as these, these thresholds are likely to correlate
to appropriate in vivo pressures - where it is more desirable that a spatial extent of
droplets is vaporized rather than a few droplets precisely at the peak in the pressure
field.
These results should be used as a guide to what in vivo pressures would be necessary
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for very short pulses (such as implementation of vaporization pulses on diagnostic
arrays) in order to minimize bioeffects introduced by longer pulses, but they can also
be used as a baseline for other measurements. For example, if gauging appropriate
acoustic parameters for activation using a phenomenological method such as release of
dye, one could first use distribution tracking to assess the relationship between bubble
formation and dye release using short pulses of varying pressure in order to achieve
a baseline. Then the researcher could increase the acoustic conditions (pulse length,
pulse repetition frequency, etc) and observe the change in the phenomenological effect.
There are certain PCCA formulations where distribution tracking may not be ap-
plicable. Several researchers have suggested that droplets composed of higher boiling
point perfluorocarbons may be useful in that they could re-condense immediately af-
ter the vaporization pulse ends, and can be made to undergo phase-transition several
times [53]. In this case, measuring the bubble distribution after the pulse ends would
be impossible. Additionally, droplet formulations with high monodispersity, which are
often found with microscale droplets in microfluidics-based approaches [110], would not
benefit from this method, as the activation would be highly uniform across the entire
distribution. Finally, nanoemulsions where the peak diameter lies on the order of 100
nm or less would produce bubbles too small to be optically observed and measured.
Though this would prevent a distribution tracking method, the bubbles produced would
be echogenic and could be measured via more commonly-used echo amplitude methods.
5.5 Summary
Based on these methods, we have shown that vaporization of decafluorobutane
droplets in the 200 nm diameter range can be achieved using very short pulses with pres-
sures relevant to diagnostic use. With a given ultrasound frequency and pulse length,
pressure required for vaporization of the distribution’s modal peak can be gauged by
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observing changes in the bubble population produced with each pulse as pressure is
increased. We additionally show that further understanding is needed of the impact
of long vaporization pulses, which may selectively destroy or fuse bubbles produced in
early cycles.
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CHAPTER 6
Detecting Acoustic Signatures of PCCAs
6.1 Introduction
The field of microbubble-based contrast agents for ultrasound has produced a host of
applications ranging from diagnostic assessment of heart function to drug delivery and
molecular imaging schemes that can be monitored in real-time [166; 41; 167]. Due to
the underlying physics of oscillating microbubbles, bubble-specific detection techniques
have been produced that exploit regimes of non-linear oscillation and/or nonlinear
relationship to ultrasound driving pressure such that they can be distinguished from
the ultrasound signals returned from tissues [168]. Use of these techniques has allowed
real-time separation of contrast and tissue signals, enabling new modes of qualitative
and quantitative imaging, many of which have been implemented on commercial clinical
and pre-clinical ultrasound platforms [169; 170; 171; 38]. Where microbubbles are
used for therapeutic applications involving ultrasound-mediated ablation of tissue, the
destruction of microbubbles creates highly nonlinear signals that can be detected over
tissue signals as a general increase in the broadband spectral content. Quantifying
this relative to the harmonics generated from the surrounding tissues allows real-time
c© 2013 IOP Publishing (ioppublishing.org) Portions reprinted, from PS Sheeran, TO Matsunaga,
and PA Dayton. “Phase change events of liquid perfluorocarbon contrast agents produce unique
acoustic signatures” Physics in Medicine and Biology, 2014 January; 59: 379-401.
127
monitoring of cavitation during the ablation procedure and has produced some unique
methods of imaging cavitation passively [172; 173; 174; 175].
Although real-time acoustic detection and isolation of microbubble-specific signals
exists, there are currently few proposed methods to detect acoustic signals unique to
phase-change contrast agents (that is, distinct from the surrounding tissue as well as
distinct from standard microbubbles). Asami et al. have suggested that the impulse
wavefront from droplets vaporizing adjacent to a rigid boundary could be detected and
used to characterize tissue properties [117]. More recently, Reznik et al. have suggested
that as bubbles produced from vaporized DDFP (boiling point 29◦C) droplets evolve
over the course of several hundred milliseconds, the change in scattered fundamental
and harmonic power over time could be used to differentiate growing bubbles (produced
by recently vaporized droplets) from nearby stable bubbles [72]. Development of a
technique to detect unique signals produced by the droplet vaporization event would
enable real-time imaging of droplet vaporization for diagnostic purposes as well as real-
time monitoring of progress in therapeutic applications involving phase-change agents.
Some of the possibilities for acoustic detection of vaporized droplets may be learned
from the underlying physical theory of expansion. A number of studies have modeled
the physics of expansion after vaporization through theory and simulations in order to
explore various aspects of parameter dependencies and in vivo implementation [79; 80;
81; 97; 98; 83; 176; 136; 177]. For those investigating droplet vaporization that produces
stable bubbles, the models have generally predicted a monotonic expansion that can be
modulated by the influence of the vaporization pulse and inward gas diffusion, which
matches experimental data for DDFP microdroplets well [83; 176; 162]. For these
types of droplets, the pressure wavefront generated by the initially high expansion
velocities may be able to be detected as a sign of droplet vaporization - similar to the
method proposed by Asami et al. [117]. Alternative models proposed by Qamar et al.
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[81; 177] have suggested that, depending on droplet size and other physical properties,
droplets may over-expand as a result of momentum of expansion and then settle to a
final resting diameter in an oscillatory manner, although the experimental results with
DDFP microdroplets did not exhibit this behavior. If this type of behavior could be
achieved experimentally, it might be possible to detect these oscillations as an acoustic
signature of droplet vaporization.
Chapters 2 and 4 explored methods of forming PCCAs from volatile perfluorocar-
bons in order to reduce vaporization thresholds and enable use of PCCAs for diagnostic
applications. In this context, PFC volatility refers to the degree to which the boiling
point of the PFC used is less than room temperature (22◦C). In this chapter, we first
demonstrate through ultra-high-speed brightfield video microscopy that when vaporized
by a brief US pulse, volatile PCCAs at micron and sub-micron sizes exhibit expansion
phenomena after the pulse has ended including over-expansion and oscillatory settling
to a stable bubble size. We next show that this radial expansion/oscillation generates
unique droplet-specific pressure signals that can be acoustically detected and differenti-
ated from microbubble-based contrast agents and tissue with respect to both temporal
and spectral content. These findings may be useful for physical studies as well as
development of droplet-specific imaging techniques for medical imaging and therapy.
6.2 Materials & Methods
6.2.1 Phase-Change Contrast Agent Preparation
Lipid-coated microscale and sub-micron droplets were formulated as in Chapter
4. The gas headspace was composed of either pure DFB (boiling point -1.7 ◦C) or
pure OFP (boiling point -36.7 ◦C). The microbubble emulsions were allowed time to
cool to room temperature, and then were immersed in an isopropanol bath maintained
between −7◦C and −10◦C and stirred gently by mechanical rotation for approximately
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1 minute. A change in consistency and translucency was typically noted by this point
for DFB emulsions, though OFP emulsions could not be condensed by temperature
alone. Vials were then connected to an adjustable pressure source and the pressure in
the vial headspace was increased incrementally with room air while the low temperature
was maintained to ensure particles reverted to the liquid state.
6.2.2 High-Speed Video Experimental Setup
The experimental setup used here was similar to the confocal acoustical/optical
setup described Chapter 5. Brightfield images were captured using an ultra-high-speed
framing camera (SIMD24, Specialised Imaging, Simi Valley, CA) capable of captur-
ing 24 images at up to 200 million frames per second. For ultra-high-speed imaging
studies, droplets were vaporized with a 7.5 MHz nominal center frequency spherically
focused transducer (2.2 cm diameter, 5 cm focus; V321, Panametrics, Inc., Waltham,
MA) driven with an adjustable-amplitude 2-cycle sinusoid at 8 MHz (insonification
time of approximately 250 ns). The camera frame spacing was set to record evenly
spaced captures within the imaging period (30-40 ns exposure times, maximum 20 µs
of continuous filming time allowed by flash duration). The brief, high-intensity acoustic
pulses were typically in the non-linear regime, and so transducers were calibrated in
the free-field at focus using a needle hydrophone (HNA-0400, Onda Corp., Sunnyvale,
CA) with a magnitude-only hydrophone deconvolution method [161].
Droplet suspensions diluted to 10% in PBS were injected into a nearly optically
and acoustically transparent 200 µm inner diameter microcellulose tube (outer diam-
eter of 216 µm; Spectrum Laboratories, Inc., Greensboro, NC) resting in the confocal
acoustic/optical plane. The droplet emulsions were injected via an in-house manual
volume injector and the forward flow stopped prior to the manually triggered vaporiza-
tion pulse. The imaging frame rate was adjusted in order to capture the size-dependent
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droplet vaporization sequences in high detail, as smaller droplets finish vaporizing more
rapidly than large droplets. Between video captures, forward flow was restored in order
to bring un-vaporized agents into the optical focus. Images were stored oﬄine and ana-
lyzed in ImageJ (NIH, Bethesda, MD). Although the setup produced images with 15.58
pixels/µm, the practical optical resolution of the system due to image noise at the low
exposure times limited measurement of particles to those greater than approximately
1 µm in diameter. The area of the droplets/bubbles in each frame were measured by
hand using elliptical ROIs and converted to diameter to track the change in size due to
vaporization. This provided up to 24 measurements (the total number of frames) per
video, which were then interpolated and analyzed with custom scripts in Matlab (The
Mathworks, Natick, MA) to extract information such as rate of radial expansion, max-
imum expansion, final diameter, and the fundamental frequency of oscillation based on
Fourier analysis of the radial oscillation. All statistical analysis was performed using a
student’s t-test (two sided, unequal variance).
6.2.3 Acoustic Interrogation Experimental Setup
The experimental setup used to capture echoes emitted from vaporizing droplets
was similar to that described above. In order to minimize reflections from the micro-
cellulose interface, the tube was angled 66◦ relative to the face of the transducer, while
keeping the tube length in a plane perpendicular to the microscope objective. Instead
of a single piston transducer aligned at the optical focus, a confocal dual-transducer
approach was used in order to vaporize the droplets at the optical focus using a brief,
higher frequency pulse, and passively listen to echoes emitted with a lower frequency
transducer having a non-overlapping bandwidth with the activation transducer. This
is analogous to, but opposite of the ‘pulse low, listen high’ scheme used in other studies
to isolate bubble signals from tissue [48; 131; 38]. Here, the ‘pulse high’ transducer
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used to activate droplets was a spherically focused piston transducer with a 7.5 MHz
nominal center frequency (1.58 cm diameter, 5.08 cm focus; V320, Panametrics, Inc.,
Waltham, MA) driven with a 2-cycle sinusoid at 8 MHz (PRF of 5 Hz). In order to
‘listen low’, a spherically focused 1 MHz annular transducer (2.2 cm inner diameter,
4.44 cm outer diameter, 5.08 cm focus; V30047, Panametrics, Inc., Waltham, MA)
was fitted around the ‘pulse high’ transducer and focused at the same spatial loca-
tion (the optical focus containing the microcellulose tube) in order to passively receive
echoes. As above, transducers were calibrated in the free-field at focus using a needle
hydrophone (HNA-0400, Onda Corp., Sunnyvale, CA) to obtain both pressure out-
put information as well as frequency response characteristics. The transmit-bandwidth
of the activation transducer had a full-width half-maximum (FWHM) between 6.067
MHz and 10.933 MHz, while the FWHM of the receiving transducer in transmit-receive
mode was between 700 kHz and 1.551 MHz. The output of the 1 MHz transducer was
sent to a receiver amplifier (BR-640A; RITEC, Inc., Warwick, RI) set to pass signals
above 100 kHz with a gain of 32 dB. The signals at the output of the receive amplifier
were digitized at a 100 MHz sample rate (PDA14; Signatec, IL), captured in LabVIEW
(National Instruments, Austin, TX), and stored for oﬄine analysis in Matlab. Samples
were injected at a constant flow rate driven by a syringe pump (PHD2000, Harvard
Apparatus, Holliston, MA) at a rate of 10 µL/min in order to ensure that the volume
exposed to the previous vaporization pulse translated a distance of at least 10 times the
vaporization transducer’s lateral pressure field FWHM prior to the next pulse. A range
of ultrasound pressures (between 100 kPa and 2500 kPa peak negative pressure) were
delivered from the activation transducer in order to assess the threshold-dependence
of the droplet vaporization signals. Two hundred instances of the ‘pulse high, listen
low’ scheme were captured at each pressure for each sample passing through the opti-
cal focus (at the pulse rate of 5 Hz). Droplet emulsions were diluted in PBS to final
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concentrations of 0.05%, 0.1%, 0.5%, 1%, 5%, 10%, and 50% in order to determine
the influence of PCCA concentration on the returned acoustic signals. For compar-
ison, similar data were captured for the cellulose tube when filled with only water,
filled with only air, and filled with the same dilutions of microbubble contrast agents
as used for the droplet emulsions. The microbubble emulsions used here consisted of
the same lipid-encapsulated DFB microbubble precursors used to form DFB droplets,
but without the additional step of condensation. Throughout these acoustic tests, the
contents of the microcellulose tube were monitored in real-time by a high-speed cam-
era (FastCam SA1.1, Photron USA, Inc., San Diego, CA) interfaced with a 60X water
immersion objective. Radio-frequency (RF) signals captured from these tests were an-
alyzed oﬄine in Matlab for both time and frequency-domain characteristics in order
to distinguish acoustic properties unique to droplet vaporization. For controls, each
signal consisted of a total acquisition time of 40 µs with the travel time to the focus of
the transducer occurring approximately 20 µs after the beginning of acquisition. For
droplet samples, each signal consisted of a total acquisition time of 60 µs beginning at
the same time point as the control samples. Prior to analysis, all signals were bandpass
filtered (between 50 kHz and 5 MHz) with a 100-order FIR Butterworth filter in Matlab
to remove broadband noise introduced by the experimental setup, as well as any signals
far outside the bandwidth of the 1 MHz receiving transducer. No windowing was used
on the data during frequency analysis.
6.3 Results and Discussion
In the following results and discussion, results from ultra-high-speed optical imaging
experiments were used to develop the acoustic interrogation approach. The acoustic in-
terrogation results, in turn, were used to implement a simple droplet-specific algorithm
capable of isolating droplet signals from control cases.
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6.3.1 Ultra-High-Speed Video Experiments
Investigations with ultra-high-speed imaging showed that droplets of the formula-
tions used were able to be vaporized with 2-cycle pulses at 8 MHz, which is consistent
with the results of Chapters 4 and 5. The pulses used to vaporize droplets had peak
negative pressures on the order of 2.5 MPa for octafluoropropane droplets, and between
3.7 and 4.2 MPa for decafluorobutane droplets. It is worth noting that the pressures in
this set of experiments were chosen because they were higher than necessary to induce
vaporization rather than being indicative of any specific activation threshold for the
emulsion. Because a short vaporization pulse was used that lasted less than 250 ns,
and because droplets large enough to be resolved in the optical setup took longer than
1 µs to complete their initial expansion phase, the pulse primarily served to initiate the
bubble nucleation, but did not influence bubble growth as a longer pulse would.
When activated with these short 8 MHz pulses, the transition from droplet to bub-
ble was captured, and the diameter of the particle measured at each time point. The
droplets showed unique vaporization properties not previously reported for droplets
composed of less volatile compounds. During vaporization, particles showed charac-
teristic over-expansion and subsequent oscillatory settling to a final bubble diameter
smaller than the maximum size reached during the initial expansion phase (Figure 6.1).
This type of activity was observed for both OFP and DFB droplets ranging from the
smallest size observable to the largest size present in the samples. The overexpansion
and oscillation are expected to be a result of momentum of expansion leading to over-
shoot of the final diameter and oscillatory return to the final bubble size. This type
of behavior has been previously predicted in simulations for vaporizing droplets under
certain conditions [81].
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This type of expansion behavior was captured for a total of 180 OFP and DFB
droplets and separated into sub-groups for analysis depending on whether certain as-
pects of the expansion were resolvable/measurable based on visual assessment. If the
initial droplet size was well-resolved against background but the bubble expansion was
not, the initial time points in the individual trace were omitted from measurement. Sim-
ilarly, if the particle vaporization and initial expansion was well resolved, but during
the course of expansion the bubble oscillation was perturbed by neighboring bubbles,
measurements were only taken up to the point of perturbation and the remaining points
omitted. Of the data produced, sub-groups were determined by assessing (1) whether
the initial droplet size could be resolved with high confidence, (2) whether the initial
expansion phase was well sampled, (3) whether the overshoot and oscillation behavior
was captured and well-sampled, and (4) whether the final bubble size was captured or
able to be predicted from oscillation behavior. During the initial expansion phase, DFB
droplets over-expanded to 6.3± 1.2 times the initial droplet diameter (N = 76), while
OFP droplets (N = 52) over-expanded to 8.3± 1.3 times the initial droplet diameter.
The over-expansion of the OFP droplet group was statistically significant compared
to the DFB droplet group (p << 0.01), and the expansion ratio did not appear to be
dependent on initial diameter for either group in the range tested. The relationship
between initial droplet size and final bubble size followed a strongly linear trend in the
range tested (Figure 6.2). The linear regression for DFB particles (N = 60) showed a
ratio of approximately 5.12 (r2 = 0.94, 95% confidence intervals of 4.94 and 5.30, RMSE
= 2.06) between final and initial diameter, while OFP particles (N = 43) showed a ra-
tio of approximately 5.53 (r2 = 0.93, 95% confidence intervals of 5.33 and 5.72, RMSE
= 1.38). The expansion of DFB particles was statistically significant compared to the
expansion of OFP particles (p << 0.01). These experimental results match well with
ideal gas law predictions for DFB and OFP expansion (eqn. 2.7). For example, DFB
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droplets measuring 1 micrometer in diameter at 37◦C would theoretically expand a fac-
tor between 4.64 (assuming air/water interfacial surface tension of 71 mN/m) and 5.43
(negligible surface tension) times the original diameter, while identical droplets of OFP
would expand a factor between 5.06 (air/water surface tension) and 5.88 (negligible
surface tension) times the original diameter. During the initial expansion phase, peak
radial expansion velocity in the imaging plane reached 9.8± 2.7 m/s (N = 84) for DFB
and 13.9± 3.9 m/s (N = 52) for OFP. The OFP velocities were statistically significant
from the DFB velocities (p << 0.01), and both groups appeared to be independent of
initial droplet size in the range tested.
Figure 6.2: Relationship between final bubble diameter and initial droplet diameter for
droplets of DFB (N = 60) and OFP (N = 43). The strong linear trends showed a ratio
of 5.12 between final and initial size for DFB (r2 = 0.94) and a ratio of 5.53 between
final and initial size for OFP (r2 = 0.93). These experimental values matched well with
ideal gas law predictions (see text) and appeared to be independent of initial diameter
in the range tested.
Results showed that as vaporized droplets over-expanded and oscillated in a de-
caying manner to a final resting bubble size, the frequency of oscillation was inversely
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dependent on final bubble size (and therefore initial droplet size). Large bubbles oscil-
lated at low frequencies near 100 kHz compared to small bubbles that oscillated above
1 MHz. This size-frequency relationship is characteristic of a resonance phenomenon.
In this case, the resonance was initiated by the overexpansion event in the initial vapor-
ization phase (Figure 6.1). By collecting these data over a wide range of particle sizes,
a final bubble size vs. resonance frequency curve can be experimentally developed to
predict the frequency of echoes emitted by a particle (Figure 6.3). Although separate
curves can be developed for the DFB and OFP droplet groups, the error in measured
frequency imposed by the small number of frames limits any comparisons made be-
tween the groups. Combining the data and produces a fit of f(r) = 2.679
r
, where f is
the measured frequency and r is the final bubble radius (r2 = 0.79, 95% confidence
intervals of 2.578 and 2.779, RMSE 1.658× 105).
Because the oscillation happened well after the vaporization pulse has passed, it
was independent of the pulse, and represents natural resonance (rather than ‘driven’
or ‘forced’ oscillations). This is unique with respect to ultrasound contrast agents, in
that the particle is ‘tipped’ and then emits an entirely original acoustic signal that
does not overlap with the acoustic pulse temporally or spectrally, which is radiated and
received by the ultrasound transducer. This is similar in some aspects to the broadband
post-excitation signals produced by microbubbles in prior studies [178; 179] that are
associated with bubble collapse/inertial cavitation as a result of high intensity pulses. In
contrast, the droplet-based signals shown here occur during stable bubble formation,
and the primary mechanism that produces the relatively narrowband droplet-based
signals is the overexpansion of the droplet during vaporization (independent of the
vaporization pulse). The classic Minnaert equation for resonance of a free bubble
[180; 181] is:
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Figure 6.3: Oscillation frequency curve of resulting bubbles. As a function of final bub-
ble radius, the particles oscillated at specific frequencies after the initial over-expansion
phase. For the OFP (N = 49) and DFB (N = 81) particles tested that were optically
resolvable, these were on the order of 100 kHz to 2.5 MHz, depending on bubble size.
Curve-fitting the data produces a relationship of f(r) = 2.679/r where f is the mea-
sured oscillation frequency and r is the final bubble radius (r2 = 0.79). Approximating
the data with a Minnaert free bubble resonance model produces a slightly worse fit
(r2 = 0.77).
fM =
1
2pir
√
3κPl
ρl
(6.1)
where fM is the natural resonance frequency, r is the radius of the bubble, κ is the
polytropic exponent, Pl is the ambient pressure, and ρl is the density of the surrounding
liquid. Here, assuming a polytropic index of κ = 1 (isothermal process), Pl = 101.325
kPa (ambient pressure), and ρl = 994 kg/cm
3 (approximate density of PBS at 37◦C)
produces a resonance curve that represents the experimental data nearly as well as the
optimal experimental fit (r2 = 0.79, RMSE 1.658 × 105), and can be used for simple
approximations of the bubble size/resonance frequency. However, this ignores several
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aspects of the experimental system that deviate from the Minnaert model. An isother-
mal assumption for the polytropic index is not suitable for the size of microbubbles and
the perfluorocarbon core of the bubbles. Most studies have suggested that adiabatic
assumptions (κ = Cp
Cv
, the ratio of specific heat at constant pressure to specific heat
at constant volume) model the behavior of perfluorocarbon microbubbles well [182],
which would produce values of κ = 1.052 for DFB and κ = 1.063 for OFP at 37◦C [19].
Using an approximate value of 1.06 for the combined data set, the Minnaert fit to the
data is shifted slightly above the experimental data fit (Figure 6.3, r2 = 0.77, RMSE =
1.735×105). The damping in the bubble oscillation accounts for the deviation between
the experimental and ideal fits. For a classic damped harmonic oscillator undergoing
un-forced oscillation, the decay of the system can be related to the measured (damped)
oscillation frequency and ideal (Minnaert) frequency by:
fdamp =
√
f 2M − (
β
2pi
)2 (6.2)
where β−1 is the time constant of the decay in the exponentially decaying harmonic
oscillation [183]. The total damping constant of a freely oscillating bubble at resonance
is the sum of radiation, thermal, and viscous damping, and can be related to β by:
δ =
2β
ωamp
=
β
pifdamp
(6.3)
Substitution of Eqns. 6.1 and 6.3 into Eqn. 6.2 gives:
fdamp = fM
√
1
1 + ( δ
2
)2
(6.4)
Fitting Eqn. 6.4 to the experimental data gives a total damping coefficient of
δ = 0.76 for the oscillations produced from phase-change droplets (r2 = 0.79, 95%
confidence intervals of 0.53 and 0.98, RMSE = 1.658× 105).
140
For the micron-sized particles characterized in these tests, the majority of particles
exhibited oscillation frequencies between 100 kHz and 1 MHz, which is well below
the bandwidth of the transducer delivering the activation pulse. Provided the new
acoustic signals generated are strong enough to be detected, they could be picked up
by an ultrasound transducer and used to localize the droplet activation event both
temporally and spatially.
6.3.2 Acoustic Interrogation Results
To determine whether acoustic signals generated by vaporizing droplets could be
detected, a ‘pulse high, listen low’ scheme was used that allowed for receiving low fre-
quency acoustic signals not strongly related to the fundamental activation pulse. Based
on the video data, any signals emitted from droplets oscillating on the order of 100 kHz
to 1 MHz would appear as distinct spectral content relative to normal microbubble
signals or tissue signals. To test this, the microcellulose tube setup previously de-
scribed was injected with droplets at a constant flow rate and exposed to a series of
2-cycle pulses at 8 MHz. For controls, the same tube was filled with either water, air,
microbubble dilutions. The water and air cases represented extremes of the microbub-
ble dilutions - where there are so few bubbles present that the suspension acoustically
appears as water, or when there are so many present that it appears as a solid air
interface.
When the tube was filled with only water (Figure 6.4A), the receiving transducer
showed weak reflections of the activation pulse due to the interface of the water and cap-
illary tube (a significant enough density difference to reflect some energy). Increasing
the activation pressure only increased the amplitude of these pulses, but the frequency
content remained noisy (Figure 6.4B). Even though the activation pulse was well out
of the frequency response of the 1 MHz transducer, the tube interface reflects back
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Figure 6.4: Control recordings with no bubbles or droplets present. Echoes reflected
from the microcellulose tube are apparent in the received signals on the 1 MHz trans-
ducer beginning near 60 µs from the pulse trigger, while a later echo is produced from
the nearby microscope objective beginning near 70 µs. A) The water-microcellulose
interface creates a small reflection when the tube is filled with water that manifests
as B) noisy frequency content in the 50 − 2000 kHz range, whereas C) the wa-
ter/microcellulose/air interface creates a very large reflection for a tube filled with
air that manifests as D) noisy frequency content in the 50 − 2000 kHz range with an
additional harmonic peak between 3−3.6 MHz. The final echo from the microcellulose
tube in both cases returns near 70 µs, and the final echo from the objective artifact
returns near 75 µs. Note: A) and C) are the mean of 200 captures of the water-only
and air-only cases. B) and D) show the Fast-Fourier Transform of A) and C).
enough of the short burst of energy to ring the 1 MHz transducer near its own reso-
nance frequency with a very minor harmonic component between 3 MHz and 3.5 MHz.
This effect was amplified in the case of the air only tube, where the interface formed
by the air produced a strong reflection off the tube (Figure 6.4C). Similar to the case
of water, the reflection off of the tube/air interface produced signals that cause the
transducer to ring at 1 MHz with a small harmonic peak present between 3 MHz and
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3.5 MHz (Figure 6.4D). As the incident pressure increased, the magnitude of the fre-
quency domain signal increased, but the fundamental frequency components remained
relatively similar. In both the air and water cases, the only acoustic energy produced
was from the activation pulse directly reflecting off of interfaces. In this experimental
setup, an additional acoustic artifact was introduced by the nearby objective used to
monitor particle flow, which manifested as an echo beginning a few microseconds after
the end of the tube reflection (Figure 6.4A,C). Once the final reflection off of this acous-
tic artifact returned (around 75 µs), no acoustic signals were detected for the remaining
period.
When the tube was filled with standard formulation microbubble contrast agents,
the time and frequency domain signals were appreciably different from the air-only and
water-only cases. At very low bubble concentrations, a sinusoidal trace was observed
between 66 µs and 68 µs (corresponding with the temporal location of the tube reflection
in Figure 6.4) that increased with the incident pressure (Figure 6.5A). The temporal
length of this signal corresponds well with the expected tube diameter when the receive
transducer’s impulse response is taken into account. Unlike the noisy spectra from
the air-only and water-only cases, the bubble signals returned spectra that strongly
resemble the receiving transducer’s frequency response centered near 1 MHz (Figure
6.5B,D,F). This is likely due to the fact that the short 8 MHz burst causes bubbles to
oscillate (or become destroyed at higher pressures) and return a brief burst of energy
back to the receive transducer that causes it to ring at its center frequency (similar to
an impulse response). At the concentrations tested, the magnitude of the time domain
signal increased with microbubble concentration up to 1% dilution (Figure 6.5C), past
which the signal magnitude decreased rapidly up to 50% dilution (Figure 6.5E). At 50%
dilution, signals approached the magnitude of the air-only tube signals with similarly
noisy frequency spectra. This can be anticipated, as the extremes of microbubble
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Figure 6.5: Individual voltage traces received from microbubble samples of varying con-
centration and associated spectra. At each concentration, signal magnitude increased
with incident pressure while retaining similar temporal characteristics. Signal magni-
tude increased from the lowest concentration tested of 0.05%, (A, B) and maximized
at 1% (C, D). Past this, signal magnitude decreased up to the maximum concentration
of 50% (E, F).
concentrations are acoustically similar to a gas-only or water-only interface. As evident
from Figure 6.5, the microbubble signal was contained within the same temporal span
as the reflection from the tube (no portion of the total signal including the objective
artifact extends beyond 75 µs), as it was a direct result of microbubbles interacting with
the pulse travelling within the tube. As also demonstrated by Figure 6.5, the bubble
signals were highly correlated for each pressure - manifesting as a short 1 MHz pulse
that begins near 66 µs with very similar amplitude across all pulses (data not shown).
When volatile phase-change contrast agents were vaporized in the microcellulose
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tube, the difference in both the time and frequency domain compared to controls could
easily be observed (Figure 6.6). At low concentrations and/or low vaporization pres-
sures, individual droplet vaporization traces could be isolated and compared to the
signals received when no droplet vaporization occurred. Unlike the control cases, which
manifested as short Gaussian-enveloped pulses between 64 µs and 75 µs with a wide
frequency band centered around 1 MHz, droplet traces appeared as exponentially de-
caying sinusoids that often extended well beyond the 75 µs timepoint (Figure 6.6A, C),
similar to the decaying radial oscillation over 10 − 20 µs observed optically. As with
the optical experiments capturing the initial rapid radial expansion of the vaporizing
droplet, the maximum pressures recorded occurred at the very beginning of each droplet
signal. Even when exposed to the same peak negative pressure, the voltage traces were
highly variable from line to line with respect to both amplitude and frequency of the
decaying sinusoid. In all cases, the pressure signal recorded began at the temporal
location of the tube. In the frequency domain, sharp, narrowband peaks were present
corresponding to the frequency of the decaying sinusoid (Figure 6.6B, D). These nar-
rowband peaks ranged from the low 100s of kHz to 1.3 MHz in this experimental setup
- matching the experimental frequencies obtained in optical experiments (Figure 6.3)
well. At higher peak negative pressures and/or concentrations, the vaporization of mul-
tiple droplets produced voltage traces that were superimpositions of individual droplet
pressure fields, and several individual narrowband peaks in the frequency domain could
be observed corresponding to the individual droplets vaporized.
Although the frequency content of the droplets appeared generally independent of
perfluorocarbon choice, the amplitude of the oscillations was significantly larger for
OFP droplets than similarly sized DFB droplets (Figure 6.6A, C), likely as a result
of a more rapid initial expansion and greater overexpansion ratio upon vaporization.
By the oscillation frequency experimental curve fit (Figure 6.3), Figure 6.6A shows the
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Figure 6.6: Signals produced by individual droplets vaporizing in the receive trans-
ducer’s focus manifest as exponentially decaying sinusoids with very narrowband fre-
quency content. Examples of A) DFB droplet vaporization and B) the associated
frequency spectrum. C) and D) OFP droplets oscillating at a similar frequency pro-
duce larger amplitude oscillations even when exposed to significantly lower incident
pressure as a result of greater droplet volatility. In both A) and C), the blue trace
shows the preceding pulse that did not produce a vaporized droplet for the same sample
and pulse pressure.
resonance (333 kHz) of a DFB bubble near 16.1 µm in diameter. By Figure 6.2, this
originated from a droplet near 3.1 µm in diameter. Similarly, the resonance (350 kHz)
of the OFP bubble (Figure 6.6C) originated from a bubble near 15.3 µm in diame-
ter, or a droplet near 2.8 µm in diameter. Despite the similar sizes and the fact that
a significantly higher pressure was used to vaporize the DFB droplet, the maximum
amplitude of the OFP bubble oscillation was 2.8 times larger than the DFB bubble os-
cillation. Interestingly, the maximum amplitude observed in both cases occured during
the compression phase just after the initial expansion, and it was apparent that the
steadily decaying sinusoids were exhibiting nonlinear oscillation behavior that generates
146
harmonics in the frequency domain.
Based on the optical results, larger droplets displace a larger volume of water dur-
ing the radial oscillations at relatively similar speeds as smaller droplets, and should
therefore generate larger amplitude pressure waves. In the acoustic detection scenario,
this should result in lower frequency oscillation signals containing larger amplitudes of
oscillation. However, this is not readily apparent from the raw data, as the frequency-
dependent sensitivity of the receiver transducer must first be accounted for. The maxi-
mum sensitivity of the receiver transducer occurs for signals near 1.2 MHz. For signals
near 330-350 kHz with the same amplitude, the received signal will be only 15% of the
1.2 MHz case. As a result, the raw signals shown in Figure 6.6 had similar amplitude
to the very largest bubble signals produced in any case once this factor is accounted
for. By scaling the raw data in order to correct for the receiving transducer’s frequency
response, the relative amplitudes across the entire frequency range can be recovered.
Figure 6.7: When scaled to correct for the receiver transducer’s frequency-dependent
sensitivity, the amplitude of single OFP droplet signals can be related to the frequency
of oscillation by a power-law fit of (fkHz)
−2.072.(r2 = 0.89). A similar relationship can
be experimentally derived for DFB droplets.
For example, the relationship between the amplitude of oscillation and the frequency
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of oscillation for single OFP droplets can be evaluated experimentally by exposing
highly dilute samples of OFP droplets to peak negative pressures large enough to va-
porize the majority of the droplets in the focal zone. Out of 200 vaporization pulses,
109 instances of the characteristic droplet oscillation were detected. Two of these were
excluded, as they contained several spectral peaks, and did not represent single-droplet
traces. For the remaining data set, mapping the amplitude of oscillation to the peak
in the frequency domain revealed a power-law relationship of (fkHz)
−2.072, (r2 = 0.89,
95% confidence intervals of −2.403 and −1.741) (Figure 6.7). As expected, the lower
oscillation frequencies produced by bigger droplets result in significantly larger oscilla-
tion amplitudes. Here, frequency peaks were observed between 216 kHz and 1.3 MHz
- corresponding to bubbles between 24.8 µm and 4.1 µm, or droplets between 4.5 µm
and 0.7 µm in diameter (by the experimental relationship in Figure 6.2).
6.3.3 A Simple Spectral Approach to Droplet Detection
As the results above show, the general characteristics of signals produced by droplets
when vaporized by a higher-frequency pulse can be easily distinguished from the control
cases temporally and with regard to frequency content. In these tests, samples were col-
lected for a single line of interrogation so that droplet signals could be localized axially.
Extending this to a linear or matrix transducer array and collecting similar data on all
channels simultaneously would allow for localization of the droplet vaporization signals
in 2D or 3D space. This would have high utility for both diagnostic and therapeutic
applications of PCCAs, such as localizing vaporization activity to correlate with in vivo
PCCA-mediated drug delivery. For the purposes of developing the techniques demon-
strated here into imaging strategies, many approaches are available. The temporal
aspects of vaporized droplet signals would be distinct from the surrounding tissue and
alternative ultrasound contrast agents, and could be isolated through correlation-based
148
approaches such as spatial coherence [184] or matched-filtering [185]. Alternatively, the
signals generated from vaporizing droplets could be detected and distinguished from
the surrounding tissue by only passing signals with narrowband frequency properties.
These types of considerations will be the subject of future investigations.
In the remainder of this manuscript, we implement a simple spectral approach to
detect vaporization from droplets within a desired size range and demonstrate that
the droplet vaporization signals can be distinguished from all control cases even at low
concentrations and peak negative pressures. In this approach, the raw signals collected
from each pulse ensemble are processed in three steps: wall-filtering, scaling to correct
for receiving transducer frequency dependence, and frequency domain integration over
a narrow frequency range related to the desired droplet sizes.
In the first processing step, the raw data ensemble obtained from the 200 pulses at
each peak negative pressure is wall-filtered similar to conventional Doppler ultrasound
processing in order to remove signals that are stationary from pulse-to-pulse. Here,
the mean echo for each temporal location across all pulses is subtracted from that
temporal location, leaving only signals that are transient from pulse to pulse. This
largely eliminates the echoes returned from the water, air, and bubble samples, where
there is very little variation from pulse to pulse. Next, the frequency spectrum of each
wall-filtered time domain signal was obtained and the magnitude of the spectrum scaled
to correct for the receive transducer’s frequency-dependent sensitivity between 50 kHz
and 2 MHz. Finally, the signals were bandpass filtered with a 100-order Butterworth
FIR filter between 50 kHz and 700 kHz and integrated in this same frequency band
to arrive at a final measure of magnitude for the band-limited signals. These edge
frequencies correspond to bubbles between 7.7 µm and 107 µm in diameter, or droplets
between 1.4 µm and 20.9 µm in diameter for both PFCs by the experimental fit in
Figure 6.2. It is worth noting here that the largest droplet characterized in the optical
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experiments was approximately 9.5 µm, and so there are likely to be very few droplets
larger than this, if any, that contribute to the measure.
Applying this processing to the data as a function of concentration and peak neg-
ative pressure allows calculation of signal statistics for comparison between droplets
and control cases. The largest value produced by any of the control cases after this
processing was for the 50% bubble dilution at the highest peak negative pressure used.
Droplet samples, on the other hand, produced a wide range of values as a result of the
presence of lines with no droplet vaporization (values below the 50% bubble dilution
reference) and those with droplet vaporization (values well above the 50% bubble dilu-
tion reference). Droplet signals can therefore be identified by choosing a control-based
threshold. In this case, the 99th percentile integrated spectral value obtained for the
50% bubble dilution case at the highest peak negative pressure was chosen as a ref-
erence, and any signals at least 10% greater than this were considered to be droplet
signals. This threshold is highly conservative, as a 50% bubble concentration is not a
physiologically relevant scenario for agents flowing in the bloodstream. However, for
the purposes of this investigation it serves as a proof-of-concept that the droplet-based
signals are distinct from any possible value of the control groups when processed in this
manner.
Applying this threshold to the 200 individual pressure traces captured at each con-
centration and peak negative pressure allows calculation of the likelihood of detecting
droplets at the given flow rate for each combination of parameters (Figures 6.8 and 6.9).
Out of the 200 pulses for each test case, DFB droplets did not begin to show significant
vaporization until the concentration was above 0.5% at the highest peak negative pres-
sure. The number of pulses with droplet vaporization increased with concentration up
to 10% concentration - after which every pulse exhibited droplet vaporization. At the
higher concentrations, a significant number of DFB droplet signals were registered at
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lower peak negative pressures, illustrating the interplay of concentration and peak neg-
ative pressure in the stochastic process. It should be noted here that some individual
droplet signals could be detected at lower concentrations and peak negative pressures
than shown in Figures 6.8 and 6.9 (such as the droplet trace in Figure 6.6A), as this
Figure is limited to tests where 5% or more of the 200 lines exhibit droplet signals.
However, for any combination of concentration and pressure where the peak negative
pressure is 1250 kPa or less, very little droplet vaporization was captured. OFP sam-
ples, on the other hand, showed significant vaporization across a range of concentrations
and peak negative pressures - reflecting the greatly reduced vaporization thresholds of
OFP droplets compared to DFB. For nearly all combinations where concentration was
above 0.5% and pressure was above 400 kPa, 5% or more of the samples showed droplet
signals. No significant vaporization was detected below 200 kPa for any concentration,
while at the lowest two concentrations used, peak negative pressures above 1000 kPa
occasionally produced vaporization at the 5% level.
At concentration/pressure combinations where at least 3 droplet-specific signals
were detected, statistics show that the spectral integration magnitude was dependent
on PFC choice, as can be expected from earlier results. The DFB droplet signals at
lower concentrations were on the order of 2 dB higher than the bubble threshold value,
while higher concentrations produced signals upward of 9 dB over the bubble thresh-
old value (Figures 6.10 and 6.11). The increase in signal strength observed for higher
concentrations as a function of peak negative pressure is expected to be a result of a
much larger number of droplets vaporizing in the focal zone (these are combinations
that produce very high vaporization percentages in Figures 6.8 and 6.9). For OFP
droplets, concentrations 1% or below produced a consistent 4 dB increase over the
bubble threshold regardless of the increase in vaporization pressure, while higher con-
centrations increased with vaporization pressure to values as high as 15 dB above the
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Figure 6.8: Percentage of 200 sequential pulses where droplet signals are detected as a
function of concentration and peak negative pressure of the incident 8 MHz ultrasound
pulse. DFB droplets show little vaporization below the higher concentration/pressure
combinations.
bubble threshold.
It should be noted here that Figures 6.10 and 6.11 show the strength of the droplet
signals relative to the 99th percentile bubble signal for the 50% dilution of bubbles. In
vivo, a more relevant reference level may be the water-only microcellulose tube control,
which mimics a blood-filled vessel. When compared to the 99th percentile water-tube
signal, DFB droplet signals were approximately 6 to 13 dB greater in magnitude, and
OFP signals were approximately 8 to 19 dB greater in magnitude, depending on con-
centration.
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Figure 6.9: Percentage of 200 sequential pulses where droplet signals are detected as a
function of concentration and peak negative pressure of the incident 8 MHz ultrasound
pulse. OFP droplets with much higher sensitivity to ultrasound than DFB show a
significant amount of vaporization at low concentration/pressure combinations.
6.3.4 Limitations and Future Directions
The results of this chapter provide a preliminary demonstration that, under the
right vaporization conditions, PCCAs emit size-dependent acoustic signals that can be
detected. To the authors’ knowledge, this is the first article that has characterized these
phenomena both optically and acoustically and implemented a specific droplet detection
technique based on the results. However, there are some fundamental limitations to
the study that warrant discussion.
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Figure 6.10: Strength of detected droplet signals relative to 99th percentile microbubble
(50% dilution) signal magnitude after processing. A) DFB droplets exceed the thresh-
old by 2 to 9 dB, depending on concentration and peak negative pressure. Note: The
lowest concentrations (0.1% and 0.05%) omitted for clarity, and traces shifted slightly
for clarity in error bars.
The experimental relationships between bubble size and resonance frequency ob-
tained by optical experiments is modeled well by the simple Minnaert resonance calcu-
lations (Figure 6.3). However, this model neglects factors such as surface tension and
shell properties that are likely to influence the physical phenomena captured here. In
this study a classic damped harmonic oscillator model was implemented to account for
some of these aspects, but the uncertainty in frequency resolution imposed by having
only 24 frames maximum during optical experiments limits implementation of more ro-
bust models. Future refinement in the size/frequency relationship through alternative
optical imaging equipment or simultaneous optical/acoustic capture may allow imple-
mentation of alternative resonance models in order to estimate physical properties of
the droplets. Alternatively, the exponentially decaying sinusoidal pressure waveforms
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Figure 6.11: Strength of detected droplet signals relative to 99th percentile microbubble
(50% dilution) signal magnitude after processing. OFP droplets exceeded the threshold
by between 4 and 15 dB, depending on concentration and peak negative pressure,
highlighting the much larger signals produced by OFP droplets as a result of greater
volatility. At concentrations 1% or below, signal strength was independent of pulse
pressure as a result of fewer droplets vaporizing in the focal plane. At combinations
of high concentration and high pulse pressure, the much greater number of vaporizing
droplets resulted in an increase in signal strength. Note: The lowest concentrations
(0.1% and 0.05%) omitted for clarity, and traces shifted slightly for clarity in error
bars.
captured during acoustic interrogation may be used to estimate physical properties
through the interaction of amplitude, frequency, and decay rate for droplets of varying
size. The decay rate, in particular (as demonstrated in Figure 6.6), is directly related
to thermal damping, which includes effects of Laplace pressure and the gas-dependent
polytropic index [181]. One aspect that warrants future study is the degree to which
the initial vaporization pulse influences the vaporization phenomena observed. It is
assumed in this study that the impact on overexpansion, oscillation, and final size of
the 2-cycle 8 MHz pulse is not significant. Future studies with shorter, higher frequency
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pulses will reveal whether this is the case or not.
Frequency-banded detection techniques such as those here may be useful for deter-
mining thresholds of activation for different perfluorocarbon emulsions under various
flow conditions and concentrations. Currently, there is no standardized method to
evaluate practical in vivo activation parameters for PCCA formulations. Many studies
measuring thresholds rely on acoustic techniques that are highly influenced by large
outliers in the typically polydisperse size distributions, and alternative optical tech-
niques of determining thresholds are limited with respect to sub-micron particles (the
topic of Chapter 5). Using the techniques demonstrated here, the frequency bands cor-
responding to sizes of interest can be isolated in order to determine relative activation
under given peak negative pressures. Therefore, these methods offer, for the first time,
the potential to determine activation of droplets of a particular size when surrounded
by droplets of different sizes through acoustic interrogation.
Here, the detection is shown only for a single point in space, and with a single
transducer element. Ongoing efforts are focused on capturing these signals with imaging
transducers (across many elements) in order to detect these signals and form images
incorporating the spatial aspects of droplet vaporization. Ultimately, detection of these
signals may enable real-time imaging of droplet activation that could be used for many
diagnostic and therapeutic applications of medical ultrasound. Although the ability to
distinguish these signals in a water bath does not directly indicate the ability to do so
in tissue, several factors suggest detection of these signals in vivo would be likely. The
frequencies of the natural resonance of droplets investigated here occur on the order
of 100 kHz to 2.5 MHz - which is relatively low in the context of diagnostic medical
ultrasound. Because the activation pulse is 8 MHz in frequency, tissue will scatter
energy back towards the transducer at this same frequency as well as higher harmonics
- but generally not at lower frequencies [186]. Bubbles driven by the ultrasound pulse,
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on the other hand, will reflect back energy across a wide range of higher harmonics
of 8 MHz, but generally not much below the 1/2 frequency harmonic [46] other than
broadband energy that occurs from microbubble destruction [187]. As a result, neither
microbubbles nor tissue will generate substantial acoustic waves on the order of 100 kHz
to 3 MHz when pulsed at 8 MHz, and the signal from droplets of this size vaporizing
in tissue will be detectable. Additionally, the signals returning from vaporized droplets
will suffer less from frequency-dependent tissue attenuation than the higher frequency
bubble and tissue signals [188], and only have to travel one-way through the tissue to
reach the transducer.
Although only the outliers in the distributions used here were investigated in order to
pair optical and acoustic results (average droplet size in each suspension was sub-micron
and not well-resolved optically), these techniques could be used to detect vaporization
of droplets much smaller than those shown here. For instance, droplets near 200 nm
in diameter would vaporize to form bubbles on the order of 1 µm in diameter. By
the isothermal Minnaert approximation, these would generate acoustic signals with
frequencies near 5-6 MHz. These frequencies would likely still be detectable through
tissue, but they overlap with the bandwidth of the vaporization pulse transducer used
here and therefore would be more difficult to discern from tissue and bubble signals.
In order to maintain signal separation, a higher frequency vaporization pulse would be
necessary, which may limit the ability to achieve droplet vaporization through a depth
of tissue. In addition to separation between the vaporization pulse frequency and the
oscillation frequencies, the underlying physics impose limits on the relationship between
droplet oscillation frequency and the length of the vaporization pulse. In order to
detect these unique signals, it is necessary that the activation pulse not extend into the
oscillation period so that the resulting bubble is not ‘driven’ by the ultrasound pulse
itself. The time to finish vaporizing depends directly on the droplet size, and so to
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detect very small droplets, very short pulses must be used to initiate vaporization. The
activation pulse can be shortened by increasing the frequency, but frequencies much
higher than 10-15 MHz do not provide sufficient penetration into tissue to be useful
in human diagnostic imaging in deep tissues, and would only be relevant to superficial
applications. Thus, with ultrasound as the activation source, there may be a practical
limit to the smallest size of droplet detectable for medical ultrasound. Despite this,
there are many therapeutic applications where droplets are large in order to deliver
large payloads of drugs [110] or enhance ablation [85; 54].
One of the most interesting possibilities of these techniques is to activate the droplets
with non-acoustic sources and detect the unique droplet signals with ultrasound. Other
groups have recently demonstrated activation with lasers through primarily thermal
mechanisms to enable applications in medical photoacoustics [130; 189], and it has
been suggested that droplet nucleation may be possible with ionizing radiation such
as X-ray [66]. In these cases, there may be little to no acoustic interference from the
activation source, and so the droplet-specific signals may be received with high fidelity.
Also, a non-acoustic source will not ‘drive’ the resulting bubbles with forced oscillations
in the same manner as an acoustic source, and so oscillations from very small droplets
on the order of 5 MHz or higher may also be isolated easily.
6.4 Conclusion
In this chapter we demonstrate that, as a result of the phenomena of over-expansion
and oscillation, unique acoustic signals are generated by vaporizing phase-change droplets
that can be detected and isolated from other acoustic sources. Beyond physical studies,
this technique may have wide applicability in real-time monitoring of therapeutic pro-
cesses involving phase-change contrast agents in ultrasound as well as other modalities,
and may result in new diagnostic techniques.
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CHAPTER 7
An In Vitro Proof-of-Principle of PCCA Molecular Imaging
7.1 Introduction
7.1.1 Ultrasound Molecular Imaging
By modifying the lipid, albumin, or polymer shell encapsulating typical MCAs to
contain specific, high-affinity targeting ligands, a number of preclinical studies have
demonstrated the feasibility of using ultrasound molecular imaging (USMI) to detect
cardiovascular disease, angiogenesis of solid tumors, inflammation processes, atheroscle-
rosis and thrombus [190; 32; 191].
However, there are some fundamental limits and confounding factors involved with
USMI based on MCAs. First, the perfluorocarbon (PFC) gas-core MCAs typically have
low stability in circulation and dissolve into the surrounding media quickly. This, in
combination with passive and active clearance by the lungs and mononuclear phagocyte
c© 2013 World Federation for Ultrasound in Medicine & Biology (wfumb.org) Portions reprinted,
from PS Sheeran, JE Streeter, LB Mullin, TO Matsunaga, and PA Dayton. “Toward Ultrasound
Molecular Imaging with Phase-Change Contrast Agents: An In Vitro Proof of Principle” Ultrasound
Med Biol, 2013 March; 39(5): 893-902.
c© 2012 Elsevier Ltd. (elsevier.com) Portions reprinted, from PS Sheeran, S Luois, LB Mullin, TO
Matsunaga, and PA Dayton. “Design of Ultrasonically-Activatable Nanoparticles Using Low Boiling
Point Perfluorocarbons” Biomaterials, 2012 April; 33(11): 3262-3269.
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system, results in a rapid elimination of contrast-providing agents over the course of
several minutes [49]. Typical USMI schemes rely on measuring accumulation of a
generally low number of targeted agents over time after a sufficient waiting period that
allows for clearance of non-targeted, circulating agents [38]. Second, the size of MCAs
that maximizes contrast once targeted (typically on the order of 1 µm in diameter; [170])
limits the MCAs to flow within the vascular space after injection. As a result, the MCAs
are designed solely to target vascular diseases, such as inflammation, or intravascular
markers that are indicators of processes beyond the vascular space, such as angiogenesis
resulting from solid tumor growth (Figure 7.1a). Many approaches to molecular imaging
and drug delivery in other modalities have exploited the enhanced permeability and
retention effect of “leaky” solid tumor vasculature to gradually accumulate particles on
the order of 100 nm in the extravascular space via passive diffusion [192]. Although
efforts have been made to generate targeted MCAs in sizes small enough to potentially
diffuse beyond the vascular space and be registered by ultrasound imaging [193], the
contrast provided will be significantly reduced by the scattering cross-section of these
particles [168] in combination with a resonance frequency much greater than those used
for human diagnostic imaging [115]. Furthermore, microbubbles on the order of 500
nm or less are more prone to collapse because of increasing Laplace pressures, which
makes stabilizing such small bubbles challenging.
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7.1.2 Phase-Change Contrast Agents
Several alternatives to MCAs exist for USMI. Contrast agents based on liquid per-
fluorocarbon nanodroplets have been proposed because they exhibit some echogenicity,
although inherently less than microbubbles, and are more stable in circulation than
MCAs [8; 17; 23; 20; 3]. The more recent concept of acoustically activated phase-
change contrast agents (PCCAs) has gained attention for diagnostic and therapeutic
ultrasound [71; 194]. For the purposes of particles capable of extravasation, PCCAs
present a unique advantage for ultrasound, in that particles in the liquid state can be
generated at sizes small enough to extravasate, but become highly echogenic bubbles
upon activation [52]. The contrast provided by activated PCCAs has been demon-
strated in several investigations [71; 50], but few studies have explored the potential of
PCCAs as diagnostic agents for USMI.
One challenge in designing diagnostic and molecular imaging PCCAs at the mi-
croscale and nanoscale stems from the increase in surface tension effects. The Laplace
pressure exerted on the core of PFC droplets as a result of surface tension scales with
the inverse of the particles radius; therefore, particles at the nanoscale can experience
several atmospheres of additional pressure [52]. Because a compound’s boiling point
increases with increasing pressure (by the Clausius-Clapeyron relation), this results in a
significantly increased effective boiling point for the compound, which increases the ul-
trasound energy needed to vaporize the droplet. Nanoscale PCCAs of the typically used
PFCs may require acoustic parameters suitable only for therapeutic purposes [114; 195].
A recent study by Wang et al. [196] demonstrated active PCCA targeting to cancer cells
in vitro through aptamer-conjugated droplets of dodecafluoropentane the most com-
monly used perfluorocarbon for PCCAs. As a result of the significant pressures needed
to induce phase-transition, the authors observed mechanical cell destruction coincid-
ing with vaporization. Although this result may be desirable for therapeutic and drug
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delivery applications, a non-invasive imaging approach should avoid the likelihood of
bioeffects.
7.1.3 Generating PCCAs from Low Boiling Point PFCs
In Chapters 2 through 4, we demonstrated the ability to create sub-micron PCCAs
with low vaporization thresholds through formulation using low-boiling-point PFCs
such as DFB, OFP, and well as mixtures of each. The ‘microbubble condensation’
method (Chapter 3) is accomplished by exploiting the ‘bi-stable’ nature of the particles
created by the influence of Laplace pressure. At larger sizes, the internal pressure is
reduced and the particles prefer the gaseous state, whereas the internal pressure is high
in small sizes (hence a greatly increased effective boiling point), and the particles will
remain stable in the liquid state well above their atmospheric pressure boiling point.
One of the primary benefits of the microbubble condensation technique is that it allows
for simple modification of droplet properties (size, composition) by altering the pre-
cursor MCAs through well-described methods. Nanodroplets capable of USMI or gene
delivery can be generated by first preparing MCAs containing targeting ligands or gene
vectors and then condensing to the droplet form. PCCAs generated via this method
have the potential to be made in sizes small enough to extravasate into the tumor
interstitium and target specific cell markers, and then be activated to form echogenic
MCAs and to be registered through ultrasound imaging (Figure 7.1c). Even as purely
intravascular agents, PCCAs can have benefits in reducing the waiting period needed
to obtain imaging contrast. Once a sufficient number of droplets have accumulated
at the vascular site of interest, an activation pulse can be delivered to vaporize the
agents in a desired location (Figure 7.1b). The remaining non-activated droplets still
in circulation will have little contrast relative to the highly echogenic targeted bubbles,
and so information on molecular expression may be gathered more quickly.
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In this chapter, we explore in vitro the feasibility of using PCCAs derived from low
boiling point PFCs as USMI agents. We demonstrate that targeting ligands can be
simply incorporated into the encapsulating shell of the precursor microbubbles, that
the shell and targeting are preserved in the condensation process to form sub-micron
droplets, and that the resulting droplets successfully target cellular markers of angio-
genesis (e.g., αV β3). Furthermore, the main benefit of using low boiling point PFCs
is demonstrated by activating targeted droplets using a clinical diagnostic ultrasound
machine while maintaining the adhesion of the resultant microbubble to the cellular
marker.
7.2 Materials & Methods
7.2.1 Microbubble Preparation
All lipid solutions consisted of DSPC, DSPE-PEG2000 and DSPE- MAL-PEG2000
(1,2- distearoyl- sn- glycero-3- phospho ethanolamine- N-maleimide (polyethylene- glycol)-
2000), in a 9:0.5:0.5 molar ratio, respectively (Avanti Polar Lipids, Alabaster, AL,
USA). To create a particle designed to target αV β3 integrins, a cyclic RGD peptide
(Cyclo-Arg-Gly-Asp-D-Tyr-Cys) cross-linked to DSPE-MAL-PEG2000 was included,
similar to previous studies by our group [170]. Similarly, non-targeted (sham con-
trol) particles were created using a cyclic RAD peptide (Cyclo-Arg-Ala-Asp-D-Tyr-Cys)
cross-linked to DSPE-MAL-PEG2000 that is known not to target αV β3 integrins. The
cyclic RAD and RGD peptides were purchased from Peptides International (Louisville,
KY, USA). The excipient solution was composed of phosphate-buffered saline, propy-
lene glycol and glycerol (16 : 3 : 1) for a total lipid concentration of 1.0 mg/mL. After
adding 1.5 mL of the resulting solution to a 3 mL glass vial, the headspace of the
vial was gas-exchanged with decafluorobutane (Fluoromed, Round Rock, TX, USA).
MCAs were formed via standard mechanical agitation techniques using a Vialmix shaker
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(Bristol-Myers-Squibb, New York, NY, USA).
7.2.2 Microbubble Condensation
MCA samples were condensed and sized using the protocols presented in Chapters
3 and 4.
7.2.3 Cell Culture
Human umbilical vein endothelial cells (HUVECs; CC-2519) were cultured in En-
dothelial Cell Basal Medium-2 (EBM-2; CC-3156) supplemented with EGM-2 Single-
Quot Kit Supplement and Growth Factors (CC-4176) (Lonza, Walkersville, MD, USA).
HUVECs in culture have been previously shown to overexpress the αV β3 [197]. Cells
were maintained in a humidified atmosphere containing 5% CO2 at 37
◦C and were grown
in a monolayer on nearly acoustically transparent Thermanox slips (Nalge Nunc Inter-
national, Rochester, NY, USA) coated with 2% gelatin. When cells reached 80− 90%
confluence, they were incubated for 15 min with 100 µL of the droplet solution diluted
in 3 mL of media. After incubation, the cover slips were rigorously washed with media
by flushing with a 3 mL syringe over the coverslip at a rate of approximately 0.5 mL/s,
and samples were placed in a metal holder. A media-filled fluid pocket was created
with a gasket and a Thermanox cover slip opposite the glass cover slip (Fig 7.2).
7.2.4 Microscopy
Bright field images were obtained at two time points: just after the cell-PCCA
sample incubation period and just after cell exposure to ultrasound. To capture micro-
scope images after ultrasonic imaging, the fluid pocket formed by the gasket and dual
Thermanox slips was taken apart, and the lower coverslip was submerged in a six-well
plate with 3 mL of phosphate-buffered saline. All images were captured using a 60×
immersion objective (NA = 1.0) with a BX51 Microscope (Olympus, Center Valley,
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Figure 7.2: Experimental Setup
PA, USA) and Metamorph Basic software (Molecular Devices, Sunnyvale, CA, USA).
7.2.5 Shell Preservation
To create microbubbles incorporating fluorescent marker in the lipid shell, 2 µL
of Vybrant DiI cell-labeling solution (Invitrogen Molecular Probes, Eugene, OR) was
added to the previously described lipid solution. The headspace of the vial was gas
exchanged with DFB and subsequently agitated to form microbubbles. Condensation of
the microbubble sample was performed with the techniques described above. Brightfield
and fluorescent digital micrographs were obtained before microbubble condensation
using a 100× objective with a fluorescence microscope (BX51) and Metamorph Basic
software.
7.2.6 Experimental Apparatus
Ultrasound imaging of each sample was performed with a Siemens Sequoia Imaging
System (Acuson Sequoia 512, Mountain View, CA, USA) with a 15L8 linear array
transducer positioned at an angle relative to the sample (Fig 7.2) to minimize specular
reflections back towards the transducer. The transducer was placed in a clamp that was
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mounted to a 2-D motion stage with the ability to elevationally control the transducer
position using a custom LabVIEW (National Instruments, Austin, TX, USA) program
for the goal of generating volumetric data. Samples contained in the metal holder
were placed in a plastic-lined degassed waterbath at body temperature (37◦C) using
acrylic standoffs to adjust the height relative to the transducer. The focal point of the
transducer was set to the axial position of the cell sample located on the Thermanox
cover slip. Volumetric B-mode scans were acquired for overlays and drawing regions
of interest using the system’s compounding mode (frequency, 14 MHz; mechanical
index [MI], 0.1) while stepping the transducer at 0.4 mm increments across the cover
slip. The elevational beam width was previously determined to be 0.8 mm [198; 199].
Similarly, baseline volumetric Cadence pulse sequencing (CPS) scans (Freq: 7 MHz,
MI: 0.18, CPS Gain: -20 dB) were acquired with elevational increments of 0.4 mm
stepped across the sample. To vaporize targeted and non-targeted droplets present in
the samples, the system was set to Bmode with an MI of 1.1 and a frequency of 8
MHz, while the transducer was elevationally translated at 1 mm/s across the sample
with an imaging frame rate of 30 Hz. These acoustic parameters were chosen based
on prior in vitro work demonstrating that two to three cycle imaging pulses (e.g.,
those delivered by the Sequoia) with mechanical indices of 1 or higher are sufficient
to cause DFB droplet vaporization (Chapters 2 through 5). After exposure to the
higher pressure, the sample was rescanned in CPS mode (7 MHz; MI, 0.18; CPS gain,
-20 dB) to capture the increase in contrast from the newly formed bubbles. All other
ultrasound parameters, such as gain and time-gain compensation, were kept constant
between samples.
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Data Analysis
Contrast enhancement was measured using the Siemens Sequoia CPS mode where
the mean pixel intensities of the volumetric data were assumed to be proportional to
the degree of molecular biomarker expression. Regions of interest were manually drawn
around the perimeter of the cover slip boundaries in each image plane using the previ-
ously acquired B-mode image data. With custom MATLAB (MathWorks, Natick, MA,
USA) scripts, the volumetric intensities for each cover slip were obtained by summing
all of the pixel intensity values for each voxel within the drawn regions of interest and
dividing that value by the total number of voxels within the volume. For each tar-
geted (N = 6) and nontargeted (N = 6) experiment, mean volumetric intensities from
pre- and post-vaporization images were calculated to yield a final volumetric measure of
αV β3 targeting. Significance between compared distributions was analyzed in Microsoft
Excel using a two-sided Students t-test with equal variance. The significance between
the different distributions was considered at a value of p < 0.05. Images were created
by setting the acquired CPS intensity data to a green-scale of 0 − 256 and creating
overlays of the CPS and B-mode data.
7.3 Results
In these results, we demonstrate the feasibility of using low boiling point PCCAs
for diagnostic USMI by comparing the in vitro contrast enhancement provided after
incubating targeted samples with αV β3 - expressing HUVECs and inducing vaporization
with a clinical diagnostic ultrasound machine.
7.3.1 Sample Sizing
Targeted and non-targeted samples had similar distributions in both the precursor
MCA stage and the condensed droplet stage. The originating cyclic RGD (targeted)
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and cyclic RAD (non-targeted) MCA samples had mean diameters (± SD) of 1.07±0.78
µm and 1.09 ± 0.94 µm, respectively (Figure 7.3a). The condensed droplets typically
formed peaks at 295 nm in diameter, with a wide distribution through the nanoscale
range (Figure 7.3b), including the presence of outlier microscale droplets resulting from
bubbles greater than 5 µm present in the original MCA distribution.
Figure 7.3: Representative sizing of (a) precursor microbubbles and (b) targeted and
non-targeted droplets. Microbubbles were measured with laser-light diffraction (Accu-
sizer) and are presented as count-weighted distributions, whereas droplets are measured
with dynamic light scattering (ZetaSizer) and are presented as intensity-weighted dis-
tributions.
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7.3.2 Shell Preservation
Brightfield and fluorescence microscopy results showed that the DiI-labeled encap-
sulating lipid shell was present after the condensation technique (Figure 7.4). Although
this can be expected, it has not been previously illustrated, and is important for preser-
vation of targeting capability.
Figure 7.4: Brightfield (a, c) and fluorescence (b, d) microscopy illustrating that the
shell is preserved when DiI-labeled DFB microbubbles (a, b) are condensed to the
liquid state (c, d), the shell is preserved through the change in volume. (Note that the
droplet in c, d did not result directly from condensation of the precursor bubbles in a,
b.). Scale bar is 5 micrometers.
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7.3.3 Ultrasonic Vaporization and Microscopy
To demonstrate the feasibility of USMI with low boiling point PCCAs, a total of
12 plated HUVEC samples expressing αV β3 were incubated with targeted (N = 6)
and non-targeted (N = 6) droplet samples and then imaged with a Siemens Sequoia.
Activation pulses over the coverslip length took approximately 20 s, and the ultrasound
imaging scan was taken within 30 s of the final activation pulse. After the imaging data
were captured (approximately 50 s), 2−3 min elapsed while the samples were transferred
to the microscope. Both contrast-specific ultrasound CPS scans and microscopy results
suggest that few bubbles were present before the activation pulse for both targeted
and non-targeted samples, indicating that any targeted particles were likely still in the
condensed liquid state (low echogenicity) after the incubation period (Figs. 7.5a, 7.6a).
In the microscopy images, the presence of outlier microscale droplets could be observed
in targeted samples, although nanoscale droplets were not optically resolvable (Figure
7.6a).
Figure 7.5: Overlays of contrast-specific CPS pixel intensity (green scale) and tradi-
tional B-mode (grey scale) ultrasound scans of HUVEC samples incubated with tar-
geted PCCAs. (a) Before activation, no contrast-specific echogenicity is detected,
suggesting that PCCAs are still in a liquid state. (b) After exposure to an MI of 1.1
at 8 MHz, targeted droplets vaporize to the highly echogenic gas state, resulting in a
region of high pixel intensity along the cell layer only.
After the HUVEC samples were exposed to the activation pulse (MI of 1.1 at 8
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Figure 7.6: Microscopy images of HUVECs incubated with targeted DFB droplet sam-
ples (a) before exposure to a vaporization pulse delivered from a diagnostic ultrasound
machine and (b) after vaporization. Before vaporization, large outlier droplets are visi-
ble, but nanodroplets are not optically resolvable. After vaporization, a high number of
small bubbles measuring 1−3 µm can be seen adhering to the cell plane. Large bubbles
were also visible in some microscope images that were likely a result of vaporization of
outlier droplets, or a result of coalescence owing to repeated pulsing of smaller formed
bubbles.
MHz), samples that were incubated with targeted droplets showed the presence of newly
created regions of high contrast (many that maximized the CPS signal), indicating
the presence of highly echogenic bubbles not previously there (Figure 7.5b). This
finding was confirmed by microscopy, where only slides incubated with targeted droplets
showed a significant presence of adherent bubbles (Figure 7.6b), although many bubbles
became detached and were lost in the process of disassembling the fluid pocket and re-
submerging the cell-bearing coverslip in the six-well plates for microscope imaging.
Throughout the course of the tests, a small degree of non-selective droplet tar-
geting was observed for samples incubated with cyclic RAD droplets that resulted in
ultrasound contrast. This finding was also confirmed by the presence of occasional
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microscale droplets (before the vaporization pulse) and MCAs (after the vaporization
pulse) on these samples in microscopy images, although a significantly smaller number
than present for targeted samples.
Figure 7.7: Overlays of contrast-specific CPS intensity (green scale) and traditional
B-mode (grey scale) ultrasound scans: 3-D rendering of the ultrasound slices across
the cell sample volume reveals the contrast enhancement provided by targeted PCCAs
after the activation pulse. Non-targeted samples resulted in a small amount of contrast
enhancement, most likely as a result of non-selective binding. The small amount of
contrast present at the top of each sample is an artifact of the metal holder, not a
result of the presence of echogenic bubbles.
Ultrasound scans were taken across the cell samples at elevational increments of
0.4 mm for a total of 41 ultrasound slices per sample before and after exposure to the
activation pulse. Rendering the ensemble of slices in 3-D allows for visualization of the
volumetric data (Figure 7.7), revealing the drastic difference in contrast enhancement
provided by αV β3-targeting droplets as well as the spatial variation in the targeting
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and activation across the cell plates. As the elevational resolution of the transducer
is approximately 0.8 mm at 7 MHz [198; 199], each intermediate image was discarded
from the dataset to ensure no overlap in data between slices, resulting in a total of
20 volumetric slices per sample for data analysis. Over the six cell samples tested for
each group (targeted, non-targeted), the ultrasound data showed a mean intensity of
approximately 19.0± 11.8 arbitrary units for samples incubated with targeted droplets
(N = 6) and a mean intensity of approximately 3.3±3.9 arbitrary units for non-targeted
droplets (N = 6; Figure 7.8). The post-vaporization data were statistically significant
over baseline for targeted samples (p = 0.01), but not for non-targeted samples (p
= 0.10). The baseline scans were not statistically significant between targeted and
non-targeted groups (p = 0.23). A comparison of the targeted to non-targeted data
shows a statistically significant (p = 0.02), nearly sixfold increase in the mean image
intensity.
7.4 Discussion
These results show proof of principle that PCCAs generated from low boiling point
perfluorocarbons can be used as effective, dynamic USMI agents with unique properties
compared with standard MCA-based USMI agents. To our knowledge, this study is
the first to demonstrate diagnostic USMI with PCCAs where vaporization pulses were
delivered from a clinical diagnostic ultrasound machine. The latter is primarily a result
of the use of low boiling point perfluorocarbons that require inherently less acoustic
energy to vaporize than do commonly used PFCs such as dodecafluoropentane. In
this study, a cyclic RGD peptide was incorporated into the encapsulating shell for the
purpose of targeting cellular αV β3 expression, although in future studies a number of
alternative ligands could be selected to target specific disease states and incorporated
in a simple method as demonstrated here.
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Figure 7.8: Volumetric mean intensity of ultrasound slices for each sample before and
after the ultrasonic activation pulse.
Results showing preservation of the lipid shell simple incorporation of elements such
as tissue-specific targeting ligands, genes, or drugs by including them at the microbub-
ble state and then condensing to form the modified droplets. Interestingly, the fact
that the bubbles resulting from vaporized droplets remained strictly in the plane of the
cells (rather than floating to the upper coverslip and showing as points of high contrast)
strongly suggests that the encapsulating shell remained intact during vaporization and
that a significant portion of the bubbles did not become dislodged as a result of vapor-
ization (Figure 7.5). Additional evidence is provided by the bubbles remaining adherent
to cells after transfer to six-well plates for microscopy (Figure 7.6). Whether the agents
demonstrated here have excess shell in the droplet state primarily as a result of the
microbubble condensation method, or whether retention of the encapsulating shell after
vaporization is a property of all PCCA generation techniques will need to be explored
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in future studies. That the resulting bubbles do not dislodge during vaporization and
remain adherent to the target sites is an important factor for PCCA-based USMI in
ensuring that the contrast-providing bubbles are viable indicators of the underlying
molecular processes. In addition, the visible confluence of the cells did not appear to
be altered by the activation, as would be expected if the cells became mechanically
disrupted or dislodged during droplet vaporization, although more work is needed to
explore whether more subtle interactions may be occurring.
One of the main sources of variation in the data was as a result of the difference
in cell confluence between the test-sets. As the experiments proceeded, it was noted
that the second set of plated cells (the last 6 samples tested) were visibly less confluent
than the first set (the first 6 samples tested), though both targeted and non-targeted
experiments were performed with an equal number of fully-confluent and less-confluent
cell plates. As the contrast provided was an indicator of the overall level of αV β3
expression, the reduced number of cells in the second set resulted in a lower degree of
targeted droplet binding as well as non-selective binding of non-targeted agents, which
is apparent in the group data (Figure 7.9). In each set of cells cultured together, the
targeted samples consistently show higher mean pixel intensity than the non-targeted
samples.
In all experiments, the cell samples incubated with targeted droplets showed con-
sistently higher mean pixel intensity than those incubated with non-targeted. Some
amount of non-selective binding occurs, which is consistent with both in vitro and in
vivo results using MCA-based USMI agents [32; 200; 201; 170; 202]; therefore, future
studies establishing the extent to which this occurs for PCCAs will be important. Be-
cause this study investigated the general feasibility of using PCCAs as USMI agents,
much work can be done to optimize parameters further. As with MCAs, careful study
is needed to define the proper waiting period that balances agent deposition at the
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Figure 7.9: Box-and-whisker plot demonstrating the shifted data as a result of dif-
ferences in cell confluence between cell set 1 and cell set 2. Each box represents the
distribution of mean intensities within the 2-D slices in a single sample. Within each
set, the targeted samples held consistently higher signal intensity than non-targeted
samples.
target site with clearance from the mononuclear phagocyte system and general agent
instability. In addition, the ideal ultrasound activation signal would be one that uses
the least amount of energy needed (to minimize unwanted bioeffects) and limits each
droplet to only a few high-energy vaporization pulses (to minimize secondary effects
such as coalescence and fragmentation; [203; 122]). In this study, droplets were exposed
to approximately 15− 20 pulses during the period that the ultrasound transducer was
translating over the sample volume. Although many small bubbles resulting from va-
porization of nano-PCCAs were present (Figure 7.6b), coalescence owing to repeated
pulsing [160] might explain the presence of some large bubbles that were observed in
the microscope images after vaporization (15− 25 µm in diameter). Although present
in much smaller quantities than bubbles 1-5 µm in diameter, these large bubbles were
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likely major contributors to the total scattered ultrasound signal. It is also possible
that these bubbles were a result of the larger outlier droplets present in the polydisperse
samples. Although the diameter distribution peak was on the order of 295 nm, DLS
measurements (Figure 7.3) and microscopy (Figure 7.6a) both show the presence of a
small amount of droplets (1− 3 µm) that could vaporize to form bubbles on this order.
In this study, the intent was to investigate the general feasibility of a PCCA-based plat-
form for molecular imaging. However, refinement in the broad size distribution used
here is needed depending on whether molecular imaging is aimed at the intravascular
space or extravascular space. For extravascular USMI, targeted emulsions should ide-
ally have droplets measuring 100 − 300 nm to enable extravasation, whereas vascular
targeting could be accomplished with much larger droplets.
7.5 Conclusion
Ultrasound-based molecular imaging with phase-change contrast agents presents a
promising new set of tools for detecting both intravascular and extravascular cellular
markers. Through the microbubble condensation technique, nanoscale PCCAs with
both high stability in biologic media and inherently high sensitivity to ultrasound can
be generated with a wide variety of targeting ligands to detect disease-specific markers
in vitro and in vivo. One of the most unique aspects of a PCCA-based molecular imag-
ing approach is that the imaging modality (ultrasound) allows for real-time spatial and
temporal specificity of the agent activation and the subsequent imaging. Our demon-
stration suggests that targeted PCCAs can be designed to target cell surface receptors.
Furthermore, continued adhesion to the receptor following activation provides strong
evidence that the avidity of both the PCCA and the resultant microbubble to the re-
ceptor is significantly robust to allow for selective molecular imaging to cell surface
markers.
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CHAPTER 8
Summary and Future Directions
8.1 Introduction
Despite the fact that phase-change agents have been under investigation for more
than 15 years [66], and despite the high number of preclinical studies that have shown
promise, no clinical studies (to our knowledge) have been conducted. A thorough
literature review of the current state of phase-change contrast agents reveals several
areas to fundamentally improve the clinical potential of the platform:
1. Overcoming the Increase in Vaporization Energy for Nanoscale Emulsions
2. Increasing the Uniformity of Activation
3. Tailoring Droplet Performance to Desired Application
4. Determining Appropriate Activation Thresholds for Polydisperse Sub-micron Dis-
tributions
5. Isolation of Signals Specific to PCCAs for in vivo Detection of Activation
c© 2014 Hindawi Publishing Corporation (www.hindawi.com) Portions reprinted, from PS Sheeran
and PA Dayton. “Improving the Performance of Phase-Change Perfluorocarbon Droplets for Medical
Ultrasonography: Current Progress, Challenges, and Prospects” Scientifica, 2014; In Press.
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6. Demonstration of Utility for Diagnostic and Molecular Imaging Purposes
Throughout this thesis and the following appendices, we describe methods to ad-
dress these challenges in order to drive PCCAs toward clinical use. In this chapter, we
summarize the studies in each section and discuss future goals and challenges as well
as remaining questions.
8.2 The Benefit of Microfluidics-Based Production
To date, PCCAs have most commonly been composed of two perfluorocarbons -
dodecafluoropentane and perfluorohexane [194]. Researchers have used techniques such
as sonication [52], extrusion [73], mechanical agitation [71], and microfluidization [76]
to generate highly concentrated emulsions of these PFCs. These processes are capable
of producing particles at both the nanoscale and microscale, although the emulsions are
typically polydisperse. In order to ensure large droplets in the distribution do not induce
unwanted bioeffects, some studies have demonstrated further emulsion processing by
filtering or microfluidic sorting [50; 108; 149; 150]. Despite the refinement of the upper
end of the droplet distribution, the polydispersity of the emulsion produces a decrease
in the uniformity of response to the acoustic beam due to the size-dependent threshold
of vaporization. Few options exist to reduce the polydispersity of sub-micron emulsions,
but techniques such as differential centrifugation [151] or microfluidic generation [110;
204] can be used to produce narrow distributions of microscale particles. Though
microscale PCCAs are not ideal as extravascular or imaging agents, they may have
high utility in therapeutic applications where droplet vaporization produces bubbles
large enough to occlude the blood vessels of target organs, increasing drug payload and
residence time, inducing hypoxia, reducing the heat-sink effect of blood flow during
thermal ablation, and acting as cavitation enhancement agents for ultrasound-mediated
therapies [71; 84; 85; 54]. One of the earliest studies applying microfluidics technology
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to PCCAs was by Couture et al. to create uniform loading of fluorescence in a composite
PFC particle [110].
In Appendices B through D, we used the microfluidics platform to generate monodis-
perse microscale droplets of DDFP encapsulated in a phospholipid shell and demon-
strate advantages and limitations of choosing this approach. In the first study, by Martz
et al., a device previously designed for generating microbubbles with diameters near
10 µm was adapted to produce monodisperse droplet distributions with diameters as
low as 7.5 µm in diameter at rates of 104 to 105 droplets/s (Appendix B). A phospho-
lipid solution was delivered via syringe pump to the outer channel (continuous phase)
of the flow-focusing device, and DDFP was pumped into the inner channel (dispersed
phase) via a separate syringe pump. By altering the flow rate of the two fluids relative,
particles of different size were generated and collected. The benefit of monodispersity
was demonstrated by testing vaporization thresholds of individual particles in vitro
using a confocal acoustical/optical experimental setup. The different droplet popula-
tions (each representing a unique size with standard a deviation less than 5% of the
mean diameter) vaporized at unique, non-overlapping acoustic thresholds when sub-
jected to 5 MHz ultrasound pulses (10 cycles) - confirming the hypothesized uniformity
of response afforded by the narrow distributions. After collection, the particles stayed
stable for more than 2 weeks in storage at 4◦C. The authors concluded that the inability
to generate monodisperse populations with mean diameters smaller than 7.5 µm was
a result of fluctuation introduced by the syringe pumps, and that this was especially
prominent in the DDFP channel where viscosity was low and vapor pressure high at
room temperature.
The second study, by Bardin et al., was performed in parallel and explored the
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relationship between reagent flow rates and droplet production regime in order to de-
termine optimal droplet production parameters (Appendix C). The authors demon-
strated that by adjusting the flow rates, the microfluidic device transitioned between
geometry-controlled droplet production (minimum droplet size determined by size of
flow-focusing orifice), dripping production (capable of producing droplets smaller than
the orifice), and jetting (producing droplets generally larger than the orifice). An ex-
perimental relationship between the droplet diameter and the reagent flow rates in the
dripping regime of Dd = (Qc/Qd)
−5/12 was developed, where Dd is the droplet diameter,
Qc is the continuous phase (phospholipid solution) flow rate, and Qd is the dispersed
phase (DDFP) flow rate. By switching the driving mechanism of the DDFP from a
syringe pump to a more stable pressure-driven pumping mechanism, the authors were
able to produce droplet samples with mean diameters on the order of 3 to 4 µm before
monodispersity was lost or a transition to the jetting regime occurred (Figure C.6).
Droplets were generated at similar rates to the above study by Martz et al. (Appendix
B) and stored at room temperature for two weeks with less than a 4% drift in size
distribution - a promising result for future commercialization. Rather than vaporiza-
tion with ultrasound, the authors tested the thermal vaporization point of the droplets.
Though the nominal boiling point of the DDFP is 29◦C, no vaporization was noted for
4.5 µm diameter droplets until the ambient temperature reached 88◦C. This high degree
of superheat before vaporization may be mostly due to the high PFC purity, but may
be in part due to a stabilizing influence of the encapsulation (via Laplace pressure).
Once vaporized, the bubbles expanded to well over 100 µm (presumably due to the
previously reported intake of ambient dissolved gases [71]) and settled to bubbles near
27 µm in diameter once equilibrium was reached.
In the final study of this series, Martz et al. extended the use of pressure-driven flow
to both the dispersed and continuous phase and increased the proportion of glycerol and
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Pluronic F-68 (Sigma Aldrich Corporation, St. Luois, MO) in the phospholipid solution
(Appendix D). Through this combination, the same device used in the previous studies
was able to produce primary sub-micron droplets an order of magnitude smaller than
the minimum feature size of the microfluidic device. The authors hypothesize that these
changes allowed the device to be operated in a ‘tip-streaming’ regime [205], generating
a fine spray of droplets as small as 300-400 nm in diameter. Although monodispersity
was not preserved, the achievement of sub-micron droplet production without the use
of techniques such as satellite droplet separation [206] may be useful for a wide range of
medical and industrial applications. When exposed to 3.2 MHz ultrasound pulses (100
cycles), droplets near 0.9 µm in diameter were vaporized at peak negative pressures
near 4 MPa, while droplets much smaller than this were not able to be vaporized at
the maximum output of the transducer (4.3 MPa peak negative pressure) as a result of
the Laplace pressure effect.
8.2.1 Summary
These studies show that when the production method allows for a monodisperse
size distributions, activation thresholds are highly uniform from droplet to droplet.
For applications requiring microscale droplets (such as temporary vascular occlusion
[50]), this will translate to an increased efficiency of vaporization in vivo compared
to polydisperse distributions, increasing the effectiveness of the treatment and likely
reducing the necessary dose. The results also show that the microfluidics-produced
microdroplets were sufficiently stable to be stored at room temperature, which was
unexpected given the nominal boiling point of the perfluorocarbon used. Despite this
progress, a number of questions and future studies remain. For example, to produce
the same number of particles as the alternative techniques (typically on the order of
109 to 1010 particles/mL [75]), the microfluidic devices must be run for several hours
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at production rates of 104 to 105 droplets/s. Though this may be improved by scale-up
and parallelization of the microfluidic device [207], it is unclear to what degree this is
necessary; if the benefit of monodispersity is that droplet activation is highly uniform,
then a fewer number of particles need to be injected to achieve the same effect as a
polydisperse emulsion. Depending on this degree of improvement, it may be that the
low production rates are sufficient, but future studies comparing monodisperse to poly-
disperse emulsions at similar concentrations or perfluorocarbon dose will be needed to
determine this. Monodisperse microscale emulsions also present a unique opportunity
to characterize some physical aspects present at the microscale: by creating distribu-
tions of different mean diameters and determining the phase transition temperature
of these droplets, an experimental relationship between droplet size and vaporization
temperature could be constructed and used to estimate Laplace pressure (and, there-
fore, surface tension) or the degree of superheat as a function of perfluorocarbon purity.
Additionally, the microfluidics approach could be adapted to create PFC droplets with
alternative encapsulations such as proteins or polymers. In summary, the microfluidics
platform presents a powerful approach to optimizing current formulations of microscale
PCCAs for clinical implementation.
8.3 Tailoring Thermal Stability and Sensitivity to Ultrasound
8.3.1 Use of Volatile PFCs to Reduce Vaporization Thresholds
In order to circumvent the increase in vaporization thresholds that occurs as droplet
size diminishes, we investigated methods of developing PCCAs with highly volatile per-
fluorocarbon species that had not been previously considered in the literature. We first
estimated the effect of Laplace pressure increase on size-dependent boiling point eleva-
tion for a range of perfluorocarbons through the Clausius-Clapeyron relation (Chapter
2). These calculations showed that two perfluorocarbons - decafluorobutane (DFB,
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C4F10, boiling point -1.7
◦C) and octafluoropropane (OFP, C3F8, boiling point -36.7
◦C) may experience a significant enough Laplace pressure at the nanoscale that the boil-
ing point elevation is above physiologic temperature (37 ◦C) depending on the droplet
size and interfacial surface tension. Under these circumstances, liquid droplets of DFB
and OFP might be stabilized at these sizes and remain in the liquid state once exposed
to physiologic temperature until activated by ultrasound.
In vitro proof-of-principle was demonstrated by condensing DFB gas at reduced
temperatures, placing an aliquot of the DFB liquid into a phospholipid solution, and
then extruding this combination through a porous membrane filter at -20 ◦C to form
phospholipid-encapsulated DFB droplets. The resulting emulsions were investigated
with brightfield microscopy and were shown to contain DFB droplets as large as 13 µm
in diameter - much larger than predicted by the Laplace pressure estimations. Whether
the presence of these large microscale droplets is a result of delayed vaporization (i.e. su-
perheat of a pure compound) or a higher Laplace pressure than expected is unknown.
Laplace pressure is not anticipated to be a significant influence at diameters on the
order of 10 µm unless surface tension is high, but the extremely elevated thermal va-
porization thresholds shown in the microfluidics studies by Bardin et al. (Appendix C)
suggest there may be some influence. Despite these questions, the results confirm that
metastable droplets can be generated from compounds more volatile than previously
considered. The vaporization thresholds of these microscale DFB droplets were tested
using a microvessel-mimicking phantom at 37 ◦C, and the results showed that when
exposed to 5 MHz (10 cycle) pulses, DFB required significantly less pressure to vaporize
than similar droplets of DDFP, and droplets of PFH were not able to be vaporized at the
maximum output of the transducer. Droplets with diameters near 1 µm (approaching
the resolution limit of the setup) were able to be vaporized at peak negative pressures
near 3.3 MPa - less than the maximum allowed for diagnostic imaging, while similarly
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sized droplets of DDFP exceeded this limit (on the order of 4.5 MPa). Curve fits to
the microscale experimental results were used to predict the vaporization threshold for
sub-micron droplets of DFB, which remained below the limit for diagnostic imaging
until droplets reached diameters smaller than 160 nm.
The experimental results with DFB and DDFP microdroplets also showed that,
once vaporized, the level of dissolved gases in the surrounding fluid plays a large role in
the bubble size produced. PFCs are known to solubilize large amounts of oxygen, which
has led to applications in liquid breathing and oxygen delivery [11; 13; 16]. This effect
for PCCAs was previously reported by Kripfgans et al. [71] and was confirmed here.
Both DDFP and DFB bubbles expanded to nearly twice the size predicted by ideal gas
laws (ideally 5-6 times the initial diameter) in the few seconds following vaporization.
When the surrounding fluids were degassed, bubbles measured at the same time points
followed ideal gas law predictions closely. This suggests that understanding the gas
concentration of the intended in vivo target is important in understanding the behavior
of the bubbles being generated by phase-change agents - especially for applications such
as vascular occlusion. For PCCAs to be used in diagnostic applications, emulsions that
vaporize to form bubbles on the order of 1 µm in diameter - similar to current clinical
microbubble formulations - would be ideal. Theoretical expansion factors based on
ideal gas laws including effects of surface tension and increased ambient pressure in
vivo developed in this study show that droplet diameters between 200-300 nm should
provide ideal bubbles once vaporized (Figure 2.6). However, droplets in this size range
are larger than ideal for exiting the vascular space at solid tumor sides via the EPR
effect (ideally diameters of 100 nm or less [91]), and so there may be a tradeoff between
ideal bubble size for imaging and ideal droplet size for extravasation.
The extrusion method used to generate droplets did not appear to be capable of
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producing viable sub-micron droplets regardless of the membrane pore size used, pre-
sumably due to the very low surface tension of the PFC and the very high viscosity of
the phospholipid solution at -20 ◦C. Future refinements to this technique may enable
sub-micron particle generation, but we chose to explore alternative means of particle
generation more amenable to the volatile compounds being investigated.
8.3.2 Microbubble Condensation
Because both DFB and OFP exist as a gas at room temperature, producing liquid
nanoscale particles through the conventional techniques (microfluidization, extrusion,
and sonication) is not simple. However, current clinical formulations of microbubbles
use mechanical agitation to generate phospholipid-encapsulated bubble distributions
with mean diameters between 1 and 3 µm, such as DefinityTM(Lantheus Medical Imag-
ing). In the next study of this series, we demonstrated that it was possible to generate
sub-micron droplets with volatile PFC cores by first generating a population of perfluo-
rocarbon microbubbles ideal for ultrasound interaction and then condensing the gaseous
precursors to the liquid state through a combination of decreased ambient temperature
and increased ambient pressure (Chapter 3). Once the particles condense to the liquid
state, the reduction in size results in a sub-micron distribution of droplets, and the
Laplace pressure may aid in stabilizing the droplets against re-expansion once room
temperature and pressure are restored until the droplets are vaporized by ultrasound
or heat. We refer to this simple, high-yield technique as ‘microbubble condensation’
(Figure 4.1).
Approaching PCCA production by this means has several advantages. First, be-
cause microbubble condensation begins from a population of microbubbles ideal for
imaging, the bubbles produced after particle vaporization are of ideal size (assuming
condensation and vaporization proceed optimally). Second, there are many published
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techniques to modify and functionalize microbubble shells to enable applications in
molecular imaging and drug/gene delivery [35; 38]. Through microbubble condensa-
tion, these modifications can be applied to the precursor microbubbles, resulting in
functionalized droplets. Third, the size of the droplets produced can be altered by
changing the size distribution of the precursor microbubbles.
In this study, we explored the changes in the precursor microbubbles and the
condensation-produced droplets as a function of lipid concentration. In all cases, mi-
crobubble condensation produced droplets with distribution peaks on the order of 200
- 300 nm in diameter, as expected from ideal gas law predictions. When tested in vitro
using the same experimental setup as in Chapter 2, few particles were visible in the
imaging plane prior to application of the vaporization pulse, as droplets near 200 nm
in diameter (below the wavelength of visible light) cannot be resolved in brightfield
microscopy. Once a 5 MHz (10 cycle) pulse with a peak negative pressure of 3.8 MPa
was delivered, the imaging plane was filled with bubbles on the order of 1-5 µm in
diameter (Figure 3.5). The amount of bubbles appeared to increase with the concen-
tration of the lipid solution, but a larger amount of large microscale droplets was also
observed at these concentrations - which may be unwanted (or cause unwanted bioef-
fects) in many applications. Finally, the bubble distributions at two different pressures
(2.7 MPa and 3.8 MPa peak negative pressure) were compared to show that higher
pressures produce a distribution with a higher proportion of small bubbles, indicating
increased efficiency in vaporizing the emulsion and producing a distribution similar to
the precursor microbubbles.
8.3.3 Fine Tuning of Properties by Perfluorocarbon Mixing
In a subsequent investigation of microbubble condensation, we reveal the inherent
tradeoffs involved with forming PCCAs from volatile compounds (Chapter 4). Although
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it has been explored little in the literature, the gains made with regard to vaporization
thresholds by increasing PFC volatility are likely to result in a decrease in thermal
stability (as the vaporization pressure and temperature are governed by the Clausius-
Clapeyron relation). This type of interplay has likely not been explored extensively in
the literature due to the fact that droplet composed of higher boiling points (such as
DDFP) are already sufficiently stable for most applications. The first portion of this
study verified that microbubble condensation could be adapted to generate nanoscale
droplets from highly volatile OFP. Some microscale droplets could be isolated in vitro,
although it is expected that these exist in a highly superheated state and do not persist
for long. By exposing both DFB and OFP microdroplets to ultrasound pulses at 8
MHz (2 cycles) at 37 ◦C, vaporization thresholds could be compared. DFB droplets
near 1 µm in diameter were able to be vaporized at peak negative pressures near 2
MPa at 37 ◦C and 3.5 MPa at 22 ◦C, while similarly sized OFP droplets vaporized at
peak negative pressures near 600 kPa at 37 ◦C and 2 MPa at 22 ◦C. Droplet stability
was assessed by measuring the change in concentration and distribution of particles ≥
500 nm in diameter at 10-minute intervals over the course of 1 hour (Accusizer 780A,
Particle Sizing Systems, Santa Barbara, CA) (Figure 4.4). DFB droplets were generally
stable in vitro during this period at 22 ◦C and 37 ◦C, while OFP concentration dropped
significantly at both temperatures in just the first 10 minutes (an 80% decrease at 37
◦C).
These results demonstrate that while choosing PFCs with lower boiling points pro-
duces droplets that are easier to vaporize by ultrasound, careful consideration must be
given to the tradeoff in thermal stability that occurs in order to create agents capable
of circulating for a sufficient period in vivo. Historically, researchers have designed
droplets based on single perfluorocarbon species. Early PCCA studies by Kawabata et
al. showed that vaporization thresholds could be modulated by creating mixtures of
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the miscible perfluorocarbons [86]. We extend that to suggest that PFC mixing is a
valuable tool to modulate both the thermal stability and the vaporization threshold in
order to create droplets ideal for specific applications. Rather than choosing a ‘one PFC
fits all’ approach, the balance can be shifted in favor of higher stability or lower vapor-
ization thresholds where appropriate. As a simple demonstration, we create droplets
composed of a 1:1 mixture of DFB and OFP and show that the resulting droplets have
intermediate vaporization thresholds as well as intermediate stability (Figure 4.7). It
is also important to note that PFC mixing is not limited to gas/gas or liquid/liquid,
but that it is possible to mix across a wide range of PFCs that exist in different states
in order to produce optimal droplet properties. In a separate study (detailed in Ap-
pendix F), we used a 1:1 mixture of DFB (gas at room temperature) and DDFP (liquid
at room temperature) to create droplets ideal for ultrasound-mediated tissue ablation,
where increased stability is desirable and higher vaporization pressures are acceptable.
8.3.4 Altering Distribution with Microbubble Size-Selection
One of the possibilities afforded by a microbubble condensation approach to PCCA
production is to alter the size of the droplets by changing the distribution of the precur-
sor microbubbles. Methods of microbubble size-selection have been explored extensively
and used to optimize particles for applications such as molecular imaging and blood-
brain barrier disruption [151; 208; 170]. We have performed preliminary experiments
showing that this approach can be adapted to produce an altered PCCA distributions
(unpublished data). Adopting a protocol from Streeter et al., size-selected DFB mi-
crobubbles were generated with an average diameter of 4.6 ± 0.6 µm (N = 116, sized
optically in the same degassed microvessel flow phantom from Section 3.1) at a concen-
tration of 5 × 108 bubbles/mL. After condensing the bubbles by the same protocol in
Chapter 3, a dilution of 20 µL droplet suspension in 1 mL of PBS was injected into the
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microcellulose tube and vaporized using an 8 MHz (2 cycle) pulse at peak negative pres-
sures between 3.8 and 4 MPa. Before the vaporization pulse was applied, no droplets
were apparent in imaging plane - implying successful condensation of the size-selected
bubbles. After the vaporization pulse, a large number of bubbles of uniform size ap-
peared on-screen with an average diameter of 2.2± 0.6 µm (N = 118). This change in
average bubble size between the precursors and the bubbles post-vaporization requires
further discussion. In our prior studies, bubbles produced by droplets tended to be
larger than the ideal gas law predictions due to gas influx in the bubble state (Chap-
ters 2 and 3). However, when the environment was kept degassed, sizes were close to
the expected values. In the microbubble condensation studies, the bubbles resulting
from droplet vaporization were similar to the precursor distributions provided ultra-
sound pressure was high enough (Chapter 3). When vaporization pressure decreased,
the distribution shifted toward larger bubbles. Here, the shift toward smaller bubbles
from the precursors is unusual, and it is expected to be a result of the presence of a
significant presence of air in the bubble in addition to the PFC. During size-selection,
the microbubbles are exposed to the air interface for long periods of time, allowing
some equilibration with the PFC content of the bubbles. During condensation, any
room air that cannot be solubilized into the liquid PFC must be pushed out of the
bubble in order for the liquid droplet state to be achieved - resulting in a decrease in
bubble diameter once the PFC is fully vaporized again. Though sizing of the droplets
was not performed, it is expected based on the vaporized bubbles that they existed in
the 400-500 nm diameter range. It should be noted that the bubbles retained a narrow
distribution despite the shift in mean size (see Figure 8.1). These preliminary results
suggest that size-selection of PFC droplets may be possible with microbubble conden-
sation, but that it requires limiting the presence of other gasses that may equilibrate
with the PFC content of the precursor bubbles. It may also be possible to size-select
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the droplets once converted (i.e. differential centrifugation of the droplets rather than
the precursor bubbles), though protocols to do this have not yet been defined.
Figure 8.1: a) Optical images of size-selected precursor microbubbles; b) optical images
of bubbles produced from vaporized droplets generated by microbubble condensation
of the size-selected precursor bubbles; c) histogram of shift in bubble distribution be-
tween precursor microbubbles (N = 116) and vaporization-produced bubbles (N = 118).
Unpublished data.
8.3.5 Summary
In this section, we demonstrated new methods of fine-tuning the performance of
PCCAs with respect to ultrasound sensitivity, thermal stability, and size. Studies
are ongoing to refine several aspects of these techniques, and many questions remain
that will require future investigation. For example, in Chapters 2 and 3, vaporization
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thresholds of microscale droplets were measured and used to predict the behavior of
nanoscale droplets, although it is uncertain how accurate these predictions are. Recent
studies have by Shpak et al. shown that frequency-dependent vaporization threshold
effects exist for microdroplets due to microfocusing of the acoustic beam within the
droplet [78], but these effects may not influence vaporization of nanoscale droplets at
frequencies relevant to medical ultrasound, and therefore trends may not be predictive
of nanoscale vaporization thresholds. Similarly, the concentration measurements used
to determine thermal stability in Chapter 4 were measures of the larger content of the
droplet distribution (particles > 500 nm in diameter). Whether the activity of this
portion of the distribution represents the smallest content in the distribution (which is
more often the content of interest) is uncertain. For example, the OFP droplets 500
nm or greater in diameter were unstable at 37 ◦C, but it may be that OFP droplets
with diameters near 100-200 nm may be sufficiently stable. Also, it is simple to as-
sume that spontaneous vaporization is the primary mechanism of degradation in the
droplet emulsion, but it may be that a significant amount of dissolution occurs at the
PFC/water interface for volatile perfluorocarbons - resulting in a gradual decrease in
particle size until completely dissolved. It is possible that spontaneous vaporization
is more common at the microscale where Laplace pressure is low, but that particle
dissolution is more prominent at the nanoscale where internal pressure is high and the
surface area-to-volume ratio has increased.
Other physical aspects of PCCA production require further investigation. For exam-
ple, the actual surface tension for different PCCAs encapsulations - which determines
the degree of Laplace pressure - is generally unknown, and is largely dependent on the
state of the encapsulating shell (i.e. likely to very different pre- vs. post-vaporization).
Determining this parameter for different shell types will be important in optimally sta-
bilizing droplets made from volatile PFCs. In most approaches to phase-change agent
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generation, the particles are encapsulated optimally in the droplet state and vaporized
to form gas bubbles. Some studies, including our extrusion-based results, have shown
that the shell appears to be present after vaporization - allowing for stabilized bubbles
that interact with ultrasound similarly to conventional bubbles (Chapter 2, [209]). The
state of the shell at these much larger sizes is currently unknown, but is likely to be
sparse. Similarly, the change in conformity of the shell during microbubble condensa-
tion is currently unknown. In this method, particles are optimally encapsulated in the
gas state and then converted to the liquid state. It may be that the phospholipid shell
buckles in the PFC liquid state and reincorporates upon vaporization, but it is more
likely that some of the lipid shell is shed during the process. Future studies are needed
to determine whether this is the case, and to determine what modifications must be
made to maximize shell retention and optimize performance in vivo. Such changes in
the encapsulating shell may have a significant impact on the ability to develop func-
tionalized droplets (for drug/gene delivery or molecular imaging). It is possible that
neither extreme (droplet encapsulation vs. bubble encapsulation) is optimal, but that
the shell must be designed to exist somewhere between both states. For example, re-
cent studies by Sirsi et al. have examined the use of microbubbles encapsulated in lung
surfactant [210] designed to fold during bubble compression and reincorporate upon
bubble expansion. Alternatively, encapsulation materials such as albumin that thicken
at the droplet state and thin to form ideal bubble shells upon vaporization may be
preferable.
Future work will focus on refining the condensation protocol itself and verifying
aspects of the approach. Estimates of concentrations for nanoscale emulsions are usu-
ally calculated by combining knowledge of the perfluorocarbon volume used with a
number-weighted distribution [154]. In a condensation-based approach, this is not
straightforward, as some of the perfluorocarbon volume persists in the gas headspace
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of the vial. Assuming a perfect 1-to-1 conversion of bubble to droplet would produce
droplet concentrations on the order of 1010 particles/mL, which may be appropriate for
perfluorocarbons such as DFB that require very little pressure to condense. The validity
of this assumption becomes weaker for droplets composed of highly volatile compounds
such as OFP, where higher ambient pressures are required to achieve condensation.
However, relatively new technologies such as the qNano (iZON Ltd., Cambridge, MA)
and the NanoSight 500 (NanoSight Ltd., Amesbury, UK) may circumvent the need to
make such assumptions by offering a means to measure both the concentration and size
distribution of nanoscale PCCAs [211]. Finally, it may be possible that some portion
of the remaining perfluorocarbon headspace condenses on exposure to reduced tem-
perature and increased pressure, causing unwanted droplet formation. If so, this can
be controlled by replacing the headspace with a lower boiling point gas that will not
solubilize into PFC and then proceeding with condensation.
Regardless of the remaining questions, microbubble condensation appears to be a
useful approach to producing sub-micron perfluorocarbon droplets. A recent study by
Seo et al. cleverly combined a modified version of this technique with microfluidics to
generate sub-micron DDFP droplets [212], and other research groups are beginning to
investigate DFB droplets for unique applications in gene transfection and monitoring
of vaporization [213; 214].
8.4 Improving Methods of Measurement, Detection, and Activation
8.4.1 Measuring Activation by Changes in Bubble Distribution
Developing an all-inclusive droplet vaporization model to accurately predict vapor-
ization thresholds remains a challenge due to the wide range of factors (many sum-
marized in Chapter 1) that influence the likelihood of droplet vaporization. As such,
methods to measure vaporization thresholds typically take two forms - physical (e.g.
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optical verification of individual droplet vaporization events at the transducer focus)
or phenomenological (e.g. measure of ultrasound backscatter produced after a vapor-
ization pulse has been delivered). As a result of the differences in these measurement
techniques and the change in experimental choices from study to study, a wide range
of reported thresholds exist with no ‘gold standard’ of measurement to compare to.
For nanoscale emulsions, both the physical and phenomenological approaches are lim-
ited for the typically broad distributions. In physical (optical) methods, the initial
size of the droplets is below the wavelength of visible light, and therefore unresolv-
able. Phenomenological methods are highly skewed by the presence of large outliers
in the distribution, and so associating the measurement with a representative size is
not straightforward. Thus, there is a need for improved measurements of activation for
nanoscale emulsions.
In Chapter 5, we expanded on results from Chapter 3 to show that the shift in
the bubble distribution produced as peak negative pressures increased could be used
as an indicator of optimized vaporization. By relating the droplet and bubble size
with ideal gas laws (eqn. 2.6), droplets near 200-300 nm in diameter should vaporize
to produce bubbles near 1 µm in diameter. At low peak negative pressures, only
the largest droplets in the emulsion vaporize, producing a bubble distribution with
a mode much higher than 1 µm. Once peak negative pressures are high enough to
vaporize a significant amount of the 200 nm droplets, the mode of the bubble diameter
distribution should reflect this by shifting to a value near 1 µm. We demonstrated this
in vitro at 1, 5.5, and 8 MHz (2 cycles), and showed that the transition point of 1 µm
bubble production could be captured experimentally (Figure 5.10). Interestingly, the
transition peak negative pressure appeared to increase with ultrasound frequency. This
result possibly reflects the influence of narrowing beam width at higher frequencies -
requiring higher pressures to produce similar bubble distributions over the same spatial
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span and at the same droplet concentration.
Although the bubble distribution tracking method is capable of capturing the acti-
vation of nanoemulsions, the measurements are fairly labor-intensive. The study above
measured the diameter of approximately 30,000 bubbles across all frequencies and pres-
sures in order to determine the distribution shifts. In the future, these measurements
could be automated to some degree, but it may be possible to combine a small set
of distribution tracking tests with a simpler measurement method to reduce the work
involved. For example, simultaneously capturing the change in bubble distribution and
the echo intensity for a subset of the total tests would allow correlation between the
transition point in the bubble distribution shift and the echo intensity that corresponds
to this. The remaining tests could be carried out with the simpler measure of echo inten-
sity once this transition point is calibrated. Another alternative was recently presented
by Xu et al. that captured the decay in acoustic intensity produced from vaporization
of un-encapsulated DDFP droplets and related the decay to estimates of the underlying
bubble distribution [215]. If this can be adapted to encapsulated droplets, it presents
an interesting acoustic method to assess similar shifts in the bubble distribution as our
microscopy-based approach.
8.4.2 Capturing Acoustic Signatures of Droplet Vaporization
Another possibility for measurement of droplet activation comes from a study show-
ing that under certain circumstances the vaporization event can produce unique size-
dependent acoustic behavior (Chapter 6). Although a wealth of techniques exists to
differentiate microbubble signals from surrounding tissue based on nonlinear behav-
ior, very few exist to differentiate PCCAs from both tissue and microbubble signals.
While in the liquid state, PCCAs are only weakly echogenic and difficult to distinguish
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over tissue, but once vaporized to form bubbles, produce signals similar to conven-
tional microbubbles [209]. Some have suggested that the pressure wavefront emitted
from a vaporization droplet could be distinguished acoustically [117], while others have
proposed that the change in acoustic signals as the vaporizing bubble evolves could
distinguish PCCA-produced bubbles from those already present [72].
In preliminary ultra-high-speed imaging of droplet-to-bubble expansion, we noticed
that when activated, DFB droplets oscillated well after the end of the activation pulse.
Further investigation showed when short pulses (8 MHz, 2 cycles) are used to initiate
bubble nucleation (but end shortly thereafter), the particle over-expands past the final
bubble size and returns to the resting size in an oscillating manner (Figure 6.1). This
over-expansion/oscillation behavior was observed for droplets of both OFP and DFB,
and measurements of the video data over many droplets showed that the relationship
between particle size and oscillation frequency matched the expected relationship for
un-forced resonance of a bubble (modeled by Minnaert resonance [181]) - with higher
frequencies being produced by smaller particles. In this case, the droplet volatility
appears to be sufficient to temporarily drive the growth of the bubble past its final
diameter, and the over-expansion initiates the oscillatory behavior as the bubble returns
to a final resting size. In the study, a damped harmonic oscillator model was applied in
order to estimate the total damping coefficient. Both the expansion velocity, maximum
overexpansion, and final bubble size were shown to increase with PFC volatility. The
larger final bubble size for OFP particles compared to DFB particles was expected
based on ideal gas laws, but the higher expansion velocity and maximum overexpansion
observed for OFP is expected to be a result of the much higher degree of superheat.
The physical oscillations of vaporized particles displaces nearby fluid, producing
new acoustic waves (not related directly to the vaporization pulse) that can be de-
tected by an ultrasound transducer. In the study, the acoustic emissions of vaporizing
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droplets were detected passively with a 1 MHz transducer (activated with an 8 MHz,
2 cycle pulse) and differentiated from signals produced under similar circumstances by
microbubble contrast agents. As expected from the physical characterization, droplet
vaporization manifested as exponentially decaying sinusoids in the time domain, and as
narrowband peaks in the frequency domain (Figure 6.6). Signals produced from OFP
droplets were larger in magnitude to those produced by DFB droplets as a result of
greater expansion and oscillation velocities. Both the frequency of oscillation and the
signal amplitude were shown to be dependent on the initial droplet size, suggesting
acoustic detection of this vaporization behavior may be a means of discerning whether
droplets of specific sizes are being activated. We followed this with demonstration of a
simple droplet-detection algorithm that measures phase-transition of droplets greater
than approximately 1.4 µm in diameter as a function of peak negative pressure and
droplet concentration. This approach could conceivably be altered to measure activa-
tion of much smaller droplets provided the activation pulse does not overlap with the
oscillation period.
Many aspects of this method of droplet detection are currently being explored. The
rate of exponential decay of the droplet oscillations is directly related to the influence
of the encapsulating shell, and much can be learned of the underlying physics from
these measurements. There is currently only one vaporization model published in the
literature that predicts this type of oscillatory behavior [81], and so comparing this with
the experimental results or developing new models will be important in understanding
specific aspects of the oscillation. For example, no other studies to date based on DDFP
droplets, including the study by Qamar et al. [81], have experimentally observed these
oscillations, which suggests there is a minimum degree of superheat needed to cause
the overexpansion behavior. Additionally, Qamar et al. show that the oscillation
behavior may not start for a given PFC until droplets are below a threshold diameter.
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Furthermore, alternative algorithms to detect the droplet signals produced could be
implemented that may perform more optimally than our simple demonstration (several
of which are suggested in Chapter 6).
Perhaps the most interesting extension of the study is to implement the droplet
signal detection on linear arrays and create droplet-specific imaging techniques capable
of localizing activation both temporally and spatially in vivo. The PCCA signals occur
at relatively low frequencies and only travel one-way through the tissue to reach the
transducer, and so it is likely that the signals can be captured in vivo provided droplets
can be activated at the desired depth. There may be a practical limit to the minimum
droplet size able to be detected, as the vaporization pulse must remain short enough
to not drive the bubble oscillation. For droplets near 200 nm in diameter, this means
that frequencies higher than 8 MHz must be used, which will provide limited depth
of penetration. Another possibility is to use other modalities to vaporize the droplets
(such as photoacoustics) that inherently do not drive the oscillation and will likely allow
very high SNR capture of the emitted signals.
8.4.3 Maximizing Bubbles and Minimizing Bioeffects
Our study on measuring shifts in bubble distributions (Chapter 5) also demon-
strated preliminary evidence that the ongoing cycles of the vaporization pulse (after
the droplet has begun vaporizing) can highly influence the resulting bubble distribu-
tion. Droplets vaporize during the rarefactional phase of the ultrasound, but can be
strongly affected by the subsequent compression and rarefaction phases. Small bubbles
(such as those generated from nanoscale droplets) tend to be destroyed by the subse-
quent compression phases of the vaporization pulse, while large bubbles (such as those
produced by microscale droplets) tend to translate toward each other due to secondary
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radiation force over several cycles and can fuse during rarefactional cycles. The likeli-
hood of these types of effects increases with the pulse length, and so long pulses will
likely result in a change toward larger bubble distributions. For diagnostic imaging this
is generally undesired and pulse lengths must be as short as possible to limit the effect,
but it may be a useful property for many therapeutic applications. In either case, a
more complete understanding of the thresholds and impact of this behavior is needed
in order to optimize the vaporization waveforms for the intended application.
One possibility that is currently being explored by our group is to design composite
waveforms in order to emphasize or minimize the compression-based aspects of the
vaporization pulse. By driving the transducer with a dual-frequency waveform, as
originally demonstrated by Umemura et al. [216] and later expanded by others [217;
218], the transducer can be driven to accentuate rarefaction and minimize compression,
or the converse. Most studies have investigated this to enhance cavitation, but we
propose that this may be a highly desirable means of maximizing bubble production
from vaporized PCCAs and minimizing bubble destruction caused by the compression
half-cycles of the continuing pulse.
8.4.4 Summary
In this section, we have demonstrated new techniques to measure droplet activation
thresholds, capture new acoustic signals produced by droplets, and proposed methods
to optimize vaporization waveforms. We envision that the combination of these will
allow more accurate assessment of the in vivo pressures required to activate nanoscale
emulsions, greater efficiency of activation, and new PCCA-specific imaging techniques.
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8.5 In Vitro and In Vivo Demonstrations
The previous sections of this chapter have summarized methods of improving PCCA
performance through a variety of in vitro techniques. In this section, we summarize
our in vitro and in vivo work highlighting the new possibilities in therapeutic and
diagnostic ultrasound afforded by these improvements.
8.5.1 In Vitro Demonstration of PCCA Molecular Imaging
The reduction in vaporization thresholds through use of volatile compounds opens
the possibility of using PCCAs as purely diagnostic contrast agents. Current ultrasound
approaches to molecular imaging modify the microbubble shell to include targeting lig-
ands that attach to vascular molecular expression (such as angiogenesis). The attached
bubbles are then differentiated from the freely circulating bubbles to gauge the level of
molecular expression [38]. Previous studies have explored the use of targeted DDFP
droplets, but it was found that the high vaporization pressures required to activate the
droplets tended to destroy the cells, restricting use to therapeutic/theranostic purposes
[219]. Targeted droplets that are able to be vaporized at diagnostic pressures may
have high utility for ultrasound molecular imaging purposes - both intravascular and
extravascular. We performed a simple in vitro proof-of-principle that DFB droplets
modified to contain cyclic RGD peptides in the encapsulating shell can preferentially
attach to expression of αvβ3 in the HUVEC cell line compared to sham controls contain-
ing cyclic RAD peptides (Chapter 7). Droplets produced by microbubble condensation
retain the lipid encapsulation (Figure 7.4), and so targeted droplets can be gener-
ated by condensation of targeted precursor bubbles. The targeted and non-targeted
droplets were incubated for 15 minutes with HUVEC cells, the cell samples washed,
and then activated by scanning a diagnostic ultrasound transducer (Acuson 15L8 linear
array transducer) over the cell layer at 8 MHz with a nominal mechanical index of 1.1
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(approximate peak negative pressure of 3.1 MPa). Prior to the vaporization sequence,
very little bubble signal was present in the cell layer (measured using a contrast-specific
imaging mode) for both droplet types, indicating that any droplets present remained
in the weakly echogenic liquid state. After vaporization, a high level of contrast was
observed in the targeted droplet samples along the cell monolayer (6-fold increase over
non-targeted, and 54-fold increase over baseline) (Figure 7.7).
Interestingly, the bubbles appeared to remain adherent to the cell monolayer rather
than detaching and drifting to the top coverslip, suggesting the shell remained intact
enough to preserve targeting. Although the results provide preliminary evidence that
molecular imaging with droplets is possible, whether this will be the case under flow con-
ditions, and how this can be mitigated by altering shell composition will be the subject
of future in vitro and in vivo tests. The droplet-based approach may be advantageous
compared to microbubble-based molecular imaging in that the degree of molecular
expression is immediately apparent after the vaporization pulse; any non-targeted or
non-associated bubbles will leave the imaging plane quickly, and unvaporized droplets
in the plane will not produce significant contrast. Optimizing this technique in vivo
may require development of new droplet processing protocols to ensure that targeted
lipid vesicles do not remain in the droplet suspension after condensation (which will
block viable target sites), and will likely require development of custom droplet-based
activation/imaging sequences on diagnostic ultrasound machines.
8.5.2 In Vitro and In Vivo Demonstration of HIFU Ablation
Perfluorocarbon phase-change contrast agents have been proposed to increase the
efficiency of high-intensity focused ultrasound (HIFU) procedures in numerous publica-
tions (see Chapter 1). The primary advantage of their use is that droplet vaporization
occurs in the region of highest ultrasound energy, and then the newly produced bubbles
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increase the cavitation activity and interaction with the tissue. In three studies, we
showed that the concept of PFC mixing is a useful tool to refine the performance for
HIFU therapy in vitro and in vivo.
The first of these studies, by Phillips et al., investigated microbubble-condensation-
produced droplets composed of a 1:1 mixture of DFB and DDFP (Appendix F) in
tissue-mimicking phantoms. In parallel studies, it was determined that DFB droplets
activate efficiently at pressures near 2 MPa using frequencies near 1 MHz (Chapter
5). Although DFB is generally stable over the course of 1 hour in vitro at physiologic
temperatures, HIFU procedures can often last for several hours [220; 221]. Therefore,
we sought to design a droplet with vaporization thresholds near 4 MPa that had high in
vitro stability. By similar tests as in those used in Chapter 4, a 1:1 mixture of DFB and
DDFP was shown to produce droplets stable for more than 48 hours when exposed to
37 ◦C in vitro. Lesion formation with these droplets was studied using an acrylamide-
albumin phantom that visibly denatures once temperature rise is similar to that used
in vivo for tissue ablation. Tests with this phantom showed that the composite droplets
enhanced lesion formation over agent-free controls at the desired ultrasound pressure
levels (1 MHz, 4 MPa peak negative pressure). Compared to similar concentrations
of microbubbles, which interacted strongly with the acoustic beam pre-focally and led
to unwanted lesion formation and surface heating at even low concentrations, droplets
were better able to preserve the focal nature of the lesion formation. This was confirmed
in MR thermometry experiments showing that microbubbles caused a high amount of
heating at the surface of the phantom, while droplets generally maintained heating at
the desired focus until concentrations very high (Figure F.8). The authors concluded
that “ ablation lesions produced in the presence of nanoscale droplets were less prone to
shape change and lesion migration than microbubble-enhanced lesions.” This highlights
what is potentially one of the biggest advantages of PCCAs in therapy: compared to
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microbubbles, PCCAs may preserve focal aspects of therapy better, maximizing the
effect where intended and minimizing it elsewhere.
The second study in this series, by Puett et al., explored the transition point in
droplet concentration and acoustic parameters where control over the lesion formation
was lost using the same in vitro tissue mimicking phantom (Appendix G). Droplet
concentrations ranging between 105 and 108 droplets/mL of phantom were tested, with
pulse lengths ranging from 5 to 20 seconds of continuous-wave ultrasound at intensities
of 140, 390, and 650 W/cm2. The study found that given a concentration of droplets
distributed throughout the tissue, an appropriate pulse length and intensity could be
chosen in order to maximize lesion size and minimize treatment time while maintain-
ing high control over the lesion formation (determined by change in lesion shape and
centroid). The study also demonstrated that vaporization of the droplets produces a
bubble cloud (registered in ultrasound imaging), but that the lesion formation always
consisted of a smaller volume within the bubble cloud. The authors conclude that
controlling formation of the bubble cloud is the key to controlling formation of the
lesion.
The third study, a recently published one by Phillips et al., demonstrated the in vivo
performance of these composite droplets at forming lesions in rat livers [222]. Using
and MR-guided focused ultrasound and MR thermometry, the heat delivery and lesion
formation in rat livers was assessed after injection of the composite nanoscale droplets.
When no agents were administered, no significant lesion formation or heat delivery
occurred during a 15 s pulse of 1 MHz ultrasound (4.1 MPa peak negative pressure). In
contrast, a single bolus injection of nanoscale droplets enhanced lesion formation over
controls out to the last time point tested (95 minutes), and lesions were approximately
constant in size at each time point.
Studies are ongoing to compare the in vivo performance of these composite droplets
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to microbubbles in both rat livers and in superficial tumors in order to determine the
relative benefits in circulation time and control over lesion formation. We are also as-
sessing biodistribution to determine whether the nanoscale droplets are, indeed, able to
extravasate at solid tumor sites. The preliminary results showing a sustained ablation-
enhancement effect in the liver does not necessarily indicate that droplets have remained
in circulation for 95 minutes, as droplet clearance is expected to result in accumula-
tion within the liver. While future studies are needed to determine actual vascular
circulation profiles (which depends on both thermal stability and immune response),
these results do show that the droplets remain thermally stable for at least 95 minutes
in vivo, despite being composed of two perfluorocarbons with boiling points far below
body temperature. This highlights the benefit of designing agents from volatile com-
ponents in order to optimize performance. If it turns out that the vascular circulation
profile is short, this can be improved by altering the encapsulation to produce particles
more ‘stealthy’ to the immune response.
One remaining question surrounding PCCA use in HIFU ablation is whether it is
better to design droplets that vaporize at the same pressures used for HIFU ablation,
or whether it is better to create droplets that vaporize at higher pressures and use a
high-intensity ‘bubble generation’ pulse to seed the bubble cloud before ablation begins
(as demonstrated by Zhang and Porter [114]). Our phantom-based studies suggest that
so long as the droplet concentration is not too high, control over lesion formation can be
maintained even when the vaporization pressures coincide with the ablation pressures.
Future comparisons are needed to evaluate tradeoffs between these two concepts of
PCCA-aided ablation.
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8.5.3 Blood-Brain Barrier Permeabilization with PCCAs
Just as reduced vaporization thresholds open new possibilities in diagnostic and
molecular imaging, they also open the possibility to use droplets in therapeutic ap-
plications that require low ultrasound pressures. Many studies have shown that the
blood-brain barrier (BBB) can be transiently permeabilized noninvasively using focused
ultrasound in order to enhance drug delivery [223; 224]. The presence of microbubbles
enhances this effect and allows delivery of a larger payload, but the ultrasound parame-
ters and microbubble size must be controlled so that no permanent damage is incurred
[225]. One of the additional benefits of blood-brain barrier opening with microbubbles
is that the acoustic emissions caused by microbubbles cavitating within the ultrasound
beam can be passively captured and used as an indicator of BBB opening [226; 227].
Most studies have found that, in the presence of typical bubble distributions and fre-
quencies near 1 MHz, peak negative pressures must remain on the order of 600 kPa or
less to avoid hemorrhage and unwanted tissue damage [225].
Similar to the previous studies involving the enhanced focal abilities of droplets vs.
microbubbles for HIFU ablation, droplet vaporization may be an alternative method of
BBB opening provided droplets vaporize at the low pressures required in this therapy.
In a study by Chen et al., we collaborated in a proof-of-principle study comparing
the performance of DFB droplets to DFB microbubbles (each agent had the same
constitutive elements, but one began in the liquid state and the other in the gas state)
(Appendix E). Our previous measurements have shown that at frequencies near 1 MHz,
DFB droplets vaporize optimally at peak negative pressures near 2 MPa, although a
small degree of vaporization is present at pressures near 1 MPa (Chapter 5). Further
high-speed imaging experiments revealed that a small amount of vaporization (primarily
of large droplets in the distribution) occurs at pressures near 0.45 MPa or higher - which
may be sufficient for initial demonstration of BBB opening.
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To test this in vivo, transcranial focused ultrasound was delivered to the left hip-
pocampus of mice based on previous protocols with microbubbles [228] and the right
hippocampus used as a control. Mice were separated into two groups - one that received
a bolus injection of microbubbles, and one that received a bolus injection of nanoscale
droplets. To compensate for the low vaporization efficiency at these pressures, the
administered droplet concentration (5× 109 particles/mL) was nearly an order of mag-
nitude higher than the bubbles (8×108 particles/mL). Though this was a higher dose in
number density, the smaller particle size (204 nm average diameter for droplets vs. 1.36
µm for microbubbles) resulted in a significantly lower volume density for the droplet
injection (1.054 µL/mL for bubbles vs. 0.022 µL/mL for droplets). In both groups, a
co-injection of dextran was administered to act as a model drug. Cavitation emissions
were captured passively during the therapy in order to correlate with BBB opening
results, and mice were monitored for 1 hour after sonication. Fluorescence histology of
the brain in the treated animals showed that DFB microbubbles were much more ef-
fective than DFB droplets at delivering dextran, with BBB opening beginning at peak
negative pressures of 0.3 MPa. Droplets were able to successfully open the BBB at
pressures of 0.45 and 0.6 MPa, corresponding well with the observed bubble formation
in vitro at these pressures. The degree of dextran delivery was similar for microbubbles
at 0.3 MPa and droplets at 0.6 MPa (Figure E.6).
The focal improvement of droplets compared to bubbles is evident in the acoustic
emissions data. No significant cavitation is registered for droplets until peak negative
pressures reach 0.6 MPa - corresponding with the pressures observed to cause BBB
opening. For bubbles, on the other hand, cavitation signal is present at even the lowest
pressures used, where no BBB opening is observed. The lack of cavitation signal for
droplets is expected to be a result of bubble formation only occurring at the focus -
minimizing bubble interaction with the beam elsewhere. Further comparison between
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the fluorescence and cavitation results corroborate this - providing a higher correlation
for droplet-based opening than bubble-based opening. In these studies, no histological
damage was observed for BBB opening with droplets, although it was observed for
BBB opening with bubbles at 0.6 MPa. The authors conclude that predicting the level
of BBB opening based on acoustic emissions may depend on the type of contrast agent
being used, but that droplets appear to provide a higher-confidence prediction.
Studies are ongoing to expand on this initial demonstration. Because the DFB
agents were chosen for similarity to the conventional agents, they were not optimized
to vaporize at the ideal pressures. In future studies, we plan on investigating use of
lower boiling point droplets that vaporize more efficiently and are expected to produce
a greater degree of BBB opening. Because droplets are significantly smaller than mi-
crobubbles, it also may be possible for droplets to diffuse past the BBB once initial
opening is achieved and allow greater drug delivery into the nearby tissue. Here, the
vaporization pulse was adopted based on microbubble protocols, but BBB permeabi-
lization with droplets may require droplet-specific pulses to optimize bubble production
(such as a short high-intensity pulse followed by a longer pulse of lower intensity). Some
aspects of this study require further investigation. For instance, whether the mecha-
nism of BBB opening with droplets is similar to the bubble mechanism, or whether
the initial expansion phase contributes significantly is currently unknown. If the latter
turns out to be the case, then more volatile PFCs such as OFP may be more effective
in permeabilizing the barrier. Also, whether the observed effect is primarily a result
of the larger droplets in the distribution is currently unknown. Optimization of the
droplet size for BBB disruption through size-selection techniques or microfluidics may
enhance performance greatly.
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8.5.4 In Vitro and In Vivo PCCA Imaging Sequences
One of the least-explored aspects of PCCAs is their utility for pure contrast gen-
eration. The molecular imaging study detailed in Chapter 7 provides initial evidence
that PCCAs with reduced thresholds can be used to gain diagnostic information, but
much work remains to demonstrate the contrast-providing abilities. For PCCA-based
diagnostic imaging to succeed in the clinic, it is likely that both activation and imaging
must be implemented on a single device (e.g. a single transducer). In order to ac-
complish this, custom pulse sequences must be developed that maximize the diagnostic
information provided. It is important to note that phase-change agents have unique
requirements as contrast agents with regard to both imaging and activation, which
makes implementation much more challenging than conventional microbubble contrast
agents. For example, baseline (pre-activation) imaging must be done at pressures low
enough so that droplet vaporization does not occur. This requires careful design of both
the pulse pressures and the PCCAs so that imaging can be performed at pressures that
provide reasonable imaging quality. Once it is desired to generate contrast, activation
pulses must be delivered at high enough pressures to maximize droplet vaporization,
but only in the desired region and in a manner that minimizes bioeffects. This requires
careful planning of the pulse spacing and pulse pressure/length. Finally, the imaging
(post-activation) must occur quickly enough that the newly-generated contrast does
not leave the imaging plane, and must use pulse pressures low enough to not disturb
the resulting bubbles (or cause additional droplet vaporization). For applications such
as molecular imaging or for droplets that have extravasated into the interstitial space
(as is the focus of much PCCA research), bubbles will theoretically remain stable in-
plane, and so the post-activation timing is less demanding. However, for non-targeted
vascular applications, newly-generated bubbles will begin to wash out of the imaging
plane with blood flow immediately after being generated. In most applications, this
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means bubbles must be imaged before leaving the elevational beam width, although
this will depend somewhat on the vascular orientation of the target.
To our knowledge, only two demonstrations to date have shown both activation
and imaging within a single transducer (those in Chapter 7 and [153]). The first, our
in vitro molecular imaging study, used two independent pulse sequences available on
a clinical diagnostic machine and performed imaging and activation at separate time
points under static conditions. The second, by Couture et al. consisted of a custom
pulse sequence to accomplish a therapeutic task of delivering a fluorescent payload and
used the received ultrasound data as confirmation. The latter study demonstrates the
potential to develop pulse sequences for droplet-specific tasks using a new generation
of highly-customizable ultrasound research machines. While theirs investigated a ther-
apeutic goal, the high degree of control over pulse sequencing and data manipulation
opens the door to developing custom sequences for PCCA-based diagnostic imaging.
Figure 8.2: Plane-wave pulse inversion images of a room-temperature water bath con-
taining OFP droplets before (left) the droplet activation sequence, and immediately af-
ter (right) the final pulse of the activation sequence. The focus of each pre-programmed
activation pulse was shifted using electronic steering to create the desired pattern in a
left-to-right, bottom-to-top order.
Studies are ongoing in our group to demonstrate this using the Verasonics research
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ultrasound platform (Verasonics, Inc., Redmond, WA) both in vitro and in vivo. Using
the rat kidney as a vascular target, we have developed PCCA-specific sequences that
accomplish synchronized activation and imaging in the same plane with high control
over timing and pressure. Imaging before and after vaporization is accomplished using
a pulse-inversion plane-wave scheme with approximate negative pressures of 0.55 MPa
(4.5 MHz, 1 cycle, pressure approximated based on depth-dependent tissue attenua-
tion), and activation was accomplished using electronically-steered focused wave pulses
(7.5 MHz, 1 cycle) with peak negative pressures near 2.40 MPa (based on approximate
tissue attenuation) that are spaced laterally and axially to overlap minimally so that
newly generated bubbles are not disturbed highly by the subsequent pulse. The tim-
ing between activation and baseline/post-activation imaging (as well as the frame-rate
of both imaging states) can be adjusted easily in order to capture contrast after it
has been generated. Control over the generation of contrast temporally and spatially
with electronically steered focused pulses can be demonstrated in vitro by exposing a
room-temperature water bath containing approximately 1 × 107 droplets/mL of OFP
particles to a pre-programmed pulse pattern (Figure 8.2). Comparing the baseline to
post-activation images reveals that contrast can be generated with high spatial speci-
ficity and captured quickly before the bubbles leave the imaging plane. Preliminary
results show that OFP droplets (injected as a 120 µL 50% droplet dilution in saline)
can be easily activated and imaged with a single transducer in vivo, and provide a
high degree of contrast relative to baseline. After injection, but before activation, no
significant contrast increase is observed in the kidney - implying the injected droplets
remain in the liquid state while in circulation. When the activation pulse is delivered
after 1 minute of circulation, mean image intensity in the imaging plane increases on
the order of 20-25 dB over baseline (Figure 8.3), and the contrast washes out of the
imaging plane over several seconds. Repeating the sequence at different time points
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allows capture of the circulation profile of the droplets. Preliminary results also suggest
that contrast generation with sub-micron droplets using PFC mixtures much higher in
boiling point than DFB result in minimal, if any, contrast generation as the ability to
get adequate pressures at depth in tissue to cause vaporization becomes a challenge
with the imaging transducer.
Figure 8.3: Overlays of contrast-specific intensity (green scale) and traditional B-mode
(grey scale) ultrasound scans within the region of interest (white dotted line). When
no droplets are present (top row), very little contrast is present before (left) and after
(right) the vaporization pulse sequence. When a bolus of OFP droplets are injected,
no significant increase in contrast is observed before the activation sequence (bottom
row, left), but once the activation sequence is delivered a high level of contrast is
visible in the region of the kidney (bottom row, right) - indicating conversion of the
droplets to form highly echogenic microbubbles.
Many aspects of this study are currently being refined. For instance, activation
must only cover the desired area so that interaction with other tissues is minimized.
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But to activate well in the desired area, several choices must be made with regard
to axial and lateral pulse spacing that also depend on PFC choice (what pressures are
actually needed to activate well) and frequency (how much the pressures are attenuated
in tissue). The timing that newly-generated contrast remains in-plane also depends
on factors such as pressure and frequency, and an understanding of how far into the
elevational plane droplet vaporization is occurring. Some other factors are currently
unexplored. For example, most droplet activation thresholds are developed in vitro,
but the higher in vivo hydrostatic pressures may impact the efficiency of vaporization.
The degree of this is not certain, but in combination with the frequency-dependent
tissue attenuation, understanding the proper frequencies and pressures needed to induce
droplet activation while in circulation will be vital.
Additionally, extensive testing on bioeffects caused by the agents is needed if PCCAs
are to have a future role in diagnostic imaging. Because of the similarity in composition
to clinical microbubble formulations (i.e. phospholipid-encapsulated perfluorocarbons),
it is expected that clearance of the particles developed in our studies results in deposi-
tion primarily in the liver and spleen, with eventual exhalation of the perfluorocarbon
through the lungs [229; 230]. In general, perfluorocarbons have proven to be relatively
non-toxic at the small doses used for most medical applications [1; 23]. Most studies
on in vivo performance of PCCAs have noted no adverse effects resulting from admin-
istration [194]. However, only a few studies have actually performed dose-dependent
survival studies. Most notably, a study by Zhang et al. using microscale droplets of
DDFP (mean diameter of 2 µm) observed that changes in blood chemistry and respi-
ratory distress occurred following intravenous injection in a canine model once doses
reached 2 × 109 droplets/kg, and doses of 3 × 109 (total perfluorocarbon dose of 0.2
g/kg) caused fatality [54]. The bolus injections used for our preliminary studies inves-
tigating PCCA use in rodents falls on the same order of magnitude (4×109 droplets/kg
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assuming a 150 g rodent) as these canine upper limits. However, the average droplet
diameter is an order of magnitude smaller than those in the study by Zhang et al.,
resulting in a much lower total perfluorocarbon dose of 4.7 × 10−4 g/kg. Accordingly,
none of the preliminary studies to date have resulted in visible symptoms of distress
in the animals tested. Future studies will be needed to determine upper dose limits
for nanoscale PCCAs as well as to evaluate the likelihood of vascular damage cause
by droplet vaporization events or from acoustic interactions with the bubbles produced
early in the vaporization pulse.
Regardless, these studies show that PCCAs can be used effectively as blood-pool
contrast agents, which implies the possibility to also develop effective droplet-based
molecular imaging sequences and evaluate new vascular applications for PCCAs.
8.5.5 Summary
In this section, we show that by combining concepts such as incorporation of volatile
compounds with those of tuning droplet size and performance, current therapeutic ap-
plications of PCCAs can be substantially improved, and new diagnostic and therapeutic
applications can be developed.
8.6 A Final Note on the Significance of Mechanical Index
Throughout this thesis, the limitations of pressure output for diagnostic imaging
have been contextualized with respect to mechanical index (MI) - which places a hard
upper limit of MI = 1.9 on all diagnostic applications of ultrasound. Thus the distinc-
tion between droplet activation pressures that are too high for diagnostic purposes and
those that are considered safe for diagnostic purposes depends entirely on the validity
of the current regulatory upper limits. This index, along with the thermal index (TI)
are entirely based on measurements taken from ultrasound machines in the 1970s and
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therefore do not represent scientifically derived ‘safety limits’ [231]. The actual safety
of the output pressures depends on a host of factors that have become better under-
stood within just the last two decades, such as the gas saturation level of the tissue,
the influence of tissue type on heat absorption, and the presence of ultrasound contrast
agents. For many studies involving contrast agents, a mechanical index of 0.4 or less
minimizes unwanted bioeffects, but short periods of high intensity (for instance, to clear
circulating agents in destruction/replenishment) have been considered acceptable and
are currently used in clinical studies. In other applications, such as acoustic radiation
force (ARF) imaging, the body of literature has proven that little to no bioeffects are
induced even at the maximum FDA-allowed output using relatively long pulses [232].
As Doherty et al. point out, “Despite the potential benefits of an increased mechanical
index (MI), most ARF elasticity imaging methods maintain an MI < 1.9 to satisfy
regulatory limits and reduce the likelihood of cavitation.” As a response to the grow-
ing sentiment that certain applications may benefit from an increased upper limit on
TI and MI, the American Institute of Ultrasound in Medicine (AIUM) Bioeffects Sub-
committee has suggested that in many cases, the ‘As Low As Reasonably Achievable’
(ALARA) principle should be used along with development of improved indices and
re-evaluated limits [231].
With regard to phase-change contrast agents, it may be that with carefuly designed
activation pulses and dosing, higher pressures than MI = 1.9 can be used without
causing significant bioeffects, provided very few bubbles are present in the focal zone
before vaporization, and provided the activation pulse interacts minimally with the
bubbles produced (limiting the destruction and fusion presented in Chapter 5). Should
this prove to be the case, it opens the possibility of designing droplets diagnostic imaging
that have higher vaporization thresholds (such as mixtures between DFB and DDFP)
in order to maximize stability in circulation. In any case, careful studies of the presence
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of bioeffects as a function of droplet design, pulse parameters, and dose are needed to
discern the regimes where PCCAs may be used safely for diagnostic imaging.
8.7 Conclusions
In this thesis, we highlighted recent progress to improve the performance of PCCAs.
In our opinion, tailoring droplet characteristics highly to each intended application
and abandoning a ‘one-size-fits-all’ approach will be critical in moving phase-change
agents toward the clinic. In addition, work with programmable ultrasound research
systems to develop ideal activation (and imaging, if the application benefits from it)
will be key in demonstrating the unique opportunities phase-change agents provide. It
likely that, due to similarity in composition and applications, the success of PCCAs
will depend somewhat on the clinical success of microbubbles, which has made slow
progress in some countries (including the USA). However, demonstrating success in new
applications not possible with microbubbles (such as extravascular imaging/therapy,
selective vascular occlusion) and showing the enhanced performance over microbubbles
in other applications will help distinguish the two agents and pave an independent path
for PCCAs.
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APPENDIX A
Guide to the Appendix
A.1 Overview
Although not an integral portion of this thesis, the following appendices highlight
extensions of the technologies developed in Chapters 2 through 8 that were published
during the same time period. Appendices B through D explore the general benefits of
using a microfluidic platform for generating PCCAs, while Appendices E through G
explore the in vitro and in vivo performance of PCCAs designed for specific therapeutic
goals.
A.1.1 Appendix B
In this study by Martz et al., initial demonstration of PCCAs produced by a mi-
crofluidic device is given - resulting in an population of droplets with highly uniform
activation characteristics. My role in this project was in original conceptualization
of the studies, optical/acoustic testing of the activation thresholds, and manuscript
preparation/editing and revisions.
A.1.2 Appendix C
In this study by Bardin et al., the authors explored the droplet formation regimes
of microscale PCCAs in a microfluidic device, with an emphasis on the relationship of
reagent flow rates to the droplet characteristics. My role in this project was primarily
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in consultation to study design and aid in manuscript editing and revisions.
A.1.3 Appendix D
In this study by Martz et al., the authors demonstrate that the performance of
PCCA production by the microfluidic platform can be enhanced by altering the nature
of the reagent delivery system - allowing production of sub-micrometer droplets from a
device with microscale features. My role in this project was in optical/acoustic testing
of droplet activation thresholds, and manuscript preparation/editing and revisions.
A.1.4 Appendix E
In this study by Chen et al., the authors show that droplets can be used to increase
blood-brain barrier permeability to model drugs in transcranial focused ultrasound,
similar to prior work showing the same is possible with microbubbles. The performance
of droplets with regard to both delivery of fluorescent molecules and passive acoustic
monitoring is evaluated. My role in this project was in formulation and generation
of the perfluorocarbon droplets used, sizing of the droplets, in vitro testing of droplet
vaporization, and assistance with manuscript preparation, editing, and revisions.
A.1.5 Appendix F
In this study by Phillips et al., the authors demonstrate that PFC mixing in con-
juction with microbubble condensation can create agents ideal for ultrasound-mediated
tissue ablation, and evaluate the influence of acoustic intensity and droplet concentra-
tion using a tissue-mimicking phantom. The performance of the composite droplets is
compared to standard microbubbles. My role in this project was in formulation and
generation of the perfluorocarbon droplets used, sizing of the droplets, and assistance
with manuscript editing and revisions.
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A.1.6 Appendix G
In this study by Puett et al., expands on the results from Appendix F by investigat-
ing in vitro the influence of pulse intensity, agent concentration, and total insonation
time. Specifically, the change in lesion shape and location are monitored to arrive at
upper limits where control over ablation is lost. My role in this project was in formu-
lation and generation of the perfluorocarbon droplets used, sizing of the droplets, and
assistance with manuscript editing and revisions.
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APPENDIX B
Precision Manufacture of PCCAs using Microfluidics
B.1 Introduction
B.1.1 Acoustic Droplet Vaporization Agents
In acoustic droplet vaporization (ADV), acoustic pressure delivered to a liquid
droplet by an ultrasound (US) transducer provides the additional energy necessary
to induce a liquid-to-gas phase transition. This phase transition allows for unique ap-
plications that are not possible with standard microbubble contrast agents, because
ADV agents exhibit a very large volume change after activation. In addition, ADV
agents are typically poorly echogenic in their liquid form, but highly echogenic as gas
bubbles.
The basic construction of an ADV agent consists of a volatile liquid core that can be
converted to a gas with additional energy. Typically, ADV droplets consist of perfluo-
rocarbons (PFC) such as perfluoropentane (PFP) [85], perfluorohexane (PFH) [73; 94]
or perfluorooctane [75]. The most commonly used perfluorocarbons, PFP and PFH,
c© 2011 World Federation for Ultrasound in Medicine & Biology (wfumb.org) Portions reprinted,
from TD Martz, PS Sheeran, D Bardin, AP Lee, and PA Dayton. “Precision Manufacture of Phase-
Change Perfluorocarbon Droplets Using Microfluidics” Ultrasound Med Biol, 2011 November; 37(11):
1952-1957.
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have boiling points near physiological temperatures (29◦C and 56◦C, respectively). Re-
cently, stabilization and ADV capability of droplets of liquid perfluorobutane (boiling
point of −1.7◦C) has been demonstrated [195].
Producing (PFC) droplets in the micron and sub-micron range increases the Laplace
pressure exerted on the liquid core, enabling small droplets to be maintained in liq-
uid form even above their vaporization temperature. The addition of a stabilizing
shell reduces droplet coalescence and increases stability of the emulsions [92; 52; 195].
Commonly used methods of producing PFC droplets include sonication or high-speed
mechanical agitation of the host solution, which typically results in a polydisperse
population [94; 113].
B.1.2 Acoustic Droplet Vaporization Applications
Liquid perfluorocarbon droplets have been shown to provide US image contrast
[50; 233], although the backscatter is notably less than similarly sized microbubble
agents. One of the first commercial applications of perfluorocarbon droplets for US
contrast enhancement was Echogen (Sonus Pharmaceuticals, Bothell, WA, USA), a
perfluoropentane emulsion [62]. Clinical trials for Echogen were abandoned in 2000
before FDA approval could be obtained.
Once vaporized, ADV agents are readily detectable by an imaging system even at
low concentrations. In very small amounts, droplets when converted to bubbles through
ADV could act as point beacons for phase aberration corrections [66; 101]. The unique
advantages of ADV droplets in the 100 nm size range is that they have the potential
to extravasate from the vasculature and into the tissue, enabling ADV-based contrast
imaging or therapy to extend beyond the vascular space, where traditional microbubbles
cannot access [51; 112; 195].
One of the most well-studied applications of ADV is embolotherapy. This technique
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enables the intentional creation of an occlusion in a specific tissue to limit blood flow.
This has been proposed to treat renal cell carcinoma, to reduce blood loss for hyper-
vascular tumors, and to treat hemmorhage [50; 85]. Kripfgans et al. [92] demonstrated
that a filtered emulsion of droplets, which is intra-arterially injected, can reduce kid-
ney perfusion by 70%. This level of organ perfusion reduction has the ability to cause
ischemic necrosis for therapeutic applications, or it can enhance the use of radiofre-
quency tissue ablation by minimizing thermally dissipative effects caused by reduced
flow. A second application of ADV agents is site-specific therapeutics, where the goal
is to deliver a potent agent only to the disease site while minimizing systemic effects.
The ADV-mediated delivery of a chemotherapeutic drug directly to the tumor has
been shown to mediate regression of ovarian and breast cancer [52]. ADV agents that
have the ability to carry a therapeutic payload to a desired vessel could be combined
with vessel occlusion upon activation to allow for an increase in residence time of the
therapeutic agent [94].
With spatial and temporal control over ADV agent activation, ADV agents can be
used as a nucleation site for high-intensity focused ultrasound (HIFU) tumor ablation.
During HIFU, the microdroplets can be activated to increase the therapeutic effect or
decrease the treatment time [114; 54].
B.1.3 Considerations of ADV Agent Size Distribution
The size of ADV agents is an important factor in determining the vaporization
threshold and the biodistribution. The Antoine equation predicts a negative logarithmic
relation between droplet size and activation energy, where larger droplets require less
energy to vaporize than smaller droplets [112]. Most who have characterized ADV-based
agents have evaluated a polydisperse droplet population. Although general trends in
thresholds have been observed, polydispersity in droplet sizes has led to a variability in
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the vaporization threshold measured for studies that examine a bulk population of ADV
droplets. In addition, the larger droplets vaporize at lower energies and the resulting
bubbles can influence the threshold energy for the smaller droplets [74], confounding
in vitro characterization of vaporization thresholds. Because microbubbles combined
with high acoustic pressures can lead to unwanted bioeffects [234], it may be desirable
to perform ADV at the minimum acoustic pressure required. A polydisperse sample
may require a higher pressure to efficiently vaporize the entire population because of
smaller droplets requiring more energy.
For micron-sized ADV agents, one of the primary applications is vessel occlusion,
where it may be important to have a well-characterized distribution of droplet sizes to
target a specific vascular diameter while not affecting other vessels [92]. For the same
reasons, a droplet designed for imaging applications that is too large could lodge in the
lungs or other organs after intravenous injection, leading to undesired vessel occlusion.
All of these limitations are motivating reasons for precise size control of ADV agents.
Previous studies to improve the size distribution characteristics of perfluorocarbon
droplets have involved microfluidic sorting [149] and filtering [92]. The microfluidics
platform is well known for the ability to create particles [235], droplets [236; 237; 238],
microbubbles [204] and multilayer/multicomponent compositions [239; 193] of uniform
size. In this manuscript, we assess the feasibility for producing a monodispersed ADV
agent through a microfluidic technique to achieve uniform activation thresholds.
B.2 Materials & Methods
B.2.1 Reagent Preparation
Liquid PFP was purchased from FluoroMed, L.P. (Round Rock, TX, USA). Lipid
solutions were created using a 9:1 molar ratio of DSPC (Avanti Polar Lipids, Alabaster,
AL, USA) and DSPE-PEG2000 (Avanti Polar Lipids) in a 110-mL solution of deionized
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(DI) water, glycerol (Fisher Scientific, Pittsburgh, PA, USA), propylene glycol (Fisher
Scientific) and pluronic F-68 (Sigma-Aldrich Corporation, St. Louis, MO, USA).
Fifty mg of DPSC and 19.6 mg of DSPE-PEG2000 were dissolved in chloroform.
The chloroform was then evaporated with N2, after which 50 mL of DI water was added
and the resulting solution was sonicated for 20 min. After sonication, 47 mL DI water, 2
mL glycerol, 1 mL propylene glycol and 10 mL pluronic F-68 were added. The solution
was vortex-mixed for 1 min and then sonicated for 10 min.
B.2.2 Microfluidic Device Fabrication
The process for developing the microfluidic wafer has been described previously by
Hettiarachchi et al. [239]. Briefly, the channels were created using Illustrator (Adobe,
San Jose, CA, USA) and printed (20,000 dpi) by CAD/Art Services (Brandon, OR,
USA). In a clean room, the wafer was first oxidized in oxygen plasma and then spin-
coated with a UV curable epoxy (SU-8-25, MicroChem, Newton, MA, USA). On ex-
posing the wafer to UV light, the channel patterns develop to use as a negative for
device production.
With the wafer in a petri dish, Polydimethylsiloxane (PDMS) (Dow Corning, Mid-
land, MI, USA) and a curing agent were poured over the wafer at a 10:1 ratio, respec-
tively. This was then placed under vacuum for 24 h and then cured at 60◦C overnight.
After the PDMS was cured, the individual microfluidic devices were removed from the
wafer. The individual microfluidic device and a clean microscope slide (2947− 75X25,
Corning, Corning, NY, USA) were placed in a plasma cleaner (Harrick Plasma, Ithaca,
NY, USA) and exposed to a plasma field under a controlled pressure of 500 mTorr
for 3 min. Upon completion of the plasma cleaning process, the PDMS and glass
slide were immediately joined, forming complete microchannels. One minute after the
bond was established, DI water was injected into the channels to create a hydrophilic
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environment.
B.2.3 Microfluidic Experimental Apparatus
The microfluidic experimental apparatus was set up similarly to that described
previously by Kaya et al. [138]. Briefly, the microfluidic device was secured to a
moving stand on an inverted microscope (Olympus 1X71 microscope, Center Valley,
PA, USA) and viewed with a 50X objective. A high-speed camera (Fastcam APX-
RS, Photron, Inc., San Diego, CA, USA) was used to capture images and videos of
the device output. Reagents were injected from syringes into device channels through
Tygon S-54-HL tubing (Saint-Gobain Performance Plastics, Akron, OH). Calibrated
syringe pumps (Harvard Apparatus, Holliston, MA) were used to control the rate of
material flow in individual microchannels.
B.2.4 Sample Production
To produce uniform samples, the PFP flow rate was fixed at a constant value and
the lipid flow rate was increased until the smallest stable droplets were formed. The
system was allowed to stabilize for 5 minutes before collection, because pressure changes
in the system required a few minutes to equalize. This process was repeated across a
range of different flow rates, as described in Table B.1. To determine the production
rate for the microfluidic device, high-speed video analysis of the droplet production was
performed. Time stamps enabled the determination of droplet production rate.
Acoustic Experimental Apparatus
The experimental setup to determine droplet vaporization thresholds was similar
to that described previously by Sheeran et al. [195]. Briefly, a heated water bath
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Table B.1: Polydispersity data for the five studied droplet pop-
ulations from the day the droplets were created and at three
days, one week, and two weeks
Creation data
Lipid PFP Average
(µL/min) (µL/min) (µm) SD Polydispersity
20 12.5 20.4 0.3 1.5
31 15 16.2 0.5 3.4
40 15 12.6 0.5 3.9
50 15 10.3 0.4 3.5
60 13.9 7.4 0.4 5.1
3-day data
20 12.5 20.6 0.5 2.6
31 15 16.2 0.4 2.6
40 15 12.6 0.4 3.4
50 15 10.5 0.4 3.9
60 13.9 7.5 0.5 6.2
1-week data
20 12.5 20.4 0.5 2.6
31 15 15.5 0.4 2.8
40 15 12.6 0.4 3.1
50 15 10.7 0.4 3.4
60 13.9 7.5 0.4 4.7
2-week data
20 12.5 20.4 0.5 2.7
31 15 15.5 0.5 3.4
40 15 12.2 0.4 3.2
50 15 10.8 0.4 3.5
60 13.9 7.5 0.7 9.0
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maintained at 37◦C was connected to an inverted microscope. Droplets were injected
through a nearly acoustically and optically transparent microcellulose capillary tube
with an inner diameter of 200 µm (Spectrum Labs, Inc., Greensboro, NC, USA). A
5-MHz piston transducer (IL0506HP, Valpey Fisher Corp., Hopkinton, MA, USA) was
positioned in the water bath confocally with a water immersion microscope objective
(100x, NA = 1.0). The output of the ultrasound transducer was calibrated by inserting
a needle-hydrophone (HNA-0400, Onda Corp., Sunnyvale, CA, USA) into the experi-
mental system at the exact location where the samples are positioned during activation
studies (the focus of the microscope objective). Droplets were exposed to single 10-
cycle sinusoidal pulses while the ultrasound pressure was increased incrementally until
droplet vaporization was observed. The procedure was repeated for at least 20 droplets
from each size distribution to verify droplet size and threshold.
B.2.5 Stability Analysis
Droplets were stored at 4◦C in 3 mL vials until sampling. For analysis, a 25
µL aliquot of droplets was placed on a glass slide and images were captured with
the Photron Fastcam camera. Size measurements were performed in ImageJ (NIH,
Bethesda, MD, USA) by comparison with a calibrated reticle (Edmund Industrial Op-
tics, Barrington, NJ, USA). A minimum of 50 droplets were measured for each popu-
lation.
B.3 Results
The dimensions of the microfluidic device, material composition and flow rates all
have the ability to alter the composition of the resulting droplet. Due to the micro-
fabrication process, there are small variations from device to device (we measured a
13% deviation in orifice widths across 10 devices). With this in mind, only one device
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was used for the duration of production to ensure that the dimensions of the device
were unchanged. The material compositions also went unchanged to ensure that the
droplets would experience a standardized reaction to the US pressure.
Figure B.1: High-speed video frames of microfluidic droplet production at diameters of
(a) 20.4 ± 0.3 µm, (b) 16.2 ± 0.5 µm, (c) 12.6 ± 0.5 µm, (d) 10.3 ± 0.4 µm and (e)
7.4± 0.4 µm, corresponding to lipid and PFP flow rates of lipid 40 µL/min; PFP 12.5
µL/min, lipid 31 µL/min; PFP 15 µL/min, lipid 40 µL/min; PFP 15 µL/min, lipid 50
µL/min; PFP 15 µL/min, lipid 60 µL/min; and PFP 13.9 µL/min, respectively.
B.3.1 Precision Size Control
The flow rates were varied over five sets of conditions for the duration of the ex-
periment to alter the droplet diameter. Results illustrated that by varying flow rates,
the PFP population diameters could be carefully selected. In general, as the lipid flow
rate was increased, droplet size decreased (Figure B.1). As the PFP flow rate was
increased, droplet size increased. Table B.1 lists the flow rates, mean droplet size,
standard deviation and polydispersity index [237].
For the populations studied, the standard deviation was largest for the smallest
droplets (SD = 0.4 for the 7.4 micron population) and smallest for the largest droplets
(0.3 for the 20.4 micron population). All populations had a polydispersity index of 5.1
or less.
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B.3.2 Production Rate
The 20-µL/min lipid and the 12.5-µL/min PFP flow rates, which resulted in 20.4
micron droplets, had a production rate of 1.85 × 104 droplets produced per second
(slowest production sample), whereas the 60-µL/ min lipid and 13.9-µL/min PFP flows,
which produced 7.4 micron droplets, had a production rate of 1.65 × 105 droplets per
second (fastest production sample). Table B.2 lists the production rates for the 5
samples.
Figure B.2: Average pressure of vaporization vs. average droplet diameter. Error bars
indicate standard deviations in pressure and diameter. The trendline is logarithmic.
B.3.3 Acoustic Responses
The five samples were diluted and injected into a cellulose microcapillary tube where
droplets from each population were individually subjected to US. The US data showed
that there was a distinct vaporization threshold pressure for each diameter (Figure B.2).
The data trend suggests a logarithmic relationship (p = −1.80 ln(D)+7.72, r2 = 0.97),
as predicted by the Antoine equation.
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B.3.4 Long-term Stability
Populations maintained a fairly low polydispersity over a two-week period (Table
B.1) and, overall, the mean diameters of the populations drifted less than 4.6% (Figure
B.3). The 16.2 and 10.3 µm mean diameter populations each maintained the same
polydispersity, and the 20.4, 12.6 and 7.4 µm mean diameter populations changed by
a factor of 1.8, 1.3 and 1.9, respectively
Figure B.3: Microscopy images of droplets one week apart illustrating size stability.
(a-e) One week after production populations of mean diameter of (a) 20.4± 0.3 µm,
(b) 16.2±0.5 µm, (c) 12.6±0.5 µm, (d) 10.3±0.4 µm and (e) 7.4±0.4 µm. (f-j) Two
weeks after production populations corresponding to (a-e), respectively, with mean
diameters of (f) 20.4± 0.5 µm, (g) 15.5± 0.5 µm, (h) 12.2± 0.4 µm, (i) 10.8± 0.4 µm
and (j) 7.5± 0.7 µm.
B.4 Discussion
The method described here demonstrates the potential of production of uniform-
sized droplets for acoustic droplet vaporization using microfluidics. Data illustrate
that this technique enabled production of a population of droplets where each droplet
responded similarly to the same acoustic parameters because of uniform size. One
advantage of using such uniform droplets would include the ability to use the lowest
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acoustic pressure possible for vaporization (because all droplets would respond sim-
ilarly), thereby achieving the highest vaporization efficiency for the lowest acoustic
pressure. Keeping the acoustic pressure as low as required would conform to the “As
Low As Reasonably Achievable (ALARA) Principle” for clinical ultrasonics. Other po-
tential advantages of uniform-sized ADV agent production, although not demonstrated
here, would be the ability to tailor droplet sizes for specific vessel occlusion, or to enable
precision drug-loading for therapeutic-carrying ADV agents.
Microfluidic techniques have previously demonstrated unique utility in the con-
trolled fabrication of droplets and microbubbles. The biggest limitation to this method
to date is that the production rate is substantially slower than other droplet and mi-
crobubble production methods. Even for the fastest production method here, it would
require nearly 3 h to achieve 1×109 droplets (a similar order of magnitude to the concen-
tration of microbubble contrast agents prepared by a mechanical agitation method).
However, in the future, microfluidic techniques may be scaled up to achieve higher
throughput, although the need to maintain identical dimensions and flow rates to each
orifice to preserve size uniformity presents a challenge. It should also be noted that
although the smallest droplets described here were approximately 7 microns, which is
likely too large for in vivo application, this size was limited only by our particular
system and is not a fundamental limit of microfluidic droplet production. It is very
reasonable to anticipate that by optimizing the channel dimensions, component flow
rates and the lipid/perfluorocarbon ratios, droplets much smaller than 7 microns can be
prepared. Previous studies have illustrated microfluidic production of liquid droplets
as small as 100 nanometers [206].
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B.5 Conclusion
A microfluidic device can produce monodisperse PFP/lipid droplets using flow-
focusing technology. Monodisperse PFP/lipid droplets that were subjected to US pres-
sure waves showed a uniform ADV response. The relationship formed by droplet diam-
eter and ADV threshold agreed with the expected negative logarithmic response based
on the size of the droplets. Droplet populations produced with microfluidics were stable
within the two-week period studied.
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Table B.2: Production rates for droplets produced with mi-
crofluidics under varying input flow conditions
Lipid (µL/min) PFP (µL/min) Prod. rate (#/s)
20 12.5 1.85× 104
31 15 3.31× 104
40 15 6.44× 104
50 15 1.03× 105
60 13.9 1.65× 105
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APPENDIX C
Clinical-Scale Microfluidic Generation of PCCAs
C.1 Introduction
Embolization has emerged as an accepted modality for the treatment of various
cancers, including hepatocellular carcinomas, hepatic metastases, and renal cell carci-
nomas [240]. The intentional occlusion of a vessel, embolization enables the reduction
of blood flow into or out of that vessel, and has typically been used in cancer ther-
apies to produce local ischemia resulting in tumor necrosis. Established methods of
embolization include the placement of a metal coil or soluble gelatin sponge within the
target blood vessel, or the injection of chemical or particulate agents such as ethanol or
polyvinyl alcohol particles to reduce blood flow at the site of injection or immediately
downstream [240; 241].
Recently the field of medical ultrasound has shown much interest in gas embolother-
apy, in which acoustic or thermal energy induces a droplet emulsion with a volatile liquid
core to undergo a liquid-to-gas phase transition, and volume expansion, to strategi-
cally form gas emboli in vivo, as shown in Figure C.1. Acoustic droplet vaporization
(ADV) specifically refers to the use of focused ultrasound to induce such a transition,
c© 2011 Royal Society of Chemistry (rsc.org) Portions reprinted, from D Bardin, TD Martz, PS
Sheeran, R Shih, PA Dayton, and AP Lee. “High-Speed, Clinical-Scale Microfluidic Generation of
Stable Phase-Change Droplets for Gas Embolotherapy” Lab on a Chip, 2011 October; 11: 3990-3998.
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in which the applied acoustic pressure supplies the necessary energy to induce super-
heated droplet emulsions to vaporize into microbubbles. The phase-change typically
results in microbubbles five to six times larger in diameter than the original droplets,
enabling these gas bubbles to occlude vessels of sufficiently small diameters, such as
capillaries and some arterioles [71; 66].
Figure C.1: Schematic of the liquid-to-gas phase transition of a phase-change droplet.
When presented with acoustic or thermal stimuli of a threshold amount, the volatile
liquid core of the droplet rapidly vaporizes within the lipid shell. Expansion to a gas
bubble enables the intentional occlusion of a target vessel in vivo. Other possible stimuli
include light and mechanical pressure.
Studies thus far have investigated the usefulness of ADV agents to enhance contrast
in ultrasound imaging [50], to deliver therapeutics [113; 94; 95], for enhanced thermal
delivery alongside high-intensity focused ultrasound (HIFU) [114], and for occlusion in
animal models [85]. The choice of liquid core consists of a number of perfluorocarbons,
including perfluoropentane [71; 94; 95; 85; 77; 74; 52; 73; 76], perfluorohexane [94; 73],
perfluorooctane [75], and perfluorobutane [195]. Encapsulation of the liquid core inside
a lipid, albumin, or polymer shell reduces coalescence among the droplet population
and increases the Laplace pressure sufficiently to enable these volatile emulsions to
remain as superheated droplets at body temperature [71; 73].
Current methods to generate these phase-change droplets which include sonication
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and high-speed mechanical agitation typically result in a polydisperse size distribution
[113; 94] and a nonuniform acoustic activation threshold, as well as in droplets either
too large for passage through the lung capillaries (> 6 µm) or too small to occlude
the desired vessel (< 1 µm) [71; 85]. Thus required are secondary methods of size
selection such as filtering [50; 108] or microfluidic sorting [149] to control the sizes of
these distributions. The Antoine equation predicts a negative logarithmic relationship
between vaporization energy and droplet diameter [52], meaning that small droplets
require more energy to vaporize than larger droplets due to increased Laplace pressure.
Hence, narrowing the droplet size distribution such that it is highly monodisperse should
result in a uniform response to focused acoustic pressure. As well, a monodisperse
population of ADV agents may better target a specific vessel diameter to improve
occlusion efficiency and efficacy, and would significantly reduce unwanted bioeffects
seen in vivo, including delayed febrile-like reactions and respiratory distress [85; 92].
Droplet-based microfluidic systems have shown to be effective technologies to pro-
duce droplets [236; 242] and microbubbles [204; 152; 243] in the micrometre diameter
range with high uniformity. Yet despite the attractiveness of precision control over
size, shape, and composition, these systems have traditionally been viewed as unvi-
able as bulk manufacturing processes owing to relatively low generation rates. At
present, reporting of clinical-scale generation of droplet or microbubble emulsions has
been limited, and virtually absent for emulsions truly useful for in vivo intravenous
or intraarterial therapeutics. Most recently Castro-Hernandez et al. [244] described a
new regime for microbubble generation dependent on the formation of a strong pressure
gradient at the bubble-producing region. Approximately 5 µm in diameter gas-in-water
bubbles were successfully generated at the tip of a long gas ligament with rates exceed-
ing 105 Hz from a single channel, though bubbles were unstable due to the lack of
significant surfactant or lipid shells. Far less impressive per-channel frequencies have
237
been observed in liquid-liquid droplet generation systems. Nisisako and Torii [245]
achieved a throughput of 320 mL/hr in generating approximately 100 µm droplets us-
ing a multilayer device with 256 droplet formation units and a breakup rate of 1.4×103
droplets per second per cross-junction. Kobayashi et al. [246] reported the formulation
of oil-in-water emulsions at cumulative rates up to 2.2 × 104 Hz using a total of 1500
submicron-channels on single-crystal silicon plates, although the emulsions were only
moderately monodisperse with a minimum coefficient of variation (CV) of 9%. In fact,
frequency distributions for various liquid-liquid droplet generation systems, whether
water-in-oil or oil-in-water, rarely exceed several thousand droplets per second from a
single channel in forming droplets seldom smaller than 10 µm in diameter [238]. From
a healthcare perspective, one could comment that there is no practical use for these
aforementioned emulsions due to either insufficient quantity or inappropriate charac-
teristics of the emulsion. Thus, a need in microfluidics still exists for systems capable
of generating clinical-scale amounts of droplet or microbubble emulsions with suitable
size and functionality for therapeutics.
To overcome the limitations of past droplet generation systems, we considered the
basic mechanisms of droplet generation with the intent to find a possible route to pro-
duce, in mass, micrometre-scale droplets with engineered biology. Recent publications
on the physics of fluids have reported the observation of a number of distinct droplet
formation modes in flow-focusing microfluidic devices [205; 247]. Under controlled
experimental conditions, such a device transitions from geometry-controlled mode to
dripping to jetting, affecting the size and generation frequency by up to an order of
magnitude. In particular, Anna and Mayer [205] allude to the dripping mode of droplet
breakup as a method to yield droplets smaller than the minimum device feature size
with a shorter primary breakup period than other modes, as yet demonstrated in the
literature with a healthcare intent. We thus set out to use the dripping regime to
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meet our objective of the clinic-ready manufacture of liquid perfluoropentane droplets
as phase-change agents for cancer treatment.
In this work we present a microfluidic device, operated in the dripping regime, for
the super high-speed generation (> 105 Hz) of monodisperse liquid perfluoropentane
droplets in the desired size range for gas embolotherapy. Resulting droplet popula-
tions exhibit polydispersity index values of < 5%, are stable at room temperature for
several weeks, and are thermally vaporized at 88◦ in a water bath. These liquid perfluo-
ropentane droplets thus exhibit phase-change and are ideal for targeted vessel occlusion
alongside such cancer therapies as HIFU, radiofrequency ablation (RFA), laser abla-
tion (LA), laser-induced thermotherapy (LITT), and chemotherapy. Our microfluidic
device, shown in Figure C.2, features a hydrodynamic flow-focusing region and ex-
panding nozzle geometry to generate monodisperse liquid perfluoropentane droplets
encapsulated in a lipid shell.
Figure C.2: Geometry of the device for the generation of liquid perfluoropentane phase-
change droplets. (a) Schematic view of the microfluidic flow-focusing device. All
channels are rectangular with a height of 25 µm. (b) Image of the flow-focusing region.
Lipid solution and liquid perfluoropentane distribution channels measure 38 µm in
width and direct flows to a 7 µm orifice. Expanding nozzle geometry precedes a post-
orifice channel 30 µm in width. (c) Overhead view of the assembled PDMS device
relative to a dime.
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C.2 Materials & Methods
C.2.1 Device Design
The microfluidic device, made of polydimethylsiloxane (PDMS) on a glass substrate,
consists of fixed geometric channels designed to direct liquid perfluoropentane and a
lipid solution to an orifice 7 µm in width. Filter channels of the same dimension
immediately follow both inlets to prevent clogging at the orifice. Serpentine distribution
channels increase the resistance between inlets and the orifice chamber, minimizing the
susceptibility of droplet generation to disruptions in the fluid flows and increasing the
pressure drop along the longitudinal axis of the device. Liquid perfluoropentane and
lipid distribution channels each measure 38 µm in width. The post-orifice channel
measures 30 µm in width.
C.2.2 Device Operation: Droplet Formation Regime
The principle behind a microfluidic flow-focusing system is to force a central stream
of a dispersed phase and two side sheath flows of a continuous phase through a small
orifice, causing a focusing effect and a breaking of the thread at the orifice into uni-
form emulsions [248]. Most traditional flow-focusing devices have been operated in
the geometry-controlled mode, termed for the large dependence of droplet size on the
smallest feature size in the device the orifice. In this mode droplets break off from
the dispersed phase finger following a protrude-and-retract mechanism [249]. Droplets
in the geometry-controlled mode are highly monodisperse but limited in minimum size
by the width of the orifice. An increase in the capillary number Ca = ηV
γEQ
, where η is
the viscosity, V is the superficial velocity of the continuous outer phase, and γEQ is the
equilibrium surface tension between the two fluid phases, leads to droplet generation
in the dripping regime [205]. This regime produces monodisperse droplets smaller than
the size of the orifice due to narrowing of the dispersed phase finger. The dripping
240
mode is characterized by a dispersed phase tip that does not retract but rather re-
mains at a fixed location in the orifice, generating a stream of droplets off the tip due
to Rayleigh capillary instability. A further increase in the capillary number leads to
droplet generation in the jetting mode, wherein the dispersed phase finger extends far
into the post-orifice channel. Droplets, which break off the tip of the dispersed phase
finger due again to Rayleigh capillary instability, tend to be as large as or larger than
the orifice width in the jetting mode and may be polydisperse. By adjusting the flow
parameters and continuous phase viscosity, we thus aimed to operate our flow-focusing
microfluidic device in the dripping regime to attain droplets of the desired size for gas
embolotherapy (1-6 µm in diameter).
C.2.3 Microfabrication and Assembly
Standard soft lithography techniques [250] were used to fabricate the microfluidic
devices. Devices were designed as vector-based fluidic channel geometries in Illustrator
(Adobe) and printed at 20,000 DPI by CAD/Art Services. In a class 10,000 clean room,
a 25 µm layer of a UV-curable epoxy (SU8-25, MicroChem) was spun onto a 3 inch
silicon wafer and exposed to UV-light through the photomask and developed. Next,
PDMS (Sylgard 184, Dow Corning), consisting of 10 : 1 prepolymer to curing agent,
was poured over the patterned silicon wafer in a Petri dish to mold a silicon elastomer
replica. The Petri dish was then vacuumed for at least half an hour to degas the PDMS
and left overnight in a 70◦C temperature-controlled dry oven to cure fully. The device
was peeled from the hard master in a laminar flow chamber and inlets and outlet were
punched using a blunt 18G needle. A soda lime glass slide was cleaned with isopropyl
alcohol prior to use as the substrate. The cured PDMS device and clean glass slide
were bonded after 150 seconds in air plasma at 250 milliTorr. DI water was added
to the outlet after plasma preparation and allowed to wick in order to maintain the
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hydrophilicity of the channels.
C.2.4 Chemicals
A lipid shell was chosen over an albumin shell, as albumin shells have shown an
increased tendency to become lodged in the pulmonary capillaries [85]. Adapted from
Hettiarachchi et al. [239], the lipid flow stream consists of an aqueous glycerol mixture
with the stabilizing lipids DSPC (1,2-distearoyl-sn-glycero-3- phosphocholine, Avanti
Polar Lipids) and DSPE-PEG2000 (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[methoxy- (polyethylene glycol)-2000], Avanti Polar Lipids). Briefly, 5 mg DSPC
and 1.96 mg DSPE-PEG2000 were combined in a glass vial and dissolved in chloroform
(Sigma) to form a homogeneous mixture. The solvent was evaporated with a nitrogen
stream and the vial was placed in a vacuum chamber for half an hour to ensure a
complete dry. Five microlitres of ultra-pure water was added to the dry lipid mixture
and sonicated at room temperature for 20 minutes. The solution was combined with
an additional 1 mL of ultra-pure water, 4 mL of glycerol (Sigma), and 1 mL of non-
ionic surfactant (Pluronic F-68, Sigma), sonicated at room temperature for 10 minutes,
and stirred overnight to ensure air saturation. The lipid solution was sonicated again
for 15 minutes immediately prior to use to minimize unwanted liposome formation.
Perfluoropentane (dodecafluoropentane, C5F12, FluoroMed) was chosen as the liquid
perfluorocarbon. Typical physical characteristics of perfluoropentane include a boiling
point of 29◦ below the body temperature, 37◦C and a molecular weight of 288 g/mole.
Imaging and Characterization
The microfluidic device was mounted on an inverted microscope (IX71, Olympus)
and external fluidic connections were made. The continuous lipid phase was supplied
to the device via flexible tubing (Tygon, Sigma) and pumped at a volumetric flow rate
of QL using a digitally controlled syringe pump (Pico Plus, Harvard Apparatus). The
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dispersed liquid perfluoropentane phase was delivered into the inlet of the microfluidic
chamber using a homemade pressure pumping system controlled by an analytic regu-
lator. Pressure pumping of the dispersed phase effectively minimized fluctuations in
the liquid perfluoropentane flow and eliminated the buildup of pressure, characteristic
of constant flow rate mechanical pumping, in the inner phase channels. Also, loading
the liquid perfluoropentane was made easier by the homemade pressure pump as the
low kinematic viscosity of this perfluorocarbon at room temperature (0.4 cSt) tends
to complicate the loading of the syringe for mechanical pumping. The volumetric flow
rate (µL/min) of the dispersed liquid perfluoropentane phase was determined from the
droplet diameter D and the droplet generation frequency fd as QP = (
piD3
6
)fd × C,
where C represents the necessary conversion factors. The 30-PSI limit of the analytical
regulator prevented the use of pressure pumping for the continuous lipid phase.
A high-speed camera (V310 Phantom, Vision Research) was used to record videos
of the droplet generation. The image analysis program ImageJ (NIH) was used for data
processing and measurements. Production rates (droplets per second) were calculated
from the videos by counting the number of droplets per 500 frames and multiplying by
the frame rate. Droplet diameters were back calculated from area measurements of at
least 50 droplets taken optically from recorded images using ImageJ. The polydispersity
index σ = δ
D
× 100% for each flow condition was calculated from the average droplet
diameter D and standard deviation δ.
C.2.5 Droplet Stability
Droplets were collected in the outlet well of the microfluidic device and transferred
to a sealed 7 mL glass vial. In contrast to previous reports, which stored droplets at
4 − 5◦ [85; 76], droplets in this study were stored at room temperature to assess the
viability of the droplets in an on-the-shelf setting. At Days 0 and 14, 300 µL aliquots
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of the droplet solution were pipetted onto glass slides for stability studies. ImageJ was
used to analyze at least 1000 droplets, imaged in population at 40x magnification, to
establish average diameter and monodispersity over the two week period.
C.2.6 Vaporization of Droplets in a Water Bath
To determine the vaporization temperature of the perfluoropentane droplets, 300
µL aliquots of the droplet solution were added to 2 mL of dilute lipid solution in a
7 mL vented glass vial. The elevated density of liquid perfluoropentane (1.66 g/mL)
relative to the solution meant that the droplets rested at the base of the vial. The vial
was suspended in a stirred water bath and the bath temperature was gradually raised
until we observed gas bubble formation and thus phase transition. The experiment
was conducted twice again with pure liquid perfluoropentane and pure lipid solution as
controls against unintended microbubble formation.
Figure C.3: Representative images of three distinct droplet formation regimes. (a)
Geometry-controlled. A series of overlaid images, successive in time, demonstrate the
protrude-and-retract mechanism of the dispersed phase finger. (b) Dripping. Droplets
break off from the tip of the dispersed phase finger at high rates due to “steady”
Rayleigh capillary instability. (c) Jetting. A series of overlaid images, successive in
time, demonstrate the break off of droplets due to “dynamic” Rayleigh capillary insta-
bility. The image height is 25 µm.
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C.3 Results and Discussion
C.3.1 Design Optimization
Channel geometry, in addition to the compositions of fluid layers and the presence of
surfactants, affects the stability of droplets post-production in the microfluidic device.
Geometric optimization of the flow-focusing region enabled droplets to be produced in
a single file, even at rates exceeding 105 Hz. To increase the distance between generated
droplets at higher lipid and liquid perfluoropentane flow rates, the expanding nozzle
and post-orifice channels were narrowed to widths of 70 µm and 30 µm. This narrowing
minimized contact inhibitions in the high-flow velocity environment of the expansion
chamber, where shell resistances are low, preventing droplet fusion before collection in
the outlet well.
C.3.2 Droplet Formation Regime
By adjusting the flow parameters in our flow-focusing device, we observed each of
the three distinct droplet formation regimes detailed. At low continuous phase flow
rates QL, and correspondingly low dispersed phase pressures PP , our device produced
droplets in the geometry-controlled mode. As shown in Figure C.3a comprising a series
of overlaid images, successive in time the dispersed phase finger, initially upstream of
the orifice in this mode, protrudes beyond the constriction of the orifice and experiences
a pinching from the sidewalls, causing droplets to shear off. This protrude-and-retract
mechanism limits the droplet diameter to the width of the orifice. Droplets generated
in the geometry-controlled mode ranged in diameter from 7.9 ± 0.1 µm at 2.44 × 104
Hz to 10.8± 0.2 µm at 3.28× 104 Hz.
Increasing the continuous phase flow (and, correspondingly, the capillary number)
causes an abrupt transition to the dripping regime of droplet formation, characterized
by a dispersed phase finger that narrows to a fine tip and remains in the orifice (Figure
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C.3b). Droplets, which break off the tip at high frequency due to “steady” Rayleigh
capillary instability, vary in size according to the width of the dispersed phase finger
rather than that of the orifice. Diameters of droplets generated in the dripping regime
ranged from 3.6± 0.2 µm at 1.36× 105 Hz to 10.8± 0.1 µm at 5.00× 104 Hz.
High continuous phase flows paired with correspondingly high dispersed phase pres-
sures transitioned droplet formation into the jetting mode. Figure C.3c overlays a series
of images, successive in time, to demonstrate the break off of droplets in this mode due
to “dynamic” Rayleigh capillary instability; relative to the dripping regime, the dis-
persed phase tip extends far beyond the orifice and fluctuates in both length and width.
Droplets at the transition to the jetting regime ranged in diameter from 9.3 ± 0.2 µm
at 7.68× 104 Hz to 13.5± 0.1 µm at 3.84× 104 Hz.
Figure C.4: Diagrams of the production characteristics as determined by the flow pa-
rameters. Boxes distinguish geometry-controlled and jetting modes of droplet formation
from dripping. Droplet diameter D as a function of the lipid flow QL and the liquid
perfluoropentane pressure PP .
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Figure C.5: Diagrams of the production characteristics as determined by the flow pa-
rameters. Boxes distinguish geometry-controlled and jetting modes of droplet formation
from dripping. Generation frequency fd as a function of QL and PP .
C.3.3 Generation of Liquid Perfluoropentane Droplets
The flow rate parameters are determinants for stable production and precise con-
trol over the size and generation frequency of the liquid perfluoropentane droplets. In
general and regardless of the droplet formation regime, the droplet diameter D and
consequently volume V increases with the dispersed phase pressure PP for a fixed
continuous phase flow QL, consistent with previous studies [204; 244; 239]. Shown in
Figure C.4, the width of the orifice limits the minimum droplet size in the geometry-
controlled mode, while much smaller droplets can be generated in the dripping regime.
The minimum droplet diameter tends to decrease with increasing QL, and thus increas-
ing the capillary number, as the smallest droplets observed in this study occurred at
the highest continuous flow rates.
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An interesting observation emerged when establishing trends in the droplet genera-
tion frequency fd (Figure C.5). In geometry-controlled mode, fd tends to increase with
PP for a fixed QL in order to conserve mass. Conversely, for a given QL in the drip-
ping regime, decreasing PP significantly quickens the generation frequency (increases
fd) while reducing D, hence achieving the desired super high-speed generation of func-
tional droplets suitable for therapeutic applications. Overall and as expected, fd tends
to increase with QL.
Figure C.6: Sequence of images showing the effect of liquid perfluoropentane pressure
for two lipid flows in the dripping regime. The droplet diameter decreases and the
generation frequency quickens as the dimensionless flow rate ratio φ = QL/QP increases.
(a) QL = 18 µL/min. Top to bottom: PP = 17 PSI, φ = 55, D = 4.9 ± .2 µm,
fd = 8.82 × 104 Hz; PP = 18 PSI, φ = 18, D = 8.6 ± 0.1 µm, fd = 5.04 × 104 Hz;
PP = 19 PSI, φ = 9, D = 10.0 ± 0.2 µm, fd = 4.80 × 104 Hz. (b) QL = 22 µL/min.
Top to bottom: PP = 20 PSI, φ = 128, D = 3.8± 0.2 µm, fd = 1.00× 105 Hz; PP = 21
PSI, φ = 20, D = 7.9±0.1 µm, fd = 7.00×104 Hz; PP = 22 PSI, φ = 12, D = 9.8±0.2
µm, fd = 6.12× 104 Hz. The image height is 25 µm.
The sequence of high-speed images in Figure C.6 illustrates the general trends ob-
served in the dripping regime. In particular as droplets become small, the width of the
dispersed phase finger heavily influences the diameter of the droplet after it breaks off
from the tip.
Shown in Figs. C.7 and C.8 are droplet generation frequencies obtained from high-
speed videos of production and corresponding polydispersity indexes, plotted as a func-
tion of droplet diameter. When operated in the dripping regime our device clearly
produces liquid perfluoropentane droplets in the desired 3 − 6 µm range with high
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Figure C.7: Plots relating the generation frequency to droplet size. The dripping
regime enables droplet formation in the appropriate 3− 6 µm range at high frequency.
Generation frequency fd as a function of droplet diameter D.
monodispersity at rates equal to or exceeding 105 Hz. Whereas no general trend ap-
pears to connect the droplet diameter and generation frequency in geometry-controlled
mode, D tends to decrease as fd quickens in the dripping regime. Simple adjustment
of the flow parameters enabled the generation of droplets spanning a wide range of
diameters, with a polydispersity index less than 5% for each condition.
Determining the liquid perfluoropentane volumetric flow rate QP as detailed, we
evaluated the influence of the dimensionless flow rate ratio φ = QL/QP on the droplet
diameter and generation frequency. As shown in Figure C.9, a key relationship emerges
in the dripping regime relating D and φ to predict the droplet diameter based solely
on the dimensionless flow rate ratio as: D = 27.445φ−0.414 (r2 = 0.99). Rounding,
we characterize our flow-focusing droplet generator, operated in the dripping regime,
in generic terms by Dd u 27(Qc/QD)−5/12 where Dd represents the droplet diameter,
and QC and QD represent the continuous and dispersed phase flow rates. Note that
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Figure C.8: Plots relating the polydispersity index to droplet size. The dripping regime
enables droplet formation in the appropriate 3 − 6 µm range at high monodispersity.
Polydispersity index (PDI) as a function of D. All flow conditions generated droplets
with PDI < 5%.
the exponent 5/12 matches the exponent reported by Castro-Hernandez et al. [244]
to calculate the gas bubble diameter based on the ratio of the flows in a high-speed
regime.
The droplet generation frequency shows relatively less dependence on the dimen-
sionless flow rate ratio (Figure C.10). In general, however, fd increases with φ in the
dripping regime and decreases with φ in geometry-controlled mode. As reported by
Anna and Mayer [205], transitions between the droplet formation regimes are weakly
dependent on φ; rather, the capillary number plays a more determining role in control-
ling the mode of droplet breakup.
This study used low lipid flow rates (12 − 26 µL/min) and correspondingly low
liquid perfluoropentane pressures in order to conserve fluids and better demonstrate
the viability of high speed droplet generation as a bulk manufacturing process. By
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Figure C.9: Diagrams of the production characteristics as determined by the ratio of
the continuous lipid flow to the dispersed liquid perfluoropentane flow, φ = QL/QP .
The droplet diameter D as a function φ. For a given φ, droplet formation in geometry-
controlled mode generates droplets of a larger size than in dripping mode. A power-
series equation, valid in the dripping regime, emerges to predict droplet size based on
the dimensionless flow rate ratio as D = 27.445φ−0.414 (r2 = 0.99).
comparison, Hettiarachchi et al. [204] supplied the lipid phase at rates between 30
and 120 µL/min. Based on the trends observed in Figure C.5 and C.10, even quicker
droplet generation frequencies may be attained by increasing the continuous phase flow
to further push the capillary number. As well, multiplexing numerous flow-focusing
circuits to expand the number of droplet formation units, while maintaining device
operation in the dripping regime, would scale the throughput. A 10x scale-up, for
instance, would reduce the time to produce 1 × 109 droplets similar in scale to the
amount of droplets formed by mechanical agitation, and well beyond the estimated
2×107 monodisperse emulsions [239] necessary for therapeutics in humans from several
hours to mere minutes.
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Figure C.10: Diagrams of the production characteristics as determined by the ratio of
the continuous lipid flow to the dispersed liquid perfluoropentane flow, φ = QL/QP .
The droplet diameter D as a function φ. For a given φ, droplet formation in geometry-
controlled mode generates droplets of a larger size than in dripping mode. A power-
series equation, valid in the dripping regime, emerges to predict droplet size based on
the dimensionless flow rate ratio as D = 27.445φ−0.414 (r2 = 0.99).
C.3.4 Stability
We assessed a population of droplets with a mean diameter of 4.5 µm for size stability
over a two-week time span. To our knowledge this study is the first to simulate an on-
the-shelf environment by storing phase-change droplets at room temperature. Over two
weeks the mean droplet diameter drifted less than 4%, from 4.5± 0.2 µm to 4.3± 0.3
µm (Figure C.11). It may be possible to prolong the shelf life beyond several weeks by
modifying the poloxamer or PEG group, though unnecessary in practice considering
that clinical phase-change and contrast agents formed via mechanical agitation are
injected immediately into the patient.
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Figure C.11: Images showing stability of a droplet population over a two-week time
period. Droplets 4.5 µm in diameter drifted less than 4% in size over 14 days in a
sealed glass vial at room temperature. Thus our phase-change droplets exhibited high
stability in a true on-the-shelf setting. Scale bar represents 5 µm.
C.3.5 Thermal Vaporization
The relatively low boiling point of liquid perfluoropentane (29◦C) suggests sponta-
neous liquid-to-gas transition at body temperature; however, consistent with previous
studies [71; 52], encapsulation of the perfluorocarbon in a lipid shell increases the
Laplace pressure sufficiently to stabilize the droplets well beyond the natural boiling
point of pure liquid perfluoropentane. We observed rapid thermal vaporization of mul-
tiple droplet populations, collected at different days, at 88◦C in a stirred water bath.
Droplets remain in a superheated state prior to this activation threshold.
As shown in Figure C.12, gas bubbles formed by vaporization expanded well beyond
the volume predicted by the ideal gas law, PV = nRT , which approximates a volume
expansion factor of 125x. Upon activation, 4.5 ± 0.2 µm droplets initially converted
into gas bubbles 106.7±4.6 µm in diameter, a diameter expansion of 24x. Kripfgans et
al. [71] detailed this further expansion as due to the intake of dissolved gases from the
host fluid after conversion of the droplet to the gas bubble of pure perfluoropentane, an
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Figure C.12: Thermal vaporization of a population of liquid perfluoropentane droplets
after heating in a stirred water bath. Rapid droplet activation was observed at a water
bath temperature of 88◦C. Upon vaporization, 4.5 µm droplets initially transitioned into
gas bubbles 106.7 µm in diameter. (Inset) Occlusive bubbles with a resting diameter
of 27.4 µm resulted following dissolution of extra gases.
effect we have observed experimentally in our previous studies with perfluorocarbons
[195]. That the carrier fluid was not degassed prior to heating contributed to this
large initial increase in size. Subsequent dissolution of these extra gases resulted in gas
bubbles with a resting diameter of 27.4±1.2 µm, a 6x increase from the original droplet
diameter, imaged several days after vaporization (Figure C.12, inset).
These experiments were repeated for vials containing pure liquid perfluoropentane
and pure lipid solution. Under observation, pure liquid perfluoropentane transitioned
directly to gas perfluoropentane, thus leaving an “empty” vial. Pure lipid solution
boiled up to 120◦C without the formation of gas bubbles.
The size stability of our droplets enabled consistent thermal activation of droplet
populations stored at room temperature over two weeks. At threshold, droplet activa-
tion occurs in a near simultaneous manner. Likewise, we demonstrate in a parallel study
that monodisperse droplets generated by our microfluidic device respond uniformly to
acoustic pressure delivered from a 5 MHz piston transducer [251]. This parallel study
254
confirms our initial hypothesis that acoustic droplet vaporization can be made homo-
geneous by the precision engineering of phase-change agents using microfluidics.
Consistent thermal and acoustic responses make these liquid perfluoro-pentane
droplets ideal for targeted vessel occlusion to enhance HIFU, RFA, LA, and LITT
in the treatment of cancers such as hepatocellular carcinomas, hepatic metastases, and
renal cell carcinomas. The inclusion of an anti-cancer drug layer within the droplet
may further potentiate these treatment modalities. Our device design lends itself to
the inclusion of such a drug layer by combining a second hydrodynamic flow-focusing
region at the droplet formation unit, as done in microbubble studies by Hettiarachchi
et al. [239]. Chemoembolization the addition of a chemotherapeutic agenthas been
used to reduce perfusion and deliver therapeutics to treat renal cell carcinoma alongside
RFA [252] and hepatocellular carcinoma alongside RFA [253] and HIFU [254]. Besides
forming polydisperse size distributions, conventional production techniques result in
inconsistent drug dosages. Manufacturing utilizing microfluidics enables the accurate
control of therapeutic payloads [239], and thus may improve localized drug delivery as
well as thermal and acoustic responses. Further, adaptation of our microfluidic device
to produce monodisperse double emulsions may enable the encapsulation of hydrophilic
drugs such as thrombin [94] to extend the duration of occlusions generated by phase-
change agents.
C.4 Conclusion
With microfluidics we can generate highly monodisperse phasechange droplets in the
size range suitable for gas embolotherapy as a cancer treatment. By adjusting the flow
rate of the continuous outer phase, we varied the capillary number and observed three
distinct droplet formation regimes: traditional geometry-controlled mode, character-
ized by a protrude-and-retract mechanism of droplet break off; dripping, characterized
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by “steady” Rayleigh capillary instability; and jetting, characterized by “dynamic”
Rayleigh capillary instability. Geometric optimization of the flow-focusing region and
operation of the device in the dripping regime enabled the single-file generation of
droplets at rates exceeding 105 Hz. To our knowledge this study is the first to report
on the generation of clinical-scale quantities of droplet emulsions truly suitable for in
vivo intravenous therapeutics.
For our flow-focusing device operated in the dripping regime, we can predict droplet
diameter Dd based on the dimensionless ratio of the flow rates of the continuous outer
phase QC and the dispersed inner phase QD. In simplified terms, we characterize our
device in the dripping regime by Dd = 27(QC/QD)
−5/12.
Droplet populations generated by our microfluidic device are monodisperse, stable
at room temperature, and transition uniformly to gas bubbles when presented with
thermal and acoustic stimuli. Looking ahead, we aim to build a drug layer into our liq-
uid perfluoropentane droplets to generate, using super high-speed microfluidics, phase-
change droplets for gas chemoembolotherapy. Simultaneous delivery of a chemother-
apeutic agent should elevate local concentrations of the drug with little escape to the
systemic circulation due to vessel occlusion. Combining gas chemoembolotherapy with
locoregional therapies such as thermal ablation and percutaneous ethanol injection
presents a nice prospect to enhance heat and alcohol trapping and more effectively
treat cancers.
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APPENDIX D
Microfluidic Generation of Acoustically Active Nanodroplets
D.1 Introduction
Liquid perfluorocarbon droplets have emerged in medical acoustics as acoustically
activatable emulsions for a variety of applications. The phase-shift of the inner core of a
perfluorocarbon (PFC) droplet from the liquid state to the gas state as a result of an ap-
plied ultrasound pressure is most commonly referred to as acoustic droplet vaporization
(ADV) [71]. While most ADV investigations have focused on droplets in the micrometer
range for intravascular procedures, there has been much recent interest in the utility of
sub-micrometer liquid perfluorocarbon droplets for extravascular applications such as
drug delivery, enhanced thermal ablation, and diagnostic imaging and tissue character-
ization [60; 194]. Capitalizing on the characteristically ‘leaky’ vasculature of many solid
tumors, sub-micrometer droplets may extravasate into the tumor interstitium through
inter-endothelial gaps and accumulate [91], or may be able to traverse the lymphatic
system. One main limitation of current methods to generate these nanodroplets is
the use of processing techniques such as emulsification [86] and sonication [116], which
result in polydisperse populations. Significant variation is reported in the activation
c© 2012 Wiley-VCH (wiley.com) Portions reprinted, from TD Martz, D Bardin, PS Sheeran, AP
Lee, and PA Dayton. “Microfluidic Generation of Acoustically Active Nanodroplets” Small, 2012
June; 8(12): 1876-1879.
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threshold due to the strong correlation between vaporization energy and perfluorocar-
bon droplet size [251; 77]. Additionally, the biodistribution of sub-micrometer ADV
agents may improve by narrowing the size distribution. Substantial clinical motivation
thus exists for a precise method to generate perfluorocarbon nanodroplets for use in
extravascular tumor therapies. The emergence of droplet-based microfluidic systems
has enabled the generation of droplets in the micrometer diameter range with high
uniformity [242; 236]; yet, the generation of nanodroplets from devices with microscale
geometry still presents a fundamental challenge. Previous microfluidic approaches to
produce nanodroplets have relied on the inherently inefficient dynamic sorting of small
satellite droplets (as small as 100 nm) from microscale droplet populations as the basis
of a monodisperse sub-micrometer emulsification system [236; 206; 248]. To overcome
this limitation, we hypothesized that by modulating the basic mechanism of droplet
generation to access a more favorable droplet formation regime [205; 247; 255], we could
yield an efficient approach for the generation of perfluorocarbon nanodroplets as the
primary emulsion.
D.2 Experimental Section
D.2.1 Reagent Preparation
The continuous phase lipid solution was prepared using a 9:1 molar ratio of DSPC
(Avanti Polar Lipids, Alabaster, AL) and DSPE-PEG5000 (Avanti Polar Lipids, Al-
abaster, AL) in saline (lipid concentration of 1.5 mg/mL). Lipid solution was combined
with glycerol (Fisher Scientific, Pittsburgh, PA) and Pluronic F-68 (Sigma Aldrich
Corporation, St. Louis, MO) in a 1:1:1 mL volumetric ratio. Liquid perfluoropentane
(FluoroMed, Round Rock, Texas) was utilized as the dispersed phase.
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D.2.2 Microfluidic Device Fabrication
The process for developing the microfluidic wafer has been previously described by
Hettiarachchi et al. [239] Briefly, microfluidic channels were designed using Illustrator
(Adobe, San Jose, CA) and printed at 20,000 dpi by CAD/ Art Services (Brandon, OR).
In a class 10,000 clean room, a silicon wafer was spin-coated with a UV-curable epoxy
(SU-8-25, Micro-Chem, Newton, MA) and exposed to UV light to develop the channels
as a negative mold. Bulk polydimethylsiloxane (PDMS) (Dow Corning, Midland, MI)
and a curing agent were cast over the wafer at a 10:1 ratio, and the mold was cured at
60◦ C for at least 8 h. Microfluidic chips were separated from the wafer and cleaned
along with the glass slides (2947 − 7525, Corning, Corning, NY) in a plasma cleaner
(Harrick Plasma, Ithaca, NY). The device components were exposed to a plasma field
under a controlled pressure of 500 mTorr for 3 min. Upon removal, the microfluidic
channels and glass slide were joined, creating a sealed microfluidic device. Then the
channels were filled with deionized water to stabilize the hydrophilic environment.
D.2.3 Optical Observation
The microfluidic device was secured to a moving stand on an inverted microscope
(Olympus IX71 microscope, Center Valley, PA) with a 50X NA = 1.0 objective. A
highspeed camera (Fastcam APX-RS, Photron, Inc., San Diego, CA) was used to cap-
ture images and videos of the device output.
D.2.4 Pressure Control Flow System
The reagent pump system was established in a similar manner to Korczyk et al. [256]
The pressure to control the flow system was supplied by a compressed nitrogen tank
connected in parallel to two precision pressure regulators that were used to control the
pressure to each reagent independently. A 60 max psi regulator was used to control the
259
Figure D.1: A) Diagram of pressure-controlled reagent flow, achieved via compressed
N2 driving the reagent through tubing to microfluidic inputs. B) Microscopy of flow-
focusing orifice illustrating tip-streaming, resulting in the generation of sub-micrometer
droplets. Perfluoropentane (center channel) is surrounded by lipid solution (outer chan-
nels). Arrows indicate direction of flow. C) Microscopy of droplets on the order of 800
nm in diameter (larger than shown in the example in (B)) taken downstream of the
orifice as the droplet stream widens, illustrating very small, uniform-size production.
continuous phase, and a 30 max psi regulator was used for the dispersed phase (R−800−
60 and R− 800− 30, Air-Trol Components, Inc., New Berlin, WI). The output of each
regulator was connected via Tygon S-54-HL tubing (Saint-Gobain Performance Plastics,
Akron, OH) to provide the pressure head to the headspace of a sealed and capped 3 mL
glass vial (Figure D.1a). Another length of tubing submerged in the reagent (typically
2 mL total) supplied the pressurized fluid to the microfluidic device. By placing a
positive pressure head in the vial, the reagent was transferred to the channels of the
microfluidic device, and the output rate controlled by manually adjusting the pressure
regulators. The system was allowed to stabilize for 1 min after pressure changes were
made before sample collection began.
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D.2.5 Optical Imaging and Sizing
Dimensions of the final microfluidic device were determined using Image J (NIH,
Bethesda, MD) and a calibrated slide reticule (Edmund Optics, Barrington NJ). The
orifice, PFP channel, and lipid solution channel, and filter spacing widths measured 12,
46, 45, and 23 µm, respectively. For micrometer sized droplets, diameter was likewise
determined optically. Sub-micrometer droplets could not be resolved optically, and were
instead collected in a pipette tip for light scattering or electron microscopy analysis.
Figure D.2: Particle size distribution produced by DLS for different submicrometer
samples produced by the same microfluidic device at different driving pressures. Sample
1 had a mean diameter of 850±150 nm, while Sample 2 had a mean diameter of 360±50
nm in the main peak. Also present in the measurement for Sample 2 are naturally
forming lipid vesicles less than 100 nm in diameter (confirmed by TEM images). For
this sample, the lipid vesicles had a mean diameter of 49 ± 7 nm. Each plot is an
average of 3 repeat data sets.
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D.2.6 DLS Sizing
A Malvern Nano ZS (Malvern Instruments Ltd., Malvern, Worcestershire, UK) was
used to determine the size of droplets in the sub-micrometer diameter range. Sub-
micrometer samples were diluted with 0.5 mL of phosphate buffered saline and placed
into a cuvette for testing. Debris less than 100 nm in diameter were assumed to be
lipid vesicles.
Figure D.3: TEM example of negatively stained sub-micrometer perfluorocarbon
droplets. The highly stained droplet circumference appears as a black ring around
the droplet core. Lipid vesicles present in the continuous phase can be seen in the
TEM image background as semi-circular particles with diameters less than 100 nm,
present in high quantities - in agreement with DLS measurements.
D.2.7 TEM and Sizing
To verify the presence of perfluorocarbon nanodroplets and corroborate the Malvern
sizing data, a negative staining procedure was used alongside TEM (Philips Tecnai 120
kV, Amsterdam, The Netherlands). The negative staining first consisted of plasma
treating the individual TEM grids for 90 s. 10 µL of the droplet sample was transferred
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via pipette onto the TEM grid and allowed to sit for 120 s. The TEM grid was dipped
in a bath of 1% uranyl acetate for 60 s, and allowed to dry prior to TEM imaging.
D.2.8 Acoustic Droplet Vaporization
To verify that the generated droplet samples could be vaporized, a procedure similar
to that described in Sheeran et al. [195] was utilized. In brief, a 3.2 MHz transducer
with a focal length of 3.45 cm was used to activate the droplets in a cellulose tube
submerged in a water bath at 37◦ C. Droplets within the optical focus were subjected
to manually triggered 100-cycle pulses with 1−2 s of rest between each trigger. Pressure
was increased in steps of approximately 0.15 MPa until the pressure was sufficient to
vaporize the majority (approximately 90% or greater) of the droplets in focus.
D.3 Results and Discussion
Our group recently demonstrated the feasibility of microfluidic generation of mi-
croscale ADV agents to achieve precision control of droplet size and uniform activation
[251; 255]. In this study, we advance upon this prior work with the development of a mi-
crofluidic system capable of generating populations of primary sub-micrometer droplets
with diameters as small as 300− 400 nm through two key refinements of the previously
explored systems. In the earliest study, syringe pumps were used to control input rates
of all reagents, but the mechanical variability inherent to syringe-pump driven systems
[256] led to a lower limit of approximately 7 µm in diameter [251]. By controlling the
dispersed perfluoropentane (PFP) phase with a custom pressure-controlled input simi-
lar to that used in prior studies [256; 257], droplet sizes were reduced to 3−5 µm [255].
Here, we demonstrate that pressure-controlled delivery of all reagents (Figure D.1a)
affords the ability to drive the microfluidic device into a tip-streaming regime [258]
with extremely low variability enabling sub-micrometer droplet production despite
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the fact that the orifice width is over an order of magnitude larger than the droplets
themselves (Figure D.1b). We also observed that increasing the viscosity of the con-
tinuous phase through the addition of glycerol greatly enhanced the ability to drive
droplet production stably in the sub-micrometer regime at the high pressures used.
Relative to satellite droplet sorting, advanced tip-streaming, as we demonstrate, allows
for efficiency in generating droplets in the sub-micrometer range, without filtration or
dynamic in-device separation.
By precisely varying the pressures and, consequently, the flow rates of the continuous
and dispersed phases, we were able to produce narrowly dispersed lipid-encapsulated
nano and microdroplets ranging from 360 nm to 11 µm with the same microfluidic device
(Table D.1). Although some variability was observed between devices generated from
the same mask, droplets between 3 and 11 µm were achieved by driving the dispersed
phase with 12− 15 psi with the continuous phase at 33− 35 psi. Droplets on the order
of 800−900 nm were achieved by driving the dispersed phase with 16−17 psi with the
continuous phase kept near 44−45 psi. By driving the dispersed phase with a pressure
of 19 − 20 psi while the continuous phase was kept at 50 psi, droplets on the order of
300− 400 nm were produced. Channel blowouts were observed when pressures on the
order of 60 psi were used to drive reagent flow.
Droplets larger than 1 µm were quantified with high speed light microscopy as
they exited the orifice. Smaller droplets could not be resolved with traditional light
microscopy, and hence were collected and then assessed by dynamic light scattering with
a Malvern Nanosizer (Figure D.2) after production (thus, production rate data was not
obtained for these flow conditions). Transmission electron microscopy (TEM) image
of a number of the samples were used to verify dynamic light scattering (DLS) results
(Figure D.3). The average diameter measured by TEM over 30 droplets was 312± 49
nm, which is in excellent agreement with the DLS measurements for the same sample
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(Figure D.2, Sample 1). One of the consequences of using a lipid-based continuous
phase in conjunction with microfluidics is a high degree of naturally occurring lipid
vesicles, typically on the order of 100 nm or less. In these experiments, the presence of
lipid vesicles was confirmed by both DLS and TEM, appearing as peaks on the order
of 30 − 70 nm in DLS measurements (Figure D.2), and resulting in a heterogeneous
background in TEM images composed of a high number of clearly visible non-PFC
particles below 100 nm in size (Figure D.3).
In order to confirm the resulting samples were acoustically vaporizable, droplets
were sonicated with 100-cycle pulses of varying amplitude at 3.2 MHz. As described
previously [251; 77; 195], the pressure required to vaporize droplets increases as droplet
size decreases. In this study, a peak rarefactional pressure of approximately 3.15 MPa
was sufficient to vaporize the majority of droplets in focus when the droplet size was
greater than approximately 7 µm in diameter. As expected, smaller samples required
substantially more pressure to vaporize. Droplets near 0.9 µm in diameter required
approximately 4 MPa to vaporize, while smaller droplets could not be vaporized due to
the maximum output limit of our ultrasound system (4.3 MPa). Activation thresholds
established from this study are in agreement with thresholds previously identified for
individual perfluoropentane droplets [251].
D.4 Conclusion
Our results demonstrate that sub-micrometer (and micrometer) droplets for acous-
tic droplet vaporization applications can be effectively generated using droplet-based
microfluidics. The pressure-controlled reagent delivery system crucially enabled the
quick and precise tuning of the continuous and dispersed phases to maintain constant
rates of flow and consistent tip-streaming. By contrast, in our prior studies utilizing
mechanical pumping, we were unable to maintain the tip-streaming of sub-micrometer
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droplets for sufficient time to collect samples. To our knowledge, this study is one
of the first examples of sub-micrometer production of primary liquid droplets from a
microfluidic device. Future studies are needed to determine the extent that similarly
small droplets can be produced with reagents other than those used here. The ability
to achieve sub-micrometer droplet production, as well as the ability to produce droplet
populations of uniform size, will have a significant impact in burgeoning medical appli-
cations requiring acoustically active nano- and microdroplets.
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APPENDIX E
Focused Ultrasound-Induced BBB Opening Using PCCAs
E.1 Introduction
Focused ultrasound (FUS)-induced blood-brain barrier (BBB) opening has been
shown to hold great promise for targeted drug delivery in the brain for the treatment
of central nervous system diseases, including Alzheimer’s [259], Huntington’s [260] and
Parkinson’s [261] diseases as well as brain cancers [262; 263]. Various therapeutic
agents, including antibodies [264], neural stem cells [265], siRNA [260], chemothera-
peutic molecules [266] and neurotrophic factors [261], have been delivered across the
BBB and shown capable of inducing therapeutic effects using this technology. The
FUS/microbubble- based drug delivery system relies on the capability of systemically-
administered and acoustically-activated microbubbles to noninvasively, transiently and
reversibly increase the cellular and vascular permeability of the BBB, thus allowing drug
molecules that are normally restricted within the vasculature to cross the barrier and
be delivered to the brain parenchyma. Previous studies by our group and others have
shown that the extent of the BBB opening, as characterized by the opening volume,
c© 2013 Elsevier Ltd. (elsevier.com) Portions reprinted, from CC Chen, PS Sheeran, SY Wu, OO
Olumolade, PA Dayton, EE Konofagou. “Targeted Drug Delivery with Focused Ultrasound-Induced
Blood-Brain Barrier Opening Using Acoustically-Activated Nanodroplets” J Control Rel, 2013; 172(3):
795-804.
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opening size and opening duration based on magnetic resonance or fluorescence imaging,
is directly linked to the acoustic energy applied during sonication [225; 267; 226; 268]
and the physicochemical properties of the microbubbles used [264; 269; 175]. Informed
selections of the acoustic exposure parameters and the type of contrast agent are crit-
ical for an effective drug delivery while minimizing the possibility of side effects. Not
accounting for these factors may result in unintended adverse bioeffects [270] or even
undesired brain damage in more severe situations [225].
Real-time passive acoustic emissions from the oscillating microbubbles could of-
fer means to identify signature characteristics that allow for the differentiation of the
complex behaviors of microbubble cavitation during sonication [271; 272; 227; 226].
During stable cavitation, the magnitude of microbubble oscillation depends on the
acoustic pressure applied. Such behavior has been assumed to induce sufficient forces
on the endothelium through either radiation or shear forces induced by microstreaming
around the microbubbles [226]. Shear stress-induced endocytosis could be a potential
mechanism to increase the transcellular permeability [273]. As the acoustic energy is in-
creased, a larger radial microbubble expansion could induce inertial cavitation, leading
to microbubble collapse and potentially generating liquid microjets to form pores within
the cell membrane improving the cellular update of nanoparticles and drugs [274]. The
disruption of the tight junction proteins between the adjacent brain endothelial cells
during inertial cavitation could increase the paracellular BBB permeability [275]. Re-
gardless of the exact mechanism, the cavitation emission during sonication could be
calculated and correlated with the outcome of the BBB opening, thus suggesting that
the acoustic signature of the microbubbles could serve as a predictive indicator for
estimating the amount of drug delivered to the targeted region [271].
Currently, FUS-induced BBB opening has only been achieved using commercially
available [259; 175; 276] or in-house manufactured [208; 228] gaseous microbubbles.
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Despite their utility as mediating vehicles, microbubbles can only be used as vascu-
lar contrast agents since their size (typically 1 − 10 µm) prevents their extravasation,
limiting the cavitation effects to regions at or near the vessels. Using fluorescence mi-
croscopy, our group [277] previously showed that homogeneous distribution of relatively
larger dextran molecules (10 kDa and 70 kDa) was more difficult to achieve than with
smaller ones (3 kDa), highlighting the need for an agent with greater ability to induce
molecular diffusion beyond the cerebral vasculature. In addition, gaseous microbubbles
have short in vivo circulation half-life, typically on the order of minutes, thus requiring
re-administration if repeated sonication is desired.
Phase-shift perfluorocarbon droplets may potentially offer the solution to address
these issues [194; 278]. Several groups have demonstrated the therapeutic utility of
this alternative class of ultrasound contrast agents for applications such as targeted
vessel occlusion [85], ablation enhancement [54], and drug delivery to solid tumors
[53; 52]. Initially in the liquid state, nanoscale droplets show high stability in circulation
(i.e., on the order of hours) and can be generated in sizes small enough to extravasate
through leaky vasculature; but once exposed to sufficient rarefactional pressures they
expand to form microbubbles capable of oscillation in a similar fashion as traditional
microbubbles - ideal for ultrasound-mediated imaging and therapy. For the purposes
of BBB opening, these agents may present a unique opportunity. Because droplet
activation is dependent on the local rarefactional pressure, the microbubbles will only
be generated within the narrow focal region where acoustic properties are the strongest,
ensuring that the therapeutic effect is limited to the desired treatment areas [222; 279].
Once initial BBB permeabilization is achieved, the droplets remaining will be small
enough for potential extravasation during subsequent passes through the vasculature.
Once entered into the interstitial space behind the barrier, the droplets could then
be acoustically activated to form vaporized gaseous bubbles outside the constraints
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of the cerebral microvessels. Therefore, the possibility exists for an extravascularly
activated contrast agent for enhanced drug delivery at sites that are located deeply
in the brain tissue or at regions with relatively low vasculature density. Activation
of typical nanodroplet formulations requires acoustic pressures which are much higher
than those used for FUS-induced BBB opening [88; 114], but recent studies have shown
that it is possible to generate nanodroplets from highly volatile perfluorocarbons by
pressurizing preformed microbubbles and condensing the gas core into liquid phase
during slow cooling [280; 281]. This methodology can produce uniform nanodroplet
size distributions with peak diameters near 200 − 300 nm that vaporize at acoustic
pressures on the order of those required for BBB opening with microbubbles.
The main objective of the present study was to show the feasibility of utilizing phase-
shift nanodroplets as the mediating agents for targeted drug delivery using FUS-induced
BBB opening in vivo. Conventional in-house generated microbubbles with the same
lipid shell composition and perfluorocarbon gaseous core were used as the “standard”
for comparing the efficiency of BBB opening based on targeted delivery of fluorescent
dextran molecules. A series of clinically relevant acoustic exposure conditions were used
to further demonstrate the safety of this technology for drug delivery in the brain.
E.2 Materials & Methods
E.2.1 Contrast Agent Generation
Nanodroplets and microbubbles were formulated using the same lipid composition
containing 90 mol% DSPC and 10 mol% DSPE-PEG-2000 (Avanti Polar Lipids, Al-
abaster, AL). The perfluorobutane gas (PFB, 99 wt.% purity) used for contrast agent
generation was obtained from FluoroMed (Round Rock, TX). All chemicals were used
as purchased without further purification.
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Microbubbles were generated via mechanical agitation using a Vialmix shaker (Bris-
tol Myers Squibb, New York, NY). A Multisizer III particle counter (Beckman Coulter,
Opa Locka, FL) with a 30 µm aperture was used to measure the microbubble suspen-
sion size distribution and concentration. Nanodroplets were generated via microbubble
condensation, in which pre-formed microbubbles of volatile compounds were reverted
to the liquid state by application of reduced temperature and increased ambient pres-
sure [280; 281]. Briefly, PFB microbubbles were generated as described above and
allowed to cool to room temperature. The vial containing the microbubbles was then
immersed in an isopropanol bath maintained at a temperature between −7◦ C and
−10◦C for approximately 1 min. The vial was subsequently connected to an adjustable
air-pressure supply, and the headspace pressure inside the microbubble vial was in-
creased by 30 − 70 kPa for approximately 30 s to facilitate condensation. A Malvern
Nano Zetasizer (Malvern Instruments Ltd., Malvern, Worcestershire, U.K.) was used
to measure the size distribution of the droplet emulsion generated.
E.2.2 In Vitro Acoustic Nanodroplet Vaporization Setup
Acoustic nanodroplet vaporization was investigated in vitro using an experimental
setup described previously [195]. An ultra-high-speed framing camera with a 24-frame
buffer (SIMD24; Specialised Imaging, Simi Valley, CA) was interfaced with an inverted
microscope (IX71; Olympus, Center Valley, PA) with a 100x (NA = 1.0) water immer-
sion objective. An acrylic-lined, continuously degassed water bath was mounted to the
microscope and maintained at 37◦C. The optical resolution of the system allowed ob-
servation of particles larger than approximately 500 nm. A 1 MHz spherically-focused
piston transducer with a 2.2 cm diameter and a focal length of 3.75 cm (IL0106HP;
Valpey Fisher Corp., Hopkinton, MA) was aligned with the optical focus by the use of
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a calibrated needle hydrophone (HNA-0400; Onda Corp., Sunnyvale, CA). The trans-
ducer was driven by sinusoidal 20-cycle pulses generated by a manually-triggered ar-
bitrary waveform generator (AFG 3101; Tektronix, Inc., Beaverton, OR) amplified 60
dB (A500; ENI, Rochester, NY). The sinusoid amplitude was adjusted to change the
peak rarefactional pressure experienced by the droplets in focus. The manual trig-
ger was synchronized with the input of the highspeed camera in order to simultane-
ously capture a video of droplet vaporization. Droplet emulsions were diluted 50% in
phosphate-buffered saline (PBS) and pumped through a nearly optically and acousti-
cally transparent microcellulose tube (Spectrum Laboratories, Inc., Greensboro, NC).
The focal plane of the tube was controlled via a 3-axis micropositioner (MMO-203;
Narishige Group, East Meadow, NY). The ultra-high-speed camera was set to operate
at 20 million frames per second with a 30 ns exposure such that many frames could be
captured within a single cycle of the ultrasound pulse. The transducer was calibrated
at focus by the needle hydrophone (HNA-0400).
E.2.3 Animal Preparation
All experiments were performed in accordance with procedures approved by Columbia
University Institutional Animal Care and Use Committee. A total of 80 male C57BL/6
mice (Harlan Laboratories; Indianapolis, IN) weighing 20-25 g were used for this study.
The animals were divided into two experimental groups using either nanodroplets
(group #1) or microbubbles (group #2) as the contrast agents for FUS-induced BBB
opening. The groups were further divided into 14 cohorts based on the experimental
protocol as listed in Table E.1. Before sonication, each mouse was anesthetized using
1−2% isoflurane-oxygen mixture (SurgiVet, Smiths Medical PM; Norwell, MA) and its
hair on the scalp was removed with an electric clipper and a depilatory cream. A mod-
ified 27-gage 1.5” butterfly catheter (Terumo Medical; Somerset, NJ) was inserted into
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the tail vein for contrast agent injection. The animal body temperature was maintained
throughout the experiment using a heated pad.
Figure E.1: Experimental setup of in vivo FUS-induced BBB opening and transcranial
cavitation detection.
E.2.4 In Vivo BBB Opening Ultrasound Setup
The experimental setup, as shown in Figure E.1, was used as previously described
[228; 277]. A single-element, spherical FUS transducer (center frequency: 1.5 MHz; fo-
cal depth: 60 mm; Imasonic, Besancon, France) was driven by a function generator (Ag-
ilent Technologies, Palo Alto, CA) through a 50 dB power amplifier (E&I, Rochester,
NY). A confocal pulse-echo transducer (center frequency: 10 MHz; focal length: 60
mm; Olympus NDT, Waltham, MA), which was attached to a computer-controlled
3D positioning system (Velmex, Lachine, QC, Canada), was used to target specific
brain structures following procedures published previously [175]. The pulse-echo trans-
ducer, which was driven by a pulser-receiver system with a 20 dB amplification in the
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receive-only mode (Model 5800; Olympus NDT), was connected to a digitizer (Gage
Applied Technologies, Lachine, QC, Canada) to passively acquire acoustic emissions
from activated nanodroplets and microbubbles within ±1 V input range.
The peak-rarefactional pressure profile used in the present study was estimated
based on previously performed calibrations done in degassed water with a 0.2 mm di-
ameter needle hydrophone (Precision Acoustics; Dorchester, Dorset, UK) [175]. The
pressure amplitude values were corrected to account for 18.1% attenuation through the
murine skull [175], whereas the axial and lateral full-widths at half-maximum intensi-
ties of the beam were 7.5 mm and 1 mm, respectively. The acoustic exposure reported
throughout the present study is given in terms of the peak-rarefactional pressure am-
plitudes.
E.2.5 In Vivo BBB Opening Protocol
Pulsed FUS (pulse length: 6.7 ms; pulse repetition frequency: 5 Hz; duration: 5
min) at acoustic pressures ranging between 0.15 and 0.60 MPa was applied transcra-
nially to the targeted left hippocampus of the mouse brain while the right hippocampus
served as the control. Prior to any contrast agent administration, a 30-s sonication using
the same acoustic parameters was applied in order to measure the baseline background
signal needed in the acoustic emission analysis, as described below. The injected con-
trast agent samples were freshly diluted before each animal injection. For group #1, a
60 µL nanodroplet suspension was first diluted at 50 vol.% using PBS to an estimated
final concentration of 5×109 #/mL based on 100% condensation during production. It
was then co-administered, via bolus injection, with 60 µL 3 kDa dextran solution (Life
Technologies; Carlsbad, CA) at 2 mg/mL concentration through the tail vein 10 s prior
to each sonication. For group #2, the microbubble suspension was diluted in PBS to
a final concentration of 8 × 108 #/mL, and 60 µL of the diluted microbubble sample,
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together with 60 µL dextran solution was bolus injected following the same protocol.
In addition, two sham cohorts to which no ultrasound was applied were injected with
either nanodroplets or microbubbles and fluorescent dextrans to serve as the basis for
comparison in the fluorescence imaging analysis (see description below).
A 1-h period was allowed after sonication to enable the dextran to circulate through-
out the vasculature and diffuse into the brain parenchyma. At the end of the allotted
time, the animal was sacrificed by transcardiac perfusion using 30 mL PBS for 5 min
followed by 60 mL 4% paraformaldehyde for 8 min. The mouse brain was extracted
from the skull, post-fixed in 4% paraformaldehyde overnight, and then prepared for
either frozen (60 µm) or paraffin (6 µm) sections. The frozen sections were used to ana-
lyze fluorescence intensity in order to determine the BBB opening magnitude, while the
paraffin sections were used to study the safety of the procedure through histological
examinations of representative brain samples from each treatment cohort via hema-
toxylin and eosin (H&E) staining. The histology image interpretation was performed
blindly, i.e., without knowledge of the FUS exposure parameters.
E.2.6 Fluorescence Imaging Analysis
Bright-field and epi-fluorescence images of the brain sections were captured using an
Olympus DP30BW digital camera mounted on an upright Olympus BX61 microscope.
The extent of BBB opening was determined based on the quantification of dextran
delivery into the targeted hippocampus. The fluorescence intensity measurement was
similarly performed following our previously published protocol [282]. Briefly, a section
representing the ventral-dorsal midline, as determined by anatomical landmarks, was
first selected, and 4 adjacent sections were then selected on either the dorsal or the
ventral side of the midline. The sonicated (left) and the control (right) hippocampus
was manually outlined using MATLAB (The Mathworks; Natick MA), and the spatial
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average of fluorescence intensity in the region of interest (ROI) was calculated using
ImageJ (National Institutes of Health, Bethesda, MD). The relative fluorescence en-
hancement was calculated by dividing the difference in fluorescence intensity between
the left and right ROIs by the spatial average of the right hippocampus. A fluorescence
intensity threshold, defined as twice that of the standard deviation of the control ROI,
was applied on each image in order to separate the fluorescence signal from dextran
molecules from the background tissue autofluorescence. For each brain, the reported
fluorescence enhancement was thus approximated as the sum of the relative fluorescence
intensity from all 9 sections. A successful dextran delivery for an individual brain was
concluded if the fluorescence enhancement was higher by two standard deviations rel-
ative to the average of the corresponding sham cohort. The fluorescence enhancement
value for each of the 12 experimental conditions was obtained by averaging all mice
sonicated under the same acoustic exposure. 100% opening efficiency was determined
when all the mice evaluated in each cohort showed significant dextran delivery.
E.2.7 Acoustic Emission Analysis
The acoustic emission analysis was performed similarly to that described previously
[228]. In order to quantify the acoustic responses of the vaporized nanodroplets or
microbubbles, two cavitation parameters were calculated: stable cavitation dose (SCD)
and inertial cavitation dose (ICD). The SCD, which was associated with the stable
nonlinear oscillation of the contrast agents,was quantified based on the peak amplitude
of the spectra around each harmonic frequency of each pulse in the range between
3 and 9 MHz over the first minute of sonication. The ICD, which was associated
with the inertial energy of the collapsing microbubbles, was quantified based on the
broadband emission after filtering the harmonic and ultraharmonic signals using a comb
filter with rectangular rejection bands centered around the harmonic and ultraharmonic
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frequencies (rejection bandwidths of 350 kHz and 100 kHz, respectively) across the same
frequency range over the same sonication duration. The net emission from the contrast
agents could then be determined by subtracting the background signal measured using
the same acoustic exposure prior to nanodroplet or microbubble administration.
E.2.8 Statistical Analysis
An unpaired two-tailed Student’s t-test was performed to evaluate the significance
of the fluorescence enhancement between the sonicated and the control hippocampus
under each of the acoustic exposures. In addition, unpaired two-tailed Student’s t-
tests were used to determine the significance of the acoustic emission responses from
the contrast agents across different sonication pressures. All statistical analyses were
performed using GraphPad Prism (La Jolla, CA).
E.3 Results
E.3.1 Contrast Agent Generation
The PFB phase-shift nanodroplet emulsions appeared partially translucent by vi-
sual inspection and were similar in stability and size to previously reported results
[281]. Figure E.2A shows a representative number-weighted size distribution obtained
by averaging 3 separate samples (3 measurements per sample). The size distributions
measured in the present in vivo study were similar across all samples, and fell within
the instrumental uncertainty of the Zetasizer. The averaged number-weighted mean,
median and mode diameters across all samples were 204 ± 10 nm, 209 ± 29 nm and
180± 25 nm, respectively.
The mechanical agitation method produced an opaque and milky microbubble sus-
pensions that were stable during the experimental timeframe. Figure E.2B shows a
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Figure E.2: Representative size distributions of nanodroplet (A) and microbubble (B)
suspensions as measured by Malvern Zetasizer and Coulter Multisizer, respectively. (A)
The averaged number-weighted mean, median and mode diameters for the nanodroplet
sample shown were 206 ± 93 nm, 190 nm and 164 nm, respectively. All nanodroplet
samples were diluted by 50 vol.% prior to injection. (B) The averaged number-weighted
mean, median and mode diameters for the microbubble sample shown were 1.36± 0.02
µm, 1.10 µm and 0.79 µm, respectively. All microbubble samples were diluted to 8×108
particles/mL prior to injection.
representative number-weighted size distribution of the microbubble sample as mea-
sured by the Multisizer III. The size distributions among all microbubble suspensions
used throughout the study were found to be statistically the same, and the averaged
number-weighted mean, median and mode diameters were 1.36± 0.32 µm, 1.08± 0.23
µm and 0.86± 0.35 µm, respectively.
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Figure E.3: Still-frame images showing nanodroplet activation within the first two cy-
cles of the pulse as a function of sonication pressure. Frames A-D and G-J were taken
in the first rarefactional half-cycle, while E-F and K-L were taken in the following
compressional cycle. No nanodroplet vaporization was detected at 0.35 MPa (left)
while micron-scale acoustically-responsive bubbles were seen expanding in the rarefac-
tional cycle at 0.45 MPa (G-J). When transitioned to the next positive pressure cycle
(K, L), the newly formed bubbles were observed to respond to the acoustic pressure
by compressing until no longer visible in the field of view. Times shown are relative to
the start of the pulse, and the scale bars indicate 5 µm.
E.3.2 In Vitro Acoustic Nanodroplet Vaporization
In order to confirm the nanodroplets generated via microbubble condensation were
acoustically vaporizable, high-speed optical microscopy was used to visually verify the
vaporization of individual stationary droplets at pressures relevant to our in vivo ex-
periment. Figure E.3 shows that at peak-rarefactional pressure of approximately 0.35
MPa, no detectable number of vaporized bubbles appeared within the focal plane. How-
ever, when the pressure amplitude was increased to 0.45 MPa, vaporized bubbles were
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observed almost immediately upon exposure to the ultrasound beam. These acous-
tically activated bubbles were within the micrometer size range and appeared to be
acoustically responsive (i.e., they could expand and contract according to the pressure
change during a single pulse). The activation of sub-micron droplets was repeatedly
observed at higher pressures (up to 1.1 MPa tested in the current study) using the
in vitro setup, complementing our finding of the in vivo pressure threshold of BBB
opening using nanodroplets (see discussion below).
Figure E.4: Fluorescence images of the two sham cohorts for which either nanodroplets
(top) or microbubbles (bottom) were co-injected with fluorescent dextran but no
ultrasound was applied. No significant fluorescence intensity difference was detected
between the two hippocampi. The quantified fluorescence enhancement value was used
as the baseline for comparison in order to determine whether sufficient amount of
dextran molecules were delivered into the targeted region. The scale bar in A depicts
1 mm.
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Table E.1: Summary of the Experimental Groups
Group Contrast agent Number of mice per experimental condition1
Acoustic Pressure (MPa)
Sham 0.15 0.225 0.30 0.45 0.60
1 Nanodroplet 6 6 6 7 7 8
2 Microbubble 5 7 7 7 7 7
1 Number shown including up to 2 mice per experimental condition used
for histology examination
Table E.2: Summary of the Fluorescence Imaging Analysis
Contrast Acoustic Fluorescence Number of mice with significant
agent pressure enhancement ± dextran delivery/total number
(MPa) S.D. (%) of mice evaluated using
fluorescence microscopy
Nanodroplet Sham 21.41± 25.97 0/6
0.15 11.04± 30.75 0/5
0.225 12.73± 38.81 0/5
0.30 18.70± 36.07 1/6
0.45 91.84± 67.91 3/5
0.60 155.09± 55.03 7/7
Microbubble Sham −7.67± 15.41 0/5
0.15 5.95± 17.04 0/5
0.225 72.26± 114.28 3/5
0.30 184.10± 110.77 5/5
0.45 353.64± 46.23 5/5
0.60 487.82± 271.31 5/5
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E.3.3 In Vivo FUS-Induced BBB Opening
Using fluorescently-labeled 3 kDa dextran as a model drug molecule, the extent
of the FUS-induced BBB opening could be quantified as the relative fluorescence en-
hancement in the sonicated hippocampus over the control. The two sham cohorts, for
which no ultrasound was applied, did not show any change in fluorescence intensity be-
tween the two hemispheres (Figure E.4). Quantified fluorescence enhancement results
confirmed this observation as no detectable increase in fluorescence intensity between
the two ROIs was calculated (Table E.2). For the rest of the 12 experimental con-
ditions, the measured fluorescence enhancement was compared to their corresponding
sham cohort in order to determine whether sufficient amount of dextran molecules were
delivered into the targeted region.
Following the systemic administration of nanodroplets and subsequent BBB open-
ing, a significant increase in dextran delivery in the targeted ROI was observed at 0.45
and 0.60 MPa (60% opening efficiency with P = 0.047 and 100% opening efficiency
with P = 0.0002, respectively) while only up to 33% of the animals evaluated showed a
significant fluorescence enhancement when sonicated at pressures below 0.45 MPa (Ta-
ble E.2). Due to the inconsistency across animals, there was no statistically significant
(P > 0.56) increase in fluorescence enhancement to clearly indicate BBB opening with
dextran delivery at sonication pressures ranging between 0.15 and 0.30 MPa (Figure
E.5A). At pressures above 0.45 MPa, fluorescence was observed not only within or near
large vessels, but diffusely distributed across the hippocampi (Figure E.6D and E).
Following the systemic administration of microbubbles and subsequent BBB open-
ing, a significant fluorescence enhancementwas detected for all mice when sonicated at
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Figure E.5: Normalized fluorescence enhancement between the targeted and the control
hippocampi using either nanodroplets (A) or microbubbles (B) to mediate BBB open-
ing at distinct sonication pressures. The normalized fluorescence enhancement with
pressure followed a linear relationship with correlation coefficient R2 being 0.76 and
0.94 for nanodroplets and microbubbles, respectively. Significant dextran delivery was
observed at pressures higher than 0.45 MPa using nanodroplets while the BBB opening
threshold was decreased down to 0.30 MPa when microbubbles were administered. All
numbers are reported as mean ± standard deviation. (ns: not significant; ∗: P < 0.05;
∗∗: P < 0.01; ∗∗∗: P < 0.001).
pressures including and above 0.30 MPa (P < 0.005). A similar inconsistency of dex-
tran delivery across animals was seen at 0.225 MPa that only 3 out of 5 mice showed
significant fluorescence enhancement in the targeted ROI (Table E.2). Thus, no suf-
ficient statistical difference (P > 0.16) could be obtained to unequivocally show BBB
opening at pressures below 0.30 MPa (Figure E.5B). The detectable fluorescence signal
was predominately contained within vessels at 0.30 MPa but more diffusely distributed
throughout the targeted region at 0.45 MPa, indicating a more homogenous distribution
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Figure E.6: Representative fluorescence images comparing the targeted and the control
(insets) hippocampi when nanodroplets (top) or microbubbles (bottom) were used to
mediate BBB opening at various sonication pressures. The left hippocampus was soni-
cated in the presence of either nanodroplets or microbubbles and fluorescently-labeled
3 kDa dextran. Sonications were achieved at distinct peak-rarefactional pressures: 0.15
MPa (A, F), 0.225 MPa (B, G), 0.30 MPa (C, H), 0.45 MPa (D, I) and 0.60 MPa
(E, J). The scale bar in A depicts 1 mm.
of dextran molecules (Figure E.6H and I). At 0.60 MPa, heterogeneous spots of partic-
ularly high levels of fluorescence in combination with diffusely distributed fluorescence
was observed (Figure E.6J).
For each acoustic pressure, microbubbles produced greater fluorescence enhance-
ment compared to nanodroplets. The normalized fluorescence enhancement with pres-
sure followed a linear relationship with correlation coefficients at 0.76 and 0.94 for
nanodroplets and microbubbles, respectively. The pressure threshold, at which signif-
icant fluorescence enhancement was detected in comparison to the sham animals, was
higher for the nanodroplets (0.60 MPa) than that for the microbubbles (0.30 MPa), al-
though the percent enhancement values at the threshold pressures were not statistically
different (P = 0.56).
E.3.4 Contrast Agent-Dependent BBB Opening Threshold
Figure E.7 shows the quantitative acoustic emission results detected before and after
the contrast agent administrations at various sonication pressures. For nanodroplets,
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Figure E.7: Quantified acoustic emission detected during BBB opening at various
sonication pressures. Stable cavitation implied that vaporized nanodroplets or mi-
crobubbles underwent stable nonlinear oscillation during sonication, while inertial cav-
itation signified particle fragmentation. Significant SCD increase was detected after
nanodroplet injection at the highest pressure level (A), but no significant ICD increase
was measured (B). On the other hand, significant increase of SCD was detected for
all pressures after microbubble administration (C), and ICD increase was detected at
the highest acoustic exposure level (D). All numbers are reported as mean ± standard
deviation. (ns: not significant; ∗: P < 0.05; ∗∗∗: P < 0.001).
the quantified SCD showed significant increase (P < 0.0001) at 0.60 MPa (Figure
E.7A), corresponding to the significant dextran delivery detected based on fluorescence
microscopy. However, no statistical difference was determined at 0.45 MPa (P = 0.21)
despite a 90% mean signal increase after nanodroplet administration owing to the large
variations among different mice. The SCD increase followed a linear relationship with
the sonication pressure (R2 = 0.99). The quantified ICD, on the other hand, showed
no detectable inertial cavitation dose across all pressures (Figure E.7B), implying that
no significant vaporized nanodroplet fragmentation was detected during sonication.
286
The acoustic emission results for the microbubble group are shown in Figure E.7C
and D. Interestingly, the SCD showed significant increase (P < 0.0005) for all pressure
levels after microbubble injections regardless of the outcome of the BBB opening (Figure
E.7C). Similar to the nanodroplet group, the SCD increase followed a linear correlation
with the FUS pressure amplitude (R2 = 0.93). The ICD measurement showed slightly
significant signal increase after microbubble injection at 0.60 MPa (P = 0.017) but
not at other pressure levels, indicating that microbubbles underwent inertial cavitation
during sonication only at the highest acoustic energy exposure (Figure E.7D).
Figure E.8: Correlation between differential stable cavitation dose (SCD) and fluores-
cence enhancement. The SCD was normalized based on the background emission signal
measured prior to contrast agent injection. Linear correlations were obtained for both
(A) nanodroplets (R2 = 0.74) and (B) microbubbles (R2 = 0.67).
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Figure E.9: Stable cavitation dose (SCD)-indicated BBB opening threshold. The SCD
was grouped based on whether significant dextran delivery was detected. Each indi-
vidual brain was concluded to have significant BBB opening when the difference in
fluorescence intensity between the sonicated and the control hippocampi was two stan-
dard deviations greater than the average value obtained for the corresponding sham
group. Sonication using microbubbles as the contrast agents produced a much wider
range of SCD values comparing to when nanodroplets were used. The SCD threshold
for predicting BBB opening appeared to be contrast agent dependent. 7 out of 10 mice
showed significant dextran delivery with SCD values greater than 74 V·s using nan-
odroplets while 92.3% of the animals showed significant dextran delivery at SCD above
1.4 kV·s using microbubbles. The slightly weaker threshold for the nanodroplet group
indicated secondary mechanism other than cavitation could induce the BBB opening.
(∗: P < 0.05; ∗∗∗: P < 0.001).
In order to test whether acoustic emissions could be used to predict the magnitude
of the BBB opening, the relative fluorescence enhancement was plotted against the
SCD for all sonications using each contrast agent (Figure E.8). Both agents showed
relatively good linear correlations between these two parameters (R2 = 0.74 for nan-
odroplets and R2 = 0.67 for microbubbles). A cavitation dose opening threshold can
be derived when SCD was grouped based on whether significant dextran delivery was
detected [271] (Figure E.9). For the mice sonicated in the presence of nanodroplets,
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a statistically higher (P < 0.0001) stable cavitation emission was detected for cases
where significant fluorescence enhancement was measured. The highest SCD value, at
which no evidence of dextran delivery was detected, was 74 V·s. Out of the 10 animals
that showed significant fluorescence increase, 3 mice (30%) had their SCD lower than
74 V·s, suggesting that this level could be used as the threshold for predicting successful
FUS-induced BBB opening using nanodroplets as the contrast agents.
Interestingly, the acoustic threshold of BBB opening appeared to be contrast agent
dependent. For the microbubble group, the highest SCD value, for which no detectable
dextran delivery was observed, was 1.4 kV·s, significantly higher (P < 0.0001) than the
SCD threshold found for the nanodroplet group. A much more prominent threshold was
held for group #2, for 1 out of 15 mice (6.7%) with significant fluorescence enhancement
had a SCD lower than 1.4 kV·s. Despite the wider range of the calculated SCDs,
in which successful BBB opening was detected, a statistical difference was obtained
(P = 0.04) between cases with or without significant dextran delivery. The threshold
for predicting FUS-induced BBB opening in the presence of microbubbles was therefore
concluded to be 1.4 kV·s (Figure E.9).
E.3.5 Safety
Histological evaluation was performed in order to assess for potential tissue damage
caused by the procedure. Figure E.10 shows the bright-field microscopic images taken
of representative brain samples at 0.45 and 0.60 MPa. These two pressure amplitudes
were chosen since a relatively consistent BBB opening was detected only at these pres-
sure levels for both groups. Close examinations did not reveal any discrete damage
sites, such as clusters of dark neurons, small erythrocyte extravasations, hemorrhage
or microvacuolations at 0.45 MPa for either the nanodroplet or the microbubble group
(Figure E.10 top). A few (< 10) dark neurons were identified from 3 nonadjacent
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sections of the representative brain sample that was sonicated at 0.30 MPa using nan-
odroplets (Figure E.11). No other tissue damage indicators were observed, indicating
that this could be an artifact due to inadequate perfusion-fixation [283]. However,
small clusters of extravasated erythrocytes in addition to a few dark neurons were ob-
served for a sample from the microbubble/0.60 MPa cohort (Figure E.10O). Less than
10 clusters were found throughout the sonicated region across all sections, indicating
minor tissue damage. The larger portion of the targeted hippocampus appeared to be
normal and the neurons appeared to be unaffected (Figure E.10M).
Figure E.10: Representative histological images of the targeted and control hippocampi.
The animals were sacrificed 1 h after sonication. (Left) No erythrocyte extravasations,
dark neurons, gross hemorrhage or microvacuolations were observed when nanodroplets
were used to mediate BBB opening at either 0.45 MPa or 0.60 MPa. (Right) When
microbubbles were used, erythrocyte extravasations or dark neurons were not seen at
0.45 MPa. However, small clusters of erythrocyte extravasations and a few dark neurons
were observed (arrow heads in O), indicating minor damage, after sonication at 0.60
MPa. The boxed regions in all 4x images are further zoomed into 10x. The scale bars
in A and C depict 1 mm and 100 µm, respectively.
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Figure E.11: Histological images showing dark neurons when nanodroplets were used
to induce BBB opening at 0.30 MPa. Less than 10 dark neurons were identified from
3 nonadjacent sections of the brain. No other tissue damage markers were observed,
indicating that this could be an artifact due to inadequate perfusion-fixation [283]. The
scale bars in A and C depict 1 mm and 100 µm, respectively.
E.4 Discussion
The current study utilized acoustically-activated nanodroplets as a new class of con-
trast agents to facilitate targeted drug delivery in the brain after FUS-induced BBB
opening in mice. Though similar agents have been used in other therapeutic applica-
tions, to the best of our knowledge, this is the first study that has explored the benefits
of a nanodroplet-based approach to FUS-induced BBB opening. Using fluorescent
dextran as a model drug, the extent of the BBB opening was quantified and compared
between nanodroplets and the conventional contrast agent, i.e., microbubbles (Figs. E.5
and E.6). The two agents were compositionally the same - having lipid-encapsulated
perfluorobutane cores - but the nanodroplet approach afforded taking advantage of the
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benefits of both the liquid and gaseous states of the cores. The acoustic emission gen-
erated from the contrast agents during sonication was recorded and analyzed in order
to gain insights to their cavitation characteristics (Figure E.7). A linear correlation
between BBB permeabilization, as indicated by the relative fluorescence enhancement
within the targeted hippocampus, and the acoustic emission, as characterized by the
SCD, was found for both nanodroplets (R2 = 0.74) and microbubbles (R2 = 0.67) (Fig-
ure E.8). Interestingly, the acoustic threshold at which a significant dextran delivery
was observed appeared to be contrast agent dependent (Figure E.9). Our results sug-
gested that future contrast agent-specific monitoring during FUS-induced BBB opening
might be needed.
The high-speed microscopy results confirmed that the nanodroplet samples were
acoustically vaporizable at exposure conditions similar to that used during BBB open-
ing in vivo (Figure E.3). The vaporization pressure threshold detected in vitro corre-
sponded to our in vivo estimation remarkably well. While it was possible that nan-
odroplet vaporization at pressures lower than 0.45 MPa could still occur, it was more
likely that the number of activated nanodroplets was too low to cause any detectable
fluorescence enhancement. Thus, nanodroplet-mediated dextran delivery to the tar-
geted hippocampus could not be consistently achieved until the sonication pressure
was higher than 0.45 MPa (Table E.2). For the purpose of direct comparison, the
droplets used in this study were formed from perfluorobutane. While the pressures
used were sufficient to cause some droplet vaporization, other studies have shown that
highly efficient vaporization at frequencies near 1 MHz required pressures on the or-
der of 1 MPa or greater [280; 284]. Further studies are needed to develop different
nanodroplet formulations in order to decrease the in vivo vaporization threshold by
incorporating more volatile perfluorocarbons, such as perfluoropropane [281]. Addi-
tionally, the not-yet-optimized droplet formulation could explain the lower fluorescence
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enhancement observed using nanodroplets than that of microbubbles even though the
injection amount of the former was much greater (Figure E.5).
Previous work reported by our group and others have been focusing on increasing the
delivered dose and distribution by optimizing ultrasonic parameters and microbubble
characteristics, including peak-rarefactional pressure [267], pulse repetition frequency
[277], pulse length [282] and microbubble size [208; 228]. Choi et al. [277] showed
that homogenous distribution of 3 kDa dextran molecules was possible by incorporat-
ing short ultrasonic pulses to allow sufficient microbubble replenishment at the focus
during sonication. The utilization of acoustically vaporized nanodroplets in this paper
produced a similar homogenous dextran distribution throughout the targeted volume
and was more prominent when compared to microbubbles under the same acoustic
exposure settings (Figure E.6D-E and E.6I-J). Similar to our previous studies, fluores-
cence was not only detected within or near large vessels but diffusely distributed within
the hippocampus, thus showing greater promise for delivery of therapeutic agents to a
wider range of cellular targets outside the microvasculature. As a preliminary feasibility
study, the sonication parameters used in the current paper were simply adapted based
on our previous FUS-induced BBB opening experiments using microbubbles. There-
fore, it is possible that nanodroplet-specific pulse sequence could be custom designed
to further enhance the delivery of larger drug molecules. Since short pulse lengths
appeared to be adequate to activate nanodroplets at clinically relevant pressures [195]
(Figure E.3), it is possible that higher delivery doses and a more homogenous distribu-
tion could be achieved using short pulses with nanodroplets as well [277]. In addition,
it is possible that a higher but safer sonication pressure could be achieved with nan-
odroplets since the threshold for inducing inertial cavitation was higher than that of
microbubbles (Figure E.7).
Initial histological examinations confirmed the safety of the nanodroplet-mediated
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FUS-induced BBB opening technology. The case where a few dark neurons were identi-
fied for the nanodroplet/0.30 MPa brain sample was believed to be an isolated incident
that was more likely due to inadequate perfusion-fixation [283] (Figure E.11). In com-
parison to nanodroplets, microbubble-mediated BBB opening resulted in minor tissue
damage at the targeted region for both brain samples evaluated from the 0.60 MPa
cohort (Figure E.10O). Based on the H&E staining results, it is reasonable to conclude
that the significantly increased dextran delivery at 0.60 MPa was caused by the in-
creased magnitude of disruption at the focal region. However, such molecular delivery
enhancement with compromised safety may not be desirable in the clinic.
Passively detected acoustic emissions originated from the oscillating contrast agents
could be used to characterize the type of cavitation events which occurred during soni-
cation, providing insights to the mechanism of the FUS-induced BBB opening. Only an
increase in the harmonic and ultraharmonic signals detected after nanodroplet admin-
istration at all pressures, suggesting that the vaporized nanodroplet underwent mainly
nonlinear stable cavitation during sonication. The quantified SCD showed significant
increase at the highest pressure amplitude (0.60 MPa), indicating that a minimum SCD
threshold was needed to induce BBB opening. Interestingly, when microbubbles were
used as the contrast agent, significant SCD increases was seen across all sonication pres-
sures regardless of the outcome of BBB opening. The SCD value for the microbubble
group at the lowest pressure (902 V·s at 0.15 MPa) was much higher than that for the
nanodroplet group even at the highest pressure (353 V·s at 0.60 MPa), suggesting that
the SCD threshold was contrast agent-dependent. This result was further demonstrated
in Figure E.9, in which significant difference was calculated between threshold base-
lines (i.e., negative cases for which no dextran delivery was observed). This finding was
very important for an acoustic emission based BBB opening monitoring since contrast
agent-specific thresholds would then need to be investigated separately. The significant
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increase in ICD for microbubbles at 0.60 MPa in combination with the minor tissue
damage observed based on histological evaluation suggested that inertial cavitation
could be used as a safety indicator to avoid undesired bioeffects.
The linear correlation between the calculated SCD and the relative fluorescence
enhancement was slightly weaker for microbubbles than that for nanodroplets (Figure
E.8). Two factors could be contributing to the dissociation between these two param-
eters for microbubble-mediated BBB opening. First, our passive cavitation detection
was sensitive to signals arising from any microbubbles in the beam path of the trans-
ducers, including those that were outside the focal region. For those microbubbles, it
was possible that their contribution to the nonlinear acoustic emission signal was not
proportionate to their contribution to the fluorescence enhancement, therefore weak-
ening the correlation between these two parameters. On the other hand, the acoustic
emission signal during nanodroplet-mediated BBB opening only came from those nan-
odroplets vaporized within the focal region, as opposed to the inherent signal from the
off-target microbubbles. This could explain the significantly lower BBB opening thresh-
old determined based on acoustic emission for nanodroplets (Figure E.9). Secondly, in
the present study, the extent of the BBB opening was determined based on intensity
measured using fluorescence microscopy. Despite the fact that precautions were taken
during image capturing to minimize over-exposure, it might be possible that signal
saturation could still occur after a large amount of dextran delivery. As a result, the
level of BBB opening might be underestimated at higher pressures, especially for the
microbubble group (Figure E.6J).
Based on optical microscopy, Sheeran et al. [280] previously reported that it was
possible to have microbubbles formed from acoustically vaporized nanodroplets larger
than those in the original parent microbubble suspension. One possible explanation
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for such an increase in size was bubble fusion or Ostwald ripening resulted from va-
porization of nanodroplets in a very close proximity at high concentration. The re-
sulting increased size distribution of the activated nanodroplets could attribute to the
lower SCD threshold for BBB opening using nanodroplets than that with microbubbles
(Figure E.9) [228]. In addition, the larger bubbles formed from vaporized nanodroplets
could amplify the shear stress induced during stable cavitation to other neighboring cells
along the microvessels [269] at higher efficiency than traditional smaller microbubbles,
thus increasing the number of BBB disrupted sites to facilitate a more homogenous dex-
tran delivery distribution without the concern of causing undesired inertial cavitation
at higher pressures (Figure E.6D and E). Finally, it is possible that the vaporization of
the volatile perfluorocarbon droplets used here introduced additional mechanical effects
beyond the standard microbubble cavitation effects, aiding permeabilization without
being registered as ICD or SCD. Recent studies have shown that the expansion of less
volatile perfluorocarbon droplets occurs on a microsecond timescale [162], but little is
known on the magnitude of the shear stresses introduced by the rapid expansion of
more highly volatile droplets, such as those formed from perfluorobutane.
Our initial results utilizing nanodroplets as the mediating agent for FUS-induced
BBB opening offer a new means of developing this technology for a potential extravas-
cular targeted drug delivery in the brain parenchyma. Our findings indicate that a
potential advantage for employing nanodroplets as the BBB-opening mediating agent
is that they would only be activated within the transducer focal zone when sufficient
acoustic energy is reached. This yields the possibility of enhancing specificity through
focusing of the ultrasound beam, thus promising more spatial and temporal control
of the targeting procedure to minimize undesired thermal and cavitation-based bio-
effects. Moreover, it eliminates the “noise” signal generated from non-activated nan-
odroplets, allowing more accurate monitoring of BBB opening based on passive acoustic
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emission detection (Figure E.8). Additionally, the nanodroplets could potentially be
conjugated with targeting ligands to allow for more specific active-targeting applica-
tions on the molecular and cellular level [281]. The previously described post-labeling
technique [285] for generating targeted microbubbles could easily be translated to pro-
duce targeted nanodroplets. This “shake and bake” methodology offers the possibility
of developing the nanodroplet-mediated FUS-induced BBB opening technology for a
potentially large number of molecular targets for future personalized nanomedicine.
E.5 Conclusion
In this paper, we have performed an initial feasibility study to explore the utilization
of phase-shift nanodroplets for targeted drug delivery in the brain with FUS-induced
BBB opening. Significant dextran delivery was achieved in the murine hippocampus us-
ing acoustically-activated nanodroplets at clinically relevant pressure amplitudes. Pas-
sive cavitation detection was used in the attempt to establish a correlation between
the amount of dextran delivered in the brain and the acoustic emission recorded dur-
ing sonication. Conventional microbubbles with the same lipid shell composition and
perfluorobutane core as the nanodroplets were used to compare the efficiency of FUS-
induced dextran delivery. It was found that nanodroplets had a higher BBB opening
pressure threshold but a lower stable cavitation threshold than the microbubbles. A
more homogeneous dextran delivery within the targeted hippocampus was achieved
using nanodroplets without inducing inertial cavitation or compromising safety. Our
results offered a new means of developing the FUS-induced BBB opening technology
for potential extravascular-targeted drug delivery in the brain.
297
APPENDIX F
PCCAs Enhance HIFU Thermal Delivery
F.1 Introduction
High intensity focused ultrasound (HIFU) is a noninvasive thermal ablation tech-
nique for the treatment of benign and malignant solid masses. In some countries, HIFU
is approved to treat prostate cancer, and in the U.S., HIFU is approved by the Food and
Drug Administration for the treatment of uterine fibroids [286; 287; 288]. HIFU is also
under preclinical investigation as a potential treatment option for tumor malignancies
located in brain, liver, prostate, pancreas, bone, and breast [289; 290; 291; 292; 293;
294; 295; 296; 297; 298; 299; 300]. Because HIFU requires no invasive procedures, radia-
tion, or chemotherapy, it offers advantages over standard cancer therapy. Nevertheless,
there are limitations to HIFU. A single ellipsoid volume (15 − 25 mm3) is exposed to
acoustic pulses with intensities above 10,000 W/cm2. This power requirement carries
a risk of uncontrolled tissue cavitation [220; 221], and therefore exposure times are
brief and separated by a period of heat dissipation. Hundreds of lesions and hours of
therapy are often needed to treat a single tumor. Additionally, healthy tissue in the
c© 2013 Acoustical Society of America (acousticalsociety.org) Portions reprinted, from LC Phillips,
C Puett, PS Sheeran, GW Miller, TO Matsunaga, and PA Dayton. “Phase-Shift Perfluorocarbon
Agents Enhance High Intensity Focused Ultrasound Thermal Delivery With Reduced Near-Field Heat-
ing” J Acoust Soc Am, 2013; 134(2) Pt. 2: 1473-1482.
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path of the high-energy acoustic beam is at risk for thermal injury [301]. Unintended
heating can also occur near structures that attenuate or reflect ultrasound (air cavities
or bone) [302; 303]. In response to these limitations, methods to lower the acoustic
power requirements and treatment times to achieve ablation with HIFU are currently
under investigation.
Research over the past decade has demonstrated that the presence of ultrasound
contrast agents, or microbubbles, in a HIFU field substantially decreases the acous-
tic energy required to ablate tissue [106; 304; 305; 306; 307; 41]. Microbubbles are
FDA-approved ultrasound contrast agents that are micron-sized gas (typically perfluo-
rocarbon) bubbles with a polymer, protein, or lipid shell [308]. Insonated microbubbles
resonate, generating additional heat, and collapse (cavitation), producing local shock
waves that cause mechanical stress at the cellular level [106; 309] thereby aiding tissue
ablation. However, the clinical translation of microbubbles as an ablation mediator
in treating tumors is fundamentally limited because microbubbles are (1) too large
to extravasate from the vascular space [33; 310] and (2) have a very short half-life in
vivo (minutes) [49]. The production of stable microbubbles smaller than a micron is
particularly challenging [311; 312; 313], and furthermore microbubbles much less than
a micron respond poorly to low frequency ultrasound [314; 315; 203]. Thus an alter-
native to traditional microbubbles is needed for focused ultrasound-mediated tumor
applications.
An alternative to microbubbles is liquid perfluorocarbon (PFC)-based agents. Liq-
uid PFC droplets can have a substantially longer circulation half-life than gas-filled
microbubbles [53]. Furthermore, under sufficient acoustic energy, certain PFCs can be
phase-shifted from liquid to gas form, resulting in microbubbles at the target site. In-
deed, phase-change PFCs have been proposed as mediators for HIFU thermal delivery
for this reason [114; 54].
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Micron-sized liquid-based PFC agents have been studied extensively in ultrasound
applications as agents for vascular occlusion [50; 92]. However, micron-sized PFC agents
cannot access the extravascular space due to their size and thus would not accumulate
in tumors. Hence the application of micron-sized PFC droplets in focused ultrasound
surgery for tumor treatment is limited.
In response to the limitations inherent in the use of microbubbles and micron-sized
droplets, efforts are now focused on nano-sized agents with the development of several
techniques to synthesize stable liquid PFC nanodroplets [86; 113; 114; 72; 280; 281; 316].
When designed appropriately, PFC nanodroplets can be phase-shifted to gaseous mi-
crobubbles by the application of sufficient acoustic energy [194]. The acoustic param-
eters (HIFU intensity) required to initiate vaporization of the PFC droplet depend on
the size of the droplet and its chemical composition [52; 280; 316]. Taking advantage
of temperature-pressure requirements for nanodroplet vaporization, our laboratory has
synthesized unique phase-shift liquid nanodroplets using highly volatile PFCs, including
decafluorobutane (DFB, C4F10, b.p.=−2◦C). Because these novel nanodroplets vaporize
at a controlled pressure, they are expected to enhance thermal energy deposition only
at the acoustic focus where the pressure is sufficiently high to vaporize nanodroplets
into microbubbles.
We hypothesized that our new nanodroplet PFC formulation would thermally and
spatially enhance HIFU ablation at the intended target site. Furthermore we predicted
that these nanodroplets would provide more control over lesion size and placement than
microbubbles and also enable shortening of heating times and/or lessening of delivered
acoustic energy. We examined the thermal enhancement of the hybrid nanodroplets
relative to standard microbubble formulations and agent free controls in a tissue mim-
icking acrylamide-albumin phantom in response to HIFU. Specifically, we assessed the
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relationship among agent concentration, acoustic pressure, and pulse length on va-
porization threshold, lesion size, lesion location, and thermal enhancement. Finally,
we examined temperature profiles during HIFU ablation by magnetic resonance (MR)
thermometry.
F.2 Materials & Methods
F.2.1 Microbubble Preparation and Condensation
The phase-shift nanodroplets used in this study and their precursor microbubbles
have PFC cores containing a mixture of DFB (C4F10) and dodecafluoropentane (DDFP,
C5F12) encapsulated in a phospholipid shell. Lipids were purchased from Avanti Polar
Lipids (Alabaster, AL), and PFCs were purchased from Fluoromed (Round Rock, TX).
Lipid emulsions were formulated by dissolving DSPC and DSPE-PEG-2000 in a 9:1M
ratio and a total lipid concentration of 1.0 mg/ml in a solution of phosphate-buffered
saline (PBS), propylene glycol, and glycerol as previously described [281]. A total of
1.5 ml lipid mixture was added to a 3 ml glass vial, and the headspace of the vial was
then gas-exchanged with a 1:1 mixture of DFB:DDFP gas. All microbubbles with a
PFC core and a phospholipid shell arranged spontaneously during agitation using a
Vialmix Shaker (Bristol-Myers-Squibb, NY, NY). Microbubble stock solutions contain
approximately 1010 microbubbles/ml.
Nanodroplets were formed by the condensation of the precursor microbubbles as
previously described [280]. Briefly, the 3 ml vials containing microbubbles were im-
mersed in an isopropanol bath controlled to a temperature between −5◦C and −10◦C
and swirled gently for approximately 1 min. The vials were connected to an adjustable
air pressure source, and headspace pressure in the vial was increased until a change
in the consistency was noted in the microbubble solution, indicating the onset of con-
densation. The combination of propylene glycol, glycerol,and PBS prevents freezing
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during the approximately 2 min exposure to sub-zero temperature. After condensa-
tion, the pressure source was removed from the vial, leaving a pressure head on the
solution until further use. Assuming a direct conversion between the gas and liquid
states, nanodroplet stock solutions also contain approximately 1010 nanodroplets/ml.
F.2.2 Nanodroplet and Microbubble Sizing
Microbubble concentration and size distributions were measured in triplicate using
an Accusizer 780 (Particle Sizing Systems, Santa Barbara, CA) with a lower detection
limit of 0.5 µm. Dynamic light scattering (Malvern Nano ZS, Malvern Instruments,
Westborough, MA) with a measurement range of 0.3 nm to 6 µm in diameter was used
to assess size distributions of the nanodroplets. The condensed nanodroplet solution
was transferred to a cuvette immediately prior to sizing. Stability of the nanodroplets
in stock solution was assessed by repeated sizing several hours/days after their conden-
sation at 37◦C as performed previously [281].
F.2.3 Tissue-Mimicking Phantoms
Acrylamide-albumin tissue mimicking phantom, similar to those previously de-
scribed [317], were created from an 8 : 7 : 5 mixture of an aqueous acrylamide solution,
liquid egg white, and deionized water, respectively. The advantage of these phantoms is
their near transparency until heated above 60◦C. Upon reaching this ablation threshold,
the egg whites are permanently denatured, creating a visibly opaque lesion. Controlled
volumes (0.0025 − 1 µl/ml of phantom material) of the stock microbubble or nan-
odroplet solutions were added to the phantom acrylamide solution to generate various
agent concentrations within the phantoms. Agents were gently dispersed throughout
the degassed acrylamide solution prior to polymerization via the addition of 1% vol./vol.
of 10% ammonium persulfate and 0.4% vol./vol. tetramethylethylenediamine, and then
the solution was poured into an angled cylindrical mold. The top and bottom diameters
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of the phantoms were 3 and 4.1 cm, respectively, with a height of 1.5 cm, resulting in
a total volume of 10 ml. Because the stock solutions of nanodroplets and microbub-
bles contained approximately 1010 agents/ml, the final concentrations of nanodroplets
and microbubbles in the tissue-mimicking phantoms ranged from 104 to 107 agents/ml.
For comparison, the prescribing information for Definity suggests injecting 1.2 × 108
microbubbles/kg (or roughly 1.2 × 105 microbubbles/g), and we incorporate roughly
the same number per gram of phantom tissue when 0.01 µl of stock agent solution
is added per milliliter of phantom material. From this point on, the nanodroplet or
microbubble concentration will be referenced by the microliters (µl) of stock solution
added per milliliter of phantom material. All phantoms were used within 48 h of their
generation.
F.2.4 Tumor-Mimicking Model for HIFU Ablation
To simulate a tumor surrounded by healthy tissue, the 10 ml phantom (mimicking
the tumor mass) was placed within an agent-free gellan gum mold and separated from
the ultrasound transducer by a 10 mm thick degassed, agent-free acrylamide-albumin
gel cap (Figure F.1). This mold and cap (mimicking healthy tissue surrounding the
tumor) were positioned below the HIFU transducer such that the center of the phantom
was at the focal point of the HIFU beam. The agent-free gels encasing the phantom
allowed for assessment of thermal damage outside of the intended ablation area. The
tissue mimicking gels and mold were placed in a bath of circulating degassed water to
maintain a constant temperature of 37◦C. An acoustic absorbent pad was placed below
the bottom mold to minimize possible sound wave reflection off the acrylic floor of the
water bath.
303
Figure F.1: (Left) A tissue-mimicking albumin-acrylamide phantom (AAP) containing
nanodroplets was positioned between a tissue mimicking gellan gum base below and an
agent free albumin-acrylamide cap above. High intensity focused ultrasound (HIFU)
was directed toward the center of the phantom from above. The image on the right is
a representative pre-HIFU acoustic image of the aligned phantoms with a nanodroplet
phantom in the center. The white ellipse denotes the location and approximate dimen-
sions of the acoustic focus where ablation was performed. Notice that no agents are
visible within the phantom prior to HIFU.
F.2.5 Focused Ultrasound
HIFU was delivered by a spherically focused, eight element, 1.2 MHz, transducer
array (Imasonic, Voray-surl’Ognon, France) driven by a therapy imaging probe system
(TIPS) (Philips Research North America, Briarcliff Manor, NY). The diameter and
focal length of the transducer were both 80 mm. Continuous-wave HIFU was applied
at 1 MHz in all studies and delivered at peak negative pressures (PNPs) of 1, 2, 3,
and 4 MPa. Calibration at each pressure was determined using a needle hydrophone
(Onda HNA-0400, Sunnyvale, CA) in a degassed water bath. The applied acoustic
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intensities are approximately 30 W/cm2 at 1 MPa, 125 W/cm2 at 2 MPa, 280 W/cm2
at 3 MPa, and 500 W/cm2 at 4 MPa. Precise axial and lateral positioning of the focal
point (TIPS focal zone: 1×1×6 mm) was achieved by using a three-dimensional (3-D)
motion stage.
F.2.6 Acoustic Imaging and Volume of the Vaporization Field
Liquid nanodroplets at the low concentrations used in this study are not acoustically
detectable by conventional ultrasound imaging prior to vaporization. Therefore both
control phantoms and those containing nanodroplets are acoustically transparent. To
date, nanodroplet vaporization has most often been assessed in small capillary tubes
containing aqueous solutions by the passive detection of emitted acoustic signatures. In
this study, nanodroplet vaporization was assessed directly in the tissue-mimicking gel
by acoustic imaging of the echogenic microbubble cloud (vaporization field) that forms
during the application of HIFU. In order to determine the onset of vaporization, acoustic
imaging was performed after the application of continuous-wave HIFU at pressures of
1, 2, 3, and 4 MPa to phantoms containing 0.1 µl of nanodroplet stock per ml for
exposure times ranging from 2 ms to 20 s.
Each phantom was sonicated only once and then immediately imaged using a 15L8
transducer probe with a Siemens Sequoia scanner (Siemens, Mountain View, CA) oper-
ating in B-mode at 14 MHz. Testing was performed in triplicate. DICOM images were
analyzed oﬄine by IMAGEJ software (http://rsbweb.nih.gov/ij/). An ellipse region
of interest (ROI) measuring the size of the known focal beam dimensions was drawn
within each image at the site of vaporization. A second equally sized ellipse was drawn
on the unaffected region of the phantom, at least 5 mm to the left or right, but within
the same image, as a measure of background intensity. Pixel intensity in each ellipse
was measured and the mean calculated. The background mean was subtracted from
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the mean pixel intensity in the vaporization ROI, and the pixel intensity was plotted
against time to determine the onset of vaporization.
In a separate set of experiments, the final volume of the vaporization field (mi-
crobubble cloud) was determined in phantoms containing 0.05, 0.1, 0.25, or 1.0 µl of
nanodroplet stock per milliliter that were insonated by continuous-wave HIFU for 20 s
at 1, 2, 3, and 4 MPa. The phantoms were imaged immediately after HIFU application
using the 15L8 transducer probe and Siemens Sequoia scanner operating in B-mode
at 14MHz (Figure F.1). The width and height of the vaporization field were mea-
sured, and the corresponding vaporization field volume was estimated as an ellipsoid
and calculated as described in the following section.
F.2.7 Lesion Formation
Acrylamide-albumin phantoms containing between 0.0025 and 1 µl of stock nan-
odroplet or microbubble solution per milliliter of phantom material were insonated by
continuous wave HIFU for 20 s at 1MHz using PNPs of 1, 2, 3, or 4 MPa. All ex-
periments were repeated in at least triplicate. Ablation lesions were visible as opaque
regions in the otherwise transparent phantom. Phantoms were cut by scalpel, and the
maximum height (vertical axis) and width (lateral axis) of each ablation lesion was de-
termined by direct visualization and measured by calipers. The volume of the ellipsoid
lesion was calculated using the formula volume
volume = (4/3) ∗ pi ∗ (maximum height/2) ∗ (maximum width/2)2 (F.1)
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Figure F.2: Schematic representation of the AAP position above the HIFU transducer.
The acoustic focus was positioned directly in the center of the phantom. Horizontal
MR slices were collected at the focus, at the surface of the phantom, and in between
these two slices. During separate scans, vertical slices were collected parallel to the
axial length of the acoustic focus.
F.2.8 MR Thermometry
MR thermometry was applied to investigate thermal deposition in phantoms con-
taining nanodroplets and microbubbles. MR imaging was performed at 3T (Magne-
tom Trio, Siemens Healthcare, Malvern, PA) using a custom 2-in. square, single-loop,
receive-only RF coil (FUS Instruments, Toronto, Canada). Ultrasound sonication was
performed inside the scanner using an MR-compatible system consisting of a focused 1
MHz transducer (75mm diameter, F#=0.8) with three-axis motor control (RKO-100,
FUS Instruments). Albumin-acrylamide gel phantoms containing no agent (control),
nanodroplets (0.005 µl/ml, 0.01 µl/ml, or 0.1 µl/ml), or microbubbles (0.005 µl/ml or
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0.01 µl/ml) were insonated by continuous wave HIFU at 1.1MHz with a PNP of 4.69
MPa (20 W) for 60 s. For each application of HIFU, the temperature was monitored
either in a single vertical slice or in three parallel horizontal (perpendicular to the axis
of the acoustic beam) slices (see Figure F.2). The center-to-center slice spacing was 4.5
mm for the horizontal scans.
All MR images were acquired using a 2D multi-slice, spoiled gradient-echo pulse
sequence with the following parameters: TR/TE = 39/5 ms, field of view = 51 × 102
mm, matrix=64 × 128, in-plane resolution=0.8 × 0.8 mm, readout bandwidth = 220
Hz/pixel, flip angle = 25◦, slice thickness = 2.5 mm, scan time = 2.5 s per image set.
For each ultrasound application, 50 consecutive image sets were acquired back to back
for a total scan time of 2 min and 5 s. Ultrasound sonication was initiated 5 s into the
MR scan (immediately following acquisition of the second image set), lasted for 60 s,
and imaging continued for an additional 60 s during cool-down.
Maps of the temperature evolution during and post each ultrasound application
were computed from the MR images using the proton resonance frequency shift method
[318; 319], similar to previously described thermometry studies [320; 321]. Specifically,
the temperature change during the scan was computed from the phase difference be-
tween the second image (acquired immediately before starting the sonication) and each
subsequent image of the scan, assuming −0.01 ppm/◦C temperature sensitivity at the
actual scanner field strength of 2.89 T.
F.2.9 Statistical Analysis
Data sets were evaluated using Students t-tests in the case of paired means and
were evaluated by one-way analysis of variance (ANOVA) when more than two groups
were compared. All results are reported as the mean of that data and its corresponding
standard deviation. In cases where n was not equal across data sets, standard error is
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reported. All experiments were performed in at least triplicate, and p values of < 0.05
were considered to be statistically significant.
F.3 Results
F.3.1 Nanodroplet and Microbubble Size
The average diameter of the nanodroplet population was measured to be 240± 65
nm by dynamic light scattering. Nanodroplets remained stable in solution at 37◦C
for at least 48 h after condensation. As assessed by laser light diffraction, the mean
microbubble diameter was 0.98± 0.68 µm.
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Figure F.3: Vaporization of nanodroplets in tissue-mimicking phantoms. (A) Repre-
sentative acoustic image of vaporized nanodroplets in a phantom containing 0.1 µl of
stock solution per milliliter. Notice no vaporization is present outside the focal zone
or in the cap. An ellipse region of interest (ROI) measuring 1.5mm × 10 mm was
measured at the site of vaporization. (B) Mean pixel intensity within the ROI was
assessed in phantoms containing 0.1 µl of nanodroplet stock per milliliter as a function
of pulse length (n ≥ 3, mean ± s.d.). (C) Vaporization volume resulting from 20 s
of HIFU as a function of nanodroplet concentration over a range of pressure from 2-4
MPa (n ≥ 3, mean ± s.d.).
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Figure F.4: Ablation lesion volume as a function of (A) nanodroplet (ND) or (B)
microbubble (MB) concentration. Lesion volumes resulted from 20 s of HIFU at 2, 3,
or 4 MPa (n ≥ 3, mean ± s.d.).
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F.3.2 Onset of Vaporization
In phantoms containing 0.1 µl of stock nanodroplets, vaporization of the nan-
odroplets at the HIFU focus generated a central bubble cloud. Acoustic B-mode imag-
ing confirmed vaporization in the focal region within 10-20 ms of HIFU exposure at 2,
3, and 4 MPa (Figure F.3(A)). No significant vaporization was observed prior to 10 ms
of HIFU exposure at any pressure. No vaporization could be detected when HIFU was
applied at a pressure of 1 MPa (corresponding to an intensity of 30 W/cm2) regardless
of the nanodroplet concentration. The mean pixel intensity within the acoustic focal
area was measured as a function of pulse length (Figure F.3(B)). Nanodroplets within
the path of the beam but outside the focal spot did not experience sufficient pressure
or heating to vaporize. HIFU delivered at 4 MPa resulted in a vaporization field (mi-
crobubble cloud) that was significantly larger than the corresponding ablation lesion
that was formed within it (400 vs 150 mm3).
F.3.3 Vaporization Field Volume
Vaporization field volumes were measured as a function of nanodroplet concentra-
tion and acoustic pressure (Figure F.3(C)). The vaporization field volume increased
both with increasing nanodroplet concentration and with the application of higher
acoustic pressures. Applying continuous wave HIFU at 1MHz for 20 s with a PNP of
4 MPa to a phantom containing 1 µl of the stock nanodroplet solution per milliliter
produced a vaporization field volume of approximately 400 mm3. At 2 MPa, the va-
porization field volume was approximately 100 mm3 (Figure F.3(C)). No vaporization
field could be detected in control phantoms (containing no nanodroplets) below 4 MPa.
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Figure F.6: Temperature change in AAPs after 60 s of continuous HIFU ablation at
20W (4.69 MPa). The (A) maximal temperature change anywhere in the vertical
cross section of the phantom, the (B) change in temperature at the location of the
acoustic focus, and the (C) change in temperature at the surface of the phantom are
all listed for each type of phantom and concentration of agents in microliters (mean ±
s.e., *indicates p ≤ 0.05 compared to 0 agents, n ≥ 3).
F.3.4 Ablation Lesion Volume
Ablation lesion volumes were measured as a function of nanodroplet and microbub-
ble concentration and acoustic pressure (Figure F.4). HIFU at 1 MPa for 20 s did not
result in ablation lesion formation at any tested nanodroplet or microbubble concen-
tration. At least 2 MPa of pressure was required to induce ablation. The volumes of
the ablation lesions were highly dependent on the concentration of nanodroplets and
microbubbles in the tissue-mimicking phantom and also on the PNP of insonation. For
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Figure F.7: MR thermometry maps of phantoms containing no agents (top row), ND
(second to fourth rows) or MB (fifth and sixth rows). Frames shown were collected
during the 60 s of HIFU ablation and indicate the intensity and location of the tem-
perature change. The dotted line across each series of frames delineates the surface of
the phantoms.
each acoustic pressure applied, ablation lesion volumes increased over several orders of
magnitude of increasing nanodroplet (0 − 1 µl/ml) and microbubble (0 − 0.1 µl/ml)
concentrations (Figure F.5). However, there were significant differences between the
volumes of ablation lesions produced in phantoms containing nanodroplets compared
to microbubbles. For each pressure, the presence of microbubbles resulted in larger
lesions than nanodroplets. At 4 MPa, ablation lesions achieved a peak average vol-
ume of approximately 300 mm3 in phantoms containing microbubbles compared to a
maximum volume approaching 150 mm3 with nanodroplets. Maximum ablation lesion
volume was achieved with microbubbles at a concentration that was a full order of
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magnitude lower than the required nanodroplet concentration (0.1 vs 1 µl/ml) to reach
the same ablation volume. Even at low concentrations, both agents enhanced lesion
volume. Microbubbles or nanodroplets at the 0.01 µl/ml concentration (0.1 × 106 per
cm3) resulted in mean lesion volumes of 80.4±33.1 and 52.8±14.2 mm3 (mean ± s.e.),
respectively, after 20 s of continuous 1 MHz HIFU at a PNP of 4 MPa (Figure F.5).
In comparison, lesion volumes of 1.0 ± 0.8 mm3 were generated in agent-free control
phantoms under the same HIFU parameters. Lesion volume continually increased with
increasing nanodroplet concentration over the entire range investigated. However, this
was not true in phantoms containing microbubbles. The lesion volume decreased in
phantoms containing more than 0.1 µl of microbubble stock per ml (Figure F.5(C)).
Eventually at concentrations of microbubbles greater than 1 µl/ml, ablation lesions
formed only at the surface of the phantom and were too flat to accurately measure. As
such, no data on these concentrations are presented.
F.3.5 Ablation Lesion Geometry and Location
Differences in the shape of the ablation lesions produced by nanodroplet or microbubble-
enhanced HIFU, as well as differences in the location of these lesions within the phan-
tom, were analyzed by direct visualization and lesion measurement. The ideal lesion is
a prolate ellipsoid (vertical axis > lateral axis) centered at the HIFU focal point. How-
ever, with increasing microbubble concentrations, the vertical axis of the ablation lesion
shortens while the lateral axis widens [Figs. F.5(A) and F.5(B)]. The resultant lesions
are more oblate rather than prolate ellipsoids as microbubble concentrations increase.
This oblate geometry occurs in phantoms with microbubble concentrations above 0.005
µl/ml and occurs at the frontal surface of the phantom not around the desired focal
point at the center of the phantom (Figure F.5(D)). At a microbubble concentration
of 0.1 µl/ml, the largest ablation lesions were produced (Figure F.5(C)), but they were
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Figure F.8: For each MR acquisition over time, the maximum change in temperature
(A) at the focus (ROI) and at the (B) surface of the phantom was extracted from
the corresponding horizontal slices from those locations. Time curves were averaged,
and data are presented as the means ± s.d. (n ≥ 3). Phantoms contained 0.01 µl of
ND/MB per milliliter of phantom material or no agents (control).
spread out over the phantom surface (Figure F.5(D)). In contrast, lesions produced in
nanodroplet phantoms retained their desired prolate shape for a greater range of con-
centrations (Figure F.5(D)). These nanodroplet-associated prolate ellipsoids remained
localized around the central focal point (Figure F.5(D)).
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F.3.6 MR Thermometry
MR thermometry was performed during the insonation of phantoms containing no
(control) agents, 0.005 µl, or 0.01 µl of nanodroplets or microbubbles per milliliter
by continuous wave HIFU for 60 s at 1 MHz and a PNP of 4.69 MPa. MR data were
collected every 2.5 s during and for another 60 s following ablation. At each time point,
the maximum intensity pixel along with its eight surrounding pixels was averaged to
obtain the localized maximum change in temperature and is referred to as the “maximal
temperature change” from here on. The maximal temperature change anywhere in the
phantom over the 2 min data collection period was determined from vertical MR slices
(Figure F.6(A)). The maximal changes in temperature at the acoustic focus (ROI) and
at the surface of the phantom were detected from the horizontal MR slices acquired at
each corresponding plane [Figs. F.6(B) and F.6(C)].
Of all five types of non-control phantoms investigated, HIFU ablation of the two
containing 0.005 or 0.01 µl microbubbles per milliliter and the phantom containing
0.1 µl of nanodroplets per milliliter resulted in a significantly enhanced temperature
rise over the control (white bar in graphs). However, it is important to note that
the maximal temperature rise did not occur at the same location within each type of
phantom (Figure F.7). The maximal temperature rise occurred near the surface in
microbubble phantoms, whereas the phantoms that contained nanodroplets incurred
a maximal temperature rise near the acoustic focus in the center of the phantom.
Maximal change in temperature at the acoustic target site was enhanced by 16.9% and
37.0% by microbubbles and nanodroplets, respectively.
The temperature vs time curves (Figure F.8) acquired at the surface of the phantoms
and at the acoustic focus in the middle of the phantoms clearly illustrate the differences
in thermal energy deposition between the nanodroplet and microbubble phantoms of
the same 0.01 µl/ml concentration. The temperature at the acoustic focus was highest
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in the nanodroplet phantom and lowest in the control phantom. The peak temperature
in the control phantoms was observed at the end of the HIFU application (60 s). The
phantoms containing 0.01 µl of nanodroplets per milliliter reached the same temperature
(15.4◦C) after only 20 s, thereby decreasing the ablation time needed. Minimal surface
heating occurred in the nanodroplet phantoms and was only higher than the control
after 40 s of ablation. The surface of the microbubble phantoms rose by more than 50◦
but only rose by about 19◦ at the targeted region of interest demonstrating that the
majority of the heating occurred away from the intended target site.
F.4 Discussion
This study explored a novel phase-shift nanoagent for enhanced HIFU ablation.
These phase-shift nanodroplets have a PFC core that combines highly volatile DFB
with less-volatile DDFP. The goal of combining PFCs was to balance stability and
acoustic sensitivity. By combining DFB and DDFP in a 1:1 mixture, vaporization
and ablation was achieved at relatively low HIFU intensities, yet droplets were stable
enough to remain intact in liquid form during phantom preparation and storage. The
results of these studies demonstrated several advantages of these novel nanodroplets
compared to gaseous PFC microbubblesthe clinical gold standard for acoustic contrast
imaging.
Vaporization of the PFC nanodroplets into microbubbles was detected by acoustic
imaging of the microbubble cloud. The vaporization field volume results from the inter-
dependent effects of the acoustic beam geometry and pressure (intensity), temperature
rise in the acoustic field, and the concentration of nanodroplets. The vaporization vol-
ume increased with increasing pulse length as was also reported previously by others
[74]. However, at a sonication pressure of 4 MPa, large variability in the vaporiza-
tion field volumes occurred within the two highest nanodroplet concentrations. This
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variability demonstrates the loss of control over lesion size, shape, and location that
occurs in the higher range of nanodroplet concentrations and acoustic pressures. To
induce an acoustically detectable vaporization cloud from the nanodroplets, a pressure
of at least 2 MPa (PNP) for more than 10 ms was required. This threshold is hypoth-
esized to be one of the main reasons why unintended heating within the prefocal zone
was minimized in phantoms containing nanodroplets. Indeed, prefocal surface heating
in nanodroplet phantoms was not significantly greater than surface heating in control
phantoms based on the MR thermometry results.
HIFU ablation lesions in phantoms containing either type of agent were statistically
larger than control lesions, but microbubbles were associated with surface heating and
loss of control over lesion placement with higher concentrations. Previous studies have
reported changes in lesion geometry with increasing microbubble concentrations such
that ablation lesions become oblate ellipsoids (lateral axis > vertical axis) massed at
the frontal phantom surface [305]. In our study, continuous-wave HIFU (20 s at 1
MHz and 4 MPa) produced ablation lesions with volumes averaging approximately 300
mm3 in phantoms containing microbubbles. Lesions of similar volume have been re-
ported in animal models of microbubble-enhanced HIFU ablation. Kaneko et al. [322]
demonstrated ablation lesions averaging almost 400 mm3 in rabbit liver in response
to 60 s of HIFU at an intensity of 400 W/cm2 using air-based Levovist. However,
these large lesions may not be desirable. Tung et al. [305] explored microbubble-
enhanced HIFU ablation using Definity, a gaseous perfluoropropane contrast agent,
in acrylamide-albumin gels. Although ablation lesions were significantly larger in mi-
crobubble containing phantoms compared to control, undesirable changes in ablation
lesion shape and location occurred with increasing microbubble concentrations. At
lower microbubble concentrations, prolate ellipsoid ablation lesions were centered at
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the HIFU focal point. As microbubble concentrations increased, larger ablation le-
sions became asymmetric ellipsoids that migrated as much as 2 cm away from the focal
point toward the ultrasound source. Finally, at the highest microbubble concentrations,
the ablation lesions flattened along the frontal phantom surface and “shadowed” deeper
sites such that no ablation occurred at the desired focal point. The largest microbubble
mediated ablation lesions were achieved at a price of lost control over lesion geometry
and location both in Tungs study and in this study.
Liquid nanodroplets offered advantages over microbubbles when exposed to HIFU
in the tissue-mimicking model. For a given concentration or pressure, lesions in re-
sponse to nanodroplets were significantly smaller than microbubble associated lesions.
However, ablation lesions produced in the presence of nanodroplets were less prone to
shape change and lesion migration than microbubble-enhanced lesions. MR thermome-
try maps of phantoms containing nanodroplets revealed HIFU heating in the phantom
center and not at its surface. The MR thermometry studies were performed at room
temperature because it was not straightforward to heat the phantoms to 37◦ inside the
MR scanner. So it is possible that the nanodroplets were not performing optimally.
Vaporization is dependent both on acoustic parameters and the ambient temperature.
Even greater thermal enhancement is therefore expected to occur during HIFU ablation
of nanodroplets at body temperature. Regardless, the results suggest that the energy
required to achieve phase transition of our novel liquid nanodroplet provides the op-
portunity to control the size and placement of ablation lesions during PFC-enhanced
HIFU.
Although we are working with nanodroplets, it is notable that the number of agents
required to enhance ablation in our studies is comparable to the number of microbubbles
injected during contrast imaging with Definity; this makes the use of this technology
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more clinically feasible. In this study, the presence of PFC nanodroplets in the tis-
sue mimicking phantoms resulted in larger HIFU-induced ablation lesions than could
be achieved in control phantoms without agent. Previous studies have also reported
enhanced HIFU ablation using liquid PFC droplets. Zhang et al. [54] demonstrated
ablation lesions with volumes approaching 600 mm3 in tissue-mimicking acrylamide
phantoms containing an estimated concentration of 3×105 DDFP droplets/ml after 5 s
of HIFU. Although these lesions are notably larger than the ablation lesions reported in
our study, despite the shorter insonation time and the use of pure, less-volatile DDFP,
it should be noted that the droplets were micron-sized and HIFU was applied at an
intensity of 4000 W/cm2. The differences in the results highlight the fact that the fi-
nal ablation response during PFC-enhanced HIFU depends on many factors, including
PFC droplet characteristics (boiling point, size, and concentration) as well as acoustic
parameters (intensity and exposure duration).
Our studies demonstrate that by controlling vaporization, the location of enhanced
thermal energy deposition can be controlled. Whereas microbubbles impede the acous-
tic beam causing surface lesions and “shadowing” of the beam, the nanodroplets do
not impede the beam prior to vaporization and allow for deeper lesion generation. We
expect our nanodroplets to be capable of extravasating due to their 100 − 300 nm
diameters; however, this will be the focus of future studies. Benefits of nanodroplet-
enhanced HIFU include shorter treatment times, decreased risk to healthy tissue along
the ultrasound path, and deeper access to tumors.
F.5 Conclusion
Our nanodroplet formulation offers several advantages over microbubbles for HIFU
ablation procedures. Microbubble-enhanced HIFU ablation is complicated by surface
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and non-targeted heating. In contrast, our nanodroplet formulation does not sub-
stantially enhance thermal energy deposition prior to vaporization. Because the nan-
odroplets require sufficient energy for vaporization, targeted ablation can be achieved
at the focal point of the transducer inside deep tissue. Nanodroplets were found to
reduce the acoustic energy and time required to ablate a tissue mimicking material. As
such, these nanodroplets have the potential both to reduce the procedure time and to
improve the safety of focused ultrasound surgery.
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APPENDIX G
Parameter Optimization for Spatial Control of HIFU Ablation
G.1 Introduction
High-intensity focused ultrasound (HIFU) is approved by the FDA in the USA
for the treatment of uterine fibroids and is being evaluated for treating other kinds
of tumors [323]. Ultrasound can kill cells by thermal effects (heating and denaturing
proteins) and mechanical effects (disrupting cellular membranes). Both effects are
enhanced if appropriately sized bubbles are present in the acoustic field [304; 106].
Bubbles in an acoustic field oscillate (stable cavitation), absorbing ultrasound energy
and releasing it as heat, and collapse (inertial cavitation), producing local shock waves
[304]. Ultrasound can draw bubbles from the dissolved gases in biologic tissue. However,
the required pressures [172] can result in the formation of bubble clusters or clouds
with an unpredictable density and therefore an unpredictable enhancement of lesion
formation. Hence, currently available HIFU systems employ acoustic parameters chosen
to limit bubble formation. Without the assistance of cavitation, high intensities in the
range of 2,000 W/cm2 are needed to reach ablative temperatures [324; 325]. These
c© 2013 Journal of Therapeutic Ultrasound (jtultrasound.com) Portions reprinted, from C Puett,
LC Phillips, PS Sheeran, and PA Dayton. “In Vitro Parameter Optimization for Spatial Control of
Focused Ultrasound Ablation when using Low Boiling Point Phase-Change Nanoemulsions” J Thera-
peutic Ultrasound, 2013; 1(16): 1-13.
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intensities place healthy tissue in the ultrasound path at risk [301]. In order to avoid
unwanted thermal damage, HIFU is delivered in short bursts separated by cool-down
periods. The transrectal application of HIFU for prostate cancer employs 3 to 5 s of
therapeutic insonation (‘on’ time), during which ablation occurs, followed by 5 to 6 s
of cool-down (‘off’ time) [324; 325]. Since each therapeutic burst results in an ablation
lesion measuring 30 to 40 mm3, 2 to 5 h is typically required to ablate the total volume
of prostate cancer. During this time, local or generalized anesthesia and tissue cooling
are required. In response to these limitations, research is underway to minimize the
energy required by HIFU to achieve tumor ablation. Enhanced focused ultrasound
seeks to take advantage of cavitation, rather than avoid it, by seeding the acoustic field
with bubbles.
Many studies to date have confirmed the ability of micron-sized bubbles or ‘mi-
crobubbles’, including commercially available ultrasound contrast agents, to enhance
HIFU in experimental models [106; 322; 222; 41; 305; 306]. Enhancement refers to
the faster production of larger ablation lesions using lower delivered energy. Ultra-
sound contrast agents are typically composed of high molecular weight gases, including
volatile perfluorocarbons (PFC) such as octafluoropropane (C3F8, b.p. = −37◦C),
encapsulated in protein, polymer, or lipid shells [326]. These agents are designed to
improve diagnostic imaging, and as such, they have short half-lives in vivo and are con-
fined to the vasculature by their size [327]. Since they cannot penetrate into diseased
tissue or remain in circulation for the time required to deliver therapeutic ultrasound,
microbubbles have limited direct clinical utility in the setting of HIFU.
As a potential solution, PFC microbubbles can be generated in tissues by vaporiz-
ing liquid PFC nanodroplets (ND) using energy delivered by ultrasound [194]. Since
the PFC core is encapsulated by surfactant, these particles are often referred to collec-
tively as phase-shift nanoemulsions (PSNEs). PSNEs remain stable for hours at body
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temperature in solution and in vivo [281; 328]. Additionally, droplets can be small
enough (< 300 nm) to extravasate through the leaky vasculature in malignant and in-
flamed tissues and have been shown to accumulate in tumors following their intravenous
administration [328]. Therefore, PSNEs hold promise as potentially useful agents to
enhance HIFU [194; 329], and their behavior in response to HIFU has been studied in
solution [281], in tissue-mimicking gels [222; 114; 330], and in animals [328].
However, control over ablation lesion geometry and placement can be problematic
when the acoustic field contains PFC microbubbles or PSNEs. In an early trial of
HIFU enhancement using octafluoropropane microbubbles in a tissue-mimicking gel,
undesirable distortion in ablation lesions was noted with increasing bubble concentra-
tions [305]. At lower bubble concentrations, the ablation lesions were ‘cigars’ (prolate
ellipsoids, vertical axis > lateral axis) corresponding with the HIFU focal zone. As bub-
ble concentrations increased, larger ablation lesions became ‘tadpoles’, describing both
their geometric appearance (asymmetric ellipsoids) and their relocation or migration
away from the focal point and closer to the ultrasound source. Eventually, the ablation
lesions flattened (oblate ellipsoids, lateral axis > vertical axis) along the frontal gel sur-
face, completely ‘shadowing’ the desired focal point. The largest ablation lesions were
therefore achieved at a price of lost control over lesion geometry and location. Similar
control problems have also been encountered during HIFU enhancement with the use of
liquid PFC droplets during phase-shift studies [222; 330; 54]. Using dodecafluoropen-
tane (DDFP) droplets in an albumin-acrylamide gel model, Zhang P. et al. described
‘teardrop’ ablation lesions at higher intensities (>830 W/cm2) [114], while Zhang M. et
al. reported complete loss of an ablation response at the highest microdroplet concen-
tration [54]. The authors hypothesized that this loss resulted from ‘backscatter from
the high-density acoustic droplet vaporization bubbles drawn proximally to shadow the
focus’.
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Research is therefore being done to manipulate the HIFU acoustic parameters and
PSNE concentrations to achieve controlled enhancement. The acoustic energy required
to trigger the critical phase-shift from liquid droplet to microbubble is dependent on
temperature, the frequency of insonation, the size of the droplet, and the type of PFC
compound [194; 76]. Smaller droplets are more difficult to vaporize than larger droplets,
and volatile PFCs are easier to vaporize than less-volatile compounds. Most studies
using phase-shift emulsions to enhance HIFU have employed PFC droplets containing
dodecafluoropentane (C5F12, b.p. = 29
◦C), which has a boiling point close to body
temperature [328; 114; 330; 54]. As shown in a tissue-mimicking gel model, there is a
large difference between the relatively high (approximately 8 MPa at a frequency of 2
MHz) peak negative pressure (PNP) required to vaporize DDFP droplets <500 nm in
diameter and the much lower acoustic pressure needed to drive inertial cavitation once
bubbles have been generated [114]. This difference provides an opportunity to control
the otherwise unpredictable ablation response in the setting of cavitation. A brief (<1
ms) high-pressure pulse is used to localize vaporization, followed by continuous wave
insonation at lower pressure to drive cavitation and achieve ablation.
Our laboratory has been exploring the possible diagnostic and therapeutic applica-
tions of PSNEs containing highly volatile PFC compounds, including decafluorobutane
(DFB, C4F10, b.p. = −2◦C) [280]. Blending PFC compounds to tune the vaporization
threshold of PSNEs has been explored since its introduction in 2005 [86]. Previous
experiments looking at HIFU enhancement using a PSNE containing a 1:1 mix of DFB
and DDFP demonstrated vaporization within 10 to 20 ms of continuous wave HIFU (1
MHz) delivered at a pressure as low as 2 MPa. This low pressure was also adequate
to drive cavitation and achieve ablation. Given this absence of a large difference be-
tween the pressures required for vaporization and cavitation, continuous wave HIFU
was applied without a vaporization pulse [222]. The results defined the upper and lower
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nanodroplet concentration and acoustic pressure limits required to achieve enhanced
ablation. Additionally, comparing the behavior of liquid nanodroplets and microbub-
bles directly demonstrated that droplet vaporization could be achieved focally, allowing
for control over the location of ablation, although the ablation lesions were contained
within larger vaporization fields of microbubbles.
The current study examined the effect of varying the insonation (‘on’) and cool-
down (‘off’) times of the HIFU treatment cycle on the resulting microbubble clouds
and ablation lesions within them over a range of PSNE concentrations and acoustic
pressures. It is now clear that control over ablation during enhanced HIFU requires
selecting the appropriate acoustic parameters for the available PFC concentration, a
fact that is of particular importance when working with more volatile PSNEs. Zhang
P. et al. have suggested that ‘there may potentially be an optimal range of acoustic
intensities that allow for taking advantage of bubble-enhanced heating while avoiding
distortion in lesion shape’ [330]. The goal of this study was therefore to optimize the
acoustic intensity and insonation time for a given concentration of this unique PFC
agent during continuous wave HIFU. The demonstration of controllable ablation in the
presence of a volatile PFC component is another step toward developing PSNEs as
useful clinical tools to enhance HIFU.
G.2 Materials & Methods
G.2.1 Preparation of the PSNEs
The PSNE was prepared by the condensation procedure described previously [280].
Lipids (DSPC and DSPE-PEG-2000), purchased from Avanti Polar Lipids (Alabaster,
AL, USA) in a 9:1 M ratio and a total lipid concentration of 1.0 mg/mL) were emulsified
in a solution of propylene glycol 15% (v/v), glycerol 5% (v/v), and phosphate buffered
saline 80% (v/v). Then, 1.5 mL of the lipid mixture was placed in a sealed 3-mL glass
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vial and the air headspace exchanged with PFC gas (equal parts decafluorobutane
(C4F10) and dodecafluoropentane (C5F12), purchased from Fluoromed (Round Rock,
TX, USA)). Microbubbles with PFC cores (1:1 ratio of DFB and DDFP) and phos-
pholipid shells formed spontaneously during agitation using a Vialmix Shaker (Bristol-
Myers-Squibb, New York, NY, USA). The concentration of microbubbles in this emul-
sion was measured in triplicate using an Accusizer 780 (Particle Sizing Systems, Santa
Barbara, CA, USA) and was found to be 1010 microbubbles per milliliter. Condensation
of the microbubbles to nanodroplets was achieved by cooling the emulsion under an
adjustable high-pressure air source in an isopropanol bath maintained at a temperature
between −5◦C and −10◦C. The mixture was swirled gently while the headspace pres-
sure in the vial was steadily increased until a change in the consistency of the solution
indicated the onset of condensation. The droplets measured 240±65 nm in diameter as
determined by dynamic light scattering (Malvern Nano ZS, Malvern Instruments, Ltd.,
Westborough, MA, USA). Assuming a 1:1 conversion from microbubble to nanodroplet,
a final PSNE stock solution containing 1010 PFC nanodroplets per milliliter was stored
and used within 24 h.
G.2.2 Tissue-Mimicking Phantom
Albumin-acrylamide tissue-mimicking phantoms were prepared and formed into 10-
mL frustums (top diameter, 3 cm; bottom diameter, 4.1 cm; height, 1.2 cm) containing
various concentrations of the stock PSNE [222; 317]. The PSNE was gently stirred into
the degassed acrylamide solution prior to polymerization in the frustum mold by the
addition of 1% v/v of 10% ammonium persulfate and 0.4% v/v tetramethylethylene-
diamine. These albuminacrylamide gels have acoustic properties similar to biologic
tissues. Based on the final albumin concentration in these gels (35%), its density was
995 kg/m3, and sound traveled within the gel at a speed of 1,543 m/s [317]. In these
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Figure G.1: Vaporization field (microbubble cloud) and ablation lesion images ob-
tained after applying continuous wave HIFU. HIFU was applied at 1 MHz to albumin-
acrylamide gel phantoms containing 5 × 105 PFC ND per milliliter. (A) This ultra-
sound image shows a cigar-shaped vaporization field generated after 20 s of HIFU at
650 W/cm2 (4 MPa). (B) These optical images show four opaque white ablation le-
sions located in each transparent gel phantom following the application of HIFU at 650
W/cm2 for 5, 10, 15 and 20 s. Larger lesions can be observed in phantoms treated
with longer insonation times. (C) A single ablation lesion cut along its vertical axis,
demonstrating the desired cigar shape.
studies, HIFU was delivered at 1 MHz, and at this frequency, attenuation by the gel
was 0.28 dB/cm [317]. Vaporization fields (microbubble clouds) within the phantoms
can be imaged by ultrasound (Figure G.1A). Furthermore, the initially transparent gel
turns opaque white in regions where the albumin is denatured at temperatures above
60◦C, allowing for direct visual measurement of the ablation lesions (Figure G.1B,C).
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G.2.3 Gel Model of Diseased Tissue
A model for HIFU delivery was constructed as described previously in order to
simulate a region of diseased tissue surrounded by healthy tissue [222]. The phantom
containing the PFC nanoemulsion sat in a gellan gum mold [331] and was covered
by a 10-mm-thick degassed, agent-free albumin-acrylamide gel cap. The mold and
cap mimicked the healthy tissue surrounding the diseased phantom. Since they have
similar acoustic impedances (albumin-acrylamide gel: 1.54 × 106, gellan gum mold:
1.62 × 106 kg/m2s) [317; 179], significant reflection should not occur at the gel and
mold interfaces. This in vitro model was designed to simulate PFC agent accumulation
in a tumor. PSNE accumulation has been demonstrated in vivo [328] and is believed
to result from the enhanced permeability of tumor vasculature [332]. The layered
arrangement of gels allowed for assessment of ablation along the HIFU beam path
and ensured that acoustic energies were low enough to avoid ablation in prefocal tissue
regions containing no PFC agent. The tissue-mimicking gels and mold were maintained
at a constant body temperature of 37◦C by a bath circulating degassed water.
G.2.4 Focused Ultrasound
A spherically focused, eight-element, annular array transducer with active outer
and inner diameters of 80 and 33.5 mm and a natural focal length of 80 mm (F# =
1) (Imasonic, Voray-sur-lOgnon, France) was driven using a Therapy Imaging Probe
System (TIPS) (Philips Research North America, Briarcliff Manor, NY, USA) to pro-
vide continuous wave HIFU at 1 MHz. The transducer was calibrated at 2, 3, and 4
MPa using a needle hydrophone (Onda HNA-0400, Sunnyvale, CA, USA) positioned
at the focal point (TIPS focal zone: 1 × 1 × 6 mm) in a degassed water bath (free-
field). Since measuring the acoustic intensity at the focal point directly in gels during
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Figure G.2: Representative acoustic images of vaporization fields (microbubble clouds)
generated by the application of continuous wave HIFU. HIFU was applied at 1 MHz for
20 s at intensities of 140, 390, and 650 W/cm2 (PNP = 2, 3, and 4 MPa) to albumin-
acrylamide phantoms containing PFC nanodroplets over a concentration range from
105 to 108 ND per milliliter. The progressive changes in the shape and location of
the microbubble clouds with increasing PSNE concentrations can be seen. The shape
change follows a predictable pattern from cigar (prolate ellipsoid) to tadpole (asym-
metric ellipsoid) to oblate ellipsoid, as vaporization concentrates in prefocal regions.
HIFU is challenging, the intensities are estimates based on calculation using the free-
field focal pressure, the acoustic impedance of the albumin-acrylamide gel, and the
frequency-dependent attenuation by the gel. The nonlinear pressure waveform am-
plitudes recorded during calibration were derated for gel attenuation and averaged to
obtain the focal pressure in the gel, which was squared and divided by the gel acoustic
impedance (density × sound speed) to estimate the spatial peak intensity (ISP ) in the
focal zone during HIFU [333]. Intensities corresponding to PNPs of 2, 3, and 4 MPa
were 140, 390, and 650 W/cm2, respectively. Previous experimentation has shown that
(1) a PNP of 1 MPa (intensity = 30 W/cm2) does not generate a vaporization field or an
ablation lesion across the nanodroplet concentration range used in this study, (2) both
vaporization and ablation occur at a pressure of 2 MPa, demonstrating no large differ-
ence between the vaporization and cavitation pressure thresholds, and (3) agent-free
(non-enhanced) ablation is just beginning to occur at a PNP of 4 MPa [222]. Acoustic
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intensities below 140 and above 650 W/cm2 were therefore not explored further. The
HIFU treatment cycle was varied with insonation times of 5, 10, 15, and 20 s followed
by cool- down times of 2, 4, and 6 s for each intensity. Four separate ablation lesions
were generated in each phantom (Figure G.1B). The same insonation time (5, 10, 15,
or 20 s) was used to create each lesion in a single phantom. The cool-down time (2, 4,
or 6 s) referred to the time separating each of the four insonations, during which time
the HIFU focus was moved to a new position in the gel. The four focal zones in each
phantom were separated by 8 mm. This separation distance was selected based on the
results of previous testing [222] demonstrating that the diameters of the vaporization
fields in the presence of this specific PSNE approach 8 mm at higher acoustic intensities
and ND concentrations. Testing at each acoustic parameter was carried out at least
eight times. The ultrasound transducer was positioned over the phantom at the focal
length of 80 mm (64 mm through degassed water, 16 mm through albumin-acrylamide
gel) and moved automatically by a programmable 3-D motion stage.
Figure G.3: Schematic representation of the changing shape of vaporization fields (mi-
crobubble clouds) with increasing PFC concentrations and acoustic energies. (A) The
desired shape is a cigar (prolate ellipsoid) centered at the acoustic focal point (white
dot). (B) Tadpole lesions (asymmetric ellipsoids) occur as vaporization begins to con-
centrate in prefocal regions. (C) Eventually, the microbubble clouds flatten (oblate
ellipsoids) and mass along the frontal phantom surface. These shape changes (dis-
tortion) can be appreciated qualitatively and can also be assessed quantitatively by
measuring the length of the lateral axis (horizontal white line), the area-to-perimeter
ratio, and the displacement of the centroid off of the focal plane (center shift).
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G.2.5 Vaporization Field Shape and Location
Liquid nanodroplets are only very weakly echogenic, since their density and com-
pressibility are similar to surrounding tissue. However, the vaporization field (mi-
crobubble cloud) resulting from their phase-shift can be imaged by conventional ultra-
sound with high sensitivity [222]. In order to determine the maximum PSNE concen-
tration allowable to produce an ablation lesion with the desired cigar shape centered at
the focal point for a given acoustic intensity, continuous wave HIFU was applied for 20
s using PNPs of 2, 3, and 4 MPa to phantoms containing 0.1, 0.5, 1.0, 2.5, 10, 50, and
100 µL of the PSNE stock solution. The resulting nanodroplet concentrations in the
phantoms were not measured directly, but assuming minimal PFC agent loss during
preparation, they were calculated to be 1× 105, 5× 105 , 1× 106 , 2.5× 106 , 1× 107
, 5 × 107, and 1 × 108 ND per milliliter, respectively. Reported as a volume fraction
(v/v) of the PSNE stock solution added to the 10 mL gel phantom, these concentra-
tions were equivalent to a range from 0.001% to 1%. This broad range (105 to 108 ND
per milliliter) was studied to document the behavior of this novel PSNE and to define
the upper and lower PSNE concentration limits for effective HIFU enhancement. The
lower concentrations are comparable to those used in other PFC microdroplet and nan-
odroplet phase-shift enhancement studies [330; 54] and are more likely to be achievable
in vivo.
The resulting vaporization fields were imaged using a 15L8 transducer probe with
a Siemens Sequoia scanner (Siemens, Mountain View, CA, USA) operating in B-mode
(frequency = 14 MHz, mechanical index = 0.7). This imaging did not trigger PFC
nanodroplet vaporization as confirmed by imaging phantoms prior to HIFU treatment.
The microbubble cloud shapes and locations in the gel phantoms were analyzed using
ImageJ software. Their lateral axis lengths, perimeters, and areas were measured and
used to quantify the changing cloud shape (distortion). The progression from cigar
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to tadpole to oblate ellipsoid (Figure G.3) can be demonstrated mathematically by a
lengthening of the lateral axis and an increasing area-to-perimeter ratio. In order to
quantify displacement of the microbubble cloud off the acoustic focus (center shift), the
centroid of the cloud was calculated in ImageJ and its distance from the acoustic focus
(assumed to be on the central plane of the phantom) was measured. Further testing
of microbubble cloud and ablation lesion volumes in response to varied insonation and
cool-down times was carried out using the maximum PSNE concentration for a given
acoustic intensity that contained predominantly cigar-shaped ablation lesions centered
at the acoustic focal point.
G.2.6 Vaporization Field and Ablation Lesion Volumes
Previous testing has demonstrated that PFC-enhanced HIFU ablation lesions in the
presence of a DFB-DDFP PSNE are located in larger vaporization fields (microbub-
ble clouds) [222]. Knowing the extent of the vaporization field is useful when plan-
ning a strategy to position adjacent ablation lesions. A 15L8 transducer probe with
a Siemens Sequoia scanner operating in B-mode at 14 MHz was used to image the
vaporization field immediately after each HIFU treatment (Figure G.1A). The PSNE
concentrationintensity combinations identified for further study yielded vaporization
fields characterized predominately as cigars when insonation times were less than 20 s.
However, early tadpole transformation was present for some microbubble clouds after
20 s of insonation. Given this asymmetry, the volumes of all microbubble clouds were
calculated using code written in Matlab. The code allowed a region of interest to be
outlined (microbubble cloud perimeter) and sectioned horizontally. Three-dimensional
disc volumes were calculated from these two-dimensional sections and the disc volumes
summed for a total volume approximation. Ablation lesions were apparent as opaque
white regions in the otherwise transparent phantom (Figure G.1B,C). To determine
335
the volume of these predominantly cigar-shaped lesions, the phantoms were cut by
scalpel through the central vertical plane of the lesion (Figure G.1C). The maximum
height (h) and width (w) of these ablation lesions were measured by calipers, and the
corresponding prolate ellipsoid volume (V ) was calculated by eqn. F.1.
G.2.7 Statistical Analysis
Means and corresponding standard deviations (S.D.) were reported and represented
on the graphs, and p values of < 0.05 (α) were considered to be statistically significant.
One-way analysis of variance (ANOVA) was used to compare the means when more
than two sample groups were present in the data set. A Bonferroni adjustment was
made to the accepted level for statistical significance (p = α/N) in order to compare
combinations of sample pairs (N) by Student’s t-test within the larger group.
G.3 Results
G.3.1 Vaporization Field Shape and Location
The maximum PFC nanodroplet concentration appropriate for a given HIFU inten-
sity was selected based on the results of evaluating the vaporization field (microbubble
cloud) shape and location across a broad range of concentrations (105 to 108 ND per
milliliter) treated by continuous wave HIFU for 20 s at 2, 3, and 4 MPa (intensities
of 140, 390, and 650 W/cm2). Figure G.2 shows the progressive shape and location
changes observed with increasing PSNE concentrations: cigar surrounding the cen-
tral acoustic focal point, tadpole with prefocal migration, and eventually flattened
microbubble clouds along the frontal surface. These changes result from vaporization
concentrating in prefocal areas and are associated with a risk of ablation occurring away
from the intended target site. Although flattening of the microbubble clouds along the
prefocal phantom surface was an artifact of the layered gel model, their appearance was
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Figure G.4: Quantitative assessment of the progressive changes in the shape and lo-
cation of the vaporization fields. (A) There is a logarithmic relationship between the
length of the lateral axis and the PSNE concentration for a given acoustic intensity
(r2 ≥ 0.94, p < 0.001, linear regression on log scale), demonstrating that most of
the change occurs in the lower PSNE concentration range. (B) Change in the area-
to-perimeter ratio reflects changes in the microbubble cloud shape (distortion). (C)
Prefocal displacement of the centroid (center shift) as a function of PSNE concentra-
tion. The arrowed bracket identifies the transformation point for an acoustic intensity
of 140 W/cm2.
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nevertheless a clear indication that control over the placement of the vaporization field
had been lost. The transformations in microbubble cloud shape (distortion) occurred
on a continuum, as reflected by the logarithmic relationship between the lateral axis
lengths and PSNE concentration for a given acoustic intensity (r2 ≥ 0.94, p < 0.001,
linear regression on log scale) (Figure G.4A). This cigar to tadpole transformation was
reflected by a statistically significant (p ≤ 0.01) change in the area-to-perimeter ra-
tio (Figure G.4B) with increasing PSNE concentration. The point of initial distortion
corresponded with a statistically significant (p ≤ 0.03) center shift (Figure G.4C). For
the range of PSNE concentrations and acoustic intensities tested, distortion and center
shift increased with increasing intensity for a given concentration and also occurred at
lower PSNE concentrations in response to higher acoustic intensities (Figure G.4B,C).
Tadpole transformations began at PSNE concentrations of 5 × 105, 2.5 × 106, and
1 × 107 ND per milliliter (0.005%, 0.025%, 0.1% v/v) using intensities of 650, 390,
and 140 W/cm2, respectively. These concentration/intensity combinations were chosen
for further study, since they were the maximum points at which predominately cigar-
shaped ablation lesions could still be found after 20 s of insonation. Of note, these
intensities and PSNE concentration ranges are similar to those reported previously
[330].
G.3.2 Vaporization Field Volume
The treatment cycle of continuous wave HIFU refers to the insonation (‘on’ or ab-
lation) time and the ‘off’ or cool-down time that separates the insonation times. For
a given intensity, there was no statistically significant difference in the volumes of the
vaporization fields (microbubble clouds) when insonation was separated by ‘off’ times
lasting 2, 4, or 6 s. This consistency was present across the entire range of insonation
times (Figure G.5). Given the fact that varying the separation times did not affect
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Figure G.5: Relationships between the volume of the vaporization field, separation
time, and insonation time. At intensities of (A) 140, (B) 390, and (C) 650 W/cm2,
no statistically significant differences were observed between the volumes of the vapor-
ization fields at separation times of 2, 4, and 6 s for any given insonation time (n ≥ 4,
mean ± S.D.).
the vaporization volume, all measurements collected for a given insonation time were
averaged for further analysis. There was a statistically significant doseresponsive rela-
tionship (ANOVA, p < 0.02) between the duration of HIFU insonation and the volumes
of the resulting vaporization fields (Figure G.6). The volumes of the vaporization field
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Figure G.6: Volume of the vaporization field (microbubble cloud) as a function of the
duration of insonation. n ≥ 12, mean ± S.D., p < 0.02 for values along each intensity
curve (ANOVA), Single asterisk (*) indicates significance (p < 0.008) between the
volumes of the vaporization fields at insonation times of 5 and 20 s for the given
acoustic intensity (Bonferroni correction to Student’s t test).
ranged from approximately 75 to 240 mm3 with the application of HIFU at 650 W/cm2
from 5 to 20 s, respectively, in phantoms containing 5 × 105 ND per milliliter. These
fields were much smaller when 140 W/cm2 was applied to phantoms containing 1× 107
ND per milliliter, ranging from approximately 15 mm3 after 5 s of insonation to 25
mm3 after 20 s. Additionally, at this lowest acoustic intensity, the vaporization re-
sponse was inconsistent, demonstrating that this is the minimum intensity required to
achieve vaporization using this PSNE.
Bubble fields were not seen by conventional acoustic imaging in the agent-free phan-
toms when HIFU was applied at intensities less than 650 W/cm2. At 650 W/cm2 for
20 s, small bubble fields averaging < 4 mm3 are formed. These areas were most likely
boiling clouds generated from dissolved gases in the phantom gel.
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Figure G.7: Ablation lesion size as a function of the separation time of the HIFU treat-
ment cycle. At intensities of (A) 140, (B) 390, and (C) 650 W/cm2, no statistically
significant differences were observed between the volumes of the ablation lesions at
separation times of 2, 4, and 6 s for any given insonation time (n ≥ 4, mean ± S.D.).
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Figure G.8: Ablation lesion size as a function of the duration of insonation (‘on’ or
ablation time). The inset shows the lowest intensity data in detail. n ≥ 12, mean
± S.D., p < 0.001 for values along each intensity curve (ANOVA), single asterisk (*)
indicates significance (p < 0.008) from all other insonation times for the given acoustic
intensity (Bonferroni correction to Student’s t test).
G.3.3 Ablation Lesion Size
Varying the ‘off’ or cool-down time that separated ablative insonation by 2, 4, and
6 s did not affect the volume of the ablation lesion for a given intensity and duration of
insonation (Figure G.7). However, a statistically significant dose responsive relationship
(ANOVA, p < 0.001) was observed between the insonation time and the volume of the
resulting ablation lesion (Figure G.8). Averaging all measurements collected at a given
insonation time demonstrated this relationship to be present even at the lowest acoustic
intensity of 140 W/cm2 (PNP = 2 MPa), although the resulting ablation lesions were
small and appeared inconsistently. On average, these ablation lesions measured just 4
mm3 after 20 s of HIFU, despite the fact that the phantoms contained the highest PFC
concentration (1 × 107 ND per milliliter). This finding again demonstrated that 140
W/cm2 should be considered the minimum required intensity to achieve controllable
ablation with this PSNE. When higher intensities were applied, the ablation lesions
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were significantly larger, even though the PFC concentrations were lower. Phantoms
containing 2.5 × 106 ND per milliliter received HIFU at an intensity of 390 W/cm2
(PNP = 3 MPa). The resulting ablation lesions measured 8 mm3 after 5 s and 37
mm3 after 20 s. Applying an intensity of 650 W/cm2 (PNP = 4 MPa) to phantoms
containing 5× 105 nanodroplets per milliliter resulted in ablation lesions ranging from
19 to 135 mm3 with insonation times from 5 to 20 s.
Minimal ablation occurred in phantoms containing no PFC agent. The average
ablation lesion in response to the maximum energy delivered during these experiments
[20 s of continuous wave HIFU at 650 W/cm2 (PNP = 4 MPa)] measured 3 mm3, and
the appearance of these lesions was inconsistent.
G.3.4 Optimizing Acoustic Parameters
The results of this study demonstrate that the size of an ablation lesion produced
during PFC-enhanced HIFU can be predicted in vitro from the acoustic intensity, the
duration of insonation, and the concentration of the PFC agent. This level of control
would theoretically allow selection of the best acoustic parameters (intensity and in-
sonation time) to produce an ablation lesion of desired size in a region of known PFC
concentration. These relationships can be visualized by a threedimensional plot relating
acoustic intensity, insonation time, PFC nanodroplet concentration, and ablation lesion
size (Figure G.9). It should be noted that these quantified relationships apply only to
this specific PSNE, although it is reasonable to assume that similar relationships could
be defined for other PSNEs.
G.3.5 Comparing Vaporization Volumes with Ablation Lesions
Both the volume of the vaporization field (microbubble cloud) and the volume of
the ablation lesion within the microbubble cloud increased with increasing insonation
times (Figures G.6 and G.8). The vaporization clouds were larger than the ablation
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Figure G.9: Relationships between acoustic intensity, insonation time, PFC nan-
odroplet concentration, and ablation lesion size. This three-dimensional grid demon-
strates the best acoustic parameters (intensity and insonation time) to produce an
ablation lesion of desired size in a region containing a known agent concentration for
this specific PSNE.
lesions contained within them. After 5 s at 650 W/cm2, the vaporization field was
four times larger than its ablation lesion. However, with increasing insonation time,
ablation occurred in a larger portion of the vaporization field. For example, after
20 s at 650 W/cm2, this ratio was down to 1.75. Similarly, ablation filled more of
the microbubble cloud when higher intensities were used. After 20 s of HIFU at 140
W/cm2, the vaporization field was about 7.5-fold larger than the ablation lesion within
it, compared to 1.75-fold at 650 W/cm2. These trends probably, at least in part,
reflected the containment of the vaporization field within the gel boundaries that are
present in this experimental setup. However, the fact that ablation fills more of the
microbubble cloud with higher intensities and insonation times also suggested that
vaporization and ablation grew outward from the central focal zone throughout the
continuous wave insonation.
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G.4 Discussion
PFC microbubbles act as cavitation nuclei and lower the acoustic intensity required
to achieve ablation by HIFU. Lowered energy requirements should improve HIFU safety
and make it a viable option to treat a broader range of disease sites. Vaporizing
liquid PFC droplets in the target area provides an attractive option for introducing
these microbubbles, given the stability of PFC droplets in circulation and the fact that
they can be manufactured small enough (< 300 nm) to extravasate through the leaky
tumor vasculature. Previous testing has confirmed that phase-shift agents using several
different PFC formulations produce larger ablation lesions with lower HIFU energies
[222; 328; 330]. However, clinical utility requires control over the size, shape, and
location of the ablation lesion, and this control can be problematic when PFC agents
are present in the acoustic field [222; 305; 330; 54], particularly if the PSNE includes a
volatile PFC component.
This study explored the use of a PSNE containing highly volatile DFB (1 : 1 mix
of DFB and DDFP) in a gel model of HIFU enhancement. Lowering the intensity
needed to achieve vaporization by the addition of a volatile PFC component can min-
imize HIFU intensity requirements. However, since the acoustic pressure that triggers
vaporization is similar to the pressure that drives cavitation, establishing a vaporiza-
tion field that does not grow during lower amplitude continuous wave insonation is
not possible. Therefore, these experiments focused on optimizing acoustic parameters
(intensity and insonation time) to achieve controllable HIFU enhancement for a given
concentration of this novel PSNE. Previous testing has defined the limits of effective
acoustic intensity for this PSNE [222]. Even when PSNE was present, no ablation
was seen at intensities below 140 W/cm2, and ablation in agent-free gels started to
occur above 650 W/cm2. Therefore, the current study explored the effects of varying
insonation (‘on’) and separation (‘off’) times of the HIFU treatment cycle within the
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intensity range from 140 to 650 W/cm2. It should be noted that this intensity range
corresponds well with the range (157 to 550 W/cm2) identified by Zhang P. et al. as
most appropriate for PFC-enhanced HIFU [330]. In contrast, current HIFU systems
in use clinically must operate at intensities at or above 2,000 W/cm2, risking injury to
tissue outside of the target site. This study demonstrated that appropriate acoustic
intensities and insonation times can be selected to maintain control over ablation lesion
size, shape, and location even in the presence of a PSNE containing a volatile PFC
component. Additionally, since the vaporization field was not fixed, relatively large
ablation lesions that propagated outward from the acoustic focus could be produced.
The ablation lesions measured up to 135 mm3 in gels with PSNE, compared to lesions
measuring < 4 mm3 in agent-free gels, when HIFU was applied at 650 W/cm2 for 20 s.
There are interesting similarities and differences between these findings and the re-
sults of other phase-shift studies looking at HIFU enhancement by PFC nanodroplets
and microdroplets in acrylamide gels. Using a DDFP-based PSNE without a more
volatile component, Zhang P. et al. were also able to produce ablation lesions larger
than 100 mm3. However, the required intensities (around 2,000 W/cm2) were higher
[330]. It is suspected that the differences in ablation response between these two studies
resulted primarily from the presence of volatile DFB in our PSNE. Testing in solution
has demonstrated that incorporating a lower boiling point PFC during the PSNE prepa-
ration decreases the vaporization threshold of the PSNE [281]. As a result of this lower
threshold, the vaporization field increased in volume throughout the continuous wave
HIFU treatment cycle in our study (Figure G.6). In contrast, in the presence of DDFP
alone, Zhang P. et al. established a stable vaporization field using a 30-cycle high-
intensity (4,586 W/cm2) pulse and followed this with 15 s of continuous wave HIFU
[330]. Additionally, it should be noted that the frequency of applied HIFU was also
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different in these two studies (1 vs. 3.2 MHz). PFC droplet vaporization is a frequency-
dependent phenomenon, and frequency differences alter ultrasound wave attenuation,
energy deposition, and microbubble cavitation [334].
Zhang M. et al. studied DDFP microdroplet enhanced HIFU delivered at a fre-
quency (1.44 MHz) similar to ours [54]. They too noted increasing ablation lesion
volumes with longer insonation times (insonation duration 2 to 5 s). However, at com-
parable PFC agent concentrations (3 vs. 5× 105 droplets per milliliter) and insonation
duration (5 s), the ablation responses were quite different. Probably reflecting the use
of larger PFC droplets (2 to 8 microns) and a higher intensity (4,000 W/cm2), Zhang
M. et al. produced ablation lesions measuring 600 mm3, compared to 20 mm3 in our
study [54].
Finally, again testing a DDFP PSNE in acrylamide gels, Kawabata et al. applied
HIFU using acoustic parameters (frequency, 1.1 MHz; intensity, 600 W/cm2; insonation
duration, 5 to 20 s) similar to our study and found increasing ablation lesion size with
longer insonation [334][29]. However, lesion size did not increase when HIFU was ap-
plied at 2.2 MHz. The similarities and differences between these studies emphasize
the fact that the ablation response during PSNE enhanced HIFU results from a com-
plex interplay of the applied acoustic parameters as well as the type and size of the
PFC agent. As a result, it is suspected that changing the ratio of DFB and DDFP
in our PSNE would alter both the vaporization and ablation responses and is a po-
tential area of future study. The ablation lesions formed in this study were located
in larger vaporization fields (microbubble clouds). The fact that the vaporization field
grows throughout the entire HIFU treatment cycle when a volatile PSNE is present
distinguishes this study from previous phase-shift enhancement studies. Continuous
vaporization provides an opportunity to generate larger ablation lesions but also intro-
duces unique challenges with regard to controlling the ablation response. Anticipating
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the extent of vaporization surrounding an ablation site is of practical importance when
positioning adjacent lesions. Separating insonation by 2, 4, or 6 s did not affect the
size of the vaporization field or the ablation lesion within this microbubble cloud when
adjacent HIFU sites were 8 mm apart. Decreasing this separation distance could result
in overlapping vaporization fields. Future study will be needed to assess the impact of
overlapping vaporization fields on tissue heating and the ablation response.
In this gel model, controlled ablation could be achieved using acoustic parameters
that did not result in lesion formation in agent-free regions (frequency = 1 MHz, in-
tensity 650 W/cm2, insonation time ≤ 20 s). However, the limitations of this model
should be noted. The phantoms and surrounding gels were acellular and avascular.
Therefore, tissue injury that would result from mechanical cavitation effects was not
captured, and heat sink effects of blood flow were not considered. Also, changes in
acoustic impedance due to trapped degassed water between the acrylamide gel cap, the
PFC-containing phantom, and the gellan gum mold resulted in echogenic boundaries,
which may have slightly attenuated transmitted energies. Such distinct separations
between agent-free and PFC-containing tissue regions would not be seen in vivo nor
would the uniform distribution of PFC agent achievable in vitro.
A PSNE concentration in the range of 105 to 107 ND per milliliter was required
for enhanced ablation in this gel model. Further experimentation will be needed to
determine how these concentrations can be achieved in vivo. Recent testing has shown
that the intravenous administration of a DDFP-based PSNE (0.5 mL/kg) resulted in the
preferential deposition of nanodroplets in the vascular periphery of a rabbit tumor [328].
These agents remained stable for hours and accumulated to a concentration sufficient to
lower the energy required to reach an ablative temperature by HIFU. The DDFP PSNE
used in this in vivo study was also tested in vitro by Zhang P. et al. in concentrations
similar to those used in our current study [330]. It is therefore reasonable to assume that
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effective tissue concentrations of our DFB-DDFP PSNE can also be achieved. However,
to date, tissue concentrations of PFC nanodroplets following the administration of a
PSNE have not been quantified in vivo. Magnetic resonance of fluorine or gadolinium-
tagged agents may provide a tool to measure PFC tissue concentrations [330; 57].
The development of such a tool may be an important step on the path toward using
PSNEs clinically for several reasons. First, there is a heterogeneous deposition of
PFC in tumor tissue following the intravenous administration of a PSNE [328], quite
different from the uniform distribution used for in vitro studies. Second, as this and
other studies have now demonstrated, controlled ablation requires selecting appropriate
acoustic parameters for a given PSNE concentration. Therefore, the safe application of
HIFU in a field containing an unequal distribution of PFC agent may require estimating
regional PFC concentrations and adjusting the acoustic parameters accordingly. We
envision a magnetic resonance-guided focused ultrasound surgery system that maps the
distribution of PFC tissue levels, selects appropriate acoustic parameters for the target
region and desired lesion size, and monitors ablation by thermometry.
G.5 Conclusion
Research in this and other laboratories has now validated the use of phase-shift
PFC nanoemulsions to enhance HIFU by seeding the acoustic target area with poten-
tial cavitation sites. Several methods are available to synthesize nanodroplets that are
stable to circulate at body temperature and small enough to extravasate into intersti-
tial tissue spaces. Additionally, appropriate nanodroplet concentrations and acoustic
parameters are being defined to achieve enhancement (larger ablation lesions using
shorter treatment cycles and lower acoustic power) while maintaining control over le-
sion shape and location. This in vitro study used a unique PSNE containing a volatile
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PFC component and found that enhanced ablation could be achieved with acoustic in-
tensities low enough to avoid ablation in agent-free regions. However, control over the
ablation response was problematic, unless specific acoustic parameters were selected for
the available PSNE concentration. These findings support continued experimentation
using PSNEs to enhance HIFU but also emphasize the importance of exploring tools
to quantify PFC tissue concentrations in vivo to guide acoustic parameter selection.
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